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Abstract 
 
Inspired by their naturally occurring members, the carbapenem class of β-lactam 
antibiotics have been heavily researched over the past forty years, resulting in the 
development of a set of broad-spectrum, β-lactamase resistant, last resort antibiotics for 
the treatment of severe bacterial infections.  Manufactured by total synthesis, 
carbapenems are limited to their use in the first world due to their high cost.  As 
antibacterial resistance increases, the need for these drugs is rising. 
 To combat the high price of manufacture, fermentation or semi-synthetic methods 
that take advantage of the enzymatic machinery of their biosynthesis to assemble the 
carbapenem core would reduce the number of synthetic steps and ultimately the cost of 
production.  The key biosynthetic steps to assemble the carbapenem core, however, 
remain unknown.  In this dissertation, we studied the MM 4550 biosynthetic gene cluster 
to examine how carbapenems are made by comparative genomics and we uncovered 
clues about how cis-carbapenems might diverge from thienamycin.  Total syntheses of 
cis-carbapenems were completed for activity assays with newly discovered enzymes in 
the MM 4550 gene cluster; CmmSu, Cmm17 and CmmPah.  Additionally, 2-thioalkyl 
carbapenam substrates were synthesized for assays with ThnK in vitro, which was found 
to perform sequential double methylation of carbapenam substrates for the installation of 
the 6-ethyl sidechain of thienamycin.  The function of ThnK has provided a path forward 
to uncovering the remaining biosynthetic steps carries out by the function of ThnL and 
ThnP. 
In collaboration with Prof. Gyanu Lamichhane at the Johns Hopkins Medical 
Institute, a new class of cell wall crosslinking transpeptidases in Mycobacteria, L,D-
ii 
transpeptidases (Ldts), was screened for their inhibition by commercially available β-
lactam antibiotics using intact protein analysis electrospray ionization high-resolution 
mass spectrometry.  We found that carbapenems form covalent adducts with Ldts and 
through efficient inhibition are potent drugs against Mycobacterium tuberculosis.  
Faropenem was found to be the most potent inhibitor of Ldts, however, unlike 
carbapenems, was unsuccessful against Tuberculosis infection in vivo.  As a result, we 
synthesized new penems that take advantage of the best carbapenem structural features 
with the goal to retain both the high potency of penems but the in vivo success of 
carbapenems.  Our lead compound has been found to have highly potent antibacterial 
activity, as evidenced by MIC90 data against M. tuberculosis and other pathogenic 
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Introduction to β-Lactam Antibiotics 
 
Discovery of β-Lactam Antibiotics 
The discovery of penicillin by Alexander Fleming is the most impactful 
contribution to modern medicine in the early 20th century. One of the most meaningful 
findings in scientific history was the serendipitous discovery that fungal contamination of 
Staphylococcus aureus plates was found to have an inhibitory growth effect on the 
bacterial culture1.  Fleming not only took note of this discovery, but he had the foresight 
to publish this important observation and predict in that first article that some agent 
produced by the fungus could be a valuable antibacterial substance.  Although Fleming 
stated in his Nobel Prize lecture that he “didn’t truthfully have this foresight at the time”, 
his speculation about the impact of this happy accident was enough to spark a 
pharmaceutical revelation when it came to curing bacterial infection that so commonly 
resulted in the loss of life or limb at the time2. 
Research associated with Fleming’s Penicillium mold continued for another 
decade, but it wasn’t until the necessities of World War II launched a monumental effort 
between Great Britain and the United States in the scale-up of penicillin fermentation to 
produce the massive quantities of antibiotic needed to treat wounded soldiers overseas.  
By the end of the war, the technologies of fermentation were advanced to the point of 
antibiotic distribution being commonplace.  However, despite this mammoth effort, it 
wasn’t until Dorothy Hodgkin’s crystal structure in 1945 that the previously proposed β-
lactam ring was confirmed as the central piece to the penicillin mystery3. 
1 
The importance of the β-lactam structure cannot be overstated.  In 1957 former 
Merck scientist John Sheehan, then at MIT, proved leading chemists wrong with his 
paramount synthesis of penicillin, which had been deemed “impossible”.  It took him 9 
years, due to the state of organic chemistry at the time that the necessary chemical 
reactions needed to synthesize such a complex molecule had not yet been discovered. 
Sheehan and his lab were able to make penicillin V using dicyclohexylcarbodiimide 
(DCC) as the key step in forming the β-lactam ring (Scheme 1.1)4.  Sheehan was quoted 
to say that using traditional chemistry to assemble the structure was like “placing an anvil 
on top of a house of cards5.”  Despite Sheehan’s triumph, penicillin and its derivatives are 
still produced by non-synthetic fermentation methods and, unfortunately, no 
pharmaceutical use came from this synthesis. 
 
Scheme 1.1: First total synthesis of (+)-penicillin V4 
2 
Mode of action 
The “magic” of penicillin is its β-lactam core.  Traditionally, amide bonds are 
extremely stable to hydrolysis or to any nucleophilic attack whatsoever.  This heightened 
stability relative to the more electrophilic aldehydes, esters, thioesters or ketones is 
attributed to amide resonance.  The electrophilicity of carbonyls can be ranked using a 
comparison of measured pKa values for α-protons as shown in Figure 1.1. 
 
Figure 1.1: Alpha proton pKa values for common acyl intermediates including amide 
resonance 
 
Resonance structures are a useful tool to understand the significant electronic 
contributors to a covalently bonded structure, and for a significant contributing structure 
to include the nitrogen lone pair as a part of a π-bond with the carbonyl carbon, planarity 
across that bond is necessary.  Remarkably, nature has provided a natural product that 
includes an amide bond as part of a 4-membered ring such that planarity of amide 
resonance is difficult to achieve due to steric constraints, weakening the stability of the 
bond.  In addition, the presence of a fused 5-membered ring forces the amide even further 
out of plane.  A typical amide bond, such as those that comprise the backbone of proteins 
and polypeptides, has a hydrolysis half-life at room temperature and neutral pH of >500 
years.  In comparison, the half-life of penicillin is on the order of 48 h under the same 
conditions6.  This presents a problem of stability when the drug is stored or administered 
in the clinic, but the reactivity is critical as a reactive acylation agent that allows for the 
inhibition of bacterial cell wall biosynthesis. 
3 
The bacterial cell wall is critical for prokaryotic structural stability.  For single-
celled organisms to survive and reproduce in a variety of environmental conditions, the 
cell wall ensures that the more fragile interior cell membrane remains intact.  This 
structural entity is comprised of a N-acetyl glucosamine (NAG) linked to N-acetyl 
muramic acid (NAM) in β-1,4 fashion to form a polymeric backbone.  This backbone is 
ultimately attached to the cell membrane through the Van der Waals interactions between 
the cellular membrane and an attached undecaprenyldiphosphate lipid.  This complex is 
referred to as lipid II, which is biosynthesized in the cellular cytoplasm before it is 
localized in the cytosolic membrane and then translocated across the membrane to the 
outer leaflet thus presenting itself as a substrate for peptidoglycan biosynthesis (Figure 
1.2).  The polysaccharide backbones are interlinked periodically by the second structural 
component, where periodically an ether linkage is formed between the polypeptide strand 
and the NAM carboxylate.  The critical polypeptide cross-links that provide the structural 
integrity of the cell wall are catalyzed through transpeptidases, related evolutionarily and 
in their mechanism of action to serine proteases. The target of penicillin, these 
transpeptidases were first discovered through their inhibition, therefore these enzymes are 
referred to as penicillin-binding proteins (PBPs).  Typically, small molecule inhibitors are 
bound to their targets through favorable polar and non-polar interactions; however the 
“binding” that occurs in the interaction between penicillin and PBPs is covalent; a result 
of the extraordinary reactivity of the β-lactam7,8.  
4 
 
Figure 1.2: Stepwise cytosolic biosynthesis of Lipid II from Fructose-6-phosphate7 
 
The polypeptide chain consists of a sequence NAM-L-Ala-γ-D-Glu-L-Lys[ε-Gly-
Gly-Gly-Gly-Gly]-D-Ala-D-Ala in Gram-positive bacteria.  Before translocation of lipid 
II across the cell membrane and outside of the cytoplasm, the polypeptide chain matures 
by the addition of an ε-linked pentaglycine structure commonly referred to as the 
“bridge” structure. In the pentaglycine bridge, where the length and sequence can vary 
5 
considerably from species to species, the addition of glycine residues occurs through the 
action of the FemA, B and X non-ribosomal peptidyl transferases7. with glycyl-tRNA 
acting as the substrate. In the case represented in Figure 1.3, the terminal glycine residue 
is shown as the nucleophile in the transpeptidation reaction.  Although the nucleophile 
may vary, most often the electrophile is at the amide bond between D-Ala-D-Ala at the 
polypeptide terminus; this linkage is referred to as a 4,3-polypeptide cross-link.  More 
recently, novel transpeptidases were found in Mycobacterium tuberculosis to create a 
different crosslink at the electrophilic terminus, in which nucleophilic attack ultimately 
occurs at the third amide bond.  These transpeptidases, namely 3,3-transpeptidases, or 
L,D-transpeptidases, have since been discovered and characterized in addition to the 
traditional 4,3-transpeptidases in many species of bacteria and are thought of as a 
possible mode of resistance and resilience against cell-wall targeted antibiotics9,10.  This 





Prokaryotes require a cell wall and its biosynthesis for growth and proliferation, yet 
eukaryotic human cells have none of these processes, making for an ideal antibacterial 
target for bacterial infection in humans.  While other drugs have been explored to inhibit 
bacterial growth through cell wall biosynthetic targets, the β-lactams have stood the test 
of time as champions of the antibiotic industry for their broad spectrum, ease of use and 
unequivocal success in curing infection with minimal side effects in most patients. 
 
β-lactamases 
As the natural product β-lactams evolved, so did the ability to defeat competing 
bacteria that produce them11.  Chemical warfare between competing bacterial colonies in 
the environment is common: the culture that can successfully proliferate will persist and 
evolve.  Once β-lactams allow a species to dominate the ecosystem by killing its 
competition, other species developed β-lactam-hydrolyzing enzymes, known as β-
lactamases, as a mode of resistance.  As new β-lactams appeared as a result, new β-
lactamases co-evolved.  This cycle continues today.  In Alexander Fleming’s 1945 Nobel 
lecture, he cautioned the world on the use of penicillin2.  He estimated that one day 
antibiotics would be available on store shelves and their common administration would 
allow bacterial resistance to develop.  He was right; the widespread use of β-lactam 
antibiotics have brought on resistant infectious strains and the β-lactam/β-lactamase cycle 
that evolved over millions of years has accelerated in the past half-century.  Even 
carbapenemases have been identified, enzymes that provide resistance to our current last-




Carbapenems form a class of β-lactams that were first discovered in soil bacteria, 
Streptomyces, in 1976.  Fortuitously, the first carbapenem characterized was none other 
than thienamycin, which was isolated from Streptomyces cattleya by researchers at 
Merck Sharp and Dohme Research Laboratories12.  The efficacy of the natural product 
against difficult-to-treat strains such as Pseudomonas and its resistance to β-lactamases 
caused a major impact in the height of the golden age of antibiotics research.  With the 
discovery coming nearly 50 years after penicillin in 1928, synthetic chemistry moved at a 
blazing pace in comparison.  By 1978 the first total synthesis of racemic thienamycin was 
completed, an impressive achievement considering its complexity and susceptiblity to 
hydrolysis under neutral conditions and degradation by intermolecular reaction upon 
concentration13. 
In the years following the discovery of thienamycin, more than 50 carbapenems 
have been isolated and characterized from natural sources12,14–23.  Modifications of the 
core structure include alkylation, oxidation and sulfonation at the C-6 sidechain, 
acetylation, oxidation, and chain length variation at the C-2 thiol sidechain, and 
diversification of the C-6 and C-8 stereocenters.  A representation of the natural 
carbapenem antibiotics is shown in Figure 1.4. 
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Figure 1.4: Representative carbapenem natural products.  The core structure of 
thienamycin is numbered, as convention dictates. 
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As anti-infective therapeutic agents, carbapenems were first sold in 1987 after 
Primaxin I.V. (imipenem/cilastatin) was approved by the FDA (Figure 1.5).  Much effort 
was contributed by Merck Sharp and Dohme to be the first “last line of defense” drug for 
the treatment of drug-resistant nosocomial infections.  Imipenem, like all natural 
carbapenems, was found to be highly susceptible to hydrolysis by renal 
dehydropeptidase-1 (RDH-1), an enzyme in human kidneys.  Without administration of 
an RDH-1 inhibitor, cilastatin, the half-life of imipenem is greatly reduced and patients 
undergoing treatment can succumb to complications with the kidneys or even organ 
failure.  As a result, imipenem is administered as a combination with an equal amount of 
cilastatin, and is sold under the name Primaxin. 
 
Figure 1.5: Structures of imipenem and cilastatin 
 
Syntheses of imipenem 
Unlike penicillin or cephalosporin derivatives produced on an industrial scale, 
efforts to achieve the fermentation or semi-synthesis of carbapenems failed24.  The 
natural producers of carbapenems are primarily Streptomyces, which produce secondary 
metabolite carbapenems in 1-10 mg/liter quantities.  Increased sensitivity of the 
carbapenems to heat, acid, base and concentration is also a hindrance to isolation efforts.  
Merck was never able to bring fermentation titers above 100 mg/liter.  A Merck chemist, 
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Dr. Edward J.J. Grabowski, quoted Dr. Edward L. Paul, the head of Chemical 
Engineering on the imipenem-thienamycin project, as saying “to produce 40,000 kg of 
imipenem per year, we would have to run the thienamycin fermentation in Lake Erie and 
pump to Lake Ontario for the workup!”25  As a result, the carbapenem total synthesis 
effort was initiated and to this day carbapenems produced for the pharmaceutical market 
are made entirely by total synthesis. 
The first total synthesis of imipenem, by chemists at Merck Sharp and Dohme, 
was achieved as shown in Scheme 1.213.  
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Scheme 1.2: First total synthesis of (+/-) thienamycin13 
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The remarkable carbene mediated insertion from an α-diazo intermediate to form 
the [2.3.0] ring system evolved from the chemistry used in the first total synthesis26.  It 
was incorporated into the synthesis of thienamycin based on acetone dicarboxylate and 
ultimately this synthesis was modified into a chiral synthesis that eventually became the 
process used for industrial thienamycin production for many years25.  The acetone 
dicarboxylate synthesis of (+) thienamycin is shown in Scheme 1.327.  
 
Scheme 1.3: Chiral synthesis of (+)-thienamycin from acetone dicarboxylate27 
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An additional synthetic strategy took advantage of commonly available and 
inexpensive penicillin as a starting material for thienamycin synthesis28.  To build the 
necessary α-diazo-β-keto-ester for the diazoinsertion reaction required for 5 membered 
ring closure, a new method was developed to react the silylenolether of benzyl-
acetoacetate with a N-acyliminium electrophilic intermediate of the β-lactam ring.  The 
chemistry described, as well as the methodology to convert penicillin to thienamycin, is 
presented in Scheme 1.4. 
 
Scheme 1.4: Chiral synthesis of (+)-thienamycin from penicillin28 
 
The route from penicillin, although not practical enough to outperform the already 
established acetone dicarboxylate process, brought the critical component of N-
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acyliminium chemistry in the construction of the carbapenem bicycle.  The convergent 
nature of this synthetic approach allowed for a new synthesis to be derived, using aspartic 
acid as a source of chirality in the construction of the β-lactam.  Grabowski described the 
modern acetoxyazetidinone process for imipenem synthesis as a “Frankenstein” process, 
because it stole key chemical steps from the effort by many groups at Merck who 
developed 6 different total syntheses for thienamycin24.  The [2.3.0] ring construction 
using the diazoinsertion reaction was “stolen” from the early medicinal chemical efforts 
of thienamycin synthesis and brought to practicality by its use in the acetone 
dicarboxylate synthesis that made plant scale production successful.  The N-acyliminium 
chemistry was “stolen” from the penicillin synthesis.  Finally, the use of the 4-
acetoxyazetidinone intermediate which has been so critical in carbapenem production in 
the modern process to imipenem was “stolen” from the aspartic acid synthesis29.   
 
Scheme 1.5: Chiral synthesis of (+)-thienamycin from L-aspartic acid29 
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The modern acetoxyazetidinone process shown in Scheme 1.6 takes advantage of 
all of the aforementioned chemistry, and utilizes a now commercially available 
intermediate. (3R,4R)-4-Acetoxy-3[(R)-1-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-




Scheme 1.6: The current acetoxyazetidinone process to imipenem 
 
The unification of all these synthetic achievements into what is now one efficient 
and convergent process to imipenem highlights the high level of work done in the Merck 
Process group over the years, and underlines the importance of collaboration to solve 
important problems in pharmaceutical drug development. 
 
Second-generation carbapenems 
In a parallel attempt to make carbapenems for the pharmaceutical market, 
Sumitomo Dainippon Pharma of Japan developed meropenem as a result of in depth 
structure-activity relationship studies from over 50 newly synthesized carbapenem 
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compounds by their lead optimization research group.  They found that a cation in the C-
2 side chain was important for resistance to RDH-1, and discovered that further stability 
to the renal enzyme was achieved with the addition of a 1-β-methyl group on the 
carbapenem bicyclic core.  The result of their study was meropenem, as a 3-
hydroxyproline-derived substituent linked to the C-2 thiol provided low central and renal 
toxicities in vivo.  As nephrotoxicity was a problem for patients treated with carbapenems 
for a long period of time (>2 weeks), meropenem had the advantage.  Additionally, the 
need for cilastatin co-administration was no longer necessary30.   
Since imipenem was approved, meropenem, ertapenem and doripenem have been 
approved in the United States.  To date, biapenem and panipenem are approved for use in 
Japan.  Other carbapenems have been developed and some are still in clinical trials, like 
tebipenem whose prodrug ester, tebipenem pivoxil is orally available.  Razupenem is an 
example of a carbapenem that failed clinical trials. 
There is great promise in the development of new carbapenems that may have 
heightened antibacterial activity in comparison to the currently used carbapenems.  
Through optimization of the C-6 and C-2 sidechains, as well as taking into account the 
possibility of oral carbapenem administration through study of carbapenem prodrug 
esters, the reign of the carbapenem as the last, best, hope against drug-resistant strains is 
far from over. 
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Figure 1.6: Structures of clinically administered carbapenems 
 
Early studies on the biosynthesis of thienamycin 
As previously noted, fermentation efforts to obtain carbapenems from 
Streptomyces yielded titers that were far too low for fermentation to be a process from 
which sufficient quantities could be produced for the pharmaceutical market.  In order to 
diverge from the exemplary, but still expensive, total synthesis process methods, the use 
of enzymes for the semi-synthesis of carbapenems is proposed to provide a more green, 
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direct and inexpensive method for carbapenem production.  Unfortunately, the 
biosynthesis of carbapenem antibiotics remains largely unknown. 
In the 1980s, early studies on the biosynthesis of carbapenems were attempting to 
better understand how these molecules are made by their producers.  One particular study 
in 1984 had success in changing the antibiotic profile by random mutational analysis of 
the strain S. fulvuviridis A93331.  Knocking out an enzyme involved in the truncation of 
the carbapenem C-2 thiol side chain, carbapenems with pantetheine as the thioether at C-
2 were isolated.  These carbapenems and a proposed biosynthetic pathway among them is 
shown in Scheme 1.7. 
OA-6129A is thought of as a direct precursor for the C-6 ethyl carbapenem PS-5, 
OA-6129B2 for N-acetyl thienamycin, OA-6129B1 for epithienamycin A, and OA-6129C 
for MM 17880.  Likely, these carbapenems are also intermediates for each other and a 
proposed biosynthesis pathway from the isolated carbapenam OA-6129D to MM 17880 
is shown in Scheme 1.7. 
 
Scheme 1.7:  Isolated compounds of S. fulvuveridis mutants and proposed biosynthetic 




In 1985, Merck chemists examined the biosynthetic precursors of thienamycin 
through radioactive and stable isotope substrates32.  It was found that the carbapenem 
bicyclic core was assembled from acetyl-CoA and glutamic acid.  The C-8 and C-9 
carbons of the C-6 hydroxyethyl sidechain each come from the methyl group of 
methionine, and the C-2 sidechain incorporated radiolabeled cysteamine.  These studies, 
along with other work, produced an early biosynthetic proposal to thienamycin, are 




Scheme 1.8: Early proposal of thienamycin biosynthesis by Merck Sharp and Dohme32 
and proposed enzymatic function by Salas et al.33 
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Some inconsistencies exist in the Merck biosynthetic proposal when all the data 
available in the literature at the time are taken into account.  With no gene sequence or 
bioinformatics analysis at their disposal as researchers commonly use today, Merck did 
their best to match isotopic labeling and isolation experiments with a biosynthetic 
proposal.  From their experiments, an attempt was made to explain the vast diversity of 
carbapenem natural products that had been isolated, for example, asparenomycins, 
epithienamycins, and thienamycin.  However, stereochemical divergence at C-6 was 
ignored.  The most egregious mistake was perhaps their disregard for the critical OA-
6129 series of isolated carbapenems.  Instead of suggesting that a larger C-2 sidechain 
may be added at C-2 for all carbapenems, their proposal merely suggests that the OA-
6129 series are outliers, and the biosynthetic pathway must occur differently for those 
compounds.  What was missed from this proposal, however, was that the OA-6129 
compounds were isolated from mutants of a strain, S. fulvuveridis that normally produces 
epithienamycins and compounds such as PS-5, 6 and 7.  Those carbapenems with 
truncated C-2 sidechains must derive from those with pantetheine at C-2.  The mistake, 
however, is forgivable because the authors were attempting to justify their own data that 
the C-2 thioether incorporated radiolabeled 13C originated from cysteine.  Apparently 
unbeknownst to them at the time, experiments in CoA biosynthesis had revealed that 
bacteria have the capability to construct CoA using cysteine as a building block in a 





Modern biosynthetic studies of carbapenems 
The advent of inexpensive DNA sequencing stimulated in part by the human 
genome sequencing project at the turn of the 21st century afforded researchers with the 
ability to sequence entire biosynthetic gene clusters for secondary metabolites, and 
indeed, entire bacterial genomes.  In 1997, the Salmond group of the University of 
Cambridge sequenced and analyzed the gene cluster for the simplest carbapenem, 
carbapenem-3-carboxylic acid in Pectobacterium carotovora34.  Mutational analysis of 
the gene cluster revealed that the only genes out of the 8 in the cluster that caused a loss 
of antibiotic production when knocked-out were carA, carB, and carC.  The earliest 
effort from the Townsend lab on carbapenem biosynthesis examined the roles of these 
three enzymes, where Rongfeng Li and Anthony Stapon published, in a series of JACS 
Communications, that the transformations catalyzed by CarA, B and C were all that was 
necessary to make carbapenem-3-carboxylic acid from acetate and L-glutamate as shown 
in Scheme 1.935–37.  CarB was discovered as important in condensing pyrrolidine 5-
carboxylate with malonyl-CoA. CarC, an α-ketoglutarate dependent non-heme iron 
oxygenase, was found through rigorous study to both epimerize the C-5 bridgehead 
position of the (3S,5R)-carbapenam-3-carboxylic acid and desaturate the C-2/C-3 bond 
successively. 
 
Scheme 1.9: Biosynthesis of (5R)-carbapenem-3-carboxylic acid in E. carotovora 
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As for thienamycin biosynthesis, the gene cluster was discovered in S. cattleya 
and published by the Salas group at the University of Oviedo, Spain, in 200333.  Analysis 
of the 22 open reading frames revealed putative functions for most enzymes.  Of these, 
thnE and thnM had high sequence homology to carA and carB, respectively, the enzymes 
responsible for the biosynthesis of the carbapenam bicycle in the simple carbapenem 
gene cluster from E. carotovora.  Strikingly, no CarC homologue was encoded in the 
thienamycin gene cluster. However, two non-heme iron oxygenases were encoded, thnG 
and thnQ, but with shared homology to known hydroxylases.  ThnK, thnL and thnP 
encoded putative radical SAM methyltransferases, and thnF an N-acetyltransferase.  
Ruling out a putative transport protein, two transcriptional activators and a β-lactamase in 
thnJ, thnI, thnU, and thnS respectively, the remaining enzymes of unknown function were 
thnH, thnN, thnO, thnR, thnT and thnV were used to fill in the remaining chemistry based 
on the biosynthetic pathway proposed in Scheme 1.8. 
A major contribution by Dr. Michael F. Freeman and Dr. Kristos A. Moshos was 
achieved to carbapenem biosynthesis revealed the function of four enzymes, ThnR, H, T 
and F, which were found by in vitro enzyme assays to be responsible for the truncation of 
coenzyme A in thienamycin biosynthesis, confirming that the C-2 cysteamine sidechain 
is derived from coenzyme A, not cysteine as thought for many years38. As previously 
stated, this finding does not contradict the early isotopic labeling experiments where 
radiolabeled cysteine that was incorporated into at C-2.  ThnF, as expected by sequence 
homology, was confirmed as the N-acylase to produce N-acetylcarbapenems38. The 
others, ThnR, H and T were found to truncate CoA to cysteamine in the order of ThnR, 
which cleaves CoA to provide phosphopantetheine, then ThnH, which cleaves the 
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terminal phosphate to produce pantetheine, and ThnF, the responsible amidohydrolase 
that cleaves pantetheine to cysteamine.  The results published in 2008, combined with 
unpublished in vitro enzyme activity assays using CoASH and phosphopantetheine 
substituted carbapenams, prove that the tailoring of CoA can occur with the 
carbapenam/em structure attached39.  ThnH, for example, requires the carbapenem 
structure present to successfully cleave the terminal phosphate.  The results of these 
experiments are outlined for the state of thienamycin biosynthesis in 2011 in Scheme 
1.1039. 
To support the hypothesis that ThnE and ThnM function in parallel to CarB and 
CarA, respectively, despite low sequence identity of 37 and 25%, Micah Bodner, Ryan 
Phelan, Kristos Moshos and I synthesized pyrrolidine and carbapenam substrates for 
enzyme activity assays of compounds with varying substitution patterns and 
stereochemistry40.  As there is not a CarC homologue encoded by the thienamycin 
biosynthetic cluster, the hope was that more diverse substrates would be accepted as the 
preferred substrates for ThnE and ThnM to solve the mysteries of how epimerization and 
desaturation might occur.  The results of these assays, along with kinetic analysis, 
revealed that ThnE and ThnM had unambiguous preferences for the natural substrates of 
CarB and CarA.  This key set of observations confirmed that all of the chemistry required 
for C-2 thioalkylation, C-5 epimerization, and C-2/C-3 desaturation must occur after 
formation of the β-lactam ring. 
To find the enzyme(s) responsible for C-5 epimerization in the absence of a CarC 
homologue, Micah Bodner and Ryan Phelan also investigated the function of the non-
heme iron oxygenases encoded in the thienamycin gene cluster, ThnG and ThnQ41.  Both 
25 
enzymes were tested individually against (5R) 2-N-acetyl-carbapenams in hopes that one 
or both would epimerize C-5 or desaturate the C-2/C-3 bond.  Where these substrates 
failed to provide enzymatic turnover, carbapenem substrates showed successful 
hydroxylation of the C-8 position when incubated with ThnQ and sulfoxidation and 
desaturation of the 2-alkylthio group was observed in assays with ThnG41.  Dual 
functionality of enzymes can never be ruled out; however it was clear at the time that 
ThnG and ThnQ were not involved in the synthesis of the (5S)-carbapenem core. 
 
Scheme 1.10:  A proposal of thienamycin biosynthesis based on confirmation of 
enzymatic substrates and products in combination with experiments highlighted in the 
literature up to 2011.  R = H or carbapenam/em, 
 
Thesis aims 
The goals of this thesis are to investigate further the steps of carbapenem 
biosynthesis.  Chapter 2 reports investigations of mutational analysis of a cis-
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carbapenem-producing gene cluster and the determination of a biosynthetic pathway is 
proposed based on the analysis of gene-disruption mutants.  Further synthetic and 
enzymatic analyses of cis-carbapenems and O-sulfonation reaction are explored in 
Chapter 3.  Investigations of sequential double methylation of C-2 thioalkyl carbapenems 
by ThnK are described in Chapter 4.  The inhibition of a L,D-transpeptidases (Ldts) in 
Mycobacterium tuberculosis by intact protein mass spectrometry is analyzed in Chapter 
5, and the resulting directed syntheses of penem antibiotics and success in the 
optimization of lead compounds, provided new penem anibiotics that are markedly 
effective against Mycobacteria and other pathogens that express Ldts is explored in 
Chapter 6..  In large measure, this work is based upon publications.  Chapters 2, 4, and 5 
mirror their respective publications on the MM 4550 gene cluster, ThnK enzymology, 
and in vitro inhibition of LdMt2 by carbapenems.  Chapter 6 is written in the format of a 
manuscript as its contents are expected to be ready for publication shortly after the 
submission of this thesis. 
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 Identification and Characterization of the Carbapenem MM 4550 and its Gene 
Cluster in Streptomyces argenteolus ATCC 11009 
 
It has been reported that 50-60% of the more than two million nosocomial 
infections in the USA each year are caused by antimicrobial-resistant bacteria1. β-lactam 
antibiotics are critically important as pharmaceutical agents to combat these bacterial 
pathogens.  Among these, carbapenems are the most potent subclass of these 
antibacterials due to their rapid penetration across bacterial cell membranes, high affinity 
to penicillin-binding proteins and resistance to a broad range of β-lactamases. With the 
rapid spread of multidrug resistance and abandoned anti-infective research and 
development programs in pharmaceutical companies, there are few antibiotics available 
for treatment and even fewer drugs in the antibiotic pipeline. 
To date, all currently used carbapenems such as imipenem and meropenem are 
manufactured by total synthesis, in part because fermentation efforts have failed to obtain 
commercially viable amounts of thienamycin and knowledge of their biosynthesis is far 
from complete. Therefore treatment of severe infections with carbapenems is very costly. 
An important role could be played by the development of semi-synthetic approaches to 
provide large quantities of carbapenems at reduced cost. 
The complex carbapenems are composed of a (5R)-carbapenem-3-carboxylic acid 
core that is commonly diversified by a sulfur-linked side chain at C-2 and an alkyl 
substituent at C-6.  The nature of these substituents, often highly oxidized, gives rise to 
approximately 50 known natural carbapenem products; the simplest and best understood 
of which is (5R)-carbapenem-3-carboxylic acid.  The biosynthesis of (5R)-carbapenem-3-
carboxylic acid (Figure 2.1) in Pectobacterium carotorovum has been discovered to be 
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exquisitely efficient requiring only three enzymes, CarA, CarB and CarC. CarB is a 
member of the crotonase superfamily and catalyzes the formation of (2S,5S)-
carboxymethylproline (CMP), the first committed intermediate in the pathway, from 
malonyl-CoA and L-pyrroline-5-carboxylate (L-P5C)1. CarA, carbapenam synthetase, 
cyclizes CMP to yield the (2S,5S)-carbapenam nucleus coupled to the hydrolysis of 
adenosine triphosphate (ATP)2. Finally, CarC, a non-heme iron α-ketoglutarate (α-KG)-
dependent oxygenase, catalyzes both epimerization at the C-5 bridgehead and C-2/C-3 
desaturation of the carbapenam to produce the final simple carbapenem3–5. 
 
Figure 2.1:  Representative carbapenems. 
The discovery of the gene cluster for thienamycin (Scheme 2.1) in Streptomyces 
cattleya led to the assignment of 23 genes (thnA-V), 21 of which are not present in the 
simple carbapenem gene cluster6. Biochemical analysis has shown that the activity of 
ThnE and ThnM mirror that of CarB and CarA, respectively, and are capable of 
producing the common bicyclic core. Additionally, ThnQ is involved in the 
hydroxylation of the C-6 side chain of PS-5 to produce N-acetyl thienamycin7–9. Efforts 
aimed at revealing the biosynthesis of the C-2 substituent have shown that ThnR, ThnH 
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and ThnT incrementally cleave CoA to 4-phosphopantetheine, pantetheine and 
cysteamine, respectively8,10. ThnF acts as an acetyltransferase to convert thienamycin to 
N-acetyl thienamycin.  In addition, ThnG is responsible for the further modification of 
the C-2 side chain as a desaturase and an oxygenase8. Gene inactivations have indicated 
that thnL, thnN, thnO, and thnP are absolutely necessary for the biosynthesis of 
thienamycin. However, reported mutational analyses give seemingly contradictory results 
as thienamycin production was still observed in thnG, thnR and thnT disruption mutants, 
suggesting that these genes are not required for thienamycin biosynthesis11. Finally, two 
pathway regulatory proteins, ThnI and CepU, positively regulate the expression of 10 
genes in the thienamycin cluster and the biosynthesis of cephamycin in S. cattleya, 
respectively12. 
These recent advances notwithstanding, many questions remain about the 
biosynthesis of complex carbapenems including how, and in what order, epimerization of 
the carbapenam bridgehead, introduction of the double bond at carbons C-2/C-3, 
incorporation of CoASH at C-2 and alkylation at C-6 occur.  Enzymatic analysis has 
demonstrated that the differences in the level of oxidation of the C-6 and C-2 side chains 
and C-6 stereochemistry give rise to many structural combinations13–18.  It remains 
unknown how these differences are genetically encoded to produce potent antibiotics, 
distinct from thienamycin.  Genetic differences across different species would explain 
these structural alterations. Apart from the silent gene cluster discovered in the S. 
flavogriseus genomic sequencing project, the thienamycin cluster in S. cattleya so far 
remains the only openly available gene cluster functionally associated with a specific 
complex carbapenem. Thus, exploration of the comparative genomics of the structurally 
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advanced carbapenems would not only give greater insight into the biosynthesis of these 
metabolites, but also provide an opportunity to apply combinatorial biosynthesis to 
generate new carbapenems with potentially improved properties. 
In the early 1980’s S. argenteolus ATCC 31589 was reported to be a producer of 
asparenomycin A (12), another potent carbapenem19,20.  In this chapter, we establish that 
MM 4550 rather than asparenomycins is the major carbapenem produced in a related 
strain of S. argenteolus ATCC 11009. In addition, we provide detailed information on the 
identification, bioinformatic analysis, and mutational analysis of the gene cluster 
responsible for the biosynthesis of MM 4550. 
 
Asparenomycins are not produced by S. argenteolus ATCC 11009 
Asparenomycin A, B and C (Scheme 2.1) were isolated from two Streptomyces 
strains, S. tokunonensis ATCC 31569 and S. argenteolus ATCC 3158920. However, a 
query of the ATCC and NRRL catalogs did not yield S. argenteolus ATCC 31589, but a 
different strain of S. argenteolus, ATCC 11009.  S. argenteolus ATCC 11009 was also 
reported to produce carbapenems and carbapenams such as an olivanic acid complex and 
17927 D15,20,21, but identifications have not been published22. We expected S. argenteolus 
ATCC 11009 to produce the asparenomycins as well, due to the similarity to the acquired 
strain with S. argenteolus ATCC 31589.  As the most direct route to confirming the 
produced carbapenem(s), the total synthesis of asparenomycin A and C was performed 
through the route shown in Scheme 2.1 in an attempt to simply compare retention time of 
the metabolite with our synthetic standards without isolation from the S. argenteolus 
medium. 
To synthesize asparenomycin A, the synthesis of Ona et al.23 was found to be reliable and 
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reproducible in both products formed and yields reported in the original publication.  Stirring 1,4 
pentadiene with chlorosulfonylisocyanate for three days in a sealed pressure tube yielded (±) 4-
allyl-2-azetidinone 1 in 61.9% yield after reductive workup of the azetidinone sulfate with 
sodium sulfite at neutral pH and at 0 °C.  Protection of the amide with tert-butyldimethylsilyl 
chloride (TBSCl) proceeded in quantitative yield to produce 2.  Trimethylsilyl (TMS) protected 
acetol was prepared from 2-hydroxyacetone and trimethylsilyl chloride in the presence of 
dimethylaminopyridine (DMAP) and triethylamine (TEA) in 80% yield after distillation.  Enolate 
addition of (±)-4-allylazetidin-2-one 1 to TMS acetol provided the alcohols 3a and 3b after acidic 
workup in a 2:1 ratio over two steps with a yield of 54%.  Two diastereomers were produced 
from each enantiomer, resulting in a total of four stereoisomers.  No 3,4-cis-compounds were 
detected by NMR spectroscopy, in agreement with the literature findings by Ona and 
coworkers23.  It was important at this stage to separate the diastereomers by silica gel 
chromatography, so that the separate pathways may converge in the later steps of the synthesis. 
The resulting 1,2-diols 3a and 3b were protected as the 1,3-dioxolidinone with 0.4 
equivalents triphosgene and 2.2 equivalents pyridine and without purification the TBS 
groups were removed with TBAF and acetic acid to yield the azetidinones 4a and 4b in 
64% yield after silica gel chromatography.  4a and 4b were further purified by 
recrystallized from toluene/ether. 
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Scheme 2.1: Synthesis of (±) Asparenomycins A and C23. 
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Ozonolysis of the 4-allyl group of 4a or 4b in dichloromethane and methanol proceeded 
cleanly at -78 °C and without purification the ozonide was reduced to the aldehyde and 
immediately oxidized to the carboxylic acid under Pinnick conditions24.  Ona and coworkers used 
potassium dichromate in sulfuric acid (Jones reagent) in the original publications23, however it 
was found that the product acid 5a and 5b was difficult to purify from contaminating chromate 
salts.  Pinnick conditions were chosen due to the mild nature of the reaction and ease of 
purification by acidic workup and subsequent extraction.  The products were crystallized from 
EtOAc/Ether to give the carboxylic acids 5a and 5b in 47% yield. 
1,1-carbonyldiimidazole was used to activate the carboxylic acid for nucleophilic 
addition of the malonic acid mono-4-methoxybenzyl ester monomagnesium salt α-carbon, prior 
to spontaneous decarboxylation.  Diazotization of the resulting β-keto esters 6a and 6b with 
mesyl azide afforded the α-diazo-β-keto esters 7a and 7b, thus priming the side chain for carbene 
addition into the amide N-H bond in the presence of catalytic rhodium (II) acetate.  
Diphenylchlorophosphate (DPCP) addition to the 2-oxopenams 8a and 8b activated the ring 
system for addition of silver-(E)-2-acetamido-1-ethenethiolate and spontaneous elimination of the 
phosphate produced the carbapenems 9a and 9b. 
DBU was used to deprotonate the C-6 hydrogen for the elimination of the cyclic 
carbonates 9a and 9b to evolve CO2 in the presence of bis-silylacetamide (BSA).  BSA wass 
necessary to cap the free alcohol with TMS during the course of the reaction, so intermolecular 
polymerization of the produced alkoxide did not hamper yields, as was evidenced in literature 
reports25.  Choice of solvent, dichloromethane or acetonitrile, dictates the mechanism of 
elimination, E2 or E1cb respectively, such that the required E isomer is made26.  The separated 
diastereomers, 3a and 3b, produced earlier in the pathway converge to the enantiomers 10. 
As hydrogenolysis might negatively impact the yield of deprotection of the benzyl ester 
in the presence of the double bond on the C-2-thiol side chain, the 4-methoxybenzylester was 
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used to allow deprotection methods that would not compete with other functional groups in the 
molecule.  AlCl3-anisole provided the appropriate Lewis-acidic conditions for cleavage of the 
PMB ester in non-acidic non-reducing conditions as established by the work of Ohtani et al.27.  
Tsuji and coworkers28 designed this protection / deprotection methodology for use in β-lactams 
chemistry, proposing that the strong affinity for aluminum halides for oxygen would draw 
electron density away from the ester bond, thus allowing the formation of a benzyl cation.  It just 
so happens that the p-methoxybenzyl system is sufficiently electron rich to stabilize a formal 
positive charge at the benzyl position, affording good yields while retaining high selectivity.  
Desalting was achieved through elution from Diaion® HP-20 polystyrene resin and lyophilization 
afforded (±) asparenomycin C 11 from the cyclic carbonate as a white powder in 15% yield from 
9a.  Intermediate 10 was not purified so no yield obtained, but crude mass suggests that compared 
to the elimination step, AlCl3-deprotection was the more efficient of the two reactions. 
It was possible to convert this antibiotic to asparenomycin A 12 simply by the addition of 
1 equivalent of m-chloroperbenzoic acid (mCPBA) in water. Reverse-phase preparatory HPLC 
was necessary to purify the resulting sulfoxide diastereomers.  A size-exclusion desalting column 
was used to remove excess salts to provide asparenomycin A 12 as the (R)-sulfoxide in 20% yield 
from asparenomycin C 11.  Though the yield of 20% seems very low, it is common to lose a great 
deal (>50%) of compound by HPLC purification.  Investigations on suspect compound recovery 




Figure 2.2: Elution of Asparenomycin A at 6.4 min as a synthetic standard (blue) and the 
fermentation product of S. tokunonensis (red) 
 
Co-injection of the fermentation medium of S. argenteolus and either asparenomycin A 
or C showed no overlap of secondary metabolites with our synthetic standards (data not shown).  
As a proof of concept, the fermentation broth of S. tokunonensis was analyzed for asparenomycin 
production, so as to validate that this experiment could determine the presence of asparenomycins 
in the culture medium.  S. tokunonensis, a known asparenomycin producer, was found to produce 
asparenomycin A in good titers, as was evidenced by overlap of a peak in the HPLC 
chromatogram with our synthetic standard, shown in Figure 2.2  The peak at 6.4 minutes, when 
isolated, produced a zone of inhibition on E. coli ESS plates indicating the presence of antibiotic. 
It was concluded that asparenomycin A is not the major carbapenem product of S. 
argenteolus, so it was decided to formally isolate the major carbapenem produced from a large 
scale fermentation and determine its structure.  The following experiments were carried out in 
close collaboration with Dr. Rongfeng Li.  Work not done either by either myself alone or done 




























Identification of the carbapenems produced in S. argenteolus ATCC 11009 
As the first step in our investigation, we conducted small-scale fermentations of S. 
argenteolus ATCC 11009 in OMYM and ISP4+ media, which showed antibiotic activity 
against the β-lactam super-sensitive E. coli ESS and inhibition of the β-lactamase in 
Klebsiella pneumoniae subsp. pneumoniae ATCC 29665 (data not shown). Bioassay of 
the fractions collected from HPLC by direct injection of supernatant broth indicated that 
the active product(s) resided in only one narrow region of the chromatogram (data not 
shown).  
Our initial efforts to identify the β-lactam product failed owing to the low titer 
from the wild-type S. argenteolus ATCC 11009. To improve production, Dr. Rongfeng 
Li took a genetic engineering approach by the overexpression of three positive regulatory 
genes, cmmI, cmm22 and cmm23 (see below). The expression of each gene was 
individually controlled by an ermE*p constitutive promoter and the final expression 
construct containing all three genes, pMS82/cmmI-22-23 was integrated into the φBT1 
site of the genome. Bioassay of his engineered strain against E. coli ESS showed an 
enlarged zone of inhibition, and HPLC analysis revealed that this altered strain still 
produced the same product as the wild-type (Figure 2.5), but in a nearly 4-fold improved 
yield based on comparison of peak areas for the active fraction. In addition, the maximal 
production in the engineered strain was at 48 h and 56 h in 50-mL and 1.3-L scale 
fermentations, respectively, compared to the wild-type strain at 72 h and 80 h. 
S. argenteolus cmmI-22-23 was used for characterization of the carbapenem 
produced.  A large-scale fed-batch fermentation procedure was developed using a 
modified minimal medium (ISP4++) to give maximal production that also minimized 
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impurities during product purification. To make large-scale growth applicable to 
laboratory purification techniques, a long-chain quaternary ammonium salt was used as a 
phase transfer catalyst to extract negatively charged carboxylates into a small volume of 
organic solvent.  Back-extraction of the resulting organic mixture with aqueous 
potassium iodide allowed recovery of the antibiotic into a volume 100 times more 
concentrated than the original fermentation filtrate. It was found that a 5% solution of 
Aliquat 336 in dichloromethane was highly effective in extracting the antibiotic where 
only two 300 mL washes were required to extract almost all of the antibiotic from 13 L of 
fermentation filtrate as monitored by E. coli ESS bioassay.  The concentrated KI solution 
was then lyophilized, and the crude salt obtained was further purified by anion exchange 
chromatography over Dowex resin.  Anion exchange chromatography was critical at this 
stage to remove the majority of impurities, salts, and residual Aliquat. Most importantly, 
this procedure resulted in highly concentrated fractions for further purification and 
analysis by HPLC. 
Reverse-phase (C18) HPLC analysis of the active fractions resolved only one 
bioactive peak, as determined by bioassay on E. coli ESS plates, with a retention time of 
16.3 min (Figure 2.5). Co-injection with a synthetic asparenomycin A standard showed a 
different retention time and UV spectrum, again supporting that the asparenomycins 
originally reported from S. argenteolus ATCC 31589 are not produced in S. argenteolus 
ATCC 1100914,20. Reaction with hydroxylamine resulted in the loss of that peak, 
consistent with the presence of a β-lactam in the active product. Additional bioactive 
material was collected by HPLC for further characterization. 
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The UV spectrum showed the product had not only a typical carbapenem 
absorbance signature at 288 nm but also an additional absorbance band was noted at 245 
nm.  A search of available UV data across all natural carbapenems resulted in only one 
potential compound that matched the spectrum of the isolated antibiotic.  1H NMR 
spectroscopy identified the compound as MM 4550, as both chemical shifts and coupling 
constants were consistent with the published characterization of this compound29,30 as is 
referenced in the experimental.  Furthermore, two-dimensional 1H-1H COSY, ROESY, 
and TOCSY experiments confirmed the assignments of all protons made in the original 
publication31. Electrospray ionization mass spectrometry provided accurate mass of 
407.0226 (±0.5 ppm; calculated 407.0224) for the anion of MM 4550.  
 
Cloning of the MM 4550 biosynthetic gene cluster 
Dr. Li did all of the cloning, cosmid library generation, and sequence analysis 
described in this section.  Sequence analysis suggested and biochemical studies 
confirmed that ThnE and ThnM in the thienamycin biosynthetic pathway mirror the 
chemistry of CarB and CarA in the simple carbapenem pathway7,8.   Alignment of CarA 
(P. carotovorum), β-LS (S. clavuligerus), β-LS3 (S. antibioticus), CpmA (P. 
luminescens), ThnM (S. cattleya), and several Asn-B (asparagine synthetase) revealed 
two motifs (M1 and M2) highly conserved in the β-lactam forming enzymes but either 
absent or present at distinctly lower homology in asparagine synthetases (Asn-B). Using 
the CODEHOP program (http://blocks.fhcrc.org/codehop.html)30, two degenerate primers 
were designed, thnM-DEG-5 and thnM-DEG-3 (Figure 2.2), to these regions. A specific 
PCR product with the expected size of ~350 bp was obtained from S. argenteolus gDNA. 
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This PCR product showed an incomplete open reading frame (ORF) encoding a truncated 
protein of 108 amino acids with 74% identity to ThnM of S. cattleya, and 32% identity to 
CarA of P. carotovorum. A BLASTP alignment also showed that the two highly 
conserved motifs, M1 and M2, were present in the partial protein. These results strongly 
suggested that a partial thnM orthologous gene had been cloned from S. argenteolus. 
A)
AsnB1 318 YVKVILSGEGA 329 - 100aa - 429 EFAQGCASSTVLE 441
AsnB2 318 YVKVILTGEGA 329 - 100aa - 429 QFDEGSGTVDLLV 441
AsnB3 318 YVKVVLSGEGA 329 – 100aa – 429 EFAQGCASSGVLE 441
AsnB4 353 GPLRILTGYGA 363 –  96aa – 459 GIHEGSGTTSAWT 471
           Motif M1                       Motif M2
BLS3  330 SGRRILTGYGA 340 – 96 aa - 436 GVHEGSGVTAAFT 448
BLS   339 PERRILTGYGA 349 – 96 aa - 445 GVHEGSGTTSSFS 457
CarA  336 QVSCMLTGYGS 346 – 99 aa - 445 GIHEGSSVNQAFA 457
CpmA  333 KVNSLITGYGS 343 – 99 aa - 442 GIHEGSSVNKSFA 454
ThnM  295 ARQVMLSGYGA 305 – 96 aa - 401 GIHEGTAMSRMFA 413
PluM  313 DRQVLLSGYGA 323 – 96 aa - 419 GIHEGTAMSRMFA 430
              :::***:                   *:***:. .  *:  
B)         
Primers:      
 thnM-DEG-5: 5’-GCGCCAGTGCATGCTGwsnggntaygg-3’ 
 thnM-DEG-3: 5’-CATGGCGGTGCCCtcrtgdatncc-3’  
Figure 2.3: (a) The two conserved motifs in the β-lactam ring-closing enzymes. The 
names and access numbers are as follows: BLS3, Streptomyces antibioticus 
(AFH74298.1); BLS, Streptomyces clavuligerus ATCC 27064 (ZP_05002824.1); CarA, 
Pectobacterium carotovorum subsp. brasiliensis PBR1692 (ZP_03825848.1); CpmA:  
Photorhabdus luminescens subsp. laumondii TTO1 (NP_927548.1); ThnM, Streptomyces 
cattleya NRRL 8057 (YP_004920124.1); PluM, Streptomyces sulfonofaciens NRRL 
16438 (unpublished); AsnB1, Nodularia spumigena CCY9414 (YP_003135129.1); 
AsnB2, Cyanothece sp. CCY0110 (ZP_01729766.1); AsnB3, Leptolyngbya sp. PCC 
7375 (ZP_18904938.1). BLS: β-lactam synthetase; AsnB: asparagine synthetase. The 
beginning and ending numbers indicate the position of amino acids in the proteins, and 
the numbers between the motifs indicate the separation in amino acid residues. (b) 
Primers designed for the M1 and M2 motifs according to the CODEHOP program. N: 
A/T/G/C; Y: C/T; M: A/C; R: A/G. 
 
A cosmid gDNA library of S. argenteulos ATCC 11009 was constructed and 
screened using the ~350-bp gene fragment as a probe.  Fourteen positive clones were 
obtained from a 2000 clone library. The sequencing analysis revealed that the T3 and T7 
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ends of the insert in cosmid 5D1 and 12B9 encoded a MarR-family transcriptional 
regulator and an AsnC-family transcriptional regulator, respectively. These proteins are 
not encoded by genes in the thienamycin gene cluster, indicating that cosmids 5D1 and 
12B9 likely contained a whole carbapenem gene cluster.  Cosmid 5D1 was chosen for 
further investigation. 
Cosmid 5D1 was sequenced in its entirety. Five gaps between five contigs were 
bridged by PCR amplification and Sanger sequencing to give the full, circular cosmid. 
Overall, we ascertained that 5D1 contained the putative MM 4550 biosynthetic genes, 
which spanned almost 43.8 kb of the S. argenteolus genome. Computer-assisted analysis 
of the sequence revealed 31 complete open reading frames (ORFs) (Figure 2.4). 
 
Figure 2.4: Gene organization of the MM 4550 and the thienamycin gene clusters in S. 
argenteolus ATCC 11009 (top) and S. cattleya NRRL8057 (below). The direction of 




Figure 2.5: (a) HPLC analysis of S. argenteolus extracts. 1. Wild-type S. argenteolus 
ATCC 11009; 2. S. argenteolus cmmI-22-23; 3. Wild-type S. argenteolus ATCC 11009 
spiked with isolated peak from S. argenteolus cmmI-22-23; 4. argE8 disruption mutant.  
Peaks (absorbance in arbitrary units) corresponding to MM4550 are indicated by a heavy 
dot (●). (b) Bioassay of the 16.3-min HPLC fractions of S. argenteolus cmmI-22-23 (left) 
and argE8 (right). 
 
 
In order to confirm the cloned gene cluster was responsible for the biosynthesis of 
MM 4550, cmmE, whose gene product showed 76% and 40% identity to ThnE and CarB, 
respectively, was inactivated by a PCR targeting strategy with an oriT-aac(3)IV cassette 
to generate a gene replacing mutant argE8. The intended disruption of cmmE was 
confirmed by Southern hybridization with cmmE and oriT-aac(3)IV probes. As expected, 
when PmlI-digested gDNA was tested with the cmmE probe, a 1.65-kb positive fragment 
was observed in the wild-type but not the argE8 mutant gDNAs. Correspondingly this 
fragment was replaced with a 2.2-kb band in the argE8 mutant when hybridized with the 
oriT-aac(3)IV probe, but this band was missing in the wild-type gDNA (Figure 2.5). 
Bioassay on E. coli ESS plates showed that the argE8 mutant failed to produce 
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antibacterial products when fermented in ISP4+ medium (Table 2.2, Figure 2.4B). I 
performed HPLC analysis of the extract from the argE8 fermentation medium to show 
that the peak corresponding to MM 4550 in the wild-type S. argenteolus was absent 
(Figure 2.4A). These results strongly suggested that the gene cluster cloned in cosmid 
5D1 is responsible for the biosynthesis of MM 4550 in S. argenteolus.    
 
Figure 2.6: (a) The organization of cmmSu, cmmE, and cmmF in cosmid 5D1 and the 
construction of the argE8 disruption mutant. The restriction maps of the wild-type cmmE 
gene and its disrupted copy in the mutant are shown. (b) Southern analysis of the wild-
type and the argE8 (∆E8) mutant, showing the positive hybridizing bands to the cmmE 
and the oriT-aac(3)IV probes, respectively.  
 
The DNA sequences of MM 4550 gene cluster have been deposited in the NCBI 
nucleotide sequence database with accession number KF042303. 
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Sequence analysis of the MM 4550 biosynthetic gene cluster 
Dr. Rongfeng Li also examined the sequences and searched for the putative 
functions of the deduced gene products summarized in Table 1.  The overall architecture 
and some gene products of the MM 4550 gene cluster are highly similar to a cryptic 
cluster in S. flavogriseus ATCC 33331 identified by gene scanning32. However, because 
no product is known from this cluster and none of the enzymes encoded by it have been 
characterized, analysis of the MM 4550 gene cluster focused principally on comparison 
with the thienamycin gene cluster.  




Proposed function Sequence similarity 
(identity/positive) 
Identity/ 
positive to  
ATCC 
33331(%) 
Orf1 238 Unknown No similar sequences --/--a 
Orf2 475 arabinofuranosidase SMCF_639, Streptomyces 
coelicoflavus ZG0656 (89/92) 
--/-- 
CmmSu 353 sulfotransferase Sfla_0165, S. flavogriseus 
ATCC 33331 (87/92) 
87/92 
CmmE 263 carboxymethylproline 
synthase 
ThnE, S. cattleya NRRL 8057 
(69/80) 
93/96 
CmmF 338 N-acetyltransferase ThnF, S. cattleya NRRL 8057 
(58/66) 
86/89 
CmmG 263 oxidoreductase ThnG, S. cattleya NRRL 8057 
(70/80) 
87/92 
CmmH 229 HAD-superfamily 
hydrolase 
ThnH, S. cattleya NRRL 8057 
(57/69) 
82/87 
CmmI 466 LysR family 
transcriptional 
regulator 
ThnI, S. cattleya NRRL 8057 
(51/64) 
83/87 
CmmJ 487 Transporter protein ThnJ, S. cattleya NRRL 8057 
(56/68) 
89/93 
CmmK 680 radical SAM 
methyltransferase 




CmmL 394 radical SAM 
methyltransferase 
ThnL, S. cattleya NRRL 8057 
(67/72) 
82/86 
CmmM 459 Carbapenam 
synthetase 
ThnM, S. cattleya NRRL 
8057 (64/76) 
86/91 
CmmN 369 AFD class I 
superfamily protein, 
acyl-CoA synthase 
ThnN, S. cattleya NRRL 8057 
(86/91) 
95/97 
CmmO 467 aldehyde 
dehydrogenase 
ThnO, S. cattleya NRRL 8057 
(75/82) 
90/94 
CmmP 482 radical SAM 
methyltransferase 
ThnP, S. cattleya NRRL 8057 
(83/91) 
97/98 
CmmQ 259 putative oxigenase ThnQ, S. cattleya NRRL 8057 
(72/81) 
93/94 
Cmm17 292 enoyl-CoA hydratase Kyg_13766, Acidovorax sp. 
NO-1 (34/46) 
89/93 
CmmR 228 nudix hydrolase ThnR, S. cattleya NRRL 8057 
(55/66) 
75/82 
CmmT 388 hydrolase ThnT, S. cattleya NRRL 8057 
(69/75) 
87/90 
CmmS 334 β-lactamase Orf11, S. clavuligerus ATCC 
27064 (63/71) 
80/87 
CmmPah 298 proclavaminate 
amidino hydrolase 
PAH, S. clavuligerus ATCC 
27064 (52/65) 
86/90 
Cmm22 227 two-component 
system response 
regulator 
SPW_1836, Streptomyces sp. 
W007 (84/90) 
--/-- 
Cmm23 506 two-component 
system sensor kinase 
Sacte_5700, Streptomyces sp. 
SirexAA-E (89/93) 
--/-- 
Cmm24 217 unknown Sacte_5699, Streptomyces sp. 
SirexAA-E (74/79) 
--/-- 
Orf25 1094 putative peptidase Sacte_5698, Streptomyces sp. 
SirexAA-E (81/88) 
--/-- 
Orf26 1029 putative glycosyl 
hydrolase 
Szn_17732, Streptomyces 
zinciresistens K42 (78/88) 
--/-- 
Orf27 294 putative RNA 
polymerase sigma 
factor 
Sfla_6134, S. flavogriseus 
ATCC 33331 (88/93) 
--/-- 
Orf28 441 putative 
serine/threonine 
phosphatase 
Sfla_6135, S. flavogriseus 
ATCC 33331 (85/91) 
--/-- 
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Orf29 164 putative MarR family 
transcriptional 
regulator 
S.fla_6136, S.  flavogriseus 
ATCC 33331 (93/95) 
--/-- 
a. --/--: not in the cluster. 
 
As shown in Figure 2.2, among the 31 complete ORFs present in the insert of 
5D1, 17 clear homologues are also present in the thienamycin gene cluster7. Genes 
cmmE-Q show the same organization as thnE-Q in the thienamycin gene cluster. Notable 
genes cmmR, cmmS and cmmT are also shared between the two clusters. However, in the 
MM 4550 gene cluster, they are organized as cmmR-cmmT-cmmS with cmmR and cmmS 
transcribed in the opposite orientation to cmmT. A new gene, cmm17, is inserted between 
cmmQ and cmmR in the MM 4550 gene cluster.  In addition to cmm17, four more new 
genes, cmmSu, cmmPah. cmm22 and cmm23 are present in the MM 4550 cluster with 
cmmSu located upstream of cmmE at one end and the other three genes are downstream 
of cmmS at the other end of the cluster. Bioinformatic analysis indicated that genes 
upstream of cmmSu and downstream of cmm24 encode proteins that are not related to the 
biosynthesis of carbapenems or are not present in known carbapenem gene clusters 
(Table 2.1). Finally, thnA-D and thnV, whose roles in the thienamycin biosynthetic 
pathway have not been determined, and cphU, which encodes a SARP-like regulator for 
cephamycin biosynthesis12, are all absent from the MM 4550 gene cluster.  
It has been reported that thienamycin and (5R)-carbapenem-3-carboxylic acid 
share the first two steps in their biosynthetic pathways to make the carbapenam bicyclic 
core. The orthologous genes in the MM 4550 cluster encode proteins sharing 69%, 37% 
and 64%, 22% identity to ThnE, CarB and ThnM, CarA, respectively, and active site 
residues are also conserved, indicating CmmE and CmmM catalyze the same reactions in 
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MM 4550 biosynthesis2,7,8,11,33. 
The three putative radical-SAM enzymes encoded by cmmK, cmmL and cmmP are 
also highly conserved in the MM 4550 gene cluster and share 79%, 67%, and 83% amino 
acid identities to ThnK, ThnL and ThnP, respectively.  CmmQ shows sequence 
homology to ThnQ that has been shown to be a Fe(II)/α-KG-dependent oxygenase 
responsible for the hydroxylation of the C-6 ethyl side chain of thienamycin9. To explain 
the difference between the C-8 sulfate of MM 4550 and C-8 hydroxyl of thienamycin, a 
BLASTP search revealed that CmmSu has 38% identity and 52% positive to the putative 
sulfotransferase in S. blastmyceticus34. A conserved 5’-phosphosulfate-binding sequence 
(5’-PSB), 17RCGSTM23, was located in a strand-loop-helix (PSB-loop) motif. A second 
motif, 89GRYAAGEVPAISL101, similar to the conserved 3’-phosphate binding sites in 
sulfotransferases is also present in CmmSu35–37. These conserved motifs strongly suggest 
that CmmSu acts as a sulfotransferase required for sulfonation of the C-6 side chain in 
MM 4550. Together, we propose that some or all of cmmK, cmmL, cmmP, cmmQ and 
cmmSu are involved in the biosynthesis of the C-6 side chain in MM 4550.  
A set of genes were designated as cmmR, cmmH, cmmT, cmmF and cmmG, whose 
products show high similarity to ThnR, ThnH, ThnT, ThnF and ThnG in the thienamycin 
biosynthetic pathway. Their roles in the biosynthesis of the C-2 cysteaminyl side chain in 
thienamycin have been demonstrated through stepwise cleavage of CoA by ThnR, ThnH 
and ThnT11. Furthermore, the acetyltransferase ThnF, is responsible for the N-acetylation 
of the cysteaminyl side chain from acetyl-CoA38. Finally, CmmG shares 70% identity 
with ThnG in the thienamycin biosynthetic pathway. In vitro characterization of ThnG 
has shown that it catalyzes the desaturation and sulfoxidation of the N-acetyl-2-
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cysteaminyl side chain of N-acetyl-thienamycin to form the sulfoxide of PS-78. 
Consistent with its structure, the C-2 side chain of MM 4550 is likely to be processed by 
these five enzymes in the order of CmmR, CmmH, CmmT, CmmF and CmmG. 
cmmI encodes a putative LysR-family positive regulator, which shares 50% and 
26% identities to ThnI and ClaR in the biosynthetic pathways of thienamycin and 
clavulanic acid, respectively12,39,40. Two new genes, cmm22 and cmm23, located at the 
right end of the gene cluster encode proteins homologous to the two-component 
regulatory systems in a wide range of microorganisms. The amino acid sequence of 
Cmm22 (227 aa) shows end-to-end similarity to response regulators, including an 
aspartate residue (Asp52) typically phosphorylated inside the N-terminal phosphorylation 
domain, a C-terminal DNA binding domain, and several other key characteristic residues 
(Asp9, Asp10, Thr80 and His101)41–43. As observed in most two-component regulatory 
systems, cmm23 encodes a protein (506 aa) with full-length homology to sensory 
histidine kinases and is located immediately downstream of cmm22.  Cmm23 contains 
three conserved domains including the H-box (269HELRTPL275) (His269 is a putative 
phosphorylation site), the N-box (376NLVGNA381), and the G-box (405VRDSGPGI412) 35. 
Structural prediction using TopPred 0.01 (http://mobyle.pasteur.fr/cgi-
bin/portal.py?#forms::toppred)44 identified three possible transmembrane domains in 
Cmm23: domain I (residues 14-34, score 1.96), II (147-167, score 1.26) and III (181-201, 
score 1.26).  The sensor domain is generally located at the N-terminus in most histidine 
kinases; therefore, domain I is likely the sensor domain of Cmm23. The organization and 
likely properties of Cmm22 and Cmm23 suggested that they belong to the OmpR family 
of two-component response regulators42. 
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Two genes, cmm17 and cmmPah, absent in the thienamycin gene cluster were 
also identified. cmm17 is located directly downstream of and in the same orientation as 
cmmQ in the gene cluster and encodes a 292-amino acid protein. BLASTP analysis 
showed Cmm17 has appreciably high similarity (35-38% identity and 50-55% similarity) 
to enoyl-CoA hydratases from a number of microorganisms. Cmm17 possesses most 
residues important for substrate binding and catalysis including Glu128. However, a His148 
residue is present instead of the Glu residue that is typically conserved in most enoyl-
CoA hydratases33,45. cmmPah is located between cmmT and cmmS and is transcribed in 
the opposite direction to cmmT and cmmS. Its gene product comprises 298 amino acids 
and belongs to the arginase-like/histone-like hydrolase superfamily46. A BLASTP search 
showed that CmmPah has significant similarity to agmatinases, a subgroup of the 
arginase superfamily and a key enzyme in an alternative metabolic pathway of arginine in 
microorganisms and plants47. The highest homology (46-52% identity and 60-67% 
similarity) is to proclavaminate amidino hydrolase (PAH), an enzyme in the clavulanic 
acid and 5S clavam biosynthetic pathways from S. clavuligerus and S. antibioticus48,49. 
However, alignment of CmmPah with three PAH enzymes from S. clavuligerus and S. 
antibioticus and two arginases from A. flavithermus and S. viridis showed that only one 
of the six Mn2+-binding residues (Asp222) is conserved in CmmPah.  Only one of the three 
guanidino binding residues (Thr232) and one of the four α-amino acid binding residues 
(Gly147) conserved in arginases and PAHs is present in CmmPah50. The Gly-Gly-Asp-
His-Ser motif conserved in all arginases is changed to 116Gly-Gly-Gly-Arg-Ser120 in 
CmmPah. Finally, secondary structure prediction (http://bioinf.cs.ucl.ac.uk/psipred/) 
showed that the N-terminal secondary structure of CmmPah is similar to the PAHs and 
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arginases, but the C-terminal region is different50.  
 
Mutational analysis of genes in the MM 4550 gene cluster 
To better understand the role of each individual gene in the biosynthesis of MM 
4550, Dr. Li generated gene-replacing mutants for twenty genes in the proposed 
biosynthetic gene cluster using λ-RED-mediated PCR mutagenesis51. Each targeted gene 
was replaced with a FRT-oriT-aac(3)IV-FRT cassette in its resultant mutant. Mutants 
derived from double crossover events with the targeted genes, and their disrupted copies 
on 5D1 were selected according to their apramycin-resistant/ kanamycin-sensitive (AmR 
/KmS) phenotype. To confirm the genotype of the mutants, gDNA was digested with 
restriction enzymes and hybridized with a oriT-acc(3)IV probe.  As expected, the gDNA 
of wild-type S. argenteolus did not hybridize to the probe, but positive hybridization was 
observed from all tested mutants and the size of each resultant band was as predicted by 
restriction analysis. The digested gDNA of each mutant was also hybridized against the 
gene-specific probe. No hybridization was observed from any potential mutant (data not 
shown), confirming that targeted gene replacement had occurred in each case. One 
mutant in each disruption of a specific gene was chosen for further characterization.  
Table 2.2: Analysis of the disruption mutants 









argSu13 + - + 
argE8 - - - 
argF7 - - - 
argG5 + + + 
argH8 + + + 
argJ4 - - - 
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argK11 - - - 
argL2 - - - 
argM7 - - - 
argN7 - - - 
argO2 - - - 
argP4 - - - 
argQ4 + - + 
arg17-4 - - + 
argR8 - - - 
argT3 - - - 
argS6 + + + 
argPah9 - - - 
arg22-6 - - - 
arg24-3 + + + 
WT + + + 
 
Together, we characterized all disruption mutants by fermentation in ISP4+ 
medium and analyzed for antibacterial activity on E. coli ESS or β-lactamase induction 
on B. licheniformis using nitrocefin as indicator52.  We observed that, in addition to 
antibiotic activity against E. coli ESS, MM 4550 also exhibits moderate β-lactamase-
inducing activity in B. licheniformis.  I further analyzed bioactive intermediates in 
disruption mutants by UPLC-MS (Table 2.3). 
As summarized in Table 2, bioassay on E. coli ESS showed that disruption of 
cmmE and cmmM completely eliminated production of MM 4550 during 7-day 
fermentation. nitrocefin assays showed that β-lactamase induction was only at 
background levels compared with the wild-type, consistent with no carbapenem(s) being 
produced in these mutants. Moreover, HPLC analysis confirmed that the peak 
corresponding to MM 4550 was completely absent in the argE8 mutant (Figure 2.3). 
Similar results were also obtained from argK11, argL2 and argP4 mutants, suggesting 
that these enzymes are also necessary for biosynthesis (Table 2.2). Bioassay against E. 
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coli ESS showed that the disruption mutant of cmmQ, argQ4, consistently produced a 
bioactive product during its fermentation, but in reduced amount or potency in 
comparison to the wild-type. The nitrocefin assay showed that argQ4 still maintains β-
lactamase induction activity, but loses detectable antibacterial activity against B. 
licheniformis (Table 2.2). The active fraction of extracted fermentation broth shared both 
the same retention time and mass with synthetic PS-5, confirming that PS-5 is 
accumulated in argQ4 (Table 2.3)9. BLASTP analysis suggested that CmmSu is the most 
likely candidate in the gene cluster to catalyze C-6 sulfonation to MM 4550. 
Interestingly, the disruption mutant of cmmSu, argSu13, still produced antibacterial 
products. However, unlike the wild-type S. argenteolus, the supernatant of the argSu3 
only showed β-lactamase induction activity rather than antibacterial activity on B. 
licheniformis, indicating that the product is likely not MM 4550. UPLC-MS analysis of 
the bioactive material in argSu13 revealed a mass for the non-sulfonated derivative of 
MM4550 (Table 2.3). 
Mixed results were obtained from genes potentially involved in the biosynthesis 
of the C-2 side chain. Mutants argR8, argT3 and argF7, disrupted at cmmR, cmmT and 
cmmF, respectively, were unable to produce MM 4550 at any time point during the 
fermentation, while the cmmH and cmmG mutants, argH8 and argG5, still produced 
bioactive products as indicated by bioassay on E. coli ESS (Table 2.2). The nitrocefin 
assay showed that both the argG5 and argH8 mutants had similar antibacterial and β-
lactamase induction activities as the wild type. UPLC-MS analysis showed the active 
intermediate in argG5 has the same mass as MM 17880 (Table 2.3). These results 




Dr. Li disrupted gene cmm22 to investigate if the two-component response 
regulators are involved in the MM 4550 biosynthesis. Both antibacterial and β-lactamase 
induction activities from the disruption mutant, arg22-6, were negative, suggesting that 
the two-component regulators encoded by cmm22/23 are essential for the biosynthesis of 
MM 4550 (Table 2.2). Thus, the biosynthesis of MM 4550 is regulated by at least two 
regulatory mechanisms; LysR-type transcription activation and the two-component 
response system, in S. argenteolus6,12.  
Dr. Li also studied the involvement of two new genes, cmm17 and cmmPah, in 
the biosynthesis of MM 4550 through gene inactivation. Disruption of cmm17 generated 
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a mutant (arg17-4) that was unable to produce any metabolites active against E. coli ESS 
and B. licheniformis. However, the fermentation supernatant showed strong β-lactamase 
induction activity as shown by the nitrocefin assay, indicating a β-lactam ring-containing 
intermediate accumulated in the mutant.  On the other hand, bioassays and β-lactamase 
induction assay showed that the cmmPah disruption mutant (argPah9) failed to produce 
metabolites positive against E. coli ESS and B. licheniformis, or induce β-lactamase 
expression. While the role of CmmPah in the biosynthesis is unknown, extensive mass 
spectroscopic analyses were unable to detect intermediates in the mutants. 
Notwithstanding, the results demonstrated that these two new genes are essential for the 
biosynthesis of MM 4550 (Table 2.2). Finally, analysis of CFEs of mutants arg17-4 and 
argPah9 showed that they displayed similar antibacterial and β-lactamase induction 
activities as their fermentation supernatants (data not shown). 
Disruption of cmm24 by Dr. Li resulted in a mutant with the same phenotype of 
antibacterial and β-lactamase induction activities as the wild-type S. argenteolus. 
Combined with the BLASTP analysis (Table 1), cmm24 may not be involved in the 
biosynthesis of MM 4550 and likely to be the 3’ boundary of the gene cluster. The ORF 
analysis also showed that the intergenic region upstream of cmmSu is nearly 1 kb and the 
gene (orf4) upstream of cmmSu encodes a protein similar to sugar metabolism that is 
clearly unrelated to carbapenem biosynthesis (Table 2.1). Thus, we propose that the MM 
4550 gene cluster harbors 21 genes involved in its biosynthesis, resistance and regulation 





Olivanic acids, including MM 4550, MM 13902 and MM 17880, were originally 
identified from S. olivaceus ATCC 31126 and S. olivaceus ATCC 21379. Although it has 
been mentioned that olivanic acids are also produced by other Streptomyces strains, 
including S. argenteolus ATCC 11009, no further information has been reported15,31,53. 
By combining genetic engineering approaches with modified extraction protocols and 
structural analysis, we have demonstrated, for the first time, that MM 4550 is the major 
carbapenem produced by S. argenteolus ATCC 11009. This finding contrasts with the 
two S. olivaceus strains in which three compounds of the olivanic acid complex are 
produced in similar titers31. NMR and UV spectroscopy, and mass spectrometry support 
the structure of the final product in S. argenteolus as MM 4550.  
The MM 4550 gene cluster is only the second gene cluster determined to be 
involved in the biosynthesis of a complex carbapenem that has been characterized. In 
comparison with thienamycin, MM 4550 is more highly functionalized, with a sulfate at 
the C-8 hydroxyl as well as an oxidatively modified C-2 side chain.  The syn relationship 
across the C-5/C-6 bond is another feature that differs, and many carbapenems have been 
discovered having this stereochemistry.  This structural feature suggests a potential 
fundamental difference in their biosynthetic pathways, despite the similarity of the gene 
clusters for thienamycin and MM 4550.  
Although genes presumed to be involved in the biosynthesis of the bicyclic core 
and the C-6 and C-2 side chains are conserved between the two gene clusters, there are 
differences that stand out. First, the genes thnA-D, cepU and thnV in the thienamycin 
gene cluster are all missing in the MM 4550 cluster. It is known that cepU is a regulatory 
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gene for cephamycin biosynthesis, but the functions of the other genes in this group are 
yet to be determined in S. cattleya. Second, we found that the biosynthesis of MM 4550 
is regulated by two regulatory mechanisms with proteins encoded by cmmI and 
cmm22/23. A helix-turn-helix (HTH) DNA-binding domain and the rare TTA codon are 
shared by ThnI and CmmI, indicating similar regulatory roles in their biosynthetic 
pathways12.  Two-component regulatory systems are generally global regulators in the 
biosynthesis of secondary metabolites54,55. Disruption of cmm22 clearly showed that 
cmm22/23 is involved in MM 4550 biosynthesis, presumably through phosphorylation of 
the regulator (Cmm22) by the membrane-bound phosphokinase (Cmm23). In addition, 
overexpression of cmmI and cmm22/23 improved the production of MM 4550, 
confirming their positive regulatory roles. Lastly, three putative biosynthetic genes that 
are unique in the MM 4550 gene cluster were identified.   
The first, cmmSu, encodes a putative sulfotransferase as predicted by sequence 
analysis. Sulfotransferases are a superfamily of enzymes catalyzing sulfonation of a 
variety of endogenous and exogenous substrates. In contrast to humans and other 
mammals, little is known about bacterial sulfotransferases36. BLASTP analysis suggested 
that CmmSu is PAPS-dependent owing to the presence of a putative PBS-loop and the 3’-
phosphate binding sites. Disruption of cmmSu resulted in a mutant with a different 
antibacterial spectrum from MM 4550. Mass-spectroscopic analysis showed the 
accumulation of a non-sulfonated derivative of MM 4550 in the argSu13 mutant, as 
expected. An earlier analysis of the OA-6129 group of carbapenems identified in a series 
of random mutants of S. fulvoviridis processing at C-6 and C-8 that was thought to be 
ordered as C-8 hydroxylation, C-6 isomerization and C-8 sulfonation.  The substrate of 
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the sulfonation enzyme, OA-6129B1, was demonstrated to be bioactive56. MM 4550 
possesses the same C-6 side chain as OA-6129C, suggesting that the C-6 side chain of 
MM 4550 is processed through a similar biosynthetic sequence as the OA-6129 
carbapenem group.  
Structurally, the major difference that distinguishes MM 4550 from thienamycin 
is the syn-relationship across C-5 and C-6.  The remaining enzymes that could be 
involved in establishing this alternate stereochemistry are Cmm17 and CmmPah as they 
are present in S. argenteolus but not in S. cattleya.  Cmm17 shows high sequence 
homology to enoyl-CoA hydratases.  It is known that the acid/base chemistry for this type 
of enzymes can hydrate α, β-unsaturated double bonds or perform the reverse reaction46. 
Interestingly, disruption of cmm17 resulted in the loss of antibacterial activities against E. 
coli ESS and B. licheniformis but gained stronger β-lactamase induction activity 
compared to the wild-type and other disruption mutants, indicating that a β-lactam-
containing intermediate was accumulated in the mutant.  We propose that Cmm17 could 
be involved in the epimerization of the C-6 side chain and, therefore, produce a different 
ultimate stereochemical outcome in MM 4550 biosynthesis (Scheme 1.3).  Although 
CmmPah displays high sequence similarity to arginases and PAHs, almost all the amino 
acid residues involved in substrate binding and co-factor binding in the comparison 
enzymes are absent from CmmPah, strongly suggesting that CmmPah catalyzes a 
different reaction(s) in the biosynthesis of MM 4550 from the arginases and PAHs.  
It is important to note that the disruption mutants for cmmG and cmmQ resulted in 
the detection of intermediates with masses for MM 17880 and PS-5, respectively, in the 
mutants (Table 2.3). As shown previously in S. cattleya, ThnQ hydroxylates the bioactive 
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substrate PS-5 to generate N-acetyl thienamycin, and the latter is further oxidized by 
ThnG to produce N-acetyl dehydrothienamycin. ThnG also catalyzes the oxidation of PS-
5 to produce PS-7 and PS-7 sulfoxide9. Thus, in keeping with this in vitro analysis, 
CmmG is responsible for the oxidation of MM 17880 to produce MM 13902 and further 
to produce MM 4550 (Scheme 2.3), CmmQ is likely involved in the C-8 hydroxylation of 
MM 4550 as observed in the OA-6129 group of carbapenems. Thus, a bioactive 
intermediate with the mass and UPLC retention of PS-5 is accumulated when cmmQ was 
knocked-out. 
Importantly, disruption of cmmR and cmmT led to MM 4550 non-producers in S. 
argenteolus. This finding contradicts reports in S. cattleya in which inactivation of 
orthologous genes thnR and thnT retained thienamycin production in the mutants12. 
Biochemical studies have shown that both ThnR and ThnT are involved in the 
incremental truncation of the C-2 side chain in thienamycin11. Our gene inactivation 
results support the in vitro analysis and confirmed that cmmR and cmmT are essential for 
the biosynthesis of MM 4550. ThnR and ThnT are similar to Nudix hydrolases and 
peptidases, respectively. Searching the recently sequenced genome of S. cattleya showed 
five putative Nudix hydrolases and 46 putative peptidases. Thus, the continued 
production of thienamycin in thnR and thnT disruption mutants could result from in trans 
complementation. 
 The questions that remain in the biosynthesis of complex carbapenems include the 
mechanism and timing of inversion of the C-5 carbapenam bridgehead, the desaturation 
of the C-2/C-3 bond, and the attachment of the C-2 and C-6 side chains.  Like the 
thienamycin cluster, there are no obvious candidates to catalyze these steps in the MM 
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4550 gene cluster. As both thienamycin and MM 4550 require these transformations, it is 
probable that enzymes conducting these steps are among those encoded in common by 
both gene clusters. Our gene disruption results ruled out the involvement of cmmQ and 
cmmG in the epimerization/desaturation as has been hypothesized9 because the disruption 
mutants retain the ability to produce bioactive intermediates. 
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Scheme 2.2: Proposed biosynthetic pathway to MM 4550 in S. argenteolus ATCC 
11009.  Solid arrows indicate steps thought to correspond to those in thienamycin 
biosynthesis in S. cattleya.  (Pant = pantetheine) 
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Based on previous reports and the results of our earlier experiments, we propose a 
biosynthetic pathway to MM 4550 shown in Scheme 2.2.  Many of the early steps are 
almost certainly shared with thienamycin biosynthesis, but diverge to achieve 
stereochemical inversion of the C-6 and C-8 stereocenters and the addition of SO3, likely 
through the action of Cmm17 and CmmSu.  The OA-6129 group of carbapenems 
identified from mutagenesis studies in S. fulvoviridis includes the C-2 side chain prior to 
pantethiene cleavage by a ThnT orthologue57. These accumulated products, presumed 
intermediates, provide possible insight into the sequence of CmmQ hydroxylation, 
dehydration/rehydration of the C-6 sidechain and O-sulfonation.  The OA-6129 
carbapenems are shown as possible intermediates in Scheme 2.2.  Additionally, the 
occurrence of the asparenomycin group of carbapenems in Streptomyces suggests the 
possibility of an ene-carbapenem intermediate during the proposed C-6 and C-8 
epimerization21. The origin of the structural diversity of many isolated carbapenems 
across the entire family can in part be rationalized by this scheme. 
It has been shown that the stereochemical relationship across C-5 and C-6 
influences both antibacterial activity and stability toward β-lactamases where the 
presence of a sulfate in C-8 also appears to enhance stability toward β-lactamases58. Fully 
understanding the biosynthesis of MM 4550 in S. argenteolus will surely provide 
information for rational development of novel carbapenems in the future. 
 
Conclusion 
The isolation and characterization of the carbapenem MM 4550 from S. 
argenteolus ATCC 11009 coupled with the data resulting from DNA sequence and 
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individual gene disruptions provide insights into the biosynthesis of the structurally 
complex carbapenem antibiotics.  The consistencies and inconsistencies apparent in 
comparisons with the thienamycin gene cluster point to specific gene products to account 
for the structural differences between thienamycin and MM 4550.  The absence of genes 
homologous to thnA-D and thnV suggest that their corresponding proteins are not 
involved in the assembly of the carbapenem, but the additional genes cmmSu, cmm17 and 
cmmPah may well be responsible for the differing stereochemical features of the C-6 side 
chain.  The knowledge provided by the sequencing of multiple carbapenem-producing 
gene clusters can offer insights into their genetic diversity and how that diversity 
translates into antibiotic structural variation.  Exploration of this diversity may provide 
cost-effective fermentation methods to produce antibiotics or semi-synthetic strategies for 





Restriction enzymes, DNA modifying enzymes, and PCR reagents were obtained from 
New England Biolabs (Ipswich, MA). Plasmid kits were from Thermo Scientific 
(Waltham, MA).  E. coli DH5α (Invitrogen) was usually used for DNA cloning and ThnK 
expression was done in E. coli Rosetta 2(DE3) (Novagen).  Plasmid DNA was sequenced 
by the Synthesis and Sequencing Facility of the Johns Hopkins University.  Solvents and 
reagents were purchased from Sigma Aldrich or Fisher Scientific in purity of ≥98%.  
Silica gel chromatography was performed using 60Å silica gel from Sorbtech.  Thin layer 
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chromatography (TLC) was performed using 250 μm Analtech GHLF silica plates.  A 
Bruker Avance (Billerica, MA) 300 or 400 MHz spectrometer was utilized for all 1H and 
13C NMR spectra, which are reported in parts per million (δ) referenced against a TMS 
standard or residual solvent peak.  The JHU Chemistry Department Mass Spectrometry 
Facility determined exact masses by fast atom bombardment (FAB) or electrospray 
ionization (ESI). 
Cloning of thnM/carA homologous gene in S. argenteolus: Degenerate PCR primers 
thnM-DEG-5 and thnM-DEG-3 were designed using the CODEHOP program30 (Figure 
2.1). The PCR reaction was performed using a ‘‘touchdown’’ program, which consisted 
of (1) denaturation at 98 °C for 5 min, (2) 7 cycles of 40 s at 98 °C, 40 s at 63–56 °C 
(decreasing 1 °C every cycle) and 1 min at 72 °C, (3) 30 cycles of 40 s at 98 °C, 40 s at 
56 °C and 1 min at 72 °C, and (4) 10min at 72 °C. The 300-bp PCR product was cloned 
into pBluescript SK(+) and the resulting recombinant was subjected to DNA sequence 
analysis. 
 
Disruption of S. argenteolus genes by λ-RED-mediated PCR targeting mutagenesis: 
A λ RED mediated PCR mutagenesis system developed by Gust et al. was employed for 
the inactivation of genes in the targeted gene cluster in S. argenteolus52. The extended 
FRT-oriT-aac(3)IV-FRT cassette amplified by PCR was used to target each individual 
gene on cosmid 5D1 in E. coli. For the overlapped ORFs in the gene cluster, primers 
were designed from outside the overlapped regions but the translation remained in-frame. 
The PCR products were used to replace the corresponding genes in the cluster in E. coli 
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BW25113 (pIJ790) by homologous recombination. The mutated cosmid was introduced 
into E. coli ET12567 (pUZ8002) for conjugation into wild-type S. argenteolus52. 
Disruption mutants generated by double crossover events were confirmed by a KmS/AmR 
phenotype and eventually by Southern hybridization using the gene-specific and oriT-
aac(3)IV probes.  
Construction of S. argenteolus cmmI-22-23: cmmI, cmm22, and cmm23 were cloned by 
PCR from cosmid 5D1 (see Supporting Information) and cloned into pBluescript SK(+) 
to give recombinants pBS/cmmI, pBS/cmm22, and pBS/cmm23, respectively. cmmI was 
excised from pBS/cmmI with NdeI-HindIII and inserted into pUWL201PW digested with 
the same enzymes to generate plasmid pUWL201/cmmI. cmm23 was also inserted into 
pUWL201PW at NdeI-EcoRI sites to yield plasmid pUWL201/cmm23. 
pUWL201/cmm23 was digested with KpnI and blunt-ended with Klenow DNA 
polymerase followed by digestion with EcoRI. The blunt-EcoRI ermE*p-cmm23 was 
cloned downstream of cmmI in pUWL201/cmmI at HindIII/Klenow-EcoRI sites to give 
recombinant pUWL201/cmmI-cmm23. cmm22 was excised as a NdeI-HindIII fragment 
from pBS/cmm22 and inserted into pET28(b) to yield plasmid pET28(b)/cmm22. The 
RBS-cmm22 obtained by digesting pET28(b)/cmm22 with XbaI-HindIII was inserted into 
pIJ4070 to give plasmid pIJ4070/cmm22. The ermE*p-RBS-cmm22 was excised as a 
blunt-end fragment by digestion of pIJ4070/cmm22 with EcoRI-PstI and followed by 
treatment with Klenow DNA polymerase.  The ermE*p-RBS-cmm22 was inserted into 
the blunt-ended HindIII site in pMS82 to give plasmid pMS82/cmm22. Finally, the 
ermE*p-cmmI-ermE*p-cmm23 was excised as a XhoI-EcoRI fragment and blunt-ended 
with Klenow DNA polymerase and inserted into pMS82/cmm22 at the blunt-ended 
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EcoRI site to give the final integrative expression vector pMS82/cmmI-22-23. 
S. argenteolus cmmI-22-23 was constructed by conjugating the wild-type S. 
argenteolus with E. coli ET12567 (pUZ8002, pMS82/cmmI-22-23).   
Fermentation and detection of the wild-type, genetic-engineered and disruption 
mutants of S. argenteolus: The wild-type S. argenteolus and its derived strains were 
grown at 30 °C on S/P medium (1% glycerol, 1% yeast extract, 2% agar, pH 7.0) for 
solid cultivation, and on tomato paste-oatmeal agar for sporulation59. For liquid 
cultivation, mycelia or spores were inoculated in S/P liquid medium and grown for 72 h 
at 30 °C. Antibiotics were added in cultures if necessary at the following final 
concentrations: apramycin (50 µg/mL); nalidixic acid (20 µg/mL); hygromycin (50 
µg/mL).  For the general antibacterial activity test, 2.5 mL seed culture was transferred to 
50 mL fermentation medium of either modified ISP4 medium (ISP4+: ISP4 plus 6 mg/L 
CoCl2 ● 6H2O and pH 7.7) or OMYM medium 22. For isolation, purification, and 
characterization of intermediates or final products, the fermentation was carried out in a 
1.3-L × 10 scale as follows: 100 mL S/P medium (containing antibiotics if necessary) 
was inoculated with 100 µL of spores at a concentration of ~106-9/mL and grown at 30 °C 
for 48-56 h and 10 mL of seed culture was transferred into 1.3 L modified ISP4 medium 
(ISP4++: ISP4 plus 6 mg/L CoCl2 ● 6H2O and 1 mg/L methylcobalamin, pH 7.7). The 
fermentation was carried out at 30 °C for 52-56 h with 250 rmp rotation.  
A 2-mL sample was taken every 24 h from each culture, and supernatant (250 µL) 
was added to a micro-cylinder on top of nutrient agar seeded with β-lactam 
supersensitive E. coli ESS60. The carbapenem MM 4550 and its bioactive intermediates 
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could be visualized as inhibition zones after incubating at 37 °C for 15 h.  The production 
of carbapenems was also detected with induction of β-lactamases in Bacillus 
licheniformis ATCC 14580 in a colorimetric assay with nitrocefin52.  
Isolation and identification of MM 4550 in S. argenteolus: Isolation and purification 
steps were performed at 4 °C, with the exception of preparatory HPLC, which was 
performed at room temperature. K2HPO4 buffer (20 mM, pH = 7.0) containing 
ethylenediamenetetraacetate (EDTA, 0.5 mM) was used to make all aqueous solutions in 
order to maintain the pH and provide a neutral environment to avoid degradation of 
carbapenem products.   
To extract antibiotics from media, the filtrate from of fermentation broth (13 L ) 
was first washed with dichloromethane (600 mL).  The resultant washed medium was 
then extracted with  Aliquat 336 (5%, 300 mL ) in dichloromethane.  The medium was 
tested for bioactivity by E. coli ESS bioassay before and after extraction, which 
confirmed efficient extraction.  The organic phase was then back-extracted with aqueous 
potassium iodide (KI, 4 × 25 mL), each of 1%, 3%, 5% and 10%.  The 3% and 5% KI 
fractions contained the greatest quantity of antibiotic as shown by bioassay on E. coli 
ESS, and were collected and lyophilized.   
The crude powder was dissolved in phosphate buffer and loaded onto a column of 
anion-exchange resin (Dowex 1 x 2, 200 x 20 mm, 100 mesh).  The antibiotic was eluted 
with NaCl (1 M) and the bioactive fractions were lyophilized and dissolved in a 
minimum amount of phosphate buffer for purification by reverse-phase HPLC.   
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HPLC was carried out using an Agilent 1100 series G1311A pump with an 
Agilent model 7725i injector fitted with a 1-mL injection loop.  The chromatogram was 
monitored by an Agilent 1100 series G1315B DAD detector at 210, 240, 270, 300, and 
330 nm wavelengths. 
HPLC conditions: Phenomonex Prodigy C18 (2) 250 x 10.00 mm 5 μ micron 
semi-preparatory column, 2 mL/min; buffer A = 20 mM K2HPO4, 0.5 mM EDTA, pH = 
7.4 with HCl, buffer B = acetonitrile.  Method 1, t = 0 min 1.5% B, t = 15 min 1.5% B, t 
= 30 min 30% B, t = 35 min 30% B, t = 40 min 1.5% B, t = 55 min 1.5% B. 
For the hydroxamate assay,  a stock solution (100 μL ) of hydroxylamine 
hydrochloride (50 mM) in phosphate buffer (pH 7.4) was added to the crude antibiotic-
containing solution (900 µL), and was incubated for 1 h at room temperature before it 
was injected for HPLC analysis using the method described above.  The fractions 
containing a peak in the control that was absent when treated with hydroxylamine were 
collected and employed for bioassay on E. coli ESS.  
To prepare samples for NMR analysis, the crude antibiotic-containing solution 
(50 mL) was HPLC purified using method described above and the peak that reacted with 
hydroxylamine was collected for all runs.  The biologically active peak was collected and 
lyophilized.  In order to remove excess salts from the resulting powder for NMR 
experimentation, the entire mixture was purified by one run of HPLC.  The peak was 
collected in 1 mL fractions and lyophilized.  Samples taken for NMR were dissolved in 
D2O (333 μL, 100% ) and placed in a 5 mm D2O Shigemi tube. 
1H NMR (600 MHz, D2O using Shigemi advanced NMR microtube, Bruker 
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Avance II 600 spectrometer at 298 K, processed using the ACD labs software from 
Advanced Chemistry Development, Inc.): 7.60 (d, J = 13.7 Hz, 1H), 6.41 (d, J = 14.7 Hz, 
1H), 4.94 (qd, J = 5.9, 14.7 Hz, 1H), 4.49 (dt, J = 3.9, 5.9 Hz, 1H), 3.98 (dd, J = 5.9, 8.8 
Hz, 1H), 3.52 (dd, J = 8.8, 17.6 Hz, 1H), 3.12 (dd, J = 10.8, 17.6 Hz, 1H), 2.14 (s, 3H), 
1.54 (d, J = 6.8 Hz, 3H).  1H NMR and UV-Vis spectrum matched the data reported in 
the literature for MM 455029,30. 
ESI Mass spec of MM 4550: C13H15N2O9S2- calc: 407.0224 found: 407.0226 . 
The analysis was run on a PerkinElmer AxIon TOF in the negative mode. 
For mass-spectroscopic analysis of carbapenem intermediates in mutants, cultures 
grown in ISP4++ were directly injected onto the UPLC-MS.   UPLC-MS was carried out 
using a Waters Acquity H-Class UPLC system with a multi-wavelength UV-Vis diode 
array detector in tandem with high-resolution MS analysis by a Waters Xevo-G2 Q-ToF 
ESI mass spectrometer. 
UPLC conditions: Waters Acquity BEH UPLC column packed with ethylene 
bridged hybrid C-18 2.1 mm X 50 mm, 1.7 micron, 0.3 mL/min; solvent A = H2O, 
solvent B = acetonitrile.  Method: t=0 min 0% B, t= 1 min 0% B. t = 7.5 min 80% B, t = 
8.4 min 80% B, t = 10 min 0% B. Samples were run in the negative mode with a 1 min 
solvent purge after injection. 
 
Synthesis of carbapenems: 
(3SR,4RS)-4-allyl-1-tert-butyldimethylsilyl-3-(1,2-dihydroxy-2-propyl)-2-azetidinone 
(3a and 3b).  The title compound was prepared as by Ona23.  A solution of 2 M LDA 
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(12.4 mL, 24.8 mmol, 1.4 eq) in THF (60 mL) at -78 ºC was added a solution of 4-allyl-
1-tert-butyldimethylslyl-azetidinone 2 (4.0 g, 17.7 mmol, 1.0 eq) in THF (10 mL).  This 
solution was stirred at -78 ºC for 40 min.  Then a solution of trimethylsilyloxyacetone 
(5.3 mL, 40.71 mmol, 2.3 eq) in THF (6 mL) was added and stirred at -78 ºC for 30 min.  
The reaction mixture was then diluted with brine and extracted with ethyl acetate (2 × 
130 mL).  The organic layer was dried with anhydrous sodium sulfate, filtered and 
concentrated in vacuo.  The oily residue was dissolved in methanol containing 1% acetic 
acid and stirred overnight at room temperature then concentrated.  The residue was 
purified by silica gel chromatography using (1:1) benzene:ethyl acetate to give 3a (1.84 
g, 35%) and 3b (1.0 g, 18.9%).  1H-NMR (400 MHz,CDCl3): 3a δ 5.0-6.2 (m, 3H), 3.0-
4.7 (m, 5H), 2.85 (d, J = 2 Hz, 1H), 2.0-2.8 (m, 2H), 1.08 (s, 3H), 1.00 (s, 9H), 0.30 (s, 
3H), 0.23 (s, 3H) 3b: δ 4.9-6.2 (m, 3H), 1.9-4.0 (m, 8H), 1.30 (s, 3H), 1.00 (s, 9H), 0.27 
(s, 3H), 0.23 (s, 3H) ppm.  1H-NMR confirmed the spectrum reported for this compound 
in the literature23. 
(3SR,4RS)-4-Allyl-3-(4-methyl-2-oxo-1,3-dioxolan-4-yl)-2-azetidinone. (4a, b).  The 
title compound was prepared as by Ona23.  Triphosgene (286.9 mg, 0.96 mmol, 0.4 eq) 
was added to the diol 3b (0.72 g, 2.4 mmol, 1.0 eq) in dichloromethane containing 
pyridine (424.8 uL, 417.2 mg, 5.3 mmol, 2.2 eq) at 0 ºC, and the mixture was stirred for 
30 min, then diluted with ethyl acetate (53 mL) and washed successively with water (21.6 
mL) and brine (20 mL).  The organic layer was dried with anhydrous sodium sulfate, 
filtered and concentrated to give crude carbonate 4b (727.7 mg, 93%). A solution of 
crude carbonate 4b (2.28 g, 7.0 mmol, 1.0 eq) in THF (37.4 mL) and acetic acid (873.4 
uL, 2.0 eq) was treated with (n-Bu)4NF (TBAF) (2.98 g, 9.4 mmol, 1.4 eq), and the 
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mixture was stirred at room temperature for 1 h, then diluted with ethyl acetate (230 mL) 
washed with brine (100 mL).  The organic layer was dried with anhydrous sodium 
sulfate, filtered, and concentrated.  The residue was purified by silica gel chromatography 
using (1:1) benzene:ethyl acetate to give 4b (1.09 g, 82%) %) 1H NMR (400 MHz, 
CDCl3): δ 6.25 (bs, 1H), 5.0-5.3 and 5.5-6.1 (m, 3H), 4.18 and 4.39 (ABq, J = 9 Hz, 2H), 
3.69 (ddd, J = 3, J = 6, J = 6 Hz, 1H), 3.14 (d, J = 3 Hz, 1H), 2.48 (bd, J = 6 Hz, 1H), 
2.41 (bd, J = 6 Hz, 1H), 1.64 (s, 3H) ppm.  
Under the same conditions 3a was reacted to form 4a (1.02 g, 63%). 1H NMR (400 MHz, 
CDCl3): δ 6.6 (br. s, 1H), 4.9-6.1 (m, 3H), 4.14 and 4.68 (ABq, JAB = 8 Hz, 2H), 3.6-3.8 
(m, 1H), 3.07 (d, J = 2 Hz, 1H), 2.3-2.6 (m, 2H), 1.53 (s, 3H) ppm. 1H-NMR confirmed 
the spectrum reported for this compound in the literature23. 
(3S, 4R)-3-(4-Methyl-2-oxo-1,3-dioxolan-4-yl)-4-carboxymethyl-2-azetidinone (5a).  
The title compound was prepared from a modified procedure as by Ona23.  Ozone was 
bubbled through a solution of 4a (6.02 g, 28.5 mmol) in a mixture of CH2Cl2 (200 mL) 
and methanol (135 mL) at -78 °C until a blue color persisted.  Excess ozone was removed 
by bubbling with nitrogen.  Dimethyl sulfide (28 mL) was added, and the reaction 
mixture was stirred for 1 h, then washed with water, dried with Na2SO4, and concentrated 
in vacuo.  The residue was dissolved in tert-butyl alcohol (150 mL) and treated with 2-
methyl-2-butene (66 mL, 0.62 mol) followed by a solution of NaH2PO4 (11.8 g, 85.5 
mmol) and NaClO2 (7.73 g, 85.5 mmol) in water (150 mL).  The resulting mixture was 
stirred at RT for 16 h, concentrated in vacuo to 200 mL, diluted with water (400 mL) and 
at 0 °C, acidified to pH = 2 with HCl (aq 1 M), saturated with NaCl, and extracted with 
methyl ethyl ketone (5 x 100 mL).  The combined organic phases were dried over 
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anhydrous Na2SO4 and concentrated in vacuo to give a white solid, which was 
recrystallized from ethyl acetate / ether to give 3.08 g pure 5a (47% yield). 1H-NMR (400 
MHz, CD3CN + DMSO-d6) δ: 1.51 (s, 3H), 2.6-2.7 (m, 2H), 3.24 (d, J = 2.5 Hz, 1H), 
3.87 (m, 2H), 4.21 and 4.56 (ABq, JAB = 8 Hz, 2H), 7.4 (br, s, 2H).  1H-NMR confirmed 
the spectrum reported for this compound in the literature23. 
(3S, 4R)-3-(4-Methyl-2-oxo-1,3-dioxolan-4-yl)-4-(3-p-methoxybenzyloxycarbonyl-2-
oxopropyl)-2-azetidinone (6a).  The title compound was prepared as by Ona23.  N,N’-
Carbonyldiimidazole (0.83 g, 1.2 eq) was added to a solution of 5a (0.98 g, 4.28 mmol) 
in acetonitrile (25 mL), and the mixture was stirred at room temperature for 2 h.  Then a 
solution of malonic acid mono-p-methoxybenzyl ester monomagnesium salt (2.42 g, 1.2 
eq) in acetonitrile (30 mL) [prepared from the malonic acid mono-PMB ester and MgCl2] 
was added.  The reaction mixture was stirred for 16 h at 45 °C, diluted with EtOAc, 
washed with 1 N HCl (3 x 25 mL) and brine (50 mL), dried with Na2SO4 and 
concentrated in vacuo.  The residue was chromatographed on a SiO2 column 
(EtOAc:hexanes gradient 30:70  70:30) to yield 6a (0.96 g, 57%) as a yellow foam.  
1H-NMR (400 MHz, CDCl3) δ: 1.48 (s, 3H), 2.7-3.2 (m, 2H), 3.02 (d, J = 2.5 Hz, 1H), 
3.49 (s, 2H), 3.77 (s, 3H), 3.7-4.2 (m, 1H), 4.09 and 4.60 (ABq, JAB = 9 Hz, 2H), 5.06 (s, 
2H), 6.8 (br. s, 1H), 6.88 and 7.28 (ABq, J = 9 Hz, 4H). 1H-NMR confirmed the spectrum 
reported for this compound in the literature23. 
(3S, 4R)-3-(4-Methyl-2-oxo-1,3-dioxolan-4-yl)-4-(3-p-methoxybenzyloxycarbonyl-2-
oxopropyl)-2-azetidinone (7a).  The title compound was prepared as by Ona23.  A 
solution of 6a (0.91 g, 2.32 mmol) in acetonitrile (25 mL) containing triethylamine (422 
μL, 1.3 eq) was treated with methanesulfonyl azide (255 mg, 1.3 eq) at 0 °C for 30 
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minutes.  The mixture was diluted with EtOAc, washed with water, dried with Na2SO4 
and concentrated in vacuo.  The residue was chromatographed on a SiO2 column 
(EtOAc/hexane 60:40) to give 7a (540 mg, 56%).  1H-NMR (400 MHz, CDCl3) δ: 1.24 
(s, 3H), 2.81 (dd, J = 17.0 Hz, J = 8.0 Hz, 1H), 2.94 (d, J = 2.0 Hz, 1H), 3.05 (dd, J = 
17.0, 5.0 Hz, 1H), 3.51 (s, 3H), 3.67 (dt, J = 8.0, 2.0 Hz, 1H), 3.91 and 4.32 (ABq, JAB = 
9.0 Hz, 2H), 4.91 (s, 2H), 6.36 (br. s, 1H), 6.64 and 7.06 (ABq, JAB = 9.0 Hz, 4H). 1H-
NMR confirmed the spectrum reported for this compound in the literature23. 
p-Methoxybenzyl (5R,6S)-2-(E)-(2-Acetamidoethenyl)thio-6-(4-methyl-2-oxo-1,3-
dioxolan-4-yl)carbapen-2-em-3-carboxylate (9a).  The title compound was prepared as 
by Ona23.  7a was dissolved in benzene (113 mL) and heated to reflux before a small 
scoop of Rh2OAc4 (5 % w/w, 24 mg) was added in one portion.  After 15 min, the 
reaction mixture was cooled, filtered through Celite and concentrated in vacuo to provide 
8a as a foam (360 mg, 82%), which was used without further purification.  A mixture of 
8a (360 mg, 0.937 mmol), diphenylchlorophosphate (214 μL, 1.03 mmol), and 
diisopropylethylamine (179 μL, 1.03 mmol) in acetonitrile (25 mL) was stirred for 10 
minutes at 0 ºC, and then silver (E)-2-acetamido-1-ethenethiolate (524 mg, 2.34 mmol) 
and sodium iodide (351 mg, 2.34 mmol) were added.  The mixture was allowed to warm 
to room temperature and was stirred for 50 min.  The mixture was diluted with ethyl 
acetate, washed with water, dried with sodium sulfate and concentrated in vacuo.  The 
residue was chromatographed on silica gel (hexane-dichloromethane-ethyl acetate-
acetonitrile 1:1:1:1) to give 9a (257 mg, 56%). 1H-NMR (400 MHz, DMSO): 9a δ 1.48 
(s, 3H), 1.93 (s, 3H), 3.17 (ABq, JAB = 4.6, 8.8 Hz, 2H), 3.74 (s, 3H), 3.97 (d, J = 2.8 Hz, 
1H), 4.18 (dt, J = 9.2, 3.2 Hz, 1H), 4.40 (ABq, JAB = 4.4, 8.4 Hz, 2H), 5.14 (q, J = 12.4 
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Hz, 2H), 5.85 (d, J = 14 Hz, 1H), 6.91 (d, J = 8.4 Hz, 2H), 7.08 (ABq, J1 = 14 Hz, J2 = 
10.4 Hz, 1H), 7.34 (d, J = 8.4 Hz, 2H), 10.38 (d, J = 10 Hz, 1H). 1H-NMR confirmed the 
spectrum reported for this compound in the literature23. 
p-Methoxybenzyl 2-(E)-(2-Acetamidoethenyl)thio-6-[(E)-1-
(hydroxymethyl)ethylidene] carbapen-2-em-3-carboxylate (10).  The title compound 
was prepared as by Ona23. DBU (78.6 μL, 0.526 mmol) was added to a solution of 9a in 
benzene (4.38 mL) and dichloromethane (21.9 mL).  The mixture was stirred at room 
temperature for 30 min.  Upon completion of the reaction the mixture was diluted with 
ethyl acetate and was washed with water, dried with sodium sulfite and concentrated in 
vacuo.  The crude oil was purified by silica gel chromatography (hexane-
dichloromethane-ethyl acetate-acetonitrile 1:1:1:1) to give 10.  The semi-crude oil 
contaminated with the 1-em isomer was used for the next reaction without further 
purification. 
Sodium 2-(E)-(2-Acetamidoetheynyl)thio-6-[(E)-1-(hydroxymethyl)ethylidene] 
carbapen-2-em-3-carboxylate ((±)-asparenomycin C) (11).  The title compound was 
prepared as by Ona23. A crude solution of 10 (obtained from 9a without purification) in 
acetonitrile was added to a solution of aluminum(III) trichloride (175 mg, 1.315 mmol) in 
anisole (2.5 mL) and dichloromethane (2.5 mL) at -60 ºC and was stirred for 10 min.  
After the reaction is complete, a solution of sodium bicarbonate in water was added, and 
the reaction mixture was allowed to warm to room temperature.  After stirring vigorously 
for 30 min, the mixture was filtered through a 0.2 μm membrane filter and washed with 
dichloromethane.  The crude mixture was immediately subject to preparative HPLC 
(Phenomonex Luna C18, 20 x 250 mm, 9:1 0.01 M pH 7 ammonium bicarbonate buffer / 
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acetonitrile).  The product was collected and lyophilized to yield (±)-asparenomycin C 11 
(30 mg, 15% from 9a) as a white powder.  1H-NMR (400 MHz, H2O): 11 δ 1.96 (s, 3H), 
2.05 (s, 3H), 3.09 (ABq, JAB = 8 Hz, 2H), 4.2 (s, 2H), 4.83 (t, J = 8 Hz, 1H), 6.01 (d, J = 
14 Hz, 1H), 7.12 (d, J = 14 Hz, 1H). HRMS (ESI, H2O) m/z:  (MH+) calc: 325.0853 
found: 325.0855.  1H-NMR confirmed the spectrum reported for this compound in the 
literature23. 
Synthesis of Sodium 2-(E)-(2-Acetamidoetheynyl)sulfinyl-6-[(E)-1-
(hydroxymethyl)ethylidene] carbapen-2-em-3-carboxylate [(±)-asparenomycin A].  
The title compound was prepared as by Ona23. The crude powder was purified by 
preparative HPLC (Phenomonex Luna C18, 20 x 250 mm, 9:1 0.01 M pH 7 ammonium 
bicarbonate buffer / acetonitrile).  The sulfoxide (S)-diastereomer (tR2 = 9 min), which 
eluted first, was cleanly separated from the desired (R)-diastereomer (tR2 = 12 min).  The 
peaks were separately collected and lyophilized to yield (±)-asparenomycin A (2 mg) as a 
white powder.  1H-NMR (400 MHz, H2O): δ 1.98 (s, 3H), 2.11 (s, 3H), 2.82 (d, J = 14.8 
Hz, 1H), 3.17 (d, J = 10.8 Hz, 1H), 3.50 (t, J = 6.4 Hz, 1H), 4.26 (d, J = 3.6 Hz, 2H), 6.34 
(d, J = 14 Hz, 1H), 7.55 (d, J = 14 Hz, 1H).  HRMS (ESI, H2O) m/z:  (MH+) calc: 







NMR Spectral Data for MM4550: 
 




1H NMR (600 MHz, D2O using Shigemi advanced NMR microtube, Bruker Avance II 
600 spectrometer at 298 K, processed using the ACD labs software from Advanced 
Chemistry Development, Inc.): 7.60 (d, J = 13.7 Hz, Ha), 6.41 (d, J = 14.7 Hz, Hb), 4.94 
(qd, J = 5.9, 14.7 Hz, Hc), 4.49 (dt, J = 3.9, 5.9 Hz, Hd), 3.98 (dd, J = 5.9, 8.8 Hz, He), 
3.52 (dd, J = 8.8, 17.6 Hz, Hf), 3.12 (dd, J = 10.8, 17.6 Hz, Hg), 2.14 (s, 3Hh), 1.54 (d, J = 
6.8 Hz, 3Hi). 1H NMR matched the data reported in the literature29,30. 
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1H-1H ROESY of MM4550 
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Total synthesis of epithienamycins and exploration into the roles of CmmSu, 
Cmm17 and CmmPah in epithienamycin biosynthesis 
 
We chose an in vitro enzymatic approach to study the biosynthetic mechanism of 
C-6 and C-8 inversion in MM 4550 biosynthesis.  Currently the enzymes of interest are 
the presumed sulfotransferase CmmSu, the putative enoyl-CoA hydratase Cmm17, and 
the hypothesized enzyme CmmPah1,2.  We proposed that these enzymes are involved in 
the epimerization of the C-6 and C-8 stereocenters as the point of divergence from the 
thienamycin biosynthetic pathway to that of the epithienamycins3.  One such biosynthetic 
transformation is shown in Scheme 3.1. 
 
Scheme 3.1: Proposed epimerization of the C-6/8 stereocenters that lead to 
epithienamycins1 
  
Epimerization of the C-6/8 positions is thermodynamically unfavorable.  There is 
no energetic reason why equilibration would favor formation of a sterically crowded 
product.  Mechanistically, it would make better sense if the C-8 hydroxyl were oxidized 
and then reduced selectively from the less hindered face for epimerization to occur.  
However, no reductases or uncharacterized oxygenases exist within the MM 4550 gene 
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cluster.  We presume that the enoyl-CoA hydratase Cmm17 and the protein CmmPah can 
perform the acid-base chemistry for either the elimination or addition of water the 
epimerize these stereocenters and hope that the steric control by the enzyme active site(s) 
would be enough to favor this chemistry. 
 
Isolation of carbapenems from S. argenteolus ΔcmmSu 
To identify target substrates for total synthesis we sought to identify the major 
antibiotic produced in the CmmSu knockout of S. argenteolus (∆cmmSu) by isolation of 
the presumed substrate for sulfuryl transfer from the mutant strain.  An initial attempt at 
isolation using Aliquat 336, as done for MM 4550 isolation, was inefficient.  These 
results, in combination with the likelihood that the intermediate is lacks a sulfate at C-8, 
led to the abandonment of the phase transfer strategy.  A different mode of extraction 
using similar principles was executed.  The published procedure for epithienamycin 
isolation from Streptomyces flavogriseus MB 4638 was used as a guide for isolation3. 
Dowex® 1x2 anion-exchange resin was suspended in filtered S. argenteolus 
∆cmmSu medium to draw antibiotic out of the medium, and the antibiotically-active 
portion of the saline eluate was purified through a column of Amberlite® XAD 
polystyrene resin.  The carbapenem was further purified by adsorption on activated 
charcoal followed by elution with 10% aqueous n-butanol before it was concentrated in 
vacuo.  It was critical that all chromatography, adsorption and elution were performed in 
the shortest time possible and at 4 °C as degradation proved to be accelerated for this 
compound vs. MM 4550.  HPLC purification and analysis by UPLC-HRMS revealed a 
compound that matched the mass and λmax (300 nm) of epithienamycin A and N-acetyl 
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thienamycin, although the UV spectrum has an apparent second λmax at 240 nm which is 
typical for 2-ethylidenethiol derivatives3 (Figure 3.1).  At -80 °C in K2HPO4 buffer (pH = 
7, 20 mM) the isolated compound degraded rapidly and after 1 week the compound was 
completely degraded.  Syntheses of multiple carbapenems for CmmSu activity assays 
would provide additional evidence for the stereochemical preferences of the enzyme. 
 




Figure 3.2: HPLC chromatogram for purified ∆cmmSu Product 
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Synthesis of thienamycins and epithienamycins for CmmSu activity assays 
The synthesis of epithienamycin A and OA6129-B1 required the construction of a 
5,6-cis-relationship on the carbapenem bicycle core.  In the literature, there exist many 
routes to “5,6-cis-carbapenems”4–8, with the most efficient published by Micah Bodner 
and Ryan Phelan9.  That synthesis, although elegant, relies on an early deprotection step 
that uses three equivalents of expensive samarium iodide and an unreliable Arndt-
Eistert10 homologation late in the synthesis that requires the use of a high-pressure 
mercury UV lamp.  Different routes were utilized to generate the kinetic product 3,4-cis-
azetidinone from N-tert-butyldimethylsilyl 4-allyl-2-azetidinone and acetaldehyde7. It 
was found that after the preparation of the initial 3,4-cis-azetidinone, all remaining steps 
were easily and repeatedly performed in good yield.    The synthetic route to 2-
oxocarbapenam 8 is shown in Scheme 3.2.  
The chiral synthesis of N-tert-butyldimethylsilyl 4-allyl-2-azetidinone 1 has been 
repeated using the efforts outlined by Ueda et al.11,12 and described in further detail by 
Dr. Kristos Moshos and Daniel Marous13,14.  Azetidinone 1 was reacted with lithium 
diisopropylamide (LDA) and acetaldehyde to produce 2, 2a and 2b with an average 
combined yield of 35%.  The optimal ratio of 3,4-cis-(2) to 3,4-trans-products (2a, 2b) 
was achieved (1:2) when quenched with acetic acid at -78 °C.  Although this overall yield 
of 2 from 1 was very low yielding (15% or less), being the first step in the synthesis 
allowed large scale to overcome this limitation.  The remaining synthetic sequence was 
reliable to stereopure 5,6-cis-carbapenems after chromatography, where 5g of 1 could 
eventually yield 100 mg or more prior to the final deprotection of the PNB esters.  
Protection of 2a with p-nitrobenzyl chloroformate in the presence of 
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dimethylaminopyridine (DMAP) provided the carbonate 3 in 80% yield.  Compound 3 
was deprotected under HF/pyridine; conditions that provide an improved yield versus 
tetrabutylammonium fluoride (TBAF) to give the free amide 4.  Where TBAF allows for 
reliable deprotection, HF/pyridine excels not only in yield, but in shortened reaction time 
(<15 min) and ease of purification.  HF/pyridine was easily removed from the crude 
reaction by workup with saturate ammonium chloride and brine, however it was found 
that silica gel chromatography immediately after workup ensured the removal of all 
residual HF, which could cause degradation in long-term storage.  It is reccomended to 
use a plastic flask when working with HF, to avoid etching of Pyrex during the course of 
the reaction and potentially contaminating the product.    
Ozonolysis followed by dimethyl sulfide reduction of the subsequent ozonide and 
further oxidation of the resulting aldehyde using Pinnick oxidation conditions15,16 
provided the acid 5 in 56% yield, although occasionally yields were much higher 
depending on the purity of the starting material.  Direct oxidation of the ozonide with 
H2O2 was attempted but resulted in unrecoverable product material.  For ease of 
purification, keeping the ozonide and product aldehyde anhydrous before Pinnick 
oxidation provided a very clean product 5, which was crystallized from ethyl 
acetate/hexanes after acidic organic extraction.  Addition of p-nitrobenzyl magnesium 
malonate to the imidazole-activated acid at 65 °C gave the β-keto ester 6, which was then 
reacted with methanesulfonyl azide and diisopropylethylamine (DIPEA) to provide the 
diazo compound 7.  Rhodium(IV) acetate-mediated carbene insertion into the β-lactam 
N-H bond yielded the 2-oxopenam 8 quantitatively.  From 8, the enol phosphate was 
produced in situ from diphenylphosphoryl chloride and DIPEA.  The intermediate was 
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then reacted with the thiol of choice; in this case either N-acetylcysteamine (SNAC) or 
O,O-1,3-bistriethylsilyl-pantetheine in 66% and 47% yield, respectively.  The SNAC 
derivative 9 was directly deprotected to produce epithienamycin A 12.  Yields of TES 
deprotection were poor when the pantetheine derivative 10 was stirred with TBAF, but 
preferable to complete degradation from the use of HF/pyridine.  It was found that the 
low-yielding TES deprotection step could be avoided by the direct addition of 
pantetheine itself to the enol phosphate, as developed using the methods described for 
conjugate addition of thiols to carbapenems17,13.  Hydrogenolysis of the p-nitrobenzyl 
esters provided OA6129-B1 (13) after purification by preparative HPLC (Scheme 3.3). 
 
Scheme 3.2: Synthesis of 5,6-cis-carbapenam 8 
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The synthesis of 5,6-trans-carbapenams was performed in parallel using 
intermediate 2b.  Conveniently, the 2-oxocarbapenam 14 (Scheme 3.4), an intermediate 
of imipenem synthesis, was purchased for $60/g from Ark Pharm, Inc.  The purchased 
intermediate was used to produce N-acetyl thienamycin (18) and OA6129-B2 (19) as 
shown in Scheme 3.4. 
 
Scheme 3.3: Synthesis of epithienamycin A and OA6129-B1  




Scheme 3.4: Synthesis of N-acetylthienamycin and OA6129-B2  
from 2-oxocarbapenam 14 
 
New strategies for the total synthesis of epithienamycins 
The current route to 5,6-cis-carbapenems employed in Scheme 3.2 as well as 
those reported the literature4–8 are highly inefficient and not currently amenable to 
industrial scale up18.  Should 5,6-cis-carbapenems be found of clinical value, it would be 
advantageous to choose a synthetic route which could account for addition of the 
necessary 1β-methyl substituent on the carbapenem bicycle; providing carbapenem 
resistance to degradation by dehydropeptidase 1 (DHP-1).  Current methods incorporate 
the 1β-methyl substituent by chiral addition into a 4-acetoxyazetidin-2-one by methods 




Scheme 3.5: Reformatsky-Mediated Addition of a Chiral Enolate to 4-acetoxy-2-
azetidinones 
 
It would be optimal to follow a similar strategy for the generation of 5,6-cis-
carbapenems.  Intermolecular nucleophilic addition to an N-acyliminium intermediate 
generated from 4-acetoxy-2-azetidinones solely produce trans-azetidinones; therefore, a 
new strategy is proposed that involves intramolecular ring closure (Scheme 3.6) to force 
nucleophilic attack from the more hindered face.  This approach will not preclude 1β-
methyl group installation, as the required stereochemistry would be set by steric 
limitations.  Favorable 6-membered ring formation would render insertion from the other 
side to form a trans-azetidinone geometrically impossible.  Once the methodology was 
implemented, the synthesis would be modified to converge to the current route to 
carbapenems as proposed in Scheme 3.6. 
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Scheme 3.6: An ideal route to 5,6-cis-carbapenems 
First, the 4-acetoxy-3-hydroxyethyl-2-azetidinone 24 was desired.  Using D-
aspartic acid, the synthesis of 4-acetoxy azetidinone 25 was possible through chemistry 
established by Merck for the synthesis of the enantiomer acetoxyazetidinone used in the 




Scheme 3.7: Synthesis of 4-acetoxy-2-azetidinones 
Following established chemistry20, Fisher esterification21 of D-aspartic acid with 
benzyl alcohol under dehydrating Dean-Stark conditions22 provided the tosyl salt 20 in 
near quantitative yield after crystallization from cyclohexane.  A primary amine was 
generated through deprotonation by sodium bicarbonate and was then reacted with tert-
butyldimethylsilyl chloride to provide the secondary amine 21.  Deprotonation of the 
amine was facilitated by tert-butyl magnesium chloride and the resulting anion was 
reacted with the benzyl ester to yield the azetidinone 22 in a yield of 69%.  
Hydrogenolysis of the remaining benzyl ester followed by recrystallization from diethyl 
ether provided the acid 23.  A dianion was generated using two equivalents of lithium 
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diisiopropylamide (LDA).  The enolate at the 3 position was reacted with acetaldehyde to 
give 3,4-trans-azetidinone diastereomeric alcohols.  Literature procedures exist for the 
oxidation of the secondary alcohol with sodium dichromate in sulfuric acid (Jones 
reagent), and the reduction of the product ketone to generate the stereopure alcohol23.  
Resolution of diasteromers was avoided, however, as our first goal was to solve the 
chemistry of cyclization.  Meanwhile, the diastereomeric alcohols 24 were carried 
forward.  The acid was oxidized with lead (IV) tetraacetate under mild heating in the 
presence of a catalytic amount of copper acetate to provide the 4-acetoxy azetidinone 25 
without the deprotection of the N-tert-butyldimethylsilyl group in 50% yield24.  The 
resulting alcohols were acylated with either propionyl chloride or 2-bromopropionyl 
bromide in 59% and 66% yields respectively.  The silyl group was cleaved with 60% 
hydrofluoric acid in pyridine.  The propionyl esters 26 and 28 were necessary for enolate 
generation and the 2-bromopropionyl esters 27 and 29 were primed for generation of an 
α-anion through a Reformatsky or Grignard mechanism25. 
The azetidinones 26-29 could not undergo ring closure.  The screening of Lewis 
acids, bases, and various highly activated metals, such as Reike zinc or freshly ground 
magnesium did not produce the desired transformation.  It was hoped that formal 
deprotonation of the azetidinone nitrogen and would allow formation of the N-acyl 
iminium species when Lewis acid methods failed; however, no intramolecular addition 
occurred. To explore other routes, closure of a five-membered ring as described by 
Gallucci and coworkers26 was investigated (Scheme 3.8).  The crucial step of 
epimerization of the aldehyde 33 at the 4-position of the azetidinone transiently provided 
the desired 3,4-cis-stereochemistry, which was preserved after spontaneous ring closure 
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to a hemiacetal.  Scheme 3.8 illustrates the synthesis of 42. 
 
Scheme 3.8: Synthesis of 1-β-methyl-epithienamycins through 42 
 The 2-hydroxytetrahydrofuran 34 was expanded to a 6-membered cyclic methyl 
acetal by reaction with a methoxymethyl triphenylphosphine ylid followed by ring 
closure in acidic conditions.  The methyl acetal 36 was converted to the hemiacetal 37 
and oxidized to the lactone 38 with N-methylmorpholine N-oxide (NMO) in the presence 
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of catalytic tetrapropylammonium perruthenate (TPAP).  For this step, Pinnick oxidation 
conditions15,16 were insufficient to oxidize the hemiacetal where pyridine dichromate was 
successful; however, TPAP/NMO was preferable due to the cleanliness of the reaction 
and higher yield.  Oxidative removal of the N-methoxyphenyl group with ceric 
ammonium nitrate (CAN) provided the free amide 39.  With 42 in hand, the remainder of 
the synthetic sequence followed the precedent of Kaga et al.27.  Through these methods, a 
route to 1-β-methyl epithienamycin would be possible when using the established 
methods of Galluci, Kaga and coworkers.  For convenience, it was also possible to 
ozonolyze the intermediate 2 to form the [4.2.0] ring system directly, and is preferred for 
the racemic synthesis of epithienamycins owing to the wide availability of (±)-4-
allylazetidin-2-one. 
 
Biosynthetic Studies of the MM 4550 producing gene cluster in S. argenteolus ATCC 
11009 
We believe the point of biosynthetic divergence from thienamycin to MM 4550 
occurs prior to truncation of the C-2 pantetheine sidechain by ThnT/CmmT because of 
the isolation of the OA-6129 carbapenems from a single strain of Streptomyces 
fulvuviridis28.   Comparison of the MM 4550 and thienamycin gene clusters revealed 
three enzymes unique to the MM 4550 cluster, which are thought to account for the 
structural differences between MM 4550 and thienamycin.  The sulfotransferase is likely 
involved in sulfonation of the C-8 hydroxyl position, leaving Cmm17 and CmmPah to 
alter the stereochemistry of the C-6 side chain. 
Dr. Rongfeng Li cloned out of S. argenteolus and into a pET29 vector cmmSu 
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with a C-terminal His6-tag.  Test expressions encountered low solubility; however, 
optimization of conditions by utilizing a 1 h cold shock before induction with IPTG and 
fermentation at 15 °C for 24 h resulted in a high quantity of soluble protein.  Typical 
procedures using a nickel column for purification of the protein were followed, and the 
purified CmmSu was buffer-exchanged into pH 7.0 potassium phosphate.  The protein 
was found to be unstable with these conditions, and, therefore, buffer screening was 
performed to optimize stability.  The most stable buffer conditions found were 50 mM 
MOPS pH = 7.8 with 10% glycerol, in which the protein would remain soluble for many 
hours at ambient temperature. 
Epithienamycin A, N-acetyl thienamycin or derivatives thereof are produced by S. 
argenteolus ΔcmmSu and these substrates were synthesized for the profiling of CmmSu 
in vitro.   Carbapenems have been isolated from Streptomyces that are functionalized at 
C-2 with pantetheine, and at C8 as a sulfate29–31, so testing of compounds with N-
acetylcysteamine and pantetheine at C-2 are necessary.  C-5/6-trans carbapenems have 
never been isolated from Streptomyces that contain a sulfate at C-8; however, these are 
likely intermediates in the biosynthetic pathway and may be substrates for CmmSu in 
vitro. 
As a negative control, a mutant of CmmSu was generated to knockout the key 
catalytic arginine residue.  Quik-change® PCR allowed for the generation of CmmSu-





CmmSu in vitro assays 
Each of N-acetyl thienamycin, epithienamycin A, OA6129-B1 and OA6129-B2 
were separately incubated with CmmSu and 3’-phosphoadenosine 5’-phosphosulfate 
(PAPS) in MOPS buffer.  The enzyme was functional at 30-37 °C, but due to increased 
precipitation of CmmSu at elevated temperatures, we chose to run the majority of assays 
at room temperature.  Analyses of the reactions by HPLC (Figure 3.3) found the 
conversion of each compound to its respective sulfate.  Conversion seemed highest with 
the reaction of CmmSu with 5,6-cis-carbapenem OA-6129B1.  UPLC ESI-MS confirmed 
the presence of a sulfonate in the products (Figure 3.4).  Repetition of the experiment 
with the R18A mutant resulted in the abolishment of O-sulfotransferase activity vs. the 






Figure 3.3: HPLC analyses of CmmSu products when incubated with (a) Epithienamycin 
A (b) N-acetylthienamycin (c) OA6129B1 (d) OA6129B2.  Peaks labeled with a heavy dot 
(●) indicate sulfonated product, as confirmed by UPLC-HRMS. 
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Retention times and good separation of substrates and products showed that direct 
analysis of sulfated product was the best course of action.  The carbapenem does have a 
significant chromophore, and the C-2 pantetheine carbapenem alcohols and their products 
give resolved peaks by HPLC.  In the future, a standard curve should be made from these 
synthetic compounds so a time course experiment would provide comparative data by 
monitoring rates of substrate consumption and product formation. 
 
Cmm17 and CmmPah in vitro assays 
Dr. Rongfeng Li was able to express soluble constructs of Cmm17 and CmmPah 
in E. coli.  CmmPah proved the more difficult to express as soluble protein was only 
isolated from the expression using a pET41 vector that adds a glutathione S-transferase 
(GST) tag at the N-terminus.  Once purified, the GST/CmmPah construct was very stable 
with no precipitation after 24 hours or after freezing in liquid nitrogen and thawing to 
room temperature.  The buffer used was 50 mM MOPS, pH = 7.8.  Cmm17 is not as 
stable in any of the buffers previously tested, so it must be purified from cells on the 
same day as experimentation, and used within hours of buffer exchange. 
In the hope that the Cmm17/Pah paired enzyme system alone is necessary for 
stereochemical inversion of the C-6/8 positions, assays were developed that included 
CmmPah, Cmm17, and both CmmPah and Cmm17 together.  Each of these scenarios was 
incubated with the synthetic carbapenem substrates OA6129B1 and OA6129B2.  The 
homologue of CmmPah in the clavulanic acid producer32 and the similar arginases 
studied in the literature use manganese as the Lewis acidic metal involved in the 
hydrolysis of a guanidinyl group2,33.  We theorized that CmmPah may use a similar 
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acid/base driven mechanism, and so 0.5mM manganese chloride was added to the assays. 
Incubations of OA6129B1, OA6129B2, epithienamycin A and N-acetyl 
thienamycin with CmmPah or Cmm17 separately or together did not produce any new 
products detectable by UV Vis in the HPLC or a new mass in the UPLC ESI-MS.  These 
negative results led to a hypothesis that carbapenems must to be o-sulfonated prior 
toward reaction with either CmmPah or Cmm17.   To test this, enzyme assays including 
CmmSu were performed, with CmmSu, CmmPah, Cmm17 and PAPS in the same 
reaction (Figure 3.4).  Each of the carbapenems previously tested was used as substrate in 
the incubations.  The results were again disappointing.  The only new products were 
sulfated derivatives of OA6129B1, OA6129B2, epithienamycin A and N-acetyl 
thienamycin, which had been seen before in the CmmSu experiments. 
 
Figure 3.4: Extracted ion chromatogram for sulfonated pantetheinyl carbapenem 
products in dual enzyme assays of CmmSu and Cmm17, incubated with OA-6129B1 
(red) or OA-6129B2 (blue).  No Cmm17 control for the reaction with OA-6129B2 is in 
green.  The no PAPS control is shown in purple.  The calculated mass for sulfonated 




Analysis of all isolated carbapenem structures revealed that only 5,6cis 
carbapenems contain a sulfate at C-8.  It is possible that stereochemical inversion can 
only occur with a sulfate present (Scheme 3.9), or conversely that it can occur with a free 
hydroxyl.  It was hoped that CmmSu would be a stereoselective gatekeeper for 
sulfonation as observed with other enzymes in thienamycin biosynthesis, such as ThnM, 
ThnQ, or ThnK, and that conclusive preference for one substrate over another would give 
insight into the order of the inversion process.  Unfortunately, sulfonation by CmmSu 
was successful with all substrates, so little insight was gained.  CmmPah and Cmm17 
were unable to alter the stereochemistry of the C-6/8 positions alone; however, these 
enzymes may not function in vitro without the proper substrates or cofactors.  Possible 
substrates may include 2-ethylidene carbapenems, which are proposed as intermediates 
after desaturation (Scheme 3.1).  Possible cofactors may be metal ions, such as Mn+2 for 
Pah.  Alternatively, identification of the β-lactamase-inducing intermediate that 
accumulates in the Cmm17 gene-disruption mutant, as seen by nitrocefin assay with 
incubation of S. argenteolus Δcmm17 medium with S. aureus, would give comprehension 
to the function of Cmm17.  Isolation could be performed in the future using previous 




 The syntheses of epithienamycins were possible following established chemistry.  
Modification of synthetic routes by Gallucci, Kaga and coworkers26,27 provided a new, 
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reliable route to epithienamycins, which could incorporate a 1β-methyl group on the 
carbapenem core if desired.  The early synthetic steps followed by Galluci and 
coworkers26 could be avoided if the chiral synthesis of 4-allylazetidin-2-one could be 
performed economically and on large scale. 
 CmmSu was found to sulfate a variety of carbapenems, with seemingly little 
preference for a particular C-6 or C-8 stereochemical orientation.  C-2 pantetheinyl 
carbapenems provided greater enzymatic turnover when compared to their N-
acetylcysteamine counterparts.  When 6-hydroxyethyl carbapenems or their sulfonated 
products are incubated with CmmPah and/or Cmm17, no apparent stereochemical 
inversion is observed from analysis by HPLC (Figure 3.4).  Further experiments which 
could uncover the mysteries of divergence from thienamycin to epithienamycins are the 
isolation of bioactive intermediates from Δcmm17, and repetition of the isolation of the 
carbapenem from ΔcmmSu with synthetic standards in hand to determine the 
stereochemistry of that compound.  If the ΔcmmSu isolate is a C-5/6-trans-carbapenem, 
that would indicate sulfonation is a necessary step prior to C-6/8 inversion.  If the isolate 
is 5,6-cis, then sulfonation is only a modification after the fact and the historical isolation 





Restriction enzymes, DNA modifying enzymes, and PCR reagents were obtained from 
New England Biolabs (Ipswich, MA). Plasmid kits were from Thermo Scientific 
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(Waltham, MA).  E. coli DH5α (Invitrogen) was usually used for DNA cloning and ThnK 
expression was done in E. coli Rosetta 2(DE3) (Novagen).  Plasmid DNA was sequenced 
by the Synthesis and Sequencing Facility of the Johns Hopkins University.  Solvents and 
reagents were purchased from Sigma Aldrich or Fisher Scientific in purity of ≥98%.  
Silica gel chromatography was performed using 60Å silica gel from Sorbtech.  Thin layer 
chromatography (TLC) was performed using 250 μm Analtech GHLF silica plates.  A 
Bruker Avance (Billerica, MA) 300 or 400 MHz spectrometer was utilized for all 1H and 
13C NMR spectra, which are reported in parts per million (δ) referenced against a TMS 
standard or residual solvent peak.  The JHU Chemistry Department Mass Spectrometry 
Facility determined exact masses by fast atom bombardment (FAB) or electrospray 
ionization (ESI). 
 
Purification of Epithienamycin A from S. argenteolus ΔcmmSu: 
15 liters of 96-h fermentation of S. argenteolus ΔCmmSu in ISP4+ medium was 
filtered through cheesecloth and 18.5 cm fast flow filter paper, and the eluate was stirred 
with 400 mL 20-50 mesh Dowex 1x2 resin for 2.5 h at 4 °C.  The resin was loaded to a 
column and the remaining media was discarded.  The carbapenem was eluted from the 
resin with 2 L 5% sodium chloride in 20 mM K2HPO4 buffer, pH = 7 at 4 °C.  The eluate 
was loaded to 400 mL Amberlite XAD-4.  The antibiotic was eluted with 4 L deionized 
water, and the remainder was eluted with 2 L 3% NaCl in 1:1 methanol/water at 4 °C.  
The eluate was incubated with 195 mL activated charcoal by stirring for 1 h at 4 °C.  The 
charcoal was filtered through 7.5 cm fast flow filter paper, and the carbon cake was 
suspended in 540 mL 10% sec-butanol in water at 4 °C.  The carbon cake was again 
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removed by filtration and the eluate was lyophilized and the resulting solids suspended in 
a minimum amount of water (50 mL).  The crude antibiotic-containing solution was twice 
filtered through a 0.2 μ nylon filter before injection onto preparatory C18 high pressure 
liquid chromatography (HPLC) (decribed in chromatographic techniques below, 
preparatory method 1).  Bioassay using extra-sensitive E. coli (ESS) verified the presence 
of antibiotic after lyophilization.  Antibiotic containing solution was injected onto a 
Phenomonex Luna® semi-preparatory C18(2) column 10 x 250 mm 5 μ, and each 2 mL 
fraction from 7 min to 24 min elution time was collected for bioassay.  Min 13 through 
24 were bioactive and the remainder of the crude solution was injected and collected for 
lyophilization. 
The fractions collected from semi-preparatory HPLC were suspended in a 
minimum amount of water and injected onto an analytical Phenomonex Polar-RP® 
column, 4.6 x 250 mm 5 μ (described in the chromatographic techniques section, 
analytical HPLC method 3).  2 mL fractions every minute from 2-16 min were collected 
for ESS bioassay and min 10-12 indicated the highest level of antibiotic.  The remainder 
of the sample was purified on a polar-RP column (Method 4), and then was subject to the 
same column with a different mobile phase that contained 5% ammonium bicarbonate, a 
volatile buffer.  The peak at 4.2 min was found to be potently bioactive and was collected 







Analytical HPLC was carried out using an Agilent 1200 series G1311A pump 
with an Agilent model G1329A injector.  The chromatograms were monitored by an 
Agilent 1200 series G1315D DAD detector at 210, 240, 270, 300, and 330 nm 
wavelengths. 
UPLC conditions: Waters Acquity BEH UPLC column packed with ethylene bridged 
hybrid C-18 2.1 mm X 50 mm, 1.7 micron, 0.3 mL/min; solvent A = H2O, solvent B = 
acetonitrile.  Method: t=0 min 0% B, t= 1 min 0% B. t = 7.5 min 80% B, t = 8.4 min 80% B, t = 
10 min 0% B. Samples were run in the negative mode with a 1 min solvent purge after injection. 
Preparative HPLC was carried out using an Agilent 1100 series G1311A pump 
with an Agilent model 7725i injector fitted with a 1-mL injection loop.  The 
chromatogram was monitored by an Agilent 1100 series G1315B DAD detector at 210, 
240, 270, 300, and 330 nm wavelengths. 
Preparatory HPLC conditions: Phenomonex Prodigy C18 (2) 250 x 10.00 mm 5 μ 
semi-preparatory column, 2 mL/min; buffer A = 20 mM K2HPO4, 0.5 mM EDTA, pH = 
7.4 with HCl, buffer B = acetonitrile, buffer C = 5 mM ammonium bicarbonate.  Method 
1: t = 0 min, 98.5% A 1.5% B; t = 15 min, 98.5% A 1.5% B; t = 30 min, 65% A 35% B; t 
= 35 min, 65% A 35% B; t = 40 min, 98.5% A 1.5% B; t = 55 min, 98.5% A 1.5% B.  
Method 2: t = 0 min, 10% C, 90% B; t = 25 min, 10% C, 90% B. 
Analytical HPLC conditions: Phenomonex Synergi Polar-RP 250 x 4.6 mm 3 μ 
analytical column, 1 mL/min; buffer A = 20 mM K2HPO4, 0.5 mM EDTA, pH = 7.4 with 
HCl, buffer B = acetonitrile, buffer C = 5 mM ammonium bicarbonate.  Method 3: t = 0 
min, 100% A 0% B; t = 3 min, 100% A 0% B; t = 10 min, 85% A 15% B; t = 14 min, 
85% A 15% B; t = 16 min, 100% A 0% B; t = 25 min, 100% A 0% B.  Method 4: t = 0 
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min, 100% C 0% B; t = 6 min, 100% C 0% B; t = 10 min, 85% C 15% B; t = 14 min, 
85% C 15% B; t = 16 min, 100% C 0% B; t = 25 min, 100% C 0% B.  Method 5: t = 0 
min, 100% A 0% B; t = 5 min, 100% A 0% B; t = 15 min, 85% A 15% B; t = 30 min, 
60% A 40% B; t = 35 min, 60% A 40% B; t = 45 min, 100% A 0% B; t = 55, 100% A 
0% B. 
 
Quik-Change PCR of cmmSu, Restriction digest of PCR products with DpnI, and 
transformation into E. coli: 
Forward (5’) and reverse (3’) primers were designed and ordered from Sigma 
Aldrich.  Forward primer (c52g_g53c-F): 
TCTGGGTACGGGAGCCTGTGGGTCGACG.  Reverse primer (c52g_g53c-R): 
CGTCGACCCACAGGCTCCCGTACCCAGA.  Two identical 100 μL reactions were 
prepared for PCR.  The reactions consisted of G/C buffer (20 μL, 5x); dNTPs (2 μL, 10 
mM); 5’-primer (2 μL, 20 mM); 3’-primer (2 μL, 20 mM); pBS/cmmSu (50 ng/μL); 
Phusion® DNA polymerase (1 μL); DMSO (5 μL); ddH2O (60 μL).  The reactions were 
placed in an Eppendorf® PCR thermocycler with the following sequence: Initial 
denaturation: 2 min, 98 °C; 20x [Denaturation: 20 s, 98 °C; Annealing: 20 s, 60 °C; 
Extension: 2.5 min, 72 °C]; Final extention: 10 min, 72 °C; Hold temp: 4 °C.   
DNA PCR products were recovered in 300 μL ddH2O and suspended in 500 μL 
phenol before the solution was vortexed for 10-20 s to precipitate proteins.  The sample 
was centrifuged for 2 min at 14,000 RPM a RT.  The aqueous phase of the supernatant 
was recovered to which was added 50 μL sodium acetate (3 M, pH = 5.2), then 1 mL 
ethanol before cooled to -20 °C over 20 min. DNA was precipitated by centrifugation at 
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14,000 RPM for 35 min at 4 °C.  The pellet was recovered and washed with 1 mL 70% 
ethanol and centrifuged at 14,000 RMP at RT for 10 min.  The pellet was resuspended in 
25 μL ddH2O to which was added 3 μL NEB buffer 4 and 2 μL Dpn1 and mixed gently.  
The restriction digestion was incubated at 37 °C for 1 h. 
 Digested PCR product (10 μL) was added to 100 μL super-competent E. coli 
DH5α (Dr. Rongfeng Li) and agitated gently with a pipette tip before incubation on ice 
for 30 min.  The transformation mixture was heat-shocked at 42 °C for 30 s and cold-
shocked for 2 min at 0 °C.  900 μL LB was added to the cells and the transformation 
mixture was shaken at 37 °C for 1 h.  The transformed E. coli was pelleted by 
centrifugation at 14,000 RPM at RT for 10 min, and the pellet was resuspended in 100 μL 
LB by gentle agitation with a pipette tip.  50 μL of the transformed cell mixture was 
plated on each of 2 LB plates with ampicillin (100 μg/mL) and incubated for 4 h at 27 °C, 
then 14 h at 37 °C after which time a multitude of colonies was visible.  Ten colonies 
were picked and each shaken in 6 mL LB overnight at 37 °C containing ampicillin (100 
μg/mL).  A mini-prep was used to purify the DNA for each sample using the following 
protocol (mini-prep kit and protocol by Fisher Scientific): 2 mL of each of 10 samples in 
2 mL Eppendorf® tubes were centrifuged for 1 min and the supernatant discarded.  This 
step was repeated two more times to recover all 6 mL of culture.  The cell pellet was 
suspended in buffer A (250 μL) to which was added lysis buffer (250 μL) and shaken by 
hand immediately 20x.  Neutralization buffer was then added (350 μL) and shaken hard 
20x, after which the mixture was centrifuged at 14,000 RPM to pellet cell debris.  The 
supernatant was recovered and added to 1 mL spin columns (Fisher scientific) and 
centrifuged for 1 min at 14,000 RPM.  The spin columns were washed with washing 
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buffer (Fisher scientific, 2x, 450 μL) and centrifuged for 1 min at 14,000 RPM, the flow-
through was discarded.  The spin columns were eluted with 100 μL ddH2O.  
Concentration of DNA was found to be 250 ng/μL from analysis by UV absorbance at 
260 nm.  Each of the ten samples was confirmed by sequencing analysis to ensure the 
integrity of the PCR products was conserved during amplification, as well as 
confirmation of the correct mutations, c52g_g53c. 
 The plasmid was transformed into electro-competent Rosetta 2 E. coli.  20 μL of a 
Rosetta2 competent cells cell stock (Dr. Rongfeng Li) was added to a 1.5 mL Eppendorf® 
tube to which 1 μL pET28/cmmSu-R18A was added at 0 °C.  The mixture was added to 
an electroporation chamber and placed into a cell porator at 0 °C.  The power supply and 
voltage booster were set to the following parameters: Capacitance = 330, kΩ = 4, Volts = 
low Ω DC.  Once triggered from 300 volts charge, the transformed cells were removed 
and added to a clean 2 mL Eppendorf® tube and shaken in 1 mL LB for 1 h at 37 °C.  
The cells were pelleted by centrifugation at 14,000 RPM for 10 min, resuspended in 100 
μL LB, and 50 μL were streaked onto each of 2 LB/agar plates with chloroamphenicol 
(25 μg/mL) and kanamycin (50 μg/mL).  Colonies were used for inoculation of starter 
cultures used for protein expression.  A sample of starter culture was suspended in 
glycerol to a final concentration of 20% and stored long term at -80 °C. 
 
Expression and Purification of CmmSu and CmmSuR18A: 
Stock culture of Rosetta2 (pET29/cmmSu or pET29/CmmSuR18A) cells were 
streaked onto LB agar with kanamycin (50 μg/mL) and chloroamphenicol (25 μg/mL)  
and grown for 16 h at 30 °C.  A single colony was picked and used for the inoculation of 
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50 mL LB with kanamycin and chloroamphenicol.  The seed culture was shaken for 15 h 
at 30 °C and used to inoculate 5 L LB medium with 100 mg chloroamphenicol (final 
concentration 20 μg/mL)  and 200 mg kanamycin (40 μg/mL).  The culture was shaken at 
37 °C for 195 min when the optical density at 600 nm (OD600) reached 0.6 absorbance 
units (AU).  The culture was cooled to 0 °C and cold-shocked at this temperature for 2 h.  
At this time 1.07 g isopropyl β-D-1-thiogalactopyranoside (IPTG) was added and the 
culture was grown for 24 h at 16 °C.  At this time the cell paste was harvested by 
centrifugation at 4000 g for 12 min at 4 °C and frozen by liquid nitrogen suspension to 
recover 23 g Rosetta2 (pET29/cmmSu) cells or 28 g Rosetta2 (pET29/cmmSuR18A) 
cells.  To 20 g each of Rosetta2 (pET29/cmmSu) cells and Rosetta2 
(pET29/cmmSuR18A) cells was added 80 mL lysis buffer (300 mM NaCl, 50 mM 
NaH2PO4, 10 mM imidazole, 10% v/v glycerol, pH = 8.0) and 160 mg lysozyme.  The 
cells were suspended and incubated on ice for 30 min before sonication for 3 min (6s on 
9s off) at 60% amplitude with the large tip.  The cell debris was removed by 
centrifugation at 16,000 rpm for 20 min at 4° C.  To the supernatant was added 4 mL Ni 
resin and incubated for 1 h at 4 °C.  The Ni resin was pelleted by centrifugation at 800 g 
for 10 min at 4 °C.  The Ni resin was suspended in 6 mL lysis buffer and loaded into a 
glass column.  The column was washed with 4 mL lysis buffer, then 10 mL wash buffer 
(300 mM NaCl, 50 mM NaH2PO4, 20 mM imidazole, 10% v/v glycerol, pH = 8.0) before 
elution of the protein with 4 mL elution buffer (300 mM NaCl, 50 mM NaH2PO4, 250 
mM imidazole, 10% v/v glycerol, pH = 8.0).  The eluted protein was loaded to a Bio-Rad 
P10 column (5 mL) that was pre-washed with 20 mL reaction buffer (50 mM MOPS pH 
= 7.8 with 10% v/v glycerol).  The protein was buffer exchanged by elution from the P10 
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column with 3 mL reaction buffer.  A protein concentration of 103 μM for CmmSu and 
146 μM for CmmSuR18A was determined by Bradford assay. 
CmmSu Reaction Conditions: 30 μM CmmSu or CmmSuR18A, 800 μM 
carbapenem substrate, 5 mM MgCl2, 7 mM PAPS, 0.1 mM DTT, 50 mM MOPS, 10% 
v/v glycerol, pH = 7.8.  Reactions were incubated for 2 h at 30 °C before the protein was 
removed by centrifugation through a 10 kD Amicon filter at 14,000 rpm for 20 min at 4 
°C.  HPLC samples were taken directly from the filtered reaction media. 
 
Expression and Purification of CmmPah and Cmm17:  
 Stock of Rosetta2 (pET41/cmmPah or pET29/cmm17) cells were streaked onto 
LB agar with kanamycin and chloroamphenicol and grown for 16 h at 30 °C.  A single 
colony was picked and used for the inoculation of 50 mL LB with kanamycin (50 μg/mL)  
and chloroamphenicol (25 μg/mL).  The seed culture was grown for 15 h at 30 °C and 
used to inoculate 5 L LB medium with 100 mg chloroamphenicol (final concentration 20 
μg/mL and 200 mg kanamycin (final concentration 40 μg/mL).  The culture was shaken 
at 37 °C for 195 min when the optical density at 600 nm (OD600) reached 0.6 absorbance 
units (AU).  The culture was cooled to 0 °C on ice and cold-shocked at this temperature 
for 2 h.  At this time 1.04 g isopropyl β-D-1-thiogalactopyranoside (IPTG) was added 
and the culture was shaken for 24 h at 15 °C.  At this time the cell paste was harvested by 
centrifugation at 4000 g for 12 min at 4 °C and frozen by liquid nitrogen suspension to 
recover 14 g Rosetta2 (pET41/cmmPah) cells and 19 g Rosetta2 (pET29/cmm17) cells.  
To 7 g each of Rosetta2 (pET41/cmmPah) cells and Rosetta2 (pET29/cmm17) cells was 
added 35 mL lysis buffer (300 mM NaCl, 50 mM NaH2PO4, 10 mM imidazole, 10% v/v 
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glycerol, pH = 8.0) and 70 mg lysozyme.  The cells were suspended and incubated on ice 
for 30 min before sonication for 3 min (6s on 9s off) at 60% amplitude with a large tip.  
The cell debris was removed by centrifugation at 16,000 rpm for 20 min at 4 °C.  To the 
supernatant was added 2 mL Ni resin and incubated for 1 h at 4 °C.  The Ni resin was 
pelleted by centrifugation at 1000 g for 10 min at 4 °C.  The pellet was suspended in 6 
mL lysis buffer and loaded to a column.  The column was washed with 15 mL lysis 
buffer (as above) before elution of the protein with 4 mL elution buffer (300 mM NaCl, 
50 mM NaH2PO4, 250 mM imidazole, 10% v/v glycerol, pH = 8.0).  The eluted protein 
was loaded to a Bio-Rad P10 column that was pre-washed with 20 mL reaction buffer (50 
mM MOPS pH = 7.8 with 10% v/v glycerol).  The protein was buffer exchanged by 
elution from the P10 column with 3 mL reaction buffer.  Protein concentrations were 
determined by Bradford assay. 
CmmPah, Cmm17 Dual Assay Conditions: 10 μM CmmPah, 10 μM Cmm17, 900 
μM carbapenem substrate, 0.5 mM MgCl2, 0.5 mM MnCl2, 250 μM PAPS, 30 mM 
MOPS, pH = 7.8.  Reactions were incubated for 1 h at ambient temperature before the 
protein was removed by centrifugation through a 10 kD Amicon filter at 14,000 rpm for 
20 min at 4 °C.  HPLC samples were taken directly from the filtered reaction medium. 
CmmPah, Cmm17, and CmmSu Triple Assay Conditions: 10 μM CmmSu, 10 μM 
Cmm17, 10 μM CmmPah, 900 μM carbapenem substrate, 0.5 mM MgCl2, 0.5 mM 
MnCl2, 250 μM PAPS, 30 mM MOPS, pH = 7.8.  Reactions were incubated for 1 h at 
room temperature before the protein was removed by centrifugation through a 10 kD 
Amicon filter at 14,000 rpm for 20 min at 4 °C.  HPLC samples were taken directly from 
the filtered reaction media. 
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Synthesis of carbapenems: 
N-tert-butyldimethylsilyl-(4R)-allyl-2-azetidinone (1):  N-tert-butyldimethylsilyl-4(R)-
allyl-2-azetidinone 1 was prepared from N-tert-butyldimethylsilyl-4(R)-3-
carbomenthyloxy-2-propen-1-yl)-2-azetidinone as described by Ueda et al..34.  Ozone 
was passed through a solution of N-tert-buyldimethylsilyl-4(R)-3-carbomenthyloxy-2-
propen-1-yl)-2-azetidinone (12.96, 31.7 mmol) in dichloromethane (300 mL) at -78 °C 
until the blue color persisted.  Argon was then passed through the solution at -78 °C until 
colorless.  The solution was warmed to 0 °C to which was added dimethylsulfide (35 mL) 
and stirred for 70 min at 0 °C.  The solution was washed twice with H2O and then with 
brine.  The organic extract was dried with anhydrous sodium sulfate, filtered, and 
concentrated in vacuo.  In a separate flask, n-butyllithium in hexane (45 mL, 2.2 M, 100 
mmol) was added to diisopropylamine (13.95 mL, 100 mmol) in tetrahydrofuran (775 
mL) at 0 °C and stirred for 20 min at which time was added methyltriphenylphosphonium 
bromide (35.5 g, 100 mmol).  The mixture was stirred for 1 h at ambient temperature. 
The ylid solution was cooled at 0 °C to which was slowly added the ozonolysis product 
crude oil and upon completion was stirred for 2 h at ambient temperature.  Diethyl ether 
(300 mL) was added to the reaction mixture and it was quenched with saturated 
ammonium bicarbonate (120 mL).  The phases were separated and the aqueous layer was 
extracted twice with diethyl ether (100 mL).  The combined organic extracts were washed 
with brine (150 mL), dried with anhydrous sodium sulfate, filtered and concentrated in 
vacuo.  The crude oil was purified by silica gel chromatography (hexanes:Et2O, 9:1) to 
afford 1 (3.28g, 52%). 1H-NMR (400 MHz, CDCl3): δ 5.78-5.68 (m, 1H), 5.14-5.08 (m, 
2H), 3.58 (ddt, J = 9.2, 5.9, 3.1 Hz, 1H), 3.41 (td, J = 10.4, 4.3 Hz, 1H), 3.09 (dd, J = 
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15.4, 5.4 Hz, 1H) 2.66 (dd, J = 15.4, 2.7 Hz, 1H), 2.62-2.56 (m, 1H), 2.21-2.13 (m, 1H), 
0.971 (s, 9H), 0.250 (s, 3H), 0.226 (s, 3H).  1H NMR data matched the spectrum reported 
in the literature34. 
N-tert-butyldimethylsilyl-(3S)-((1R)-hydroxyethyl)-(4R)-allyl-2-azetidinone (2a), N-
tert-butyldimethylsilyl-(3S)-((1S)-hydroxyethyl)-(4R)-allyl-2-azetidinone (2b), N-tert-
butyldimethylsilyl-(3R)-((1S)-hydroxyethyl)-(4R)-allyl-2-azetidinone (2): The 
synthesis of 2a, 2b, and 2c from 1 was modified from the procedure of Bateson et al..35.  
A solution of n-butyllithium in hexanes (11.6 mL, 2.11 M, 24.4 mmol) was added to a 
solution of diisopropylamine (3.44 mL, 24.4 mmol) in THF (60 mL) at -78 ºC and stirred 
for 30 min.  A solution of 1 (2.5 g, 11.1 mmol) in THF (20 mL) was slowly added to the 
LDA mixture by addition funnel over 30 min during which time the solution became red.  
This solution was stirred at -78 ºC for an additional 30 min.  Then a solution of 
acetaldehyde (5 mL, 89.7 mmol) in THF (5 mL) was cooled to -78 ºC and then added 
slowly by addition funnel and stirred at -78 ºC for 30 min during which time the solution 
became colorless.  At this temperature the reaction was then quenched with acetic acid (5 
mL) in THF (20 mL) and the mixture was stirred for 15 min at room temperature.  The 
solution was then diluted with brine and extracted with ethyl acetate (3 × 100 mL).  The 
organic layer was dried with anhydrous sodium sulfate, filtered and concentrated in 
vacuo.  The oily residue was purified by silica gel chromatography (hexanes:EtOAc, 8:2) 
to give the diastereomers 2a (320 mg, 11%), 2b (480 mg, 17%), and 2 (344.8 mg, 12%).  
1H-NMR (400 MHz, CDCl3) 2a: δ 5.83-5.66 (m, 1H), 5.18-5.12 (m, 2H), 3.75 (ddd, J = 
11.2, 6.2, 2.4 Hz, 1H), 3.61 (ddd, J = 9.5, 3.4, 2.6 Hz, 1H), 2.88 (dd, J = 5.2, 2.5, 1H), 
2.62 (dtd, J = 5.1, 3.4, 1.6, 1H), 2.35-2.34 (m, 1H), 2.22-2.15 (m, 1H), 1.38 (d, J = 5.1 
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Hz, 3H), 0.96 (s, 9H), 0.27 (s, 3H), 0.22 (s, 3H).2b: δ 5.83-5.66 (m, 1H), 5.18-5.12 (m, 
2H), 3.98 (td, J = 6.6, 3.3 Hz, 1H), 3.41 (ddd, J = 9.7, 3.6, 2.5 Hz, 1H), 2.84 (dd, J = 7.1, 
2.5 Hz, 1H), 2.57 (dddt, J = 6.7, 4.0, 2.8, 1.4 Hz, 1H), 2.34 (d, J = 3.7 Hz, 1H), 2.27-2.21 
(m, 1H), 1.29 (d, J = 5.2 Hz, 3H), 0.96 (s, 9H), 0.26 (s, 3H), 0.21 (s, 3H). 2: δ 5.69 (dq, J 
= 17.2, 8.6 Hz, 1H), 5.13-5.07 (m, 2H), 3.95 (quintet, J = 6.4 Hz, 1H), 3.39 (d, J = 9.5 
Hz, 1H), 2.81 (dd, J = 6.7, 2.3 Hz, 1H), 2.53 (dd, J = 6.6, 6.0 Hz, 1H), 2.17 (dt, J = 14.0, 
8.1 Hz, 1H), 1.21 (d, J = 6.3 Hz, 3H), 0.92 (s, 9H), 0.2166 (s, 3H), 0.17 (s, 3H). 1H NMR 
data matched the spectrum reported in the literature35. 
N-tert-butyldimethylsilyl-(3S)-[(1R)-p-nitrobenzyloxycarbonyloxyethyl)-(4R)-allyl-2-
azetidinone (3a), N-tert-butyldimethylsilyl-(3S)-((1S)-p-nitro-benzyl-oxy-carbonyl-
oxyethyl)-(4R)-allyl-2-azetidinone (3b):  Dimethylaminopyridine (DMAP) was added 
to the diasteromeric alcohols 2a and 2b (720 mg, 2.97 mmol) in dichloromethane (3 mL) 
at 0 °C.  A solution of p-nitrobenzylchloroformate (768 mg, 3.56 mmol) in 
dichloromethane (3 mL) was added to the reaction mixture at 0 °C and was allowed to 
stir for 1 h at this temperature.  The reaction was diluted with dichloromethane (50 mL) 
and water (10 mL).  The phases were separated and the aqueous layer was extracted with 
dichloromethane (10 mL).  The combined organic fractions were washed with brine (20 
mL) and dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo.  The 
crude oil was purified by silica gel chromatography (hexanes:EtOAc, 8:2) to yield 3a and 
3b as a mixture of diastereomers (799 mg, 67%).  1H-NMR (400 MHz, CDCl3) 3a: δ 8.23 
(d, J = 8.7 Hz, 2H), 7.53 (d, J = 8.8 Hz, 2H), 5.77-5.65 (m, 1H), 5.28 (s, 1H), 5.23 (s, 
2H), 5.16-5.08 (m, 1H), 5.03 (dd, J = 6.5, 4.6 Hz, 2H), 3.61 (dt, J = 9.4, 3.0 Hz, 1H), 3.01 
(dd, J = 6.3, 2.6 Hz, 1H), 2.62-2.56 (m, 1H), 2.20 (td, J = 15.1, 8.2 Hz, 1H), 1.38 (d, J = 
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6.4 Hz, 3H), 0.96 (s, 9H), 0.27 (s, 3H), 0.20 (s, 3H). 3b: δ 8.23 (d, J = 8.7 Hz, 2H), 7.53 
(d, J = 8.8 Hz, 2H), 5.77-5.65 (m, 1H), 5.28 (s, 1H), 5.23 (s, 2H), 5.16-5.08 (m, 1H), 5.03 
(dd, J = 6.5, 4.6 Hz, 1H), 3.46 (dt, J = 9.4, 3.0 Hz, 1H), 3.11 (dd, J = 4.5, 2.7 Hz, 1H), 
2.62-2.56 (m, 1H), 2.20 (td, J = 15.1, 8.2 Hz, 1H), 1.43 (d, J = 6.5 Hz, 3H), 0.96 (s, 9H), 
0.27 (s, 3H), 0.20 (s, 3H). 
N-tert-butyldimethylsilyl-3(R)-[1(S)-p-nitro-benzyl-oxy-carbonyloxy-ethyl]-4(R)-
allyl-2-azetidinone (3). 3 was synthesized from 2 following the procedure described 
above for 3a and 3b. The crude oil was purified by silica gel chromatography 
(hexanes:EtOAc, 8:2) to yield 3 as a colorless oil (760 mg, 43%).  1H-NMR (400 MHz, 
CDCl3) 3: δ 8.23 (d, J = 8.7 Hz, 2H), 7.54 (d, J = 8.7 Hz, 2H), 5.76-5.66 (m, 1H), 5.26 (q, 
J = 16.0 Hz, 2H), 5.13-5.08 (m, 2H), 5.02 (dd, J = 17.2, 1.5 Hz, 1H), 3.77 (dt, J = 10.7, 
5.1 Hz, 1H), 3.39 (dd, J = 5.7, 3.2 Hz, 1H), 2.47 (qd, J = 16.7, 7.9 Hz, 2H), 1.48 (d, J = 
6.4, 3H), 0.97 (s, 9H), 0.27 (s, 3H), 0.22 (s, 3H). 
(3S)-[(1R)-p-nitro-benzyl-oxy-carbonyl-oxy-ethyl]-(4R)-allyl-2-azetidinone (4a), 
(3S)-[(1S)-p-nitro-benzyl-oxy-carbonyl-oxy-ethyl]-hydroxyethyl)-(4R)-allyl-2-
azetidinone (4b):  A solution of HF/pyridine (6 mL) in pyridine (2 mL) was added to a 
solution of 3a and 3b (2.00 g, 4.46 mmol) in THF (50 mL) at 0 °C.  The reaction mixture 
was stirred for 10 min before it was quenched with saturated ammonium chloride.  The 
reaction was diluted with ethyl acetate and the organic layer was washed with saturated 
ammonium chloride.  The combined aqueous fractions were washed with ethyl acetate.  
The combined organic phase was washed with brine and dried with anhydrous sodium 
sulfate, filtered, and concentrated in vacuo.  The crude oil was purified by silica gel 
chromatography (hexanes:EtOAc, 7:3) to yield 4a and 4b as a mixture of inseparable 
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diastereomers (990 mg, 66%).  Further purification can be achieved by crystallization 
from ethyl acetate and hexanes.  Melting point = 119-122 °C. 1H-NMR (400 MHz, 
CDCl3) 4a: δ 8.21 (d, J = 8.8 Hz, 2H), 7.52 (d, J = 8.9 Hz, 2H), 6.26-6.20 (br s, 1H), 5.7 
(ddt, J = 17.1, 10.0, 7.1 Hz, 1H), 5.23 (s, 2H), 5.15-5.05 (m, 3H), 3.67 (td, J = 6.6, 2.2 
Hz, 1H), 2.98 (ddd, J = 7.2, 2.3, 0.9 Hz, 1H), 2.39-2.33 (m, 2H), 1.41 (d, J = 6.3 Hz, 3H). 
4b: δ 8.21 (d, J = 8.8 Hz, 2H), 7.54 (d, J = 8.9 Hz, 2H), 6.26-6.20 (br s, 1H), 5.7 (ddt, J = 
17.1, 10.0, 7.1 Hz, 1H), 5.23 (s, 2H), 5.15-5.05 (m, 3H), 3.55 (td, J = 6.6, 2.4 Hz, 1H), 
3.09 (ddd, J = 5.1, 2.3, 1.0 Hz, 1H), 2.39-2.33 (m, 2H), 1.43 (d, J = 6.4 Hz, 3H).  13C-
NMR (101 MHz, CDCl3) 4a: δ 166.4, 154.1, 147.8, 142.3, 132.7, 128.3, 123.8, 118.6, 
72.9, 67.9, 60.7, 51.4, 39.1, 18.5. 4b: δ 166.4, 154.2, 147.8, 142.3, 132.7, 128.3, 123.8, 
118.6, 72.1, 67.9, 59.6, 49.8, 38.8, 17.4.   FAB MS: MH+: calc = 335.1238, found = 
335.1251. 
3(R)-[1(S)-(p-nitrobenzyloxycarbonyloxy)ethyl]-4(R)-allyl-2-azetidinone (4):  4 was 
synthesized from 3 following the procedure described above for 4a and 4b.The crude oil 
was purified by silica gel chromatography with (hexanes:EtOAc, 7:3) to yield 4 (500 mg, 
88%).  Further purification can be achieved by recrystallization from ethyl acetate and 
hexanes.  Melting point = 93-95 ºC. 1H-NMR (400 MHz, CDCl3) 4: δ 8.21 (d, J = 8.8 Hz, 
2H), 7.52 (d, J = 8.9 Hz, 2H), 6.26-6.20 (br s, 1H), 5.7 (ddt, J = 17.1, 10.0, J3 = 7.1 Hz, 
1H), 5.23 (s, 2H), 5.15-5.05 (m, 3H), 3.67 (td, J = 6.6, 2.2 Hz, 1H), 2.98 (ddd, J = 7.2, 
2.3, 0.9 Hz, 1H), 2.39-2.33 (m, 2H), 1.41 (d, J = 6.3 Hz, 3H). 13C-NMR (101 MHz, 
CDCl3) 4: δ 166.7, 154.1, 142.5, 133.2, 128.2, 123.7, 118.2, 71.0, 67.9, 56.6, 50.4, 35.0, 




azetidinone (5b):  Ozone was passed through a solution of 4a and 4b (280 mg, 0.838 
mmol) in dichloromethane (6.03 mL) and methanol (4.02 mL) at -78 ºC until blue.  
Nitrogen was bubbled through the solution until it turned colorless, at which point the 
temperature was raised to 0 ºC and dimethylsulfide (838 μL) was added.  After stirring 
for 1 h at 0 ºC, the solution was washed with H2O and the organic layer was dried with 
anhydrous sodium sulfate, filtered and concentrated in vacuo.  The crude foam was 
dissolved in tert-butyl alcohol (7 mL) to which was then added 2-methyl-2-butene (3 mL) 
and a solution of monosodium phosphate (347 mg, 2.51 mmol) and sodium chlorite (227 
mg, 2.51 mmol) in H2O (7 mL) at ambient temperature.  After 1 h the reaction was 
concentrated in vacuo to remove the tert-butyl alcohol, diluted with water, and acidified 
to pH = 2 with 1 M HCl in saturated sodium chloride.  The aqueous mixture was 
extracted 5 times with ethyl acetate (5 mL) and the combined organic fractions were 
dried with anhydrous sodium sulfite, filtered, and concentrated in vacuo.  5a and 5b were 
purified by crystallization from ethyl acetate and diethyl ether to yield white crystals (306 
mg, 99%). 1H-NMR (400 MHz, CDCl3) 5a: δ 8.24 (d, J = 8.8 Hz, 2H), 7.54 (d, J = 8.7 
Hz, 2H), 6.59 (br s, 1H), 5.25 (s, 2H),  5.14 (dt, 1H, J = 12.8, J = 6.2), 3.94 (ddd, J = 9.8, 
3.7, 2.5 Hz, 1H), 3.04 (dd, J = 7.4, 2.3 Hz, 1H), 2.80 (t, J = 4.4, 1H), 2.57 (d, J = 10.8 Hz, 
1H), 1.45 (d, J = 6.4 Hz, 3H). 5b: δ 8.24 (d, J = 8.8 Hz, 2H), 7.55 (d, J = 8.7 Hz, 2H), 
6.59 (br s, 1H), 5.25 (s, 2H), 5.14 (dt, J = 11.8, 6.2 Hz, 1H), 3.82 (ddd, J = 9.3, 4.1, 2.6 
Hz, 1H), 3.14 (dd, J = 4.6, 2.3 Hz, 1H), 2.75 (t, J = 4.4 Hz, 1H), 2.63 (t, J = 10.2 Hz, 1H), 
1.47 (d, J = 6.5 Hz, 3H). FAB MS MH+ calc = 353.0979, found = 353.0983. 
3(R)-[1(S)-(p-nitrobenzyloxycarbonyloxy)ethyl]-4(R)-carboxymethyl-2-azetidinone 
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(5):  5 was synthesized from 4 following the procedure described above for 5a and 5b.  5 
were purified by crystallization from ethyl acetate and diethyl ether to yield white solid 
crystals (297 mg, 56%). 1H-NMR (400 MHz, CDCl3) 5: δ 8.19 (d, J = 8.7 Hz, 2H), 7.54 
(d, J = 8.8 Hz, 2H), 6.44 (br s, 1H), 5.26 (q, J = 19.2 Hz, 2H),  5.04 (quintet, J = 5.7 Hz, 
2H), 4.06 (q, J = 6.3 Hz, 1H), 3.45 (t, J = 4.5 Hz, 1H), 2.64 (d, J = 7.1 Hz, 2H), 1.47 (d, J 
= 6.4 Hz, 3H). 13C-NMR (101 MHz, CDCl3) 5: δ 174.7, 168.5, 153.9, 147.8, 142.4, 
128.4, 123.8, 71.0, 68.1, 56.3, 47.7, 34.5, 19.5. FAB MS MH+: calc = 353.0979, found = 
353.0985. 
(3S)-[(1R)-(p-nitrobenzyloxycarbonyloxy)ethyl]-(4R)-(3-p-nitrobenzyloxycarbonyl-2-
oxopropyl)-2-azetidinone 6a and (3S)-[(1S)-(p-nitrobenzyloxycarbonyloxy)ethyl]-
(4R)-(3-p-nitrobenzyloxycarbonyl-2-oxopropyl)-2-azetidinone 6b:  6a and 6b was 
synthesized from 5a and 5b following the procedures of Salzmann et al.36.  
Carbonyldiimidazole (169 mg, 1.042 mmol) was added to 5a and 5b (306 mg, 0.869 
mmol) in a solution of acetonitrile (8.7 mL) at ambient temperature.  After stirring for 1 
h, the magnesium salt of the mono-p-nitrobenzyl ester of malonic acid (435 mg, 0.869 
mmol) was added and the resulting mixture was stirred for 16 h at ambient temperature.  
The reaction mixture was diluted with ethyl acetate and washed three times with 1N HCl 
(25 mL).  The organic layer was washed with brine (50 mL), dried with anhydrous 
sodium sulfate, filtered, and concentrated in vacuo. The crude oil was purified by silica 
gel chromatography (hexanes:EtOAc, 7:3 to 3:7) to yield 6a and 6b as a mixture of 
inseparable diastereomers (270 mg, 59%).  1H-NMR (400 MHz, CDCl3) 6a: δ 8.20 (d J = 
8.8 Hz, 4H), 7.52 (m, 4H), 6.27 (br s, 1H), 5.25 (s, 2H),  5.23 (s, 2H), 5.12 (quintet, J = 
12.4 Hz, 1H), 3.95 (ddd, J = 9.0, 4.1, 2.4 Hz, 1H), 3.56 (s, 2H), 3.08-2.97 (m, 2H), 2.84 
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(dd, J =18.2, 8.9 Hz, 1H), 1.42 (d, J = 6.4 Hz, 1H). 6b: δ 8.20 (d, J = 8.8 Hz, 4H), 7.54-
7.49 (m, 4H), 6.24 (br s, 1H), 5.25 (s, 2H), 5.24 (s, 2H), 5.12 (quintet, J = 12.4 Hz, 1H), 
3.84 (ddd, J = 8.4, 4.7, 2.6 Hz, 1H), 3.57 (s, 2H), 3.08-2.97 (m, 2H), 2.84 (dd, J = 18.2, 
8.9 Hz, 1H), 1.44 (d, J = 6.5 Hz, 3H). FAB MS MH+ calc = 530.1405, found = 530.1399.  
1H NMR data matched the spectrum reported in the literature36. 
(3R)-((1S)-p-nitrobenzyloxycarbonyloxyethyl)-(4R)-[3-(p-nitrobenzyloxycarbonyl-2-
oxo)propyl]-2-azetidinone 6:  6 was synthesized from 5 following the procedure 
described above for 6a and 6b5.   1,1-Carbonyldiimidazole (169 mg, 1.042 mmol) was 
added to 5 (306 mg, 0.869 mmol) in a solution of acetonitrile (8.7 mL) at ambient 
temperature.  After stirring for 1 h, the magnesium salt of the malonic acid mono-p-
nitrobenzyl ester (435 mg, 0.869 mmol) was added and the resulting mixture was stirred 
for 16 h at ambient temperature.  The reaction mixture was diluted with ethyl acetate and 
washed three times with 1 N HCl (25 mL).  The organic layer was washed with brine (50 
mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude 
oil was purified by silica gel chromatography (hexanes:EtOAc, 7:3 to 3:7) to yield 6 (270 
mg, 59%).  1H-NMR (400 MHz, CDCl3) 6: δ 8.18 (d, J = 8.8 Hz, 2H), 8.16 (d, J = 8.8 
Hz, 2H), 7.52 (d, J = 8.8 Hz, 2H), 7.48 (d, J = 8.8 Hz, 2H), 6.49 (br s, 1H), 5.27 (s, 2H), 
5.22 (s, 2H), 5.01-4.95 (m, 1H), 4.10 (dt, J = 13.8, 6.7 Hz, 1H), 3.50 (s, 2H), 3.44 (t, J = 
4.3 Hz, 1H), 2.97-2.91 (m, 2H), 1.44 (d, J = 6.4 Hz, 3H).  1H NMR data matched the 
spectrum reported in the literature5. 
(4R)-(3-Diazo-3-p-nitro-benzyl-oxy-carbonyl-2-oxopropyl)-(3S)-[(1R)-p-nitro-
benzyl-oxy-carbonyl-oxy-ethyl]-2-azetidinone 7a and (4R)-(3-Diazo-3-p-nitro-
benzyl-oxy-carbonyl-2-oxopropyl)-(3S)-[(1S)-p-nitro-benzyl-oxy-carbonyl-oxy-
123 
ethyl]-2-azetidinone 7b:  7a and 7b was synthesized from 6a and 6b following the 
procedures of Kametani et al.5.  Methanesulfonylazide (69 mg, 0.57 mmol) was added to 
6a and 6b (270 mg, 0.51 mmol) in a solution of acetonitrile (10.8 mL) at ambient 
temperature.  A solution of diisopropylethylamine (319 μL, 1.84 mmol) in acetonitrile (3 
mL) was added and the reaction mixture was stirred for 1.5 h. The reaction mixture was 
concentrated in vacuo and the resulting crude oil was purified by silica gel 
chromatography (hexanes:EtOAc, 1:1 to 8:2) to yield 7a and 7b as a mixture of 
inseparable diastereomers (188 mg, 66%).  1H-NMR (400 MHz, CDCl3) 7a: δ 8.25-8.21 
(m, 4H), 7.55 (d, J = 8.7 Hz, 4H), 6.03 (br s, 1H), 5.36 (s, 2H),  5.24 (d, J = 2.8 Hz, 2H), 
5.16 (q, J = 11.6 Hz, 1H), 4.00 (ddd, J = 9.3, 4.0, 2.1 Hz, 1H), 3.25 (t, J = 5.0 Hz, 2H),  
3.14-2.96 (m, 2H), 1.45 (d, J = 7.2 Hz, 3H). 7b: δ 8.26 (d, J = 8.6 Hz, 2H), 8.24 (d, J = 
8.4 Hz, 2H), 7.54 (d, J = 8.8 Hz, 4H), 6.00 (br s, 1H), 5.36 (s, 2H), 5.25 (d, J = 2.9 Hz, 
2H), 5.16 (dt, J = 12.9, 6.6 Hz, 1H), 3.85 (ddd, J = 8.7, 4.2, 2.7 Hz, 1H), 3.30 (t, J = 5.0 
Hz, 1H), 3.17 (dd, J = 4.6, 2.4 Hz, 1H), 3.11-3.04 (m, 1H), 1.47 (d, J = 6.6 Hz, 3H). 1H 
NMR data matched the spectrum reported in the literature5. 
(4R)-(3-Diazo-3-p-nitrobenzyloxycarbonyl-2-oxopropyl)-(3R)-[(1S)-(p-nitro-benzyl-
oxy-carbonyl-oxy)ethyl]-2-azetidinone 7:   7 was synthesized from 6 following the 
procedure described above for 7a and 7b.   The resulting crude oil was purified by silica 
gel chromatography (hexanes:EtOAc, 1:1 to 8:2) to yield 7 (270 mg, 61%).  1H-NMR 
(400 MHz, CDCl3) 7: δ 8.24 (d, J = 8.8 Hz, 2H), 8.22 (d, J = 8.7 Hz, 2H), 7.54 (d, J = 8.8 
Hz, 2H) 7.50 (d, J = 8.8 Hz, 2H), 6.00 (br s, 1H), 5.30 (d, J = 5.8 Hz, 2H), 5.26 (s, 2H), 
5.09 (qd, 1 = 6.2, 4.5 Hz, 1H), 4.17 (ddd, J = 9.5, 5.4, 3.9 Hz, 1H), 3.47 (td, J = 5.1, 1.7 
Hz, 1H),  3.27 (dd, J = 18.2, 3.9 Hz, 1H), 3.15 (dd, J = 18.2, 9.4 Hz, 1H), 1.50 (d, J = 6.4 
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Hz, 3H). 1H NMR data matched the spectrum reported in the literature5. 
p-Nitrobenzyl (5R), (6S)-[(1S)-(p-nitro-benzyl-oxy-carbonyl-oxy)ethyl]-3,7-dioxo-1-
azabicyclo[3.2.0]heptane-2-carboxylate 8.  8 was synthesized from 7c following the 
procedures of Kametani et al.5.  A catalytic amount of rhodium (II) acetate was added to 
7c (78 mg, 0.140 mmol) in a solution of benzene (6 mL) at 80 ºC and was stirred for 30 
min. The reaction mixture was filtered through Celite and concentrated in vacuo to yield 
8 as a white foam (75 mg, 99%).  1H-NMR (400 MHz, CDCl3) 8: δ 8.25 (d, J = 7.3 Hz, 
4H), 7.54 (d, J = 8.6 Hz, 4H), 5.31 (q, J = 11.3 Hz, 2H),  5.24 (s, 2H), 5.12 (dt, J = 12.8, 
6.5 Hz, 2H), 4.74 (s, 1H), 4.30 (dd, J = 13.1, 7.6 Hz, 1H), 3.85 (t, J = 6.0 Hz, 1H),  2.72 
(dd, J = 18.6, 8.0 Hz, 1H), 2.61 (dd, J = 19.1, 7.8 Hz, 1H), 1.47 (d, J = 6.3 Hz, 3H). 1H 
NMR data matched the spectrum reported in the literature5. 
p-Nitrobenzyl (5R)-(2-Acetamidoethylthio)-(6R)-[(1S)-1-(p-nitro-benzyl-oxy-
carbonyl-oxy)ethyl]-7-oxo-1-azabicyclo-[3.2.0]hept-2-ene-2-carboxylate 9.  9 was 
synthesized from 8 following the procedures of Kametani et al.5.  Diisopropylethylamine 
(37 μL, 0.213 mmol) was added to 8 (75 mg, 0.142 mmol) in acetonitrile (1.23 mL) at 0 
ºC.  Diphenylchlorophosphate (36 μL, 0.174 mmol) was added, and after stirring for 1 h 
at 0 ºC solutions of diisopropylethylamine (37 μL, 0.213 mmol) in acetonitrile (1 mL) 
and N-acetylcysteamine (21 μL, 0.198 mmol) in acetonitrile (1 mL) were added.  After 1 
h of stirring at 0 ºC, the reaction was diluted with ethyl acetate (20 mL) and washed three 
times with 100 mmol K2HPO4 pH = 7.0 (20 mL).  The organic layer was washed with 
brine and dried with anhydrous sodium sulfite, filtered, and concentrated in vacuo.  The 
crude oil was purified by silica gel chromatography (DCM:MeOH, 97:3) to give 9 (51 
mg, 57%) as a yellow oil. 1H-NMR (400 MHz, CDCl3) 9: δ 8.19 (d, J = 8.4 Hz, 2H), 8.18 
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(d, J = 8.5 Hz, 2H), 7.62 (d, J = 8.5 Hz, 2H), 7.53 (d, J = 8.7 Hz, 2H), 5.94 (br t, J = 5.6 
Hz, 1H), 5.35 (q, J = 13.7 Hz, 2H), 5.22 (dd, J = 9.2, 4.8 Hz, 2H), 5.15 (dt, J = 13.5, 6.7 
Hz, 1H), 4.32 (td, J = 9.4, 6.1 Hz, 1H), 3.77 (dd, J = 7.5, 6.3 Hz, 1H), 3.31 (dd, J = 17.9, 
9.7 Hz, 1H),  3.14 (dd, J = 18.1, Hz, 1H), 3.00 (dt, J1 = 13.3, J2 = 6.8 Hz, 2H), 2.88-2.80 
(m, 1H), 2.65 (q, J = 7.4 Hz, 2H), 1.95 (s, 3H), 1.43 (d, J = 6.3 Hz, 3H). 1H NMR data 
matched the spectrum reported in the literature5. 
p-Nitrobenzyl (5R)-[2-(N-(3-amino-3-oxopropyl)-3,3-dimethyl-(2R),4-
bis((triethylsilyl)oxy)butanamide)ethylthio]-(6R)-[(1S)-1-(p-nitro-benzyl-oxy-
carbonyl-oxy)ethyl]-7-oxo-1-azabicyclo-[3.2.0]hept-2-ene-2-carboxylate 10:  10 was 
synthesized from 8 following the procedure described above for 95.  The crude oil was 
purified by silica gel chromatography (DCM:MeOH, 97:3)  to give 10 (108 mg, 47%) as 
a colorless oil. 1H-NMR (400 MHz, CDCl3) 10: δ 8.27-8.20 (m, 4H), 7.66-7.50 (m, 4H), 
6.74 (br s, 1H), 6.26 (br s, 1H), 5.39 (q, J = 13.9 Hz, 2H), 5.28-5.22 (m, 3H), 4.37-4.10 
(m, 1H), 4.01 (s, 1H), 3.62-3.42 (m, 6H), 2.81 (t, J = 6.4 Hz, 2H), 2.5 (t,  J = 6.0 Hz, 2H),  
1.44 (d, J = 6.3 Hz, 3H), 1.02-0.94 (m, 18H), 0.67-0.59 (m, 12H).  HRMS (ESI), 
C34H39N5O14S [M+H+] calculated: 1002.4022; found: 1002.4089. 
p-Nitrobenzyl (5R)-[2-(N-(3-amino-3-oxopropyl)-3,3-dimethyl-(2R),4-
butanamide)ethylthio]-(6R)-[(1S)-1-(p-nitrobenzyloxycarbonyloxy)ethyl]-7-oxo-1-
azabicyclo-[3.2.0]hept-2-ene-2-carboxylate 11.  Acetic acid (24 μL, 0.426 mmol) was 
added to 10 (108 mg, 0.106 mmol) in tetrahydrofuran (3 mL) at 0 ºC.  A solution of 
tetrabutylammonium fluoride in tetrahydrofuran (234 μL, 1M, 0.234 mmol) was added, 
and after stirring for 1 h at 0 ºC the reaction was diluted with ethyl acetate (20 mL) and 
washed two times with water (10 mL).  The organic layer was washed with brine and 
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dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo.  The crude oil 
was purified by silica gel chromatography (DCM:MeOH, 95:5)  to give 11 (29 mg, 37%) 
as a colorless oil. 1H-NMR (400 MHz, MeOD) 11: δ 8.11 (d, J = 8.8 Hz, 2H), 8.11 (d, J = 
8.9 Hz, 2H), 7.61 (d, J = 8.8 Hz, 2H), 7.52 (d, J = 8.8 Hz, 2H), 5.21 (s, 2H), 5.20 (ABq, 
JAB = 13.8 Hz, 2H), 5.17-5.10 (m, 1H), 4.29 (td, J = 9.4, 6.0 Hz, 1H), 3.82-3.79 (m, 2H), 
3.79 (s, 1H), 3.44-3.33 (m, 4H), 3.32 (ABq, JAB = 11.0 Hz, 2H), 2.92 (dt, J = 13.5, 6.7 
Hz, 1H), 2.82 (dt, J = 13.7, 7.0 Hz, 2H), 2.32 (t, J = 6.6 Hz, 1H), 1.36 (d, J = 6.3 Hz, 3H). 
13C-NMR (101 MHz, MeOD) 11: 175.7, 174.6, 172.6, 160.7, 147.5, 143.7, 142.9, 128.2, 
127.8, 123.2, 123.1, 75.9, 71.8, 68.9, 67.8, 64.7, 60.1, 56.8, 52.4, 39.4, 39.0, 35.4, 35.0, 
34.9, 19.9, 19.5, 19.4, 17.9, 13.0. HRMS (ESI), C34H39N5O14S [M+H+] calculated: 
774.2292; found: 774.2291. 
(5R)-(2-Acetamidoethylthio)-(6R)-[(1S)-1-hydroxyethyl]-7-oxo-1-azabicyclo-
[3.2.0]hept-2-ene-2-carboxylate (epithienamycin A) 12: 12 was synthesized from 9 
following the procedures of Kametani et al.5.   A small scoop of palladium hydroxide (50 
mg, 50% suspension in water) was added to a solution of 11 in tetrahydrofuran (5 mL) 
and aqueous sodium bicarbonate (5 mL, 0.0319M) in a bomb flask.  The flask was fitted 
to a Parr-shaker apparatus to which hydrogen was added to 40 psi.  The reaction mixture 
was shaken for 1 h and the mixture was filtered through Celite and washed with diethyl 
ether (10 mL).  The aqueous layer was collected and purified immediately by HPLC 
(semi preparatory C18, method 2).  The desired peak eluted at 10 min and was collected 
and lyophilized to yield 12 as a white powder.  1H NMR (400 MHz, D2O) δ ppm 4.22-
4.35 (m, 1H), 4.18 (dd, J = 8.3, 6.4 Hz, 1H), 3.61 (dd, J = 8.4, 5.7 Hz, 1H), 3.40 (t, J = 
6.6 Hz, 2H), 3.12 (quin, J = 8.6 Hz, 1H), 3.02 (ddd, J = 13.4, 8.6, 6.5, 1H), 2.89 (ddd, J = 
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13.9, 11.8, 6.8, 1H), 2.66-2.82 (m, 1H), 1.99 (s, 3H), 1.25 (d, J = 6.3 Hz, 3H). 1H NMR 
matched the spectrum reported in the literature5. 
(5R)-[2-(N-(3-amino-3-oxopropyl)-3,3-dimethyl-(2R),4-butanamide)ethylthio]-(6R)-
[(1S)-1-(hydroxy)ethyl]-7-oxo-1-azabicyclo-[3.2.0]hept-2-ene-2-carboxylate 
(OA6129-B1) 13:  13 was synthesized from 11 following the procedure described above 
for 125.  The peak eluted at 10 min (method 2), was collected and lyophilized to yield 1.9 
mg 13 as a white powder. 1H-NMR (400 MHz, D2O) 13: δ 4.20 (dt, J = 12.3, 6.6 Hz, 2H), 
3.49 (s, 1H), 3.50-3.47 (m, 2H), 3.40-3.30 (m, 2H), 3.27 (dd, J = 17.6, 9.8 Hz, 2H), 3.11 
(dd, J = 17.3, 9.0 Hz, 1H), 2.99 (dt, J = 13.4, 6.5 Hz, 1H), 2.89 (dt, J = 13.3, 6.6 Hz, 1H), 
2.49 (t, J = 5.7, 2H), 1.27 (d, J = 6.2, 3H), 0.90 (s, 3H), 0.086 (s, 3H). 13C-NMR (101 
MHz, MeOD) 13: 179.5, 175.1, 174.0, 168.3, 160.9, 145.6, 139.5, 130.0, 75.7, 68.3, 64.9, 
52.4, 39.3, 38.6, 35.4, 35.3, 30.7, 20.5, 20.5, 20.0. 1H NMR matched the spectrum 
reported in the literature28. 
p-Nitrobenzyl (5R), (6S)-[(1R)-(p-nitrobenzyloxycarbonyloxy)ethyl]-3,7-dioxo-1-
azabicyclo[3.2.0]heptane-2-carboxylate 14a and p-Nitrobenzyl (5R), (6S)-[(1S)-(p-
nitrobenzyloxycarbonyloxy)ethyl]-3,7-dioxo-1-azabicyclo[3.2.0]heptane-2-
carboxylate 14b.  14a and 14b was synthesized from 7a and 7b following the procedure 
described above for 836.  14a and 14b were obtained as a mixture of diastereomers (179 
mg, 99%).  1H-NMR (400 MHz, CDCl3) 14a: δ 8.24 (d, J = 8.9 Hz, 4H), 7.55 (d, J = 8.9 
Hz, 2H), 7.55 (d, J = 8.9 Hz, 2H), 5.31 (q, J = 14.2 Hz, 2H),  5.39-5.22 (m, 3H), 4.78 (s, 
1H), 4.07 (td, J = 7.3, 1.9 Hz, 1H), 3.48 (dd, J = 4.8, 2.0 Hz, 1H),  2.90 (ddd, J = 6.9, 3.8, 
0.6 Hz, 1H), 2.47 (dd, J = 19.2, 7.5 Hz, 1H), 1.53 (d, J = 6.5 Hz, 3H). 14b: δ 8.24 (d, J = 
8.9 Hz, 2H), 7.55 (d, J = 8.9 Hz, 2H), 7.55 (d, J = 8.9 Hz, 2H), 5.31 (q, J = 14.2 Hz, 2H), 
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5.39-5.22 (m, 3H), 4.77 (s, 1H), 4.14 (td, J = 7.3, 2.3, 1H), 3.38 (dd, J = 8.0, 2.0 Hz, 1H),  
2.96 (ddd, J = 6.9, 3.9, 0.7 Hz, 1H), 2.47 (dd, J = 18.8, 7.8 Hz, 1H), 1.51 (d, J = 6.4 Hz, 
3H). 1H NMR matched the spectra reported in the literature36. 
p-Nitrobenzyl (5R)-(2-Acetamidoethylthio)-(6S)-[(1R)-1-p-nitro-benzyl-oxy-
carbonyl-oxy-ethyl]-7-oxo-1-azabicyclo-[3.2.0]hept-2-ene-2-carboxylate 15a and p-
Nitrobenzyl (5R)-(2-Acetamidoethylthio)-(6S)-[(1S)-1-p-nitro-benzyl-oxy-carbonyl-
oxy-ethyl]-7-oxo-1-azabicyclo-[3.2.0]hept-2-ene-2-carboxylate 15b.  15a and 15b was 
synthesized from 14 following the procedure described above for 9. The crude 
diastereomers were purified by silica gel chromatography (DCM:MeOH, 95:5) to give 
15a and 15b (178 mg, 80%) as a mixture of diastereomers.  4.22-4.44 (m, 2H), 3.35-3.6 
(m, 2H), 3.12 (dd, J = 17.5, 8.0 Hz, 1H), 2.81-3.22 (m, 2H), 2.66-2.82 (m, 2H), 1.99 (s, 
3H), 1.41 (d, J = 6.0 Hz, 3H).  1H NMR matched the spectra reported in the literature37. 
p-Nitrobenzyl (5R)-[2-(N-(3-amino-3-oxopropyl)-3,3-dimethyl-(2R),4-
bis((triethylsilyl)oxy)butanamide)ethylthio]-(6S)-[(1R)-1-(hydroxyl)ethyl]-7-oxo-1-
azabicyclo-[3.2.0]hept-2-ene-2-carboxylate 16:  16 was synthesized from 14 following 
the procedure described above for 9. The crude oil was purified by silica gel 
chromatography using (DCM:MeOH, 97:3) to give 16 (380 mg, 86%) as a colorless oil.  
1H NMR (300 MHz, CDCl3) δ ppm 8.18-8.27 (m, 2H), 7.60-7.68 (m, 2H), 6.90 (s, 1H), 
6.72 (d, J = 0.4 Hz, 1H), 5.45-5.53 (m, 1H), 4.18-4.32 (m, 1H), 4.06 (s, 1H), 3.48-3.57 
(m, 2H), 3.37-3.47 (m, 3H), 3.27-3.34 (m, 1H), 3.19-3.24 (m, 1H), 3.06-3.17 (m, 1H), 
2.94-3.06 (m, 1H), 2.90 (s, 1H), 2.35-2.49 (m, 2H), 1.30-1.40 (m, 3H), 0.85-1.01 (m, 
18H), 0.80 (s, 3H), 0.77-0.82 (m, 3H), 0.51-0.68 (m, 12H). HRMS (ESI), C34H39N5O14S 




ene-2-carboxylate 17.  17 was synthesized from 16 following the procedure described 
above for 11.  The crude oil was purified by silica gel chromatography using 5% 
methanol in dichloromethane to give 17 (89.5 mg, 51%) as a colorless oil. 1H NMR (400 
MHz, MeOD) δ ppm  8.13 (d, J = 8.8 Hz, 2H), 7.6 (d, J = 19.6 Hz, 2H), 5.3 (dd, J = 1.0 
Hz, 2H), 4.1-4.2 (m, 1H), 4.01 (t, J = 6.44 Hz, 1H), 3.79 (s, 1H), 3.29-3.41 (m, 7H), 3.27 
(d, J = 6.44 Hz, 1H), 3.11-3.20 (m, 1H), 2.95 (d, J = 6.9 Hz, 1H), 2.88 (d, J = 7.0 Hz, 
1H), 2.3 (t, J = 6.7 Hz, 2H), 1.20 (d, 3H, J = 6.3 Hz), 0.94 (t, J = 7.3 Hz, 2H), 0.82 (s, 
6H). HRMS (ESI), C34H39N5O14S [M+H+] calculated: 774.2292; found: 774.2301. 
(5R)-[2-(N-(3-amino-3-oxopropyl)-3,3-dimethyl-(2R),4-butanamide)ethylthio]-(6S)-
(1R)-1-hydroxyethyl-7-oxo-1-azabicyclo-[3.2.0]hept-2-ene-2-carboxylate (OA6129-
B2) 19:  19 was synthesized from 17 following the procedure described above for 125.  
The aqueous layer was collected and purified immediately by HPLC (semi preparatory 
C18, method 2).  The peak eluted at 9 min was collected and lyophilized to yield 5.2 mg 
19 as a white powder. 1H NMR (400 MHz, D2O) δ ppm 4.19 (spt, J = 1.0 Hz, 2H), 3.96 
(s, 1H), 3.52-3.52 (m, 3H), 3.45-3.56 (m, 3H), 3.33-3.43 (m, 3H), 3.26 (dd, J = 1.0 Hz, 
1H), 3.11 (dd, J = 1.0 Hz, 1H), 3.00 (dd, J = 1.0 Hz), 2.89 (dd, J=1.0 Hz, 1H), 2.49 (br s, 
2H), 1.27 (d, J = 6.2 Hz, 1H), 0.90 (s, 4H), 0.86 (s, 3H). 1H NMR matched the spectrum 
reported in the literature28. 
 
Synthesis of 3,4-cis-azetidinones: 
D-aspartic acid dibenzyl ester p-toluenesulfonic acid salt 20:  p-toluenesulfonic acid 
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(145.6 g) was added to D-aspartic acid (50 g) in benzyl alcohol (300 mL) and benzene 
(150 mL) and was heated to reflux in a 1 L round-bottom flask fitted with a Dean-Stark 
trap and a reflux condenser.  The reaction mixture was stirred for 16 h ,then allowed to 
cool before it was diluted with benzene (600 mL) and diethyl ether (1.2 L).  The resulting 
white crystals were filtered and rinsed with diethyl ether to yield 20 (384 g, 99%).1H 
NMR (400 MHz, CDCl3) δ ppm 7.13 - 7.55 (m, 14H). 5.19 (br. s, 3H) 4.46 (t, J = 6.00 
Hz, 1H) 3.01 (m, 2H), 2.28 (s, 3H).  1H NMR results matched the spectrum reported in 
the literature38.  
N-tert-butyldimethylsilyl-D-aspartic acid dibenzyl ester 21:  A solution of 20 (150 g, 
309 mmol) in dichloromethane (1 L) was washed twice with 500 mL saturated sodium 
bicarbonate.  Once the evolution of carbon dioxide ceased, the phases were separated and 
the organic layer was washed with water (500 mL), dried with anhydrous magnesium 
sulfate and filtered.  tert-Butyldimethylsilyl chloride (51.24 g, 339.99 mmol), 
dimethylaminopyridine (1.89 g, 15.45 mmol), and triethylamine (108 mL, 772.5 mmol) 
were added sequentially to the free amine in dichloromethane and the reaction mixture 
was stirred for 16 h.  The reaction mixture was washed with saturated ammonium 
chloride (1 L), with saturated sodium bicarbonate (500 mL), water (500 mL), brine (500 
mL) and was dried with anhydrous magnesium sulfate, filtered, and concentrated in 
vacuo to give 21 (123.4 g, 93%), which was used without purification. 1H NMR (400 
MHz, CDCl3) δ ppm 7.27 - 7.50 (m, 10H). 5.18 (br. s, 1H) 4.07 (dd, J = 6.00, 2.84 Hz, 
1H) 3.33 (dd, J = 15.2, 6.0 Hz, 1H), 3.07 (dd, J = 15.2, 2.8 Hz, 1H), 0.92 (s, 18H), 0.24 
(s, 3H), 0.08 - 0.11 (m, 3H). 1H NMR results matched the spectrum reported in the 
literature20. 
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N-tert-butyldimethylsilyl 4(R)-carboxy-2-azetidinone benzyl ester 22:  tert-
Butylmagnesium chloride in diethylether (194 mL, 1.7 M, 300 mmol) was added to a 
solution of 21 in diethylether (1.2 L) dropwise at 0 °C and was stirred overnight.  The 
reaction mixture was cooled to 0 °C and quenched with saturated ammonium chloride 
(200 mL), the phases were separated and the organic layer was washed with water (500 
mL).  The combined aqueous layers were extracted twice with diethyl ether (200 mL).  
The combined organic fractions were dried with anhydrous sodium sulfate, concentrated, 
and immediately purified by silica gel (800 mL) chromatography using a gradient of 
100% hexanes to 30% ethyl acetate in hexanes to yield 22 (63 g, 69%) as a yellow oil. 1H 
NMR (300 MHz, CDCl3) δ ppm 7.29 - 7.42 (m, 5H), 4.07 (dd, J = 6.0, 2.9 Hz, 1H), 3.33 
(dd, J = 15.1, 6.0 Hz, 1H) 3.07 (dd, J = 15.16, 2.87 Hz, 1H) 0.92 - 0.94 (m, 9H) 0.24 (s, 
3H) 0.10 (s, 3H).  1H NMR results matched the spectrum reported in the literature20. 
N-tert-butyldimethylsilyl 4(R)-carboxy-2-azetidinone 23:  A catalytic amount of 
palladium on carbon (1 g, 2% w/w) was carefully added to a solution of 22 (68.7 g, 215 
mmol) in ethanol (100 mL) in a bomb flask that was pressurized to 40 psi with hydrogen 
gas in a Parr-shaker apparatus.  The reaction mixture was shaken for 1 h before it was 
filtered through Celite and concentrated in vacuo.  The crude oil was purified by 
crystallization in a minimum amount of hot diethyl ether.  The remaining of the product 
can be crystallized from the mother liquor by the addition of petroleum ether to yield 23 
(37 g, 75%).  1H NMR (400 MHz, CDCl3) δ ppm 4.07 (t, J = 1.0 Hz, 1H), 3.39 (dd, J = 
15.3, 6.1 Hz, 1H) 3.12 (d, J = 15.7 Hz, 1H), 0.89 (s, 9H) 0.30 (s, 3H), 0.11 (s, 3H). 1H 
NMR results matched the spectrum reported in the literature20. 
N-tert-butyldimethylsilyl 4(R)-carboxy-3(R)-(1(R)-hydroxy)ethyl-2-azetidinone 24a 
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and N-tert-butyldimethylsilyl 4(R)-carboxy-3(R)-(1(S)-hydroxy)ethyl-2-azetidinone 
24b:  A solution of n-butyllithium in hexanes (22.8 mL, 2.1 M, 48 mmol) was added to 
diisopropylamine (6.7 mL, 48 mmol) tetrahydrofuran (50 mL) dropwise at 0 °C.  After 
stirring for 15 min, a solution of 23 (5.0 g, 21.8 mmol) in tetrahydrofuran (50 mL) was 
added over 5 min and then stirred vigorously for 15 min at 0 °C.  Acetaldehyde (3.7 mL, 
65.4 mmol) was added to the reaction mixture and then it was stirred for 1 h at 0 °C 
before allowing to warm to ambient temperature over an additional hour.  The reaction 
mixture was diluted with ethyl acetate (100 mL) and quenched with saturated monobasic 
potassium sulfate (100 mL).  The phases were separated and the aqueous layer was 
extracted twice with ethyl acetate (125 mL).  The combined organic layers were washed 
with water (125 mL), brine (125 mL), dried with anhydrous sodium sulfate and 
concentrated in vacuo.  The crude red oil was used for the next reaction without 
purification. 
N-tert-butyldimethylsilyl 4(S)-acetoxy-3(R)-(1(R)-hydroxy)ethyl-2-azetidinone 25a 
and N-tert-butyldimethylsilyl 4(S)-acetoxy-3(R)-(1(S)-hydroxy)ethyl-2-azetidinone 
25b:  25a and 25b were synthesized from 24a and 24b following the procedures of Ito et 
al.24. Dried lead (IV) tetraacetate and copper (II) acetate was added to 24a and 24b (10.8 
g, 39.5 mmol) in acetonitrile (198 mL).  A constant stream of nitrogen was bubbled 
through the reaction mixture while it was heated to 65 °C and stirred for 2 h.  The 
reaction mixture was filtered through Celite, and the Celite plug was washed with ethyl 
acetate.  The combined eluate was concentrated in vacuo.  The residue was redissolved in 
ethyl acetate (100 mL) and saturated sodium bicarbonate (100 mL) was added.  The pH 
of the aqueous phase was adjusted to 7 and the phases were separated.  The organic layer 
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was washed with brine, dried with anhydrous sodium sulfate and concentrated in vacuo.  
The crude oil was purified by silica gel chromatography with 50% diethyl ether in 
hexanes to give 25a and 25b as a mixture of diastereomers (3.06 g, 48%).  25a: 1H NMR 
(400 MHz, CDCl3) δ ppm) 5.81 (d, J = 0.9 Hz, 1H). 4.04 - 4.17 (m, 1H) 3.20 (dd, J = 4.5, 
1.0 Hz, 1H), 2.10 (s, 3H), 1.35 (d, J = 6.6 Hz, 2H) 0.97 (s, 9H), 0.31 (s, 3H), 0.24 (s, 3H). 
25b: 1H NMR (400 MHz, CDCl3) δ ppm 5.80 (s, 1H), 4.17 - 4.26 (m, 1H), 3.88 - 4.00 (m, 
1H), 3.08 - 3.16 (m, 1H), 2.12 (s, 3H), 1.33 (d, J = 6.4 Hz, 3H), 0.96 (s., 9H), 0.31 (s, 
3H), 0.24 (s, 3H).  1H NMR results matched those reported in the literature24. 
N-tert-butyldimethylsilyl 4(S)-acetoxy-3(R)-(1(R)-ethylcarbonyloxy)ethyl-2-
azetidinone 26a and N-tert-butyldimethylsilyl 4(S)-acetoxy-3(R)-(1(S)-
ethylcarbonyloxy)ethyl-2-azetidinone 26b:  Dimethylaminopyridine (425 mg, 3.48 
mmol) was added to 25a and 25b (500 mg, 1.74 mmol) in dichloromethane (15 mL) at 0 
°C.  Propionyl chloride (313 μL, 3.48 mmol) was added to the reaction mixture and was 
allowed to stir for 16 h at 0 °C.  The reaction was quenched with saturated ammonium 
chloride (10 mL) and the phases were separated.  The aqueous layer was extracted with 
dichloromethane (10 mL) and the combined organic layers were washed with brine (20 
mL), filtered and concentrated in vacuo.  The crude oil was purified by silica gel 
chromatography to yield 26a and 26b as a mixture of diastereomers (351 mg, 59%).  26a: 
1H NMR (400 MHz, CDCl3) δ ppm = 5.76 (s, 1H), 5.24 (q, J = 6.4 Hz, 1H) 3.28 (d, J = 
3.5 Hz, 1H) 2.31 (q, J = 7.5 Hz, 2H) 1.40 (d, J = 6.51 Hz, 1H) 1.13 (t, J = 7.52 Hz, 3H) 
0.97 (s, 9H) 0.26 (s, 3H) 0.22 (s, 3H).  26b: 1H NMR (400 MHz, CDCl3) δ ppm = 6.05 
(s, 1H), 5.30 (qd, J1 = 6.5, J2 = 3.2 Hz, 1H), 3.24 (d, J = 6.3 Hz, 1H), 2.31 (s, 3H), 2.08 
(q, J = 7.54 Hz, 2H), 1.36 (d, J = 6.38 Hz, 3H), 1.13 (t, J = 7.52 Hz, 3H), 0.97 (s, 9H) 
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0.25 (s, 3H), 0.21 (s, 3H). 
4(S)-acetoxy-3(R)-(1(R)-ethylcarbonyloxy)ethyl-2-azetidinone 27a and 4(S)-acetoxy-
3(R)-(1(S)-ethylcarbonyloxy)ethyl-2-azetidinone 27b: A solution of hydrogen fluoride 
in pyridine (200 μL, 30% w/v) was added to 26a and 26b (65 mg, 0.189 mmol) in 
tetrahydrofuran (1.89 mL) at 0 °C and was stirred for 10 min.  The reaction mixture was 
diluted with ethyl acetate (20 mL) and washed twice with saturated ammonium chloride 
(10 mL).  The combined aqueous layers were extracted with ethyl acetate (10 mL) and 
the combine organic fractions were washed with brine (10 mL), dried with anhydrous 
sodium sulfate, filtered and concentrated in vacuo.  The crude oil was purified by silica 
gel chromatography using 30% ethyl acetate in hexanes to give 27a and 27b as a mixture 
of diastereomers (36 mg, 83%).  27a: 1H NMR (300 MHz, CDCl3) δ ppm 6.62 (br. s., 
1H), 5.58 (d, J = 1.3 Hz, 1H), 5.25 (q, J = 13.0 Hz, 1H), 3.39 (dd, J = 3.8, 1.4 Hz, 1H), 
2.35 (t, J = 1.0 Hz, 2H), 2.10 (s, 3H), 1.41 (d, J = 1.0 Hz, 3H), 1.14 (t, J = 1.0 Hz, 3H).  
27b: 1H NMR (300 MHz, CDCl3) δ ppm 6.64 (br. s., 1H), 5.79 (d, J = 1.3 Hz, 1H), 5.30 
(dq, J = 6.6, 3.3 Hz, 1H), 3.33 (dd, J = 6.3, 1.3 Hz, 1H), 2.30 (t, J = 1.0 Hz, 2H), 2.11 (s, 
3H), 1.37 (d, J = 6.4 Hz, 3H), 1.11 (q, J = 1.0 Hz, 3H). 
N-tert-butyldimethylsilyl 4(S)-acetoxy-3(R)-[1(R)-(1-bromoethylcarbonyl)oxy]ethyl-
2-azetidinone 28a and N-tert-butyldimethylsilyl 4(S)-acetoxy-3(R)-[1(S)-(1-
bromoethylcarbonyl)oxy]ethyl-2-azetidinone 28b: Dimethylaminopyridine (170 mg, 
1.392 mmol) was added to 25a and 25b (200 mg, 0.696 mmol) in dichloromethane (5 
mL) at 0 °C.  2-bromopropionyl bromide (147 μL, 1.392 mmol) was added to the reaction 
mixture and was allowed to stir for 2 h at 0 °C.  The reaction was quenched with 
saturated ammonium chloride (10 mL) and the phases were separated.  The aqueous layer 
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was extracted with dichloromethane (10 mL) and the combined organic layers were 
washed with brine (20 mL), filtered and concentrated in vacuo.  The crude oil was 
purified by silica gel chromatography to yield 28a and 28b as a mixture of diastereomers 
(194 mg, 66%) and was carried forward without further purification. 
4(S)-acetoxy-3(R)-[1(R)-(1-bromoethylcarbonyl)oxy]ethyl-2-azetidinone 29a and 
4(S)-acetoxy-3(R)-[1(S)-(1-bromoethylcarbonyl)oxy]ethyl-2-azetidinone 29b: A 
solution of hydrogen fluoride in pyridine (600 μL, 30%w/v) was added to 28a and 28b 
(194 mg, 0.459 mmol) in tetrahydrofuran (4.6 mL) at 0 °C and was stirred for 10 min.  
The reaction mixture was diluted with ethyl acetate (20 mL) and washed twice with 
saturated ammonium chloride (20 mL).  The combined aqueous layers were extracted 
with ethyl acetate (20 mL) and the combine organic fractions were washed with brine (20 
mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuo.  The crude 
oil was purified by silica gel chromatography using 30% ethyl acetate in hexanes to give 
29a and 29b as a mixture of diastereomers (116 mg, 82%). 29a: 1H NMR (300 MHz, 
CDCl3) δ ppm 5.81 (d, J = 1.4 Hz, 1H), 5.21 - 5.40 (m, 1H), 4.27 - 4.48 (m, 1H), 3.43 
(dd, J = 3.5, 1.4 Hz, 1H), 2.12 (s, 3H) 1.83 (t, J = 2.9 Hz, 3H) 1.47 (d, J = 3.4 Hz, 3H).  
29b: 1H NMR (300 MHz, CDCl3) δ ppm 5.81 (d, J = 1.4 Hz, 1H), 5.24 - 5.42 (m, 1H), 
4.30 - 4.44 (m, 1H), 3.38 (ddd, J = 6.7, 3.9, 1.3 Hz, 1H), 2.11 (s, 3H) 1.80 (t, J = 2.9 Hz, 
3H), 1.45 (d, J = 3.4 Hz, 3H). 
(3R,4R)-N-(4-methoxyphenyl)-3-((R)-1-hydroxyethyl)-4-[(E)-styryl]-2-azetidinone 
(32a) and (3R,4S)-N-(4-methoxyphenyl)-3-((R)-1-hydroxyethyl)-4-[(E)-styryl]-2-
azetidinone (32b).  32a and 32b was synthesized following the procedures of Gallucci et 
al26. A solution of (3R)-hydroxybutyric acid ethyl ester (5.00g, 37.8 mmol) in 
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tetrahydrofuran (25 mL) was added dropwise to a solution of lithium 
bis(trimethylsilyl)amide in tetrahydrofuran (96.8 mL, 0.809M, 78.3 mmol) at -78 °C and 
stirred for 1h.  A solution of 47 (8.98 g, 37.8 mmol) in tetrahydrofuran (75 mL) was 
added dropwise to the solution at -78 °C and was allowed to warm to room temperature 
while stirring over 20 h.  The reaction mixture was diluted with dichloromethane (500 
mL) and washed with saturated aqueous ammonium chloride (500 mL).  The aqueous 
layer was extracted twice with dichloromethane (400 mL).  The combined organic layers 
were dried with anhydrous magnesium sulfate, filtered and concentrated in vacuo.  The 
crude oil was purified by silica gel chromatography (hexanes:ethyl acetate, 7:3) to yield 
26a and 26b as a mixture of diastereomers (6.85 g, 53%).  TLC (hexanes:ethyl acetate, 
7:3) = 0.35.  32a: 1H-NMR (300 MHz, CDCl3) δ. 7.37-7.41 (m, 5H), 7.27 (d, J = 8.4 Hz, 
2H), 6.84 (d, J = 7.6 Hz, 2H), 6.30 (dd, J = 15.7, 10.5 Hz, 1H), 4.49 (d, J = 8.3 Hz, 1H), 
4.21 (tt, J = 10.9, 5.5 Hz, 1H), 3.76 (s, 3H), 3.14 (d, J = 6.2 Hz, 1H), 1.41 (d, J = 6.3 Hz, 
3H). HRMS (FAB), C20H22NO3 [M+H+] calculated: 324.15997; found: 324.16013; Δ 0.5 
ppm.  32b: 1H-NMR (300 MHz, CDCl3) δ  7.37-7.41 (m, 5H), 7.27 (d, J = 8.4 Hz, 2H), 
6.84 (d, J = 7.6 Hz, 2H), 6.4 (dd, J = 16.2, 9.0 Hz, 1H), 4.75 (t, J = 7.4 Hz, 1H), 4.22 (tt, 
J = 11.4, 5.7 Hz, 1H), 3.76 (s, 3H), 3.45 (t, J = 6.3 Hz, 1H), 1.33 (d, J = 6.3 Hz, 3H).  
HRMS (FAB), C20H22NO3 [M+H+] calculated: 324.15997; found: 324.1601. 1H NMR 
results matched those reported in the literature26. 
(1S,2R,4S,5R)-4-Hydroxy-6-(4-methoxyphenyl)-2-methyl-3-oxa-6-
azabicyclo[3.2.0]heptan-7-one (33).  33 was synthesized following the procedures of 
Gallucci et al26. Ozone was passed through a solution containing a mixture of 32a and 
32b (8.61g, 26.6 mmol) in dichloromethane (270mL) at -78 °C until the color of solution 
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changed from yellow to near colorless.  The bubbling of ozone must cease before the 
solution becomes blue or green as over-oxidation by degradation of the 4-methoxyhenyl 
group occurred.  The reaction can also be monitored by TLC.  Once complete, dimethyl 
sulfide (45 mL) is added and stirred at room temperature.  The crude solution was 
concentrated directly in vacuo to provide 33 as a pale yellow oil.  Silica chromatography 
(hexanes:ethyl acetate, 3:2) provides 33 and the trans aldehyde 34, which are purified as 
a mixture (4.02 g, 16.1 mmol, 85%).  34 and 33 in dichloromethane (100 mL) were 
subjected to 1,8-diazobicyclo[5.4.0]undec-7-ene (0.6 mL, 4.0 mmol) and the reaction 
mixture was refluxed for 70 min.  The product solution was diluted with dichloromethane 
(300 mL), washed with 0.2 N HCl (300 mL), and the aqueous layer was extracted twice 
with dichloromethane (200 mL).  The combined organic layers were dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo.  Purification by silica gel 
chromatography (hexanes:ethyl acetate, 1:1) provided 33 as a white solid (2.53 g, 10.15 
mmol, 63% from 34, 38% from 32a and 32b). 33: TLC (hexanes:ethyl acetate, 3:2) = 
0.25. 1H NMR (400 MHz, CDCl3) δ 7.30 (d, J = 8.8 Hz, 2H), 6.86 (d, J = 9.0 Hz, 2H), 
5.55 (s, 1H), 4.42 (t, J = 6.1 Hz, 2H), 4.39 (d, J = 4.0 Hz, 1H), 3.77 (s, 3H), 3.73 (q, J = 
3.2 Hz, 1H), 1.51 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 162.45, 156.21, 
130.89, 117.61, 114.51, 94.96, 71.30, 61.18, 60.42, 56.59, 55.48, 21.02, 15.67, 14.15.  
HRMS (FAB), C13H16NO4 [M+H+] calculated: 250.10793; found: 250.1079.  1H and 13C 
NMR results matched those reported in the literature26. 
[3R,4R(E)]-3-[1(R)-Hydroxyethyl]-4-(2-methoxyethenyl)-1-(4-methoxyphenyl)-2-
azetidinone (35) and (1R,2R,4S,6R)-4-Methoxy-7-(4-methoxyphenyl)-2-methyl-3-
oxa-7-azabicyclo[4.2.0]octan-8-one (36).  36 was synthesized following the procedures 
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of Gallucci et al26. A solution of n-butyllithium (2.0 M, 40.6 mmol, 20.3 mL) in hexanes 
was added to a solution of diisopropylamine (5.73 mL, 40.6 mmol) in tetrahydrofuran 
(100 mL) at -78 °C and stirred for 20 min at this temperature.  (Methoxymethyl)-
triphenylphosphonium chloride (10.4 g, 30.45 mmol) was added in one portion and the 
slurry was stirred for 10 min at -78 °C before it was allowed to warm to 0 °C in an ice 
bath and stirred for another 10 min.  The ylid was then cooled to -78 °C and a solution of 
33 (2.53 g, 10.15 mmol) in tetrahydrofuran (100 mL) was added over 5 min.  Once 
addition was complete, the dry ice/acetone bath was removed and the reaction mixture 
allowed to warm to room temperature and then stirred for 20 h.  If desired, the reaction 
can be concentrated and chromatographed (hexanes:ethyl acetate 3:2) at this stage to give 
35 as a white solid.  However, it is much more efficient to proceed directly to 36 without 
purification.  The crude reaction was cooled to 0 °C before it was quenched with 1 N HCl 
(100 mL) over 5 min and then stirred for 5 h.  The solution was diluted with 
dichloromethane (400 mL) and washed with saturated sodium bicarbonate (500 mL).  
The aqueous layer was extracted twice with dichloromethane (200 mL).  The combined 
organic extracts were dried with anhydrous sodium sulfate, filtered and concentrated in 
vacuo.  The crude oil was purified by silica gel chromatography (hexanes:ethyl acetate, 
3:2) to provide 36 as a white solid (1.58 g, 56%).  35: TLC (hexanes:ethyl acetate, 3:2) = 
0.20. MP = 187-188 °C. 1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 9.1 Hz, 2H), 6.85 
(d, J = 9.1 Hz, 2H), 6.74 (d, J = 12.8 Hz, 1H), 4.95 (q, J = 7.5 Hz, 2H), 4.55 (q, J = 5.2 
Hz, 1H), 4.16 (m, 1H), 3.78 (s, 3H), 3.58 (s, 3H), 3.33 (q, J = 4.1 Hz, 1H), 1.34 (d, J = 
6.3 Hz, 3H).  13C NMR (101 MHz, CD3CN_SPE) δ 165.76, 155.99, 152.50, 131.35, 
118.55, 114.21, 97.69, 65.07, 59.67, 56.36, 55.44, 54.73, 22.08.  HRMS (FAB), 
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C15H19NO4 [M+] calculated: 277.13141; found: 277.1315.  36: TLC (hexanes:ethyl 
acetate, 3:2) = 0.40. MP = 120-123 °C. 1H NMR (400 MHz, CDCl3) δ 7.34 (q, J = 3.0 
Hz, 1H), 6.88 (d, J = 9.1 Hz, 1H), 4.73 (q, J = 4.7 Hz, 1H), 4.29 (m, J = 1.9 Hz, 1H), 4.24 
(m, J = 3.1 Hz, 1H), 3.79 (s, 1H), 3.34 (s, 1H), 3.27 (q, J = 2.7 Hz, 1H), 2.60 (m, J = 3.5 
Hz, 1H), 1.82 (m, J = 3.9 Hz, 1H), 1.49 (d, J = 6.5 Hz, 1H). HRMS (FAB), C15H19NO4 
[M+] calculated: 277.13141; found: 277.1315.  1H NMR results matched those reported in 
the literature26. 
(1R,2R,4S,6R)-4-Methoxy-7-(4-methoxyphenyl)-2-methyl-3-oxa-7-azabicyclo-[4.2.0]-
octan-8-one (36).  36 was synthesized following the procedure of Gallucci et al26. 
Dowex 50WX8-100 hydrogen-form resin was added to a solution of 35 (400 mg, 1.4 
mmol) in methanol (25 mL) and the suspension was stirred for 5 h.  The resin was filtered 
and washed with dichloromethane (25 mL) and the filtrate was concentrated in vacuo.  
The product was purified by silica gel chromatography (hexanes:ethyl acetate, 3:1) to 
provide 5 as a white solid (122.5 mg, 31%). 
(1R,2R,4S,6R)-4-Hydroxy-7-(4-methoxyphenyl)-2-methyl-3-oxa-7-
azabicyclo[4.2.0]octan-8-one (37). 36 was synthesized following the procedure of 
Gallucci et al26. 36 (830 mg, 2.99 mmol) was dissolved in 70% formic acid in water (25 
mL) and was stirred for 8 h.  The product was extracted with ethyl acetate, dried with 
anhydrous sodium sulfate, filtered, concentrated, and crystallized from dichloromethane 
and hexanes to provide 37 as white crystals (628 mg, 80%).  37: TLC (hexanes:ethyl 
acetate, 3:2) = 0.20. MP = 155-158 °C. 1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 9.0 
Hz, 2H), 6.88 (d, J = 9.0 Hz, 2H), 5.25 (q, J = 4.7 Hz, 2H), 4.37 (m, J = 2.7 Hz, 1H), 4.31 
(m, J = 3.0 Hz, 1H), 3.79 (s, 1H), 3.27 (q, J = 2.7 Hz, 1H), 2.64 (m, J = 3.4 Hz, 1H), 1.86 
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(m, J = 3.9 Hz, 1H), 1.48 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 171.16, 
164.08, 156.13, 130.93, 118.16, 114.55, 90.16, 63.60, 60.39, 55.50, 52.71, 47.87, 28.05, 
21.04, 18.46, 14.18. HRMS (FAB), C14H17NO4 [M+] calculated: 263.11576; found: 
263.1153. 1H and 13C NMR results matched those reported in the literature26. 
(1R,2R,6R)-7-(4-methoxyphenyl)-2-methyl-3-oxa-7-azabicyclo[4.2.0]octan-4-8-dione 
(38).  Tetra-n-propylammonium perruthenate (6.2 mg, 0.018 mmol) was added to a 
solution of 37 (93 mg, 0.35 mmol), N-methylmorpholine-N-oxide (61.5 mg, 0.525 mmol) 
and 3 Å molecular sieves (10 mg) in dichloromethane (4 mL) and the reaction mixture 
was shielded from light and stirred for 1 h.  The solution was filtered, concentrated and 
purified directly by silica gel chromatography (ethyl acetate) to provide the product as a 
pure solid (59 mg, 65%). 38: TLC (hexanes:ethyl acetate, 1:4) = 0.20. MP = 207-
207.5°C. 1H NMR (400 MHz, CDCl3) δ 7.26 (d, J = 8.9 Hz, 2H), 6.87 (d, J = 9.0 Hz, 
2H), 4.63 (d, J = 3.2 Hz, 1H), 4.53 (d, J = 2.2 Hz, 1H), 3.79 (s, 3H), 3.59 (q, J = 2.8 Hz, 
1H), 3.25 (q, J = 6.1 Hz, 1H), 2.76 (q, J = 6.7 Hz, 1H), 1.69 (d, J = 6.5 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 168.24, 161.11, 156.78, 129.56, 118.78, 114.68, 71.80, 55.51, 
51.90, 48.28, 32.28, 17.90. HRMS (FAB), C14H15NO4 [M+] calculated: 261.10011; 
found: 261.0998. 1H and 13C NMR results matched those reported in the literature26. 
(1R,2R,6R)-2-methyl-3-oxa-7-azabicyclo[4.2.0]octan-4-8-dione (39).  HCl (12.1 N, 2 
mL) was added dropwise to a solution of 41 (900 mg, 3.34 mmol) in methanol (10 mL) 
and was stirred while carefully monitoring by TLC.  Once complete, the solution was 
concentrated in vacuo and purified by silica gel chromatography (ethyl acetate) to 
provide 39 as a white solid (429 mg, 83%).  39: TLC (ethyl acetate) = 0.20.  1H NMR 
(300 MHz, CDCl3) δ 6.01 (br. s, 1H), 4.76 (qd, J = 6.5, 3.3, 1H), 3.92 (dd, J = 3.3, 1.7, 
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1H), 3.52 (ddd, J = 5.3, 3.2, 2.2, 1H), 3.04 (m, 2H).  1H NMR matched those reported in 
the literature27. 
(1R,2R,4S,6R)-4-Hydroxy-7-(tertbutyldimethylsilyl)-2-methyl-3-oxa-7-
azabicyclo[4.2.0]octan-8-one (40).  Ozone was passed through a solution of 2 (2.3 g, 8.5 
mmol) in dichloromethane (128 mL) at -78 °C until a blue color persisted.  The ozonide 
was quenched with dimethylsulfide (21.3 mL) and the reaction mixture was stirred for 2 
h while warming to room temperature.  The solution was concentrated in vacuo and 
directly purified by silica gel chromatography (hexanes:ethyl acetate, 7:3) to provide 40 
(1.9 g, 82%). 40: TLC (hexanes:ethyl acetate, 7:3) = 0.20. 1H NMR (300 MHz, CDCl3) δ 
5.43 (q, J = 4.7 Hz, 1H), 4.25 (m, J = 3.1 Hz, 1H), 3.84 (m, J = 2.9 Hz, 1H), 3.22 (q, J = 
2.8 Hz, 1H), 2.33 (m, J = 3.5 Hz, 1H), 1.77 (m, J = 3.9 Hz, 1H), 1.40 (d, J = 6.5 Hz, 3H), 
0.97 (s, 9H), 0.28 (s, 3H), 0.21 (s, 3H).  HRMS (FAB), C13H26NO3Si [M+H+] calculated: 
272.16820; found: 272.1677. 
(1R,2R,4S,6R)-4-Hydroxy-7-(tertbutyldimethylsilyl)-2-methyl-3-oxa-7-
azabicyclo[4.2.0]octan-8-one (41).  A solution of 10 (450 mg, 1.66 mmol) in 
dichloromethane (3.3 mL) was added to a solution of pyridinium chlorochromate (716 
mg, 3.3 mmol) in dichloromethane (6.6 mL).  The solution was stirred for 3 h and filtered 
through Celite.  The filter cake was washed twice with ethyl acetate (5 mL) and the 
filtrate was dried with anhydrous sodium sulfate, filtered and concentrated in vacuo.  The 
crude product was purified by silica gel chromatography (hexanes:ethyl acetate, 1:1) to 
provide 41 (270 mg, 60%). 41: TLC (hexanes:ethyl acetate, 3:2) = 0.20. MP = 82-84°C 
1H NMR (400 MHz, CDCl3) δ 4.49 (m, 1H), 4.05 (m, 1H), 3.53 (q, J = 2.8 Hz, 1H), 2.90 
(q, J = 6.1 Hz, 1H), 2.67 (q, J = 6.5 Hz, 1H), 1.58 (d, J = 6.5 Hz, 3H), 0.95 (s, 9H), 0.26 
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(s, 3H), 0.22 (s, 3H). 13C NMR (101 MHz, CD3CN_SPE) δ 169.56, 169.19, 71.81, 53.88, 
46.55, 35.15, 26.02, 18.29, 17.61, -5.58, -5.76.  HRMS (FAB), C13H24NO3Si [M+H+] 
calculated: 270.15255; found: 270.1529. 
 (1R,2R,5R,6R)-2,5-dimethyl-3-oxa-7-azabicyclo[4.2.0]octan-4-8-dione (42).  42 was 
synthesized from 39 following the procedures of Kaga et al27. A solution of n-
butyllithium in hexanes (2.29 M, 6.09 mmol, 2.66 mL) was added to a solution of 
diisopropylamine (860 µL, 6.09 mmol) in tetrahydrofuran (14 mL) at -78 °C and stirred 
at this temperature for 30 min.  A solution was 39 (429 mg, 2.77 mmol) in 
tetrahydrofuran (7 mL) was added to the LDA solution at -78 °C and stirred at this 
temperature for 40 min.  A solution of methyl iodide (379 µL, 6.09 mmol) was added to 
the reaction mixture at -78 °C and stirred for 1 h.  The reaction mixture was quenched at -
78 °C with saturated ammonium chloride and allowed to warm to room temperature.  The 
organic layer was separated, and the aqueous layer was washed with ethyl acetate.  The 
combined organic layers were dried with anhydrous sodium sulfate, filtered and 
concentrated in vacuo.  The crude oil was purified by silica gel chromatography (ethyl 
acetate) and the purified product is recrystallized with ethyl acetate and hexanes to 
provide 42 as white needles (310 mg, 66%).   42: TLC (ethyl acetate) = 0.25. 1H-NMR 
(300 MHz, CDCl3) 1H NMR (300 MHz, CDCl3) δ 6.00 (s, 1H), 4.75 (m, J = 3.2 Hz, 1H), 
3.92 (q, J = 2.3 Hz, 1H), 3.52 (m, J = 1.8 Hz, 1H), 3.05 (m, J = 3.6 Hz, 1H), 1.62 (d, J = 
6.5 Hz, 1H), 1.32 (d, J = 7.8 Hz, 3H). 1H NMR matched those reported in the literature27. 
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(1E,2E)-N-(4-methoxyphenyl)-3-phenylprop-2-en-1-imine (47).  (trans)-
cinnamaldehyde (6.61 g, 50 mmol) was added to a solution of p-anisidine (6.78 g, 55 
mmol) in ethanol (100 mL) dropwise at room temperature.  After 30 min, yellow crystals 
began to form in the reaction solution.  The crystals were filtered and washed with 
ethanol to yield 25 as yellow needles (9.79 g, 83%).  47: TLC (hexanes:ethyl acetate, 7:3) 
= 0.70. 1H-NMR (300 MHz, CDCl3) δ 8.30 (t, J = 4.2 Hz, 1H), 7.53 (dd, J1 = 8.1, J2 = 1.5 
Hz, 2H), 7.38 (q, J = 7.5 Hz, 3H), 7.21 (d, J = 9.0 Hz, 2H), 7.12 (d, J = 4.6 Hz, 2H), 6.92 
(d, J = 9.0 Hz, 2H), 3.83 (s, 3H).  1H NMR results matched those reported in the 
literature26. 
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Consecutive radical S-adenosylmethionine methylations form the ethyl side chain in 
thienamycin biosynthesis and attachment of extended, CoA-derived thiols in 
complex carbapenem biosynthesis 
 
 
Figure 4.1:  Biosynthesis of thienamycin and activity of ThnK. Two enzymes ThnE and 
ThnM form the (3S,5S)-carbapenam 2, which is then acted upon by other enzymes, likely 
including ThnK, ThnL, and ThnP to form thienamycin.  Correspondingly, CarB and 
CarA can also form 2 that CarC can convert to the simple carbapenem 3.  The 
demonstrated activity of ThnK is highlighted in gray. 
 
 Bacterial resistance to penicillin and cephalosporin has placed increased clinical 
reliance on the carbapenem class of β-lactam antibiotics, notably synthetic variants of the 
naturally-occurring thienamycin (Figure 4.1)1. Approximately 50 “complex” 
carbapenems are known, which are distinguished by a vinylthio substituent at C-2 and a 
short alkyl chain at C-6. These natural products have been isolated from actinomyces 
while the lone “simple” carbapenem-3-carboxylic acid 3 is known from an 
enterobacterium, Pectobacterium carotovorum1. Despite their evolutionary distance, the 
first two biosynthetic steps to each are shared2. Thus, CarB encoded in the latter and 
ThnE from Streptomyces cattleya, and correspondingly CarA and ThnM give (3S,5S)-
carbapenam 2 as shown in Figure 4.1. At this point the two pathways diverge in a striking 
148 
manner where the simple carbapenem 3 is produced by both configurational inversion at 
the bridgehead and C-2/3-desaturation mediated by CarC3. In contrast, the path to 
thienamycin 7, and likely all complex carbapenems, involves an entirely separate 
sequence of transformations. Apart from the identification of ThnR, ThnH, and ThnT in 
the stepwise truncation of coenzyme A (CoASH) to the C-2-cysteamine side chain of 
thienamycin4, the timing of these tailoring events with respect to the introduction of the 
C-2-substituent onto the carbapenam(em) nucleus, alkylation at C-6, ring inversion and 
desaturation remain shrouded in mystery, although compound 6 is hypothesized to be an 
intermediate. Unique to the complex carbapenems are three apparent cobalamin-
dependent radical S-adenosylmethionine (RS) enzymes ThnK, ThnL, and ThnP (all 
annotated as Class B RS methylases)5, which we now demonstrate likely play critical 
roles in the central undefined steps of thienamycin biosynthesis.   
 RS enzymes are commonly identified by a conserved Cx3Cx2C motif, typically 
responsible for coordinating a [4Fe-4S] cluster6, which enables this protein family to 
perform more than 40 so-far-identified biochemical transformations including sulfur 
insertion and methylation relevant to thienamycin biosynthesis7. The three thienamycin 
RS enzymes also contain N-terminal extensions thought to be cobalamin (B12)-binding 
domains, which would appear in keeping with early observations that CoII and cobalamin 
increased carbapenem titers in cultures of producing strains8. Indeed the low turnover of 
RS enzymes may account for why thienamycin could not be produced by cost-effective 
fermentation methods, and as a consequence all clinically–used carbapenems are 
manufactured synthetically1. 
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 While probable that the carbapenem RS enzymes perform several intermediate 
biosynthetic steps and potentially use unprecedented chemistry, the challenge of 
deciphering their activities is exacerbated by their intrinsic instability, unknown 
substrates, and multiple possible reactions. Fellow graduate student Daniel Marous and I 
took the first step in illuminating the obscure center of the thienamycin biosynthetic 
pathway by identifying substrates for ThnK and establishing that this enzyme performs 
two consecutive methylations to generate the C-6-ethyl side chain stereospecifically 
(Figure 1). While other RS cobalamin-dependent enzymes that act on carbon have been 
investigated9–12, this is the first in vitro characterization of a RS methylase acting 
sequentially to form a side chain.   
 
Construction of an initial synthetic library for ThnK activity assays 
Daniel Marous and I collaborated very closely on the synthesis of a library of 
candidate substrates the preparation of product standards, including the simple (3S,5S)-
carbapenam 2 and related C-2 and C-6-substituted derivatives 12-15, 38 and 39 as shown 
in Scheme 4.1. Often times we performed the same reactions separately, and in some 
instances either he or I performed a certain reaction, many of which followed the thesis 
work of Dr. Kristos Moshos, who made many similar carbapenams for his studies with 
ThnR, T, H and F.  Our library was biased toward structures with the (3S,5S)-
stereochemistry, matching that of the ThnM product 2, and those bearing the 6R-
configuration (38, 39) matching that of thienamycin (Figure 4.4A). A pantetheinyl moiety 
was selected for the side chain at C-2 (12-15) in keeping with the OA-6129 series of 
metabolites that has been isolated from carbapenem producers13,14.  
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Scheme 4.1: Synthesis of an initial library for ThnK substrates 
 Synthesis of carbapenam PNB esters 10 and 11 proceeded easily through 
conjugate addition of pantetheine thiol in the presence of trimethylamine.  
Hydrogenolysis of the PNB esters followed by HPLC purification afforded the pure 
diastereomers 12, 13, 14 and 15.    To produce initial C-6 methyl carbapenams as 
substrates or product standards, racemic 4-allylazetidinone was used as an easily 
accessible starting material.  TBS protection of the amide followed by enolate addition to 
methyl iodide and subsequent TBS removal provided the 4-allyl-3-methylazetidinone 18.  
Reaction of the resulting amide with PNB glyoxalate using 3Å molecular sieves was 
followed by conversion of the resulting aminal with thionyl chloride to provide a reactive 
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intermediate for the production of the triphenylphosphine ylid 20.  The carbapenem 21 
was produced in one step after ozonolysis and reduction of the ozonide to an aldehyde.  
The product aldehyde is not recovered, as spontaneous Wittig closure of the ylid and 
aldehyde occurs upon quenching with sodium bicarbonate. The presence of 
trifluoroacetic acid was necessary during the addition of ozone to protonate the ylid, 
making it unreactive until basic workup.  With carbapenem 21 in hand, facile conjugate 
addition of pantetheine thiol and hydrolysis of the 3-PNB ester affords the methyl 
carbapenam 23 as a mixture of C-2 diastereomers. 
 
Expression, purification, and analysis of ThnK 
 
Figure 4.2: UV-Visible spectrum and SDS PAGE of ThnK. The UV-visible spectrum of 
ThnK shows a 420 nm shoulder, indicative of a bound iron sulfur cluster. 
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The best behaved of the three RS enzymes, ThnK, was cloned from Streptomyces 
cattleya by Dr. Rongfeng Li, where Andrew Buller originally found experimental 
conditions that gave moderate levels of soluble protein when expressed with a C-terminal 
His6-tag in E. coli Rosetta 2(DE3). Because ThnK was expected to utilize both an iron-
sulfur (Fe/S) cluster and cobalamin, protein production was conducted in ethanolamine-
M9 medium due to the suggestion of Tyler Grove in the laboratory of Squire Booker.  
Ethanolamine-M9 facilitates uptake of externally supplied hydroxocobalamin into E. coli, 
and with concurrent expression of the Azotobacter vinelandii isc operon, encoded on 
plasmid pDB1282.  Daniel Marous and I purified ThnK under strictly anaerobic 
conditions.  The UV-visible spectrum of purified ThnK revealed a 420 nm shoulder 
(Figure 4.2) typical of a bound iron-sulfur cluster.  The relative stoichiometry of iron and 
sulfide bound by the as-isolated protein was determined to be 7.4 ± 1.4 and 3.7 ± 0.8 per 
polypeptide, respectively, consistent with the presence of a [4Fe-4S] cluster.  Excess iron 
has been observed with other RS enzymes11,15, and was similarly seen in an alanine 
variant control (Figure 4.7). 
 
Figure 4.3:  Detection of SAM-derived products of ThnK with compounds 2, 38, and 39. 
LC-MS/MS was used to detect SAM-derived coproducts, SAH (385.4 -> 136 m/z) and 
5’-dA (252.1 -> 136 m/z).  The extracted-ion chromatograms (EICs) for the transitions of 
SAH and 5’-dA are overlaid for each reaction.  The reactions with compounds 2, 38, and 
39 show about the same level of turnover as the reaction without substrate.  Reactions 
were run for approximately 2 hours at room temperature. 
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Figure 4.4:  Carbapenam synthetic library and detection and quantification of SAM 
products of ThnK.  (A) Compounds synthesized to probe ThnK activity. (B) LC-MS/MS 
detection of enzymatic SAM co-products, SAH (385.4 -> 136 m/z) and 5’-dA (252.1 -> 
136 m/z).  The extracted-ion chromatograms (EICs) for the transitions of SAH and 5’-dA 
are shown for each reaction.  The reaction with compound 13 gave the highest levels of 





Analysis of SAH and 5’da produced from ThnK turnover 
 To determine whether any of our library compounds was a substrate for ThnK, 
Tyler Grove and Anthony Blaszczykk, graduate students in the Booker lab, helped 
develop a LC-MS analytical screen whereby enzymatic reactions were monitored for 
appearance of the expected RS methylase co-products, S-adenosylhomocysteine (SAH) 
and 5'-deoxyadenosine (5’-dA)16,17. Initial screens were conducted with ThnK, SAM, and 
potential carbapenam substrates in the presence of methyl viologen and NADPH as Fe/S 
cluster reductants10. The (3S,5S)-carbapenam and related C-6-methyl and ethyl 
derivatives (2, 38, and 39) gave nearly background (no-substrate control) levels of SAH 
and 5’-dA (Figure 4.3). In contrast, SAM co-products accumulated when ThnK was 
incubated with C-2-substituted carbapenams, suggesting that the full methyl transfer 
reaction(s) had occurred (Figure 2B). Alternate Fe/S cluster reductants, including 
dithionite and the flavodoxin/flavodoxin reductase/NADPH reducing system were also 
examined, but did not give improved activity (Figure 4.5). To assess enzymatic turnover, 
the amounts of SAH and 5’-dA were quantified by LC-MS/MS (Figure 2B). Compounds 
bearing the now (3R,5R)-stereochemistry with a pantetheine side chain at C-2 gave the 
greatest levels of turnover of the pantetheinyl carbapenams. Therefore, each C-2 
diastereomer (compound 12 or 13) was tested individually. The (2R,3R,5R)-carbapenam 
13 yielded ~2-fold higher amounts of SAM co-products. These stereochemical 
preferences were found to be reproducible (Figure 4.6) and SAH and 5’dA were present 
in approximately equimolar amounts in each reaction. 
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Figure 4.5:  LC-MS/MS comparison of enzymatic turnover using different iron-sulfur 
cluster reductants.  The extracted-ion chromatograms (EICs) for the transitions of SAH 
(385.4 -> 136 m/z) and 5’-dA (252.1 -> 136 m/z) are overlaid for each reaction.  Methyl 
viologen with NADPH gave higher turnover than dithionite or flavodoxin with 
flavodoxin reductase and NADPH.  Reactions were run for approximately 2 hours at 
room temperature with substrate 13. 
 
Figure 4.6:  Reproducibilty of SAM-derived products of ThnK. LC-MS/MS was used to 
detect SAM-derived coproducts, SAH (385.4 -> 136 m/z) and 5’-dA (252.1 -> 136 m/z).  
The extracted-ion chromatograms (EICs) for the transitions of SAH and 5’-dA are 
overlaid for each reaction.  The reaction with compound 13 gave the highest levels of 
these SAM-derived coproducts.  Reactions with ThnK (~80 μM) were run for 1.5 hours 
at room temperature and included 1 mM HOCbl, though added cobalamin was 
determined not to be required for activity. 
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Analysis of the [4Fe-4S] cluster 
 To test the role of the [4Fe-4S] cluster in catalysis, Daniel Marous generated a 
variant of ThnK where the conserved cluster binding motif Cx3Cx2C was changed from 
three cysteine to three alanine residues. The variant protein was prepared as described for 
wild-type ThnK and incubated with substrate 13. The inactivated enzyme did produce 
low levels of SAH, but no detectable 5’-dA (Figure 4.7), consistent with reliance of the 
wild-type enzyme on a functional Fe/S cluster. WT ThnK was also expressed in M9 
medium lacking hydroxocobalamin for another control experiment. The purified protein 
with substrate 13 did not produce SAH or 5’dA; however, enzymatic activity could be 
rescued if cobalamin was added to the reaction mixture (Figure 4.8). 
 
Figure 4.7:  Fe/S cluster required for ThnK activity.  LC-MS/MS was used to detect 
SAM-derived coproducts, SAH (385.4 -> 136 m/z) and 5’-dA (252.1 -> 136 m/z).  The 
extracted-ion chromatograms (EICs) for the transitions of SAH and 5’-dA are overlaid 
for each reaction.  Alteration of the Cx3Cx2C motif to Ax3Ax2A resulted in little SAH 
production and no 5’-dA production.  Reactions were run for approximately 2 hours at 
room temperature with substrate 13. 
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Figure 4.8:  Cobalamin required for ThnK activity.  LC-MS/MS was used to detect 
SAM-derived coproducts, SAH (385.4 -> 136 m/z) and 5’-dA (252.1 -> 136 m/z).  The 
extracted-ion chromatograms (EICs) for the transitions of SAH and 5’-dA are overlaid 
for each reaction.  ThnK, expressed in and isolated from E. coli cultured in the absence of 
cobalamin, was either given no cobalamin, HOCbl, or MeCbl.  Added cobalamin was 
able to rescue ThnK activity with MeCbl yielding higher levels of SAH and 5’-dA than 
HOCbl.  Reactions were run for 1 hour and 10 minutes at room temperature with 
substrate 13. 
 
Chemo- and stereoselectivity of methyl transfer by ThnK 
We next sought to determine how the substrate was transformed during the 
reaction with ThnK. Assays with 13 were analyzed by UPLC-HRMS.  Exact masses were 
obtained matching methylated (calc: m/z 446.1961, found: 446.1954) and twice-
methylated (calc: m/z 460.2117, found: 460.2104) modifications of the substrate. The 
extracted-ion chromatograms for these masses showed retention times that were 
consistent with increasing hydrophobicity relative to the substrate (Figure 4.9). The 
highly diagnostic β-lactam mass fragment (calc: m/z 390.1699) corresponding to the loss 
of a ketene from cleavage of the β-lactam ring18 was observed (found: m/z 390.1701) 
(Figure 4.10), which was further consistent with methylation at C-6. To establish SAM as 
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the methyl donor, additional ThnK reactions were performed in vollaboration with the 
Booker lab using biosynthesized S-adenosyl-L-[methyl-d3]methionine (d3-SAM) that they 
provided us. The corresponding M+3 m/z shift was observed for the methylated product 
and an M+5 m/z shift was seen for the twice-methylated product (Figure 4.10), fully in 




Figure 4.9:  Carbapenam synthetic library and detection and quantification of SAM 
products of ThnK.  (a) Compounds synthesized to probe ThnK activity. (b) LC-MS/MS 
detection of enzymatic SAM co-products, SAH (385.4 -> 136 m/z) and 5’-dA (252.1 -> 
136 m/z).  The extracted-ion chromatograms (EICs) for the transitions of SAH and 5’-dA 
are shown for each reaction.  The reaction with compound 13 gave the highest levels of 




Figure 4.10: Product detection of ThnK assays with d3-SAM. (a) UPLC-HRMS 
detection of carbapenams from ThnK reaction with compound 13 and d3-SAM.  The 
bottom, middle, and top traces show the extracted-ion chromatograms (EICs, m/z ± 0.05) 
for unreacted substrate (432.18 m/z), methylated product (449.22 m/z), and ethylated 
product (465.24 m/z), respectively.  The middle and top traces show a +3 m/z and a +5 
m/z shift, respectively, from Figure 4.9A.  (b) UPLC-HRMS detection of carbapenams 
from ThnK reaction with compound 13 and natural abundance SAM.  The shifted masses 
observed in A are not present in B. 
 
 
 To secure the stereochemistry of the first methylation, synthesis of a set of C-6-






Marous and myself before assaying with ThnK. While compounds 44 and 23 displayed 
trace or no measurable activity, respectively, 45 afforded unequivocal production of SAH 
and 5’-dA (Figure 4.11). This result underscored the importance of the stereochemical 
relationship between the C-3-carboxylate and the pantetheinyl side chain and confirmed 
that the C-6-methyl is attached in the R-configuration, as occurs in thienamycin. By 
UPLC-ESI/MS analysis, the ethylated product of 45 (resulting from a single methyl 
transfer) matched the exact mass and retention time of the ethylated product of compound 
13 (Figure 4.9A and 4.9D). In further support, the (6R)-ethyl standard 46 was synthesized 
and determined to match the retention time, exact mass, and fragmentation pattern for the 
aforementioned products, as expected (Figure 4.9A and 4.9D). The observed activity of 
ThnK is summarized in Figure 4.9B. 
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Scheme 4.2: Synthesis of 5,6-cis-carbapenams 
 In order to obtain cis-6-alkylcarbapenams, a different synthetic strategy was 
implemented to set the appropriate stereochemistry of the C-6 alkyl substituent19.  
Reaction of the lithium enolate of either tert-butylpropionate or tert-butylbutyrate with 
the amide carbonyl of N-carboxybenzylpyroglutamic acid benzyl ester opened the 
pyrrolidin-2-one to provide the β-ketoesters 25 and 26 as a mixture of α-diastereomers.  
Hydrogenolysis of the N-carboxybenzyl group liberates the primary amine so that imine 
condensation occurs in situ, followed by reductive amination to produce the pyrrolidines 
28 and 29.  Protection of the secondary amine with Boc anhydride followed by 
esterification to the PNB ester allowed for its hydrolytic removal later in the production 
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of non-2-substituted carbapenams 38 and 39.  To our surprise, we found through attempts 
to deprotonate the C-3 position with LiHMDS later in the synthesis that the acidic benzyl 
protons of the PNB ester were incompatible.  Since our goal was to synthesize 2-
pantetheinyl carbapenams, formation of a methyl ester was necessary to avoid this pitfall.  
To close the β-lactam ring, deprotection of the tert-butyl ester and carbamate was 
possible using anhydrous conditions, which were necessary for a good yield during N,N-
dicyclohexylcarbodiimide coupling.  After the carbapenam was made, epimerization of 
the C-3 position with DBU in acetonitrile at 60 °C for 72 h provided diastereomers which 
were separable by flash chromatography.  With enantiopure 34 and 36 in hand, 
production of the lithium enolate allows for addition into phenylselenyl bromide.  The 
selenium adducts rapidly eliminated upon oxidation with m-CPBA at -30 °C to provide 
the carbapenems 40 and 41, although in poor yield due to unstable reaction conditions 
that degrade the carbapenem.  Recovery could be improved with careful monitoring of 
reaction progress by TLC, but a yield of 30% over two steps was typical.  Conjugate 
addition of pantetheine to the carbapenems 42-43 followed by saponification of the 
methyl esters and separation of the diastereomers by HPLC provided the desired cis-
carbapenams 44-46.  It is a lengthy synthesis without stereochemical control, but 
divergence to separable diasteromers was used to our advantage for the testing of each 







ThnK Substrate Profiling with C-2-Thioether Variants 
 
Scheme 4.3: Overview of the Synthesis of C-2-Substituted Carbapenams to Test with 
ThnK. The enzyme PanK was used to install the terminal phosphate on the 
phosphopantetheinyl side chain 
 
 Once the function of ThnK was established, it was anticipated that the substrate 
specificity of ThnK could be leveraged to provide insight into which thiol is added to the 
bicyclic core.  That is, it could be possible to deduce the function of ThnL. Beginning 
with CoA, three enzymes in the thienamycin cluster, ThnR, ThnH, and ThnT, 
successively cleave to yield 4-phosphopantetheine, pantetheine, and cysteamine, 
respectively4.  Knowing this sequence, four thiols are potentially available for 
attachment. As possible substrates for ThnK, carbapenams with C-2-substituents 
representing all the truncation states were desired, although the cysteamine side chain 
was replaced with the more chemically inert N-acetylcysteamine (SNAC). The 
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carbapenem 8 was synthesized using previously established methods20 to facilitate the 
generation of these compounds (Scheme 4.3). From the common intermediate 8, 
pantetheine or SNAC could be inserted by β-addition been demonstrated4,21,22. 
Additionally, it was found that CoA itself could be added into the carbapenem, enabling a 
direct route to the CoA-substituted compounds. High-performance liquid 
chromatography (HPLC) was utilized to separate the resulting C-2-diastereomers, giving 
compounds 47, 48, 49, 50, 51 and 52 (Scheme 4.3). To address the synthetic challenge of 
generating the phosphopantetheinyl carbapenams, we employed a chemoenzymatic 
strategy. The pantetheinyl compounds 12 and 13 were converted into their corresponding 
phosphopantetheinyl analogs 49 and 50 using the enzyme pantothenate kinase as done 
previously (PanK, CoA)23.  
 
Figure 4.11:  Detection of SAM-derived products of ThnK with compound 45.  LC-
MS/MS was used to detect SAM-derived coproducts.  The fragmentation patterns of 
SAH (385.4 -> 136 m/z) and 5’-dA (252.1 -> 136 m/z) were specifically measured to 
generate an extracted ion chromatogram (EIC).  The EICs for the transitions of SAH and 
5’-dA are overlaid for each reaction.  The reaction with compound 45 shows increased 
turnover compared to the no substrate control.  Reactions were run for 2 hours and ten 




 With the synthetic targets in hand, ThnK was expressed and purified 
anaerobically as previously described22. To evaluate the synthetic substrates, each 
compound (1 mM) was incubated with ThnK along with [4Fe-4S] cluster reductants 
(methyl viologen, 1 mM and NADPH, 2 mM), and SAM (1 mM). ThnK was confirmed 
to perform consecutive methylations at C-6, as expected (Figure 4.13). 
 
Figure 4.12: Sequential Methylations by ThnK. UPLC-HRMS detection of carbapenams 
from the ThnK reaction with compound 15. The bottom, middle, and top traces show the 
extracted-ion chromatograms (EICs) (m/z ± 0.05) for unreacted substrate 50 (512.15 m/z), 
methylated product (526.16 m/z), and ethylated product (540.18 m/z), respectively. 
 
 For assessment of the relative turnover with the various substrates, the RS 
methylase SAM-derived coproducts S-adenosylhomocysteine (SAH) and 5′-
deoxyadenosine (5′-dA)17 were again monitored by LC-MS/MS. Several trends were 
apparent from sampling the levels of accumulated 5′-dA (Figure 4.14A). Three 
compounds consistently gave the lowest turnover: both C-2-SNAC molecules (47 and 48) 
and the (2S)-pantetheine-substituted 12. The (2R)-carbapenam 13 gave higher levels of 




(13, 48, 50, 52), extending the side chain to phosphopantetheine 50 or CoA 52 did not 
hinder turnover, but rather led to modest gains. Strikingly, with the (2S)-series (12, 47, 
49, 51), the phosphopantetheine 49 and CoA 51 analogs gave significantly improved 
activity compared to the pantetheine compound 12. In fact, CoA-functionalized 51 
produced the greatest amounts of 5’-dA of all the substrates tested. Correspondingly, 
these trends with 5’-dA levels mirrored those of SAH accumulation (Figure 4.14B). 
Overall, the compounds with longer C-2 side chains were better substrates than their 
shorter side chain counterparts.  
 
Figure 4.13: LC-MS/MS Detection of Enzymatic SAM-Derived Coproducts 5’-dA and 
SAH from Assays with Compounds 10-17. (a) The extracted-ion chromatograms (EICs) 
for the transition of 5′-dA (252.1→136 m/z). (b) The EICs for the transition of SAH 
(385.4 → 136 m/z). 
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Discussion 
Mechanistically, ThnK resembles GenK, a cobalamin-dependent RS C-methylase 
in gentamicin biosynthesis10, as both produce near equimolar amounts of SAH and 5’-dA 
during catalysis. Early labeling experiments established that the C-6-ethyl side chain of 
thienamycin was derived from methionine24. A labeled carbon was also found in the C-6-
hydroxymethyl side chain of northienamycin, a minor co-metabolite of thienamycin, 
suggesting a singly-methylated intermediate in the formation of the ethyl side chain24. 
The present in vitro analysis of ThnK agrees with these early experiments. An experiment 
incorporating chiral [1H, 2H, 3H-methyl]-L-methionine demonstrated that the absolute 
configuration of the terminal methyl in the C-6-side chain was largely retained, consistent 
with an overall methyl transfer process involving two inversions and a methylcobalamin 
intermediate25. The B12-dependence of ThnK reactions established above supports the 
role of a methylcobalamin intermediate, as has been implicated in other 
methyltransferases including TsrM9 and GenK10. While the tryptophan methylase TsrM 
may utilize a similar intermediate, the enzyme is likely mechanistically distinct from 
ThnK and GenK because it does not produce detectable levels of 5’-dA9. 
 The catalysis of consecutive methylations observed for ThnK likely occurs 
elsewhere in nature. Within the carbapenem family, the carpetimycins have three carbons 
in their C-6 side chain8 suggesting that a ThnK ortholog may be responsible for three 
methyl transfers. The natural product pactamycin has traditionally been compared to 
thienamycin because both possess a hydroxyethyl side chain24. A recent genetic knockout 
study suggests, however, that more than one enzyme takes part in attaching the ethyl 
group26. While sequential methylations appear not to occur by a single enzyme in 
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pactamycin biosynthesis, other RS enzymes including Swb927 and PoyB or PoyC28 in 
quinomycin and polytheonamide biosynthesis, respectively, have been implicated in 
multiple methylations of a single substrate chain.  
 The preference for long C-2 sidechains is a critical topic in terms of the placement 
of the activity by ThnK in thienamycin biosynthesis.  Increased turnover of ThnK with 
carbapenams that have either CoA or phosphopantetheine at C-2 implies that adenosyl or 
phosphoryl cleavage occurs after methylation at C-6.  The stereochemical preference of 
C-2 thioalkyl substituents changes in CoA or phosphopantetheinyl carbapenams when 
compared to pantetheinyl carbapenams.  It is possible that with either less room or 
different charge interactions in active site binding of the larger substrates, the 
stereochemical preferences change.  However, without a reliable crystal structure of 
ThnK with substrates bound, these specific binding interactions are only speculative.  
 
Conclusion 
 The data reported here establish notable catalytic roles for ThnK. It methylates in 
two distinct chemical environments (alpha to the β-lactam ring and on an unactivated 
methyl group). The second methyl transfer presumably involves a primary radical 
intermediate, a particularly high-energy species. The substrates that exhibit the highest 
efficiency for ThnK methylation are those that contain 2(S)-SCoA or 2(S)-
phosphopantetheine substituents.  By identifying favorable substrates for ThnK and 
elucidating its activity, we have gained additional clues about the unknown central steps 
in thienamycin biosynthesis as well. With formation of the ethyl side chain accounted for, 
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ThnL and ThnP can provisionally be assigned non-methyltransferase functions, 
potentially distinct chemistry for the RS-cobalamin family, as both proteins are essential 
for carbapenem production29,30. Since ThnK activity was only observed when a C-2-side 
chain was present (compounds 12-15, 46-52 vs. 2, 38, and 39), we deduce that C-2-
thioether formation likely mediated by ThnL or ThnP precedes C-6-methylation in the 
pathway. The stereochemical preference for (2R)-pantetheinyl carbapenams 13 and 45 
indicates that the thiol is likely introduced in the 2-exo-configuration, however is 
contradicted by CoA or phosphopantetheinyl carbapenams, where the (2S) configuration 
is favored. Furthermore, the observation of activity with substrates matching the (3S,5S)-
carbapenam 2 at C-5 (compounds 12, 13, and 45) suggests that bridgehead epimerization 
occurs after C-6-methylation (ethylation). Consequently, C-2-thiol attachment, C-6-
alkylation, and C-5-epimerization likely occur in that order. The orchestration of these 
biosynthetic events with C-2/3-desaturation and maturation of the C-2-cysteamine will be 
addressed in due course. 
 
Experimental 
General methods and abbreviations: 
Hydroxocobalamin (HOCbl), 4-(2-hydroxyethyl)-1-piperazineethane- sulfonic acid 
(HEPES), isopropyl β-D-1-thiogalactopyranoside (IPTG), 2-mercaptoethanol (BME), 
methylcobalamin (MeCbl), methyl viologen (MV), nicotinamide adenine dinucleotide, 
phosphate hydrate (NADPH), phenylmethysulfonyl fluoride (PMSF). 
 
Restriction enzymes, DNA modifying enzymes, and PCR reagents were obtained from 
171 
New England Biolabs (Ipswich, MA). Plasmid kits were from Thermo Scientific 
(Waltham, MA).  E. coli DH5α (Invitrogen) was usually used for DNA cloning and ThnK 
expression was done in E. coli Rosetta 2(DE3) (Novagen).  The plasmid pDB1282 was 
utilized for Fe/S cluster expression10.  SAM and S-adenosyl-L-[methyl-d3]methionine (d3-
SAM) were synthesized as described previously22.  Recombinant flavodoxin (Flv) and 
flavodoxin reductase (Flx) were over-produced in E. coli as previously described31.  
Plasmid DNA was sequenced by the Synthesis and Sequencing Facility of the Johns 
Hopkins University.  Solvents and reagents were purchased from Sigma Aldrich or Fisher 
Scientific in purity of ≥98%.  Silica gel chromatography was performed using 60Å silica 
gel from Sorbtech.  Thin layer chromatography (TLC) was performed using 250 μm 
Analtech GHLF silica plates.  A Bruker Avance (Billerica, MA) 300 or 400 MHz 
spectrometer was utilized for all 1H and 13C NMR spectra, which are reported in parts per 
million (δ) referenced against a TMS standard or residual solvent peak.  The JHU 
Chemistry Department Mass Spectrometry Facility determined exact masses by fast atom 
bombardment (FAB) or electrospray ionization (ESI). 
 
Cloning and Expression of Streptomyces cattleya ThnK. The thnK gene was PCR 
amplified from genomic DNA of Streptomyces cattleya (NRRL8057) using the following 
primers: 5’ – CAAGACATATGACCGTCCCCGCCGCGC – 3’,  
5’ TATCTCGAGCCGCTGCTCGGTCAGGACGGG – 3’.  The thnK PCR product was 
digested using NdeI and XhoI and ligated into the vector pET29b (Novagen) to obtain the 
C-terminal 6-His construct of thnK.  The plasmid was sequence-verified. The 
pET29b:thnK was transformed into E. coli Rosetta DE3 for expression of ThnK as a C-
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terminal His6 construct.  The thnK Rosetta strain was also transformed with the vector 
pDB1282, containing the ISC operon with arabinose induction32.   The resulting strain 
was grown in 4 x 3.5 L of Ethanolamine-M9 medium33, which included 
hydroxocobalamin (HOCbl), and was supplemented with FeCl3 (~0.14 mM) at 37 °C and 
shaken at 180 rpm.  When the optical density of the cultures reached 0.3 at 600 nm, 25 
μM FeCl3, 150 μM cysteine, and 0.1% arabinose were added.  When the optical density 
of the fermentation reached 0.4-0.6 (8-10 h), the cultures were chilled on ice (~45 min) 
and an additional 25 μM FeCl3, 150 μM cysteine, and 0.1% arabinose were added.  ThnK 
expression was induced with 1 mM IPTG and the cultures were shaken at 180 rpm 
overnight at 19 °C.  Cells were collected by centrifugation (4,000g, 12 min), which were 
then frozen on liquid nitrogen and stored for later use. 
 
Anaerobic Purification of ThnK. Enzyme purification was performed in an anaerobic 
chamber (Coy).  Frozen cells were resuspended in lysis buffer (10% glycerol, 300 mM 
KCl, 50 mM HEPES pH 8.0, 10 mM BME, 2-5 mM imidazole) along with lysozyme (1 
mg/mL final volume), PMSF (1 mM), DNAse (~ 0.1 mg/mL final volume), and optional 
HOCbl (~0.4 mg/g cell paste).  Cells were lysed by sonication and insoluble material was 
removed by centrifugation (50,000 × g for 1 h at 4 °C).  Soluble ThnK was allowed to 
bind to pre-equilibrated TALON CoII resin (Clontech) and purified by immobilized metal 
affinity chromatography.  The resin was washed with 5 mM and 10 mM imidazole in 
lysis buffer. The protein was eluted using 250 mM imidazole in the lysis buffer.   The 
enzyme was concentrated using Amicon centrifugal filter devices (Millipore) with a 10 
kDA molecular weight limit.  Using a PD-10 column (GE Biosciences), the protein was 
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transferred into assay buffer (10% glycerol, 300 mM KCl, 50 mM HEPES pH 7.5, 10 
mM BME). 
 
ThnK Protein Analysis. The concentration of ThnK was determined by the Bradford 
assay34 (Varian Cary 50 Bio UV/ Visible Spectrophotometer) using Coomassie Protein 
Assay Reagent (Thermo Scientific).  A concentration correction factor was obtained 
using amino acid analysis (Molecular Structure Facility, UC Davis).  The amount of iron 
bound by ThnK was determined by established methods35, and the amount of sulfide was 
determined as reported36.  
 
ThnK Activity Assays. ThnK was mixed with 50-100 mM HEPES pH 7.5, 200 mM 
KCl, 1 mM SAM or d3-SAM, 1 mM methyl viologen, 4 mM NADPH, and 1 mM 
substrate.  Initial activity screens also included 0.5 mM HOCbl and 0.5 mM MeCbl, 
though it was later determined not to be necessary to add cobalamin for activity.  Assays 
of potential substrates lacking a C-2-substituent also included 1 mM cysteine and 1 mM 
coenzyme A.  When utilized, dithionite (3 mM) or flavodoxin (90 μM), flavodoxin 
reductase (9 μM), and NADPH (1 mM) were supplemented at the indicated 
concentrations in place of methyl viologen and NADPH (default reductant unless 
otherwise noted).  Assays were conducted anaerobically at room temperature and were 
typically run for 1-2 h. 
 
ThnK SAH and 5’-dA Quantification Assays. ThnK (50 μM, final concentration) was 
mixed with 100 mM HEPES pH 7.5, 200 mM KCl, 1 mM SAM or d3-SAM, 1 mM 
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methyl viologen, 4 mM NADPH, and 1 mM substrate.  Assays were run anaerobically for 
2 h and 10 min at room temperature.   
 
No-cobalamin ThnK Expression, Purification, and Activity. The ThnK wt Rosetta 
strain was grown in standard M9 medium lacking cobalamin, but supplemented with 
FeCl3 (~0.14 mM) and thiamine (0.074 mM).  Expression and purification of the no-
cobalamin ThnK was conducted as described for the wild-type protein, but no HOCbl 
was added during purification.  Assays were conducted with 50 μM ThnK and 1 mM 
HOCbl or 1mM MeCbl when utilized and were otherwise as described for ThnK from 
ethanolamine medium. 
 
Knockout of CX3CX2C Motif in ThnK and Mutant Protein Expression, Purification, 
and Activity. The pET29b:thnK plasmid was used as a template for a two-step PCR 
method that utilized the following primers:  5’-CGC GGC GCC CCC TAC TCG GCT 
GCC TTC GCC GAC TGG-3’ and 5’-CCA GTC GGC GAA GGC AGC CGA GTA 
GGG GGC GCC GCG-3’.  The C206A C210A C213A PCR product was digested with 
NdeI and XhoI and ligated into the pET29b vector.  The resulting plasmid was sequenced 
and found to be without error.  The mutant thnK vector was transformed into an E. coli 
Rosetta DE3 strain containing the pDB1282 plasmid.  Expression, purification, and 
assays of the mutant ThnK (85 μM final concentration) were conducted as described for 
the wild type protein.  
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LC-MS Analysis of Carbapenams.  UPLC-MS detection of carbapenams was 
conducted on a Waters Acquity H-Class UPLC system equipped with a Waters Acquity 
BEH UPLC column packed with an ethylene bridged hybrid C18 stationary phase (2.1 
mm x 50 mm, 1.7 um) followed by a multi-wavelength UV-Vis diode array detector 
coupled with accurate mass analysis by a Waters Xevo-G2 Q-ToF ESI mass 
spectrometer.  Mobile phase: 0-1 min 100% water + 0.1% formic acid, 1-7.5 min up to 
80% acetonitrile + 0.1% formic acid, 7.5 – 8.5 min isocratic 80% acetonitrile + 0.1% 
formic acid, 8.5-10 min 100% water + formic acid.  The flow rate was 0.3 mL/min.  The 
first min of eluant was discarded prior to MS analysis. 
 
LC-MS Analysis of SAH and 5’-dA. LC-MS detection of S-adenosyl-homocysteine 
(SAH) and 5'-deoxyadenosine (5’-dA) was carried out on an Agilent Technologies (Santa 
Clara, CA) 1200 system equipped with an autosampler and an Agilent Technologies 
Zorbax Rapid Resolution Extended-C18 column (4.6 mm × 50 mm, 1.8 μm particle size) 
and coupled to an Agilent Technologies 6410 QQQ mass spectrometer.  Assay mixtures 
were quenched with H2SO4 and insoluble material was pelleted prior to analysis.  Method 
1 (Compounds 2, 8, 9): method is similar to that reported previously31. Mobile phase:  
The initial conditions included 95% solvent A (40 mM aqueous ammonium acetate, pH 
6.0 with glacial acetic acid, and 5% methanol) and 5% solvent B (methanol), 0.5-5 min 
up to 13% B, 5-6.5 min up to 27% B, 6.5-7.0 min up to 53% B, 7.0-7.5 min isocratic 53% 
B, 7.5-8 min down to 5% B, 8.0-10.0 min re-equilibrate at 5% B. Method 2 (Compounds 
10-15): Mobile phase:  The initial conditions included 90.5% solvent A (0.1% formic 
acid, pH 2.6) and 9.5% solvent B (methanol), 0-0.2 min 9.5% B, 0.2-3.3 min up to 9.8% 
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B, 3.3-4.1 min up to 30% B, 4.1-4.7 min up to 60% B, 4.7-5.1 min isocratic 60% B, 5.1-
5.5 min down to 9.5% B, 5.5-8.7 min isocratic 9.5% B.  Data collection and analysis 
were conducted with the associated MassHunter software package.  Detection of SAH 
and 5’-dA was performed using electrospray ionization in the positive mode (ESI+) with 
multiple reaction monitoring (MRM).  The masses used for the detection of SAH and 5’-
dA are shown in Table 4.1.  Quantification of SAH and 5’d-A levels was conducted using 
the MassHunter software with appropriate standard curves and utilized a tyrosine internal 
standard.  The mass transition from the parent ion to product ion 1 was used for 
quantification. 
Table 4.1:  LC-MS mass fragments for detection of SAH and 5’d-A 
 Parent Ion Product Ion 1 Product Ion 2 
SAH 385.4 136 134 
5’-dA 252.1 136 119 
Tyrosine 182.0 165 123 
 
Table 4.1:  Detection of SAH and 5’-dA was performed using electrospray ionization in 
the positive mode (ESI+) with multiple reaction monitoring (MRM).  The masses used 
for the detection of SAH and 5’-dA are shown.  The mass transition from the parent ion 
to product ion 1 was used for quantification.   
 
Synthesis of Substrates. 
Compounds 10-12, 15: 
The p-nitrobenzyl (5R)-carbapenem-3-carboxylate (9) and the p-nitrobenzyl (5S)-
carbapenem-3-carboxylate (8) were prepared as previously described37. 
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General procedure for pantetheine 1,4-addition: 
p-Nitrobenzyl (2R,3R,5R)-2-pantetheinyl-carbapenam-3-carboxylate (10b).  To 
pantetheine acetonide (563.6 mg, 1.77 mmol) was added tetrahydrofuran (1.7 mL) and 1 
M HCl (1.7 mL) and the solution was stirred for about 30 min or until the reaction was 
complete by TLC (10% ethanol/chloroform).  Then 1 M NaOH (1.7 mL) was added 
followed by triethylamine (149.4 µL).  This solution was added to a separate flask 
containing p-nitrobenzyl (5S)-carbapenem-3-carboxylate 8 2,4 (340 mg, 1.18 mmol) [or p-
nitrobenzyl (5R)-carbapenem-3-carboxylate 9 and acetonitrile (4.8 mL)].  The reaction 
mixture was stirred at room temperature for 40 min, then diluted with ethyl acetate (75 
mL) and washed with saturated ammonium chloride (8 mL) and brine (20 mL).  The 
aqueous layer was extracted with ethyl acetate (25 mL).  The organic layers were 
combined, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to 
yield a yellow oil.  The oil was purified by silica gel chromatography using 5% 
ethanol/chloroform to provide a mixture of the two isomers 10a and 10b (398 mg, 55%) 
oil; TLC (ethanol:chloroform, 1:9 v/v) major isomer Rf = 0.33, minor isomer Rf = 0.29. 
Repeated chromatography enriched each isomer for characterization.     
p-Nitrobenzyl (2S,3R,5R)-2-pantetheinyl-carbapenam-3-carboxylate (10a). major 
isomer [α] 24.0 °C = -60.6° (c = 1.020, CHCl3); IR 3408, 1769, 1667, 1644, 1530, and, 1348 
cm-1; 1H NMR (400 MHz, CDCl3): δ 8.22 (d, J = 8.8 Hz, 2H), 7.54 (d, J = 8.3 Hz, 2H), 
7.40 (bt, J = 5.8 Hz, 1H), 6.61 (bt, J = 5.4 Hz, 1H), 5.29 (s, 2H), 4.41 (d, J = 5.8 Hz, 
1H), 3.97 (s, 1H), 3.86-3.93 (m, 1H), 3.78-3.85 (m,1H), 3.54 (q, J = 5.5 Hz, 1H), 3.46 (s, 
2H), 3.36-4.44 (m, 2H), 3.35  (dd, J = 15.9, 5.1 Hz, 1H), 2.86 (dd, J = 16.0, 1.6 Hz, 1H), 
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2.74-2.82 (m, 1H), 2.58-2.70 (m, 2H), 2.44 (t, J = 5.5 Hz, 1H), 1.64-1.74 (m, 1H), 0.98 
(s, 3H), 0.89 (s, 1H) ppm; 13C NMR (100 MHz, CDCl3): δ 175.8, 173.9, 171.7, 169.4, 
147.6, 142.2, 128.3, 123.7, 77.2, 70.5, 65.7, 60.3, 52.5, 51.7, 44.1, 39.1, 38.5, 38.3, 35.6, 
35.1, 31.7, 21.1, 20.4 ppm; HRMS m/z: [M+H]+ calcd. for C25H34N4O9S 567.2125; found 
567.2126.  The assignment of stereochemistry of the C-2 and C-3 -positions were based 
on Nuclear Overhauser Effect (n.O.e.) NMR experiments performed and described in the 
thesis of Kristos Moshos37. 
p-Nitrobenzyl (2R,3R,5R)-2-pantetheinyl-carbapenam-3-carboxylate (10b). minor 
isomer [α]22.5 °C = -23.0° (c = 0.90, CHCl3); IR 3396, 1769, 1660, 1650, 1608, 1522, and, 
1347 cm-1; 1H NMR (400 MHz, CDCl3): δ 1H NMR (400 MHz, CDCl3): δ 8.25 (d, J = 
8.8 Hz, 2H), 7.56 (d, J = 8.3 Hz, 2H), 7.32 (bt, J = 5.0 Hz, 1H), 6.33 (bt, J = 5.8 Hz, 
1H), 5.29 (s, 2H), 4.80 (d, J = 7.1 Hz, 1H), 4.08-4.14 (m, 1H), 4.00 (s, 1H), 3.60-3.68 (q, 
J = 8.0 Hz, 1H), 3.58 (t, J = 5.9 Hz, 2H), 3.49 (s, 2H), 3.33-3.45 (m, 3H), 2.81 (dd, J = 
16.5, 2.8 Hz, 1H), 2.60-2.80 (m, 2H), 2.41 (t, J = 5.1 Hz, 2H), 2.23-2.32 (m, 1H), 2.12-
2.22 (m, 1H), 1.02 (s, 3H), 0.91 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 176.5, 
174.0, 171.7, 168.0, 147.7, 142.2, 128.7, 124.7, 77.2, 70.5, 65.4, 60.3, 52.1, 48.8, 44.2, 
42.5, 39.2, 35.6, 35.2, 32.3, 24.1, 21.0, 20.4 ppm; HRMS m/z:  [M+H]+ calcd. for 
C25H34N4O9S 567.21248; found 567.212229. The assignment of stereochemistry of the 
C-2 and C-3 -positions were based on Nuclear Overhauser Effect (n.O.e.) NMR 
experiments performed and described in the thesis of Kristos Moshos37. 
p-Nitrobenzyl (2R,3S,5S)-2-pantetheinyl-carbapenam-3-carboxylate (11a). major 
isomer [α]24.8 ° C = +29.3° (c = 1.55, CH2Cl2); IR 3408, 1769, 1667, 1644, 1609, 1530, 
and, 1348 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.22 (d, J = 8.8 Hz, 2H), 7.54 (d, J = 8.3 
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Hz, 2H), 7.40 (bt, J = 5.8 Hz, 1H), 6.61 (bt, J = 5.4 Hz, 1H), 5.29 (s, 2H), 4.41 (d, J = 
5.8 Hz, 1H), 3.97 (s, 1H), 3.86-3.93 (m, 1H), 3.78-3.85 (m, 1H), 3.54 (q, J = 5.5 Hz, 1H), 
3.46 (s, 2H), 3.36-4.44 (m, 2H), 3.35  (dd, J = 15.9, 5.1 Hz, 1H), 2.86 (dd, J = 16.0, 1.6 
Hz, 1H), 2.74-2.82 (m, 1H), 2.58-2.70 (m, 2H), 2.44 (t, J = 5.5 Hz, 1H), 1.64-1.74 (m, 
1H), 0.98 (s, 3H), 0.89 (s, 1H) ppm; 13C NMR (100 MHz, CDCl3): δ 175.9, 173.7, 171.7, 
169.5, 147.8, 142.2, 128.4, 123.9, 77.2, 70.7, 65.9, 65.6, 52.6, 51.8, 44.2, 39.3, 38.6, 38.3, 
35.7, 35.2, 31.8, 21.3, 20.4 ppm; HRMS m/z:  [M+H]+ calcd. for C25H34N4O9S 567.2125; 
found 567.2124. The assignment of stereochemistry of the C-2 and C-3 -positions were 
based on Nuclear Overhauser Effect (n.O.e.) NMR experiments performed and described 
in the thesis of Kristos Moshos37. 
p-Nitrobenzyl (2S,3S,5S)-2-pantetheinyl-carbapenam-3-carboxylate (11b). minor 
isomer [α]22.5 °C = +44.3° (c = 0.970, CHCl3); IR 3373, 1749, 1650, 1523, and, 1347 cm-1; 
1H NMR (400 MHz, CDCl3): δ 8.25 (d, J = 8.8 Hz, 2H), 7.56 (d, J = 8.3 Hz, 2H), 7.32 
(bt, J = 5.0 Hz, 1H), 6.33 (bt, J = 5.8 Hz, 1H), 5.29 (s, 2H), 4.80 (d, J = 7.1 Hz, 1H), 
4.08-4.14 (m, 1H), 4.00 (s, 1H), 3.60-3.68 (q, J = 8.0 Hz, 1H), 3.58 (t, J = 5.9 Hz, 2H), 
3.49 (s, 2H), 3.33-3.45 (m, 3H), 2.81 (dd, J = 16.5, 2.8 Hz, 1H), 2.60-2.80 (m, 2H), 2.41 
(t, J = 5.1 Hz, 2H), 2.23-2.32 (m, 1H), 2.12-2.22 (m, 1H), 1.02 (s, 3H), 0.91 (s, 3H) ppm; 
13C NMR (100 MHz, CDCl3): δ 176.5, 174.0, 171.7, 168.0, 147.7, 142.2, 128.7, 124.7, 
77.2, 70.5, 65.4, 60.3, 52.1, 48.8, 44.2, 42.5, 39.2, 35.6, 35.2, 32.3, 24.1, 21.0, 20.4 ppm; 
HRMS m/z:  [M+H]+ calcd. for C25H34N4O9S 567.2125; found 567.2124. The assignment 
of stereochemistry of the C-2 and C-3 -positions were based on Nuclear Overhauser 




General procedure for deprotection of p-nitrobenzyl esters: 
The p-nitrobenzyl ester (310 mg, 0.76 mmol) was dissolved in tetrahydrofuran (10 mL) 
and potassium bicarbonate (76.09 mg, 0.76 mmol) in water (5 mL) was added followed 
by 10% Pd on carbon (36 mg).  Hydrogen (40 psi) was admitted to the reaction mixture 
in a pressure tube and shaken on a Parr apparatus for 2 h.  The catalyst was removed by 
filtration on Celite.  The filtrate was washed twice with ethyl acetate (15 mL).  The 
aqueous layer was filtered through 0.2 µm nylon filter and lyophilized to give an 
amorphous solid.  The solid was dissolved in a minimum amount of water and applied to 
a bed of Diaion® HP-20 resin and eluted with distilled water.  After any excess salt was 
removed, 10% ethanol/water was used to elute the product.  The presence of salt was 
detected using silver nitrate solution and the presence of desired compound was detected 
using potassium permanganate solution.  Fractions that contained product and were salt 
free were pooled and lyophilized. 
Potassium (2S,3R,5R)-2-pantetheinyl-carbapenam-3-carboxylate (12). major isomer 
[α]22.4 ° C = -36.1° (c = 1.050, H2O); 1H NMR (400 MHz, D2O): δ 4.17 (d, J = 5.3 Hz, 
1H), 3.97 (s, 1H), 3.94-4.00 (m, 1H), 3.78 (dd, J = 12.6, 6.6 Hz, 1H), 3.20-3.60 (m, 7H), 
2.90 (dd, J = 16.6, 2.3 Hz), 2.74-2.95 (m, 3H), 2.60 (td, J = 13.6, 6.8 Hz, 1H), 2.50 (t, J 
= 6.4 Hz, 2H), 1.70 (td, J = 13.7, 6.8 Hz, 1H), 0.92 (s, 3H), 0.88 (s, 3H) ppm; 13C NMR 
(100 MHz, D2O): δ 181.2, 177.4, 175.7, 174.5, 76.4, 69.4, 69.0, 53.1, 53.1, 43.6, 39.2, 
39.2, 37.6, 36.1, 35.8, 31.5, 21.2, 19.8 ppm; HRMS m/z:  [M-H]- calcd. for C18H29N3O7S 
430.1653; found 430.1665. 
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Potassium (2R,3R,5R)-2-pantetheinyl-carbapenam-3-carboxylate (13). minor isomer 
[α]23.1 °C = -59.0° (c = 0.7300, H2O); 1H NMR (400 MHz, D2O): δ 4.52 (d, J = 6.6 Hz, 
1H), 4.05-4.14 (m, 1H), 3.99 (s, 1H), 3.90-3.97 (m, 1H), 3.35-3.55 (m, 6H), 3.31 (dd, J = 
16.9, 4.5 Hz), 2.75-2.93 (m, 3H), 2.51 (t, J = 6.2 Hz, 2H), 2.30-2.37 (m, 1H), 2.07 (td, J 
= 13.4, 6.6 Hz, 1H), 0.92 (s, 3H), 0.88 (s, 3H) ppm; 13C NMR (100 MHz, D2O): δ 181.7, 
176.0, 175.7, 174.4, 76.3, 69.0, 67.5, 53.1, 51.7, 41.6, 39.2, 38.5, 37.7, 36.1, 35.9, 32.2, 
21.2, 19.8 ppm; HRMS m/z:  [M+H]+ calcd. for C18H29N3O7S 432.1805; found 432.1797. 
The diastereomers 13 and 14 were separated and purified using an Agilent model 1100 
HPLC equipped with a multi-wavelength ultraviolet–visible detector in conjunction with 
a reverse-phase Phenomenex Luna 10μ C18(2) 100 Å preparatory column (250 x 21.20 
mm ID).  The mobile phase was 25% methanol and 75% buffer (10 mM potassium 
phosphate, pH 6.65) at a flow rate of 5 ml per min.  Compound 13 eluted at 29 min and 
compound 14 eluted at 22 min. 
Potassium (2R,3S,5S)-2-pantetheinyl-carbapenam-3-carboxylate (14). major isomer 
1H NMR (400 MHz, D2O): δ 4.17 (d, J = 5.0 Hz, 1H), 3.97 (s, 1H), 3.94-4.00 (m, 1H), 
3.78 (dd, J = 12.8, 6.0 Hz, 1H), 3.20-3.60 (m, 7H), 2.90 (dd, J = 16.6, 2.4 Hz), 2.74-2.95 
(m, 3H), 2.60 (td, J = 13.4, 6.8 Hz, 1H), 2.50 (t, J = 6.2 Hz, 2H), 1.70 (td, J = 13.7, 6.9 
Hz, 1H), 0.92 (s, 3H), 0.88 (s, 3H) ppm; 13C NMR (100 MHz, D2O): δ 181.2, 177.4, 
175.7, 174.5, 76.3, 69.4, 69.0, 53.1, 53.1, 43.6, 39.2, 39.2, 37.6, 36.1, 35.9, 31.5, 21.2, 
19.8 ppm; HRMS m/z:  [M+H]+ calcd. for C18H29N3O7S 432.1799; found 432.1808. 
 
Potassium (2S,3S,5S)-2-pantetheinyl-carbapenam-3-carboxylate (15). minor isomer 
1H NMR (400 MHz, D2O): δ 4.52 (d, J = 6.6 Hz, 1H), 4.05-4.14 (m, 1H), 3.98 (s, 1H), 
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3.90-3.97 (m, 1H), 3.35-3.55 (m, 6H), 3.31 (dd, J = 17.0, 4.8 Hz), 2.75-2.93 (m, 3H), 
2.51 (t, J = 6.2 Hz, 2H), 2.33 (td, J = 13.1, 5.0 Hz, 1H), 2.06 (td, J = 13.6, 6.8 Hz, 1H), 
0.91 (s, 3H), 0.87 (s, 3H) ppm; 13C NMR (100 MHz, D2O): δ 181.8, 176.1, 175.7, 174.5, 
76.3, 69.0, 67.5, 53.1, 51.7, 41.5, 39.2, 38.5, 37.6, 36.1, 36.0, 32.2, 21.2, 19.7 ppm; 
HRMS m/z:  [M+H]+ calcd. for C18H29N3O7S 432.1799; found 432.1780.  C-2 and C-3 
stereochemical assignments were established by Nuclear Overhauser Effect (n.O.e.) 
NMR experiments and confirmed previous stereochemical analyses38.  
(±)-4-Allylazetidin-2-one (16).  The procedure was carried out as described previously38. 
To 1,4-pentadiene (6.6 g, 96.9 mmol), chlorosulfonyl isocyanate (7.79 ml, 12.7 g) was 
added at 0 °C, then stirred at room temperature for 3 days in a pressure bottle.  The 
reaction mixture was diluted with dichloromethane (110 mL) and was then add slowly to 
a solution of sodium sulfite (14.5 g) and dibasic potassium phosphate (8.51 g) in water 
(52.5 ml) at 0 °C.  Then aqueous sodium hydroxide (1 M) was added to maintain pH = 
7.0 - 8.0.  After the addition, the reaction mixture was stirred at room temperature for 2 h, 
then extracted with ethyl acetate (3 × 100 ml).  The organic layers were combined, dried 
with anhydrous sodium sulfate, filtered, and concentrated to give 16 as a light yellow oil, 
which was used crude in the next reaction (5.57g, 52%). TLC (ethyl acetate:hexanes, 3:7 
v/v): Rf = 0.67; 1H NMR (400 MHz, CDCl3): δ 6.67 (s, 1H),  5.64-5.78 (m, 1H), 5.00-
5.10 (m, 2H), 3.58-3.66 (m, 1H), 2.97 (dd, J = 14.9, 5.1 Hz, 1H), 2.53 (dd, J = 14.9, 1.1 
Hz, 1H), 2.24-2.36 (m, 2H); 13C NMR (100 MHz, CDCl3): δ 168.1, 133.1, 117.8, 46.9, 
42.7, 39.2 ppm.  1H and 13C NMR matched the data as previously reported in the 
literature38. 
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(±)-4-Allyl-1-dimethyl-t-butylsilyl-azetidin-2-one (17).  The procedure was carried out 
as described previously38. Triethylamine (16.15 ml, 115.8 mmol) and N,N-
dimethylaminopyridine (1.1g, 9.26 mmol) were added to 16 (5.15g, 46.3 mmol) in 
tetrahydrofuran (173 ml) at 0 °C. t-Butyldimethylsilyl-methanesulfonate (12.8 ml, 55.56 
mmol) was then added to the reaction mixture slowly.  The solution was stirred at 0 °C 
for 20 min before it was allowed to warm to room temperature for 1 h.  After 
concentration in vacuo, the mixture was dissolved in ethyl acetate (200 ml) and washed 
with saturated ammonium chloride (80 ml) and brine (100 ml), dried with anhydrous 
sodium sulfate, filtered, and concentrated in vacuo.  The crude oil was purified by silica 
gel chromatography (diethyl ether:hexanes, 1:9) to yield 17 as a light yellow oil (8.71 g, 
83%); TLC (ethyl acetate:hexanes, 3:7 v/v): Rf = 0.67; 1H NMR (300 MHz, CDCl3): δ  
5.65-5.80 (m,1H), 5.50-5.15 (m, 2H), 3.54-3.63 (m, 1H), 3.09 (dd, J = 15.4, 5.5 Hz, 1H), 
2.66 (dd, J = 15.3, 2.7 Hz, 1H), 2.52-2.62 (m, 1H), 2.10-2.24 (m, 1H), 0.96 (s, 9H), 0.25 
(s, 3H), 0.22 (s, 3H) ppm. 1H NMR matched the data as previously reported in the 
literature38. 
(±)-(3S,4S)-4-Allyl-1-dimethyl-t-butylsilyl-3-methylazetidin-2-one (18).  The 
procedure was carried out as described previously38. A solution of 17 (7.0 g, 31.1 mmol) 
in tetrahydrofuran (77.8 mL) was added to lithium diisopropylamine (2 M, 34.21 mL, 
68.4 mmol) in tetrahydrofuran (155 mL) at -78°C under a nitrogen atmosphere.  After 
stirring for 30 min at -78 °C, methyl iodide (19.4 mL, 44.14g, 310.9 mmol) was added 
and the reaction mixture was stirred at -78 °C for 30 min before it was allowed to warm 
to room temperature for 1 h.  Acetic acid (3.9 mL) was added to the solution, and the 
reaction mixture was concentrated in vacuo.  The resulting oil was dissolved in ethyl 
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acetate (155 mL) and washed with brine (85.5 mL), dried with anhydrous sodium sulfate, 
filtered, and concentrated in vacuo.  The resulting oil was purified by silica gel 
chromatography (diethyl ether:hexanes, 1:9) to provide 18 as a light yellow oil (7.13 g, 
96%).  TLC (ethyl acetate:hexanes, 2:8 v/v): Rf = 0.72; IR 2940, 2860, 1725, and, 1640 
cm-1; 1H NMR (400 MHz, CDCl3): δ  5.65-5.80 (m, 1H), 4.91-5.21 (m, 2H), 3.15 (ddd, J 
= 9.0, 4.0, 3.0 Hz, 1H), 2.77 (qd, J = 8.0, 3.0 Hz, 1H), 1.9-2.6 (m, 2H), 1.21 (d, J = 8.0 
Hz), 0.91 (s, 9H), 0.21 (s, 3H), 0.20 (s, 3H) ppm. 1H NMR matched the data as 
previously reported in the literature38. 
(±)-(3S,4S)-4-Allyl-3-methylazetidin-2-one (19).  The procedure was carried out as 
described previously38. Acetic acid (5.11 mL, 89.4 mmol) followed by tetra-n-
butylammonium fluoride (13.2 g, 41.72 mmol) was added to a solution of 18 (7.13 g, 
29.8 mmol) in anhydrous tetrahydrofuran (150 mL) at 0 °C.  The reaction mixture was 
stirred at 0 °C for 30 min, diluted with ethyl acetate (500 mL) and washed with water (2 
× 140 mL) and brine (150 mL).  The organic layer was dried with anhydrous sodium 
sulfate, filtered and concentrated in vacuo.  The resulting oil was purified by silica gel 
chromatography (ethyl acetate:hexanes, 3:7 to 4:6) to provide 19 as a colorless oil (1.18 
g, 70%).  TLC (ethyl acetate:hexanes, 2:3 v/v): Rf = 0.36; IR 3420, 1755, and, 1640 cm-1; 
1H NMR (400 MHz, CDCl3): δ 6.5 (br s, 1H), 5.8 (m, 1H), 5.15-5.25 (m, 1H), 4.95-5.1 
(m, 1H), 3.30 (td, J = 6.0, 2.0 Hz, 1H), 2.80 (qd, J = 7.0, 2.0, 1H), 2.36 (td, J = 6.0, 1.0 
Hz, 2H), 1.30 (d, J =7.0 Hz, 3H), ppm. 1H NMR matched the data as previously reported 
in the literature38. 
p-Nitrobenzyl (±)-2-(2-allyl-3-methyl-4-oxoazetidin-1-yl)-2-(triphenyl-λ5-
phosphanylidene)acetate (20).  The procedure was carried out as described previously38. 
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p-Nitrobenzyl glyoxylate hydrate (6.03 g, 26.5 mmol), triethylamine (432.7 μL, 3.08 
mmol), and 4.9 g 3Å molecular sieves were added sequentially to a solution of 19 (3.32 
g, 26.5 mmol) in anhydrous tetrahydrofuran (93.2 mL) and stirred at room temperature 
for 16 h.  The reaction mixture was filtered through Celite, washed with ethyl acetate, and 
concentrated in vacuo.  The crude residue was dissolved in anhydrous tetrahydrofuran 
(82.2 mL), cooled to -15 °C to which was then added 2,6-lutidine (5.85 mL, 50.4 mmol) 
followed by thionyl chloride (2.70 mL, 37.1 mmol) dropwise.  The reaction mixture was 
stirred for 1 h at -15 °C. The solution was filtered through Celite, and the filtrate was 
washed with ethyl acetate and concentrated in vacuo.  The crude oil was dissolved in 1,4-
dioxane (85.1 mL) and triphenylphosphine (9.02 g, 34.4 mmol) and 2,6-lutidine (3.38 
mL, 39.2 mmol) were added.  The resulting mixture was stirred at room temperature for 
16 h, diluted with ethyl acetate (858.7 mL), and washed with water (244.4 mL) and brine 
(244.4 mL).  The organic layer was dried with anhydrous sodium sulfate, filtered, and 
concentrated in vacuo.  The resulting brown oil was purified by silica gel 
chromatography (ethyl acetate:hexanes, 1:1 to 7:3) to yield 20 as an orange foam (3.07g, 
20 % yield).  The product was characterized by subsequent transformation to the 
respective bicyclic β-lactams (vide infra). TLC (diethyl ether:ethyl acetate, 1:1 v/v): Rf = 
0.52. 
p-Nitrobenzyl (±)-(5S,6S)-6-methylcarbapenem-3-carboxylate (21).  The procedure 
was carried out as described previously38. Trifluoroacetic acid (7.17 mL) was added to a 
solution of 20 (3.07 g, 5.3 mmol) in dichloromethane (117 mL) at 0 °C.  The reaction 
mixture was cooled to -78 °C and ozone was bubbled through the solution until a blue 
color persisted.  The solution was stirred for 5 min at -78 °C, then a stream of nitrogen 
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was bubbled through the reaction mixture until the color changed from blue to yellow.  
Dimethyl sulfide (7.83 mL) was added to the solution at 0 °C and the solution was stirred 
for 1 h. The reaction mixture was diluted with dichloromethane (70 mL) and washed with 
saturated sodium bicarbonate (2 × 200 mL) and brine (201 mL).  The organic layer was 
dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo.  The crude 
brown oil was purified by silica gel chromatography (ethyl acetate:hexanes, 3:7 to 6:4) to 
give a diastereomeric mixture of the cis and trans methyl isomers (1.24 g, 78%).  
Repeated purification gave the desired trans methyl isomer 21 (0.70 g, 44%). TLC (ethyl 
acetate:hexanes, 4:6 v/v): Rf = 0.45 epi-21, 0.37 21; IR 2970, 1778, 1730, 1608, 1521, 
and, 1348 cm-1; 1H NMR (400 MHz, CDCl3): δ  8.23 (d, J = 8.6 Hz, 2H), 7.62 (d, J = 
8.3 Hz, 2H), 6.54 (t, J = 2.8 Hz, 1H), 5.45, 5.28 (ABq, JAB = 16, 2H),  3.98 (ddd, J = 
10.3, 7.8, 2.8 Hz, 1H), 3.23 (dq, J = 7.5, 2.8 Hz, 1H), 2.97 (ddd, J = 19.5, 9.7, 3.1 Hz, 
1H), 2.80 (ddd, J = 19.4, 7.8, 2.5 Hz, 1H), 1.45 (d, J = 7.3 Hz, 3H), ppm; 13C NMR (100 
MHz, CDCl3): δ 180.1, 160.0, 147.6, 142.7, 134.5, 132.3, 128.1, 123.7, 65.3, 59.1, 54.5, 
36.0, 13.9 ppm;  HRMS m/z:  [M+H]+ calcd. for C15H14N2O5 303.0981; found 303.0978. 
1H and 13C NMR matched the data as previously reported in the literature38. 
p-Nitrobenzyl (±)-(3R,5S,6S)-6-methyl-2-pantetheinyl-carbapenam-3-carboxylate 
(22).   Pantetheine acetal (1.1 g, 3.45 mmol) in tetrahydrofuran (3.5 mL) was added 1 M 
HCl and stirred at room temperature for 30 min or until deprotection was determined to 
be complete by TLC.  The reaction mixture was then neutralized by the addition of 
aqueous NaOH (3.5 mL, ~1 M) followed by triethylamine (297.5 µL).  This was added to 
p-nitrobenzyl 21 (0.70 g, 2.3 mmol) in acetonitrile (9.4 mL).  After stirring for 20 min at 
room temperature, the reaction mixture was diluted with ethyl acetate (125 mL) and 
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washed with saturated ammonium chloride (16 mL) and brine (35 mL). The aqueous 
layer was removed and extracted with ethyl acetate (40 mL).  The combined organic 
layers were dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo.  
The product was purified by silica gel chromatography (ethanol:chloroform, 1:9) to give 
22 as inseparable C-2 stereoisomers (560 mg, 42%).  1H NMR analysis of the crude 
mixture revealed the C-2 diastereomers in a ratio of 4:1. TLC (ethanol:chloroform, 1:9 
v/v): major isomer 22a Rf = 0.36, minor isomer 22b Rf = 0.32; IR 3408, 2967, 2856, 
1772, 1749, 1661, 1643, 1525, 1442, and, 1346 cm-1; 22a: 1H NMR (400 MHz, CDCl3): 
δ 8.24 (d, J = 8.6 Hz, 2H), 7.54 (d, J = 8.3 Hz, 2H), 7.36 (bt, J = 5.6 Hz, 1H), 6.44 (bt, J 
= 5.4 Hz, 1H), 5.28 (s, 2H), 4.45 (dd, J = 8.8, 4.9 Hz, 1H), 3.92-4.08 (m, 2H), 3.74-3.82 
(m, 1H), 3.20-3.60 (m, 6H), 3.12 (dq, J = 7.5, 2.1 Hz, 1H), 2.40-2.80 (m, 5H), 1.68-1.78 
(m, 1H), 1.40 (d, J = 7.6 Hz, 3H), 1.00 (s, 3H), 0.91 (s, 3H) ppm; 22b: 1H NMR (400 
MHz, CDCl3): δ 8.24 (d, J = 8.6 Hz, 2H), 7.54 (d, J = 8.3 Hz, 2H), 7.36 (bt, J = 5.6 Hz, 
1H), 6.44 (bt, J = 5.4 Hz, 1H), 5.28 (s, 2H), 4.79 (dd, J = 7.1, 3.8 Hz, 1H), 3.92-4.08 (m, 
2H), 3.74-3.82 (m, 1H), 3.20-3.60 (m, 6H), 3.01 (dq,  J = 7.3, 2.8 Hz, 1H), 2.40-2.80 (m, 
4H), 2.24-2.34 (m, 1H), 2.06-2.19 (m, 1H), 1.39 (d, J = 7.3 Hz, 3H), 1.00 (s, 3H), 0.91 (s, 
3H) ppm; 13C NMR (100 MHz, CDCl3): δ 179.2, 173.9, 171.8, 169.4, 147.8, 142.2, 
128.4, 123.8, 70.7, 65.8, 65.3, 60.1, 53.1, 51.7, 39.2, 38.5, 37.3, 35.7, 31.9, 31.8, 21.3, 
21.0, 20.4, 13.8 ppm; HRMS m/z:  [M+H]+ calcd. for C26H36N4O9S 581.2281; found 
581.2277. 
Potassium (±)-(3R,5S,6S)-6-methyl-2-pantetheinyl-carbapenam-3-carboxylate (23). 
Water (4.9 mL) containing potassium bicarbonate (74.5 mg, 0.74 mmol) was added to a 
solution of 22 (360.0 mg, 0.62 mmol) in tetrahydrofuran (10.4 mL) in a pressure flask. 
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10% palladium on carbon (40 mg) was carefully added to the solution.  The flask was 
fitted to a Parr apparatus to which hydrogen was added (40 PSI) and shaken for 2 h.  The 
catalyst was removed by filtration of the reaction mixture through Celite and the filtered 
solids were washed with water (6 mL) followed by ethyl acetate (30 mL).  The aqueous 
layer was separated from the filtrate and washed with ethyl acetate (25 mL).  The washed 
aqueous layer was filtered through a 25 mm 0.2 µm nylon syringe filter and lyophilized.  
The resulting solids were dissolved and desalted by Diaion-HP resin chromatography 
(water).  Fractions that contained 23 (visualized with potassium permanganate) that were 
free of salt (visualized by silver nitrate precipitation) were lyophilized to produce 23 
(239.6 mg, 80%) as a white solid. 1H NMR analysis of the crude mixture revealed the 
ratio of C-2 diastereomers in a ratio of 7:3 (23a:23b). 23a: 1H NMR (400 MHz, CDCl3): 
δ 4.21 (d, J = 4.3 Hz, 1H), 4.00 (s, 1H), 3.75-3.95 (m, 2H), 3.35-3.60 (m, 6H), 3.18 (qd, J 
= 7.3, 1.1 Hz, 1H), 2.70-2.90 (m, 2H), 2.59 (dt, J = 13.9, 7.1 Hz, 1H), 2.52 (t, J = 6.4 Hz, 
2H), 1.76 (dt, J = 13.9, 6.1 Hz, 1H), 1.36 (d, J = 7.6 Hz, 3H), 0.93 (s, 3H), 0.89 (s, 3H) 
ppm; 23b: 1H NMR (400 MHz, CDCl3): δ 4.52 (d, J = 6.6 Hz, 1H), 4.00 (s, 1H), 3.70 (bt, 
J = 5.6 Hz, 2H), 3.35-3.60 (m, 6H), 3.07 (qd, J = 6.6, 1.1 Hz, 1H), 2.70-2.90 (m, 2H), 
2.52 (t, J = 6.4 Hz, 2H), 2.25-2.35 (m, 1H), 2.08-2.18 (m, 1H), 1.36 (d, J = 7.6 Hz, 3H), 
0.93 (s, 3H), 0.89 (s, 3H) ppm;  13C NMR (100 MHz, CDCl3): δ 184.5, 177.1, 175.7, 
174.5, 76.4, 69.2, 69.0, 60.6, 53.1, 52.6, 39.2, 39.1, 36.5, 36.1, 35.9, 31.5, 21.2, 19.8, 13.5 
ppm; HRMS m/z:  [M+H]+ calcd. for C19H31N3O7S 446.1956; found 446.1977. 
Benzyl (2R)-1-carboxybenzyl-5-oxopyrrolidine-2-carboxylate (24).  
Diisopropylethylamine (54 mL, 310 mmol was added to D-pyroglutamic acid (20 g, 155 
mmol, TCI America/AK Scientific) in dichloromethane (500 mL).  Benzyl bromide (22 
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ml, 185 mmol) was added and the solution was refluxed for 4h.  The reaction mixture 
was concentrated in vacuo and the crude oil was redissolved in ethyl acetate (400 
ml).  The cloudy mixture was filtered through silica on top of Celite and the silica/Celite 
plug was washed twice with ethyl acetate (200 mL).  The eluate was concentrated in 
vacuo and redissolved in tetrahydrofuran (600 mL) to which was added lithium 
bis(trimethylsilyl)amide (154.5 mL, 1.0 M, 155 mmol) at -78 ˚C and stirred for 10 
min.  Benzyl chloroformate (30.8 mL, 202 mmol) was added and the reaction mixture 
was allowed to stir for 10 min.  The reaction was quenched with aqueous ammonium 
chloride (400 mL) and the solution was warmed to room temperature and the phases were 
separated.  The aqueous layer was extracted 5× with ethyl acetate (400 mL) and the 
combined organic fractions were washed with brine, dried with anhydrous magnesium 
sulfate, filtered, and concentrated in vacuo.  The solid crude product was recrystallized 
from hot ethyl acetate/hexanes to give 24 as white crystals (34.4 g, 63% yield). 1H-NMR 
(400 MHz; CDCl3): δ 7.36-7.28 (m, 10H), 5.22 (d, J = 1.3 Hz, 2H), 5.13 (s, 2H), 4.72 
(dd, J = 9.4, 2.7 Hz, 1H), 2.68-2.58 (m, 1H), 2.50 (ddd, J = 17.6, 9.3, 3.3 Hz, 1H), 2.34 
(ddt, J = 13.4, 10.4, 9.4 Hz, 1H), 2.09-2.02 (m, 1H) ppm; 13C NMR (101 MHz; CDCl3): 
δ 172.9, 170.9, 150.9, 135.10, 135.08, 128.80, 128.73, 128.69, 128.56, 128.41, 128.26, 
68.5, 67.5, 58.9, 31.1, 21.9 ppm.  HRMS (FAB) m/z:  [M+H]+ calcd. for C20H19NO5 
354.13415; found 354.13342.  
7-Benzyl 1-tert-butyl (6R)-6-(benzyloxycarbonylamino)-2-methyl-3-
oxoheptanedioate (25).  This synthesis was adapted from the procedures of Ohta et al.19.   
A solution of lithium diisopropylamide in tetrahydrofuran (17 mL, 2.0 M, 33.6 mmol) 
was added to a solution of tert-butyl propionate (4.26 ml, 28 mmol) in tetrahydrofuran 
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(300 mL) at -78 ˚C and allowed to stir for 30 min.  A solution of 24 in tetrahydrofuran 
(40 mL) was added slowly to the reaction mixture.  After stirring for 30-60 min at -78 ˚C, 
the reaction was quenched with saturated ammonium chloride and the phases were 
separated.  The aqueous layer was extracted three times with dichloromethane (50 
mL).  The combined organic layers were washed with brine, dried with anhydrous 
magnesium sulfate, and concentrated in vacuo.  The crude oil was purified by silica gel 
chromatography using 25% ethyl acetate in hexanes to give 25 (9.88 g, 72%) as a 
colorless oil, which solidified overnight at room temperature. TLC (ethyl 
acetate:hexanes, 2:3 v/v): Rf = 0.75; 1H-NMR (400 MHz; CDCl3): δ 7.35 (s, 10H), 5.30-
5.46 (m, 1H), 5.17 (s, 2H), 5.09 (s, 2H), 4.31-4.47 (m, 1H), 3.34-3.36 (m, 1H), 2.47-2.73 
(m, 2H), 1.94-2.22 (m, 2H), 1.42 (s, 9H), 1.23 (bd, J = 6.8 Hz, 3H) ppm; 13C NMR (101 
MHz; CDCl3): δ 205.2, 171.8, 169.6, 156.0, 136.2, 135.3, 128.74, 128.62, 128.44, 
128.29, 128.20, 82.0, 67.4, 67.2, 53.9, 53.6, 37.3, 28.0, 26.4, 12.8 ppm; HRMS (FAB) 
m/z:  [M-OH]+ calcd. for C27H33NO7 466.2230; found 466.2207.  1H and 13C NMR 
matched the data as previously reported in the literature19.    
tert-Butyl butyrate (26).  Conditions were modeled after a similar reaction 
(http://orgprepdaily.wordpress.com/2007/07/25/2-chloro-5-iodobenzoic-acid-tert-butyl-
ester/. [Accessed 09 April 15]). Butyryl chloride (20 mL, 191 mmol) in tetrahydrofuran 
(40 mL) was added to a slurry of tetrahydrofuran (400 mL) and potassium tert-butoxide 
(23.4 g, 209 mmol) at 0 ˚C.  Mixture was stirred for 90 min and then warmed to room 
temperature.  Silica gel (76 g, 1.3 mol) and distilled water (1.14 mL, 62.6 mmol) were 
added and allowed to stir 20 min.  Slurry was filtered through silica gel and concentrated.  
A yellow oil (18.1 g, 66%) was isolated.   The crude product was purified by vacuum 
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distillation (heating at 35-40 ˚C, and collected over liquid nitrogen) to give a clear oil.  
1H-NMR (400 MHz; CDCl3): δ 2.18 (t, J = 7.4 Hz, 2H), 1.61 (sext, J = 7.4 Hz, 2H), 1.44 
(s, 9H), 0.93 (t, J = 7.4 Hz, 3H) ppm; 13C NMR (101 MHz; CDCl3): δ 173.3, 80.0, 37.6, 
28.2, 18.7, 13.7 ppm. 1H and 13C NMR matched the data as previously reported in the 
literature39. 
7-Benzyl 1-tert-butyl (6R)-6-(benzyloxycarbonylamino)-2-ethyl-3-oxoheptanedioate 
(27).  Reaction was conducted similarly to that for compound 25, but utilized 26.  The oil 
was purified by silica gel chromatography using ethyl acetate/hexanes (3:20) to give the 
titled product (56%) as an oil, which solidified to a white solid. TLC (ethyl 
acetate:hexanes, 2:3 v/v): Rf = 0.69; 1H-NMR (400 MHz; CDCl3): δ 7.34 (bs, 10H), 5.40-
5.34 (m, 1H), 5.16 (s, 2H), 5.09 (s, 2H), 4.42-4.36 (m, 1H), 3.21-3.16 (m, 1H), 2.64-2.48 
(m, 2H), 2.20-1.90 (m, 2H), 1.81-1.73 (m, 2H), 1.42 (s, 9H), 0.89-0.85 (m, 3H) ppm; 13C 
NMR (101 MHz; CDCl3): δ 204.7, 171.87, 171.85, 168.9, 156.0, 136.2, 135.3, 128.75, 
128.62, 128.43, 128.29, 128.19, 82.01, 81.97, 67.4, 67.2, 61.7, 53.57, 53.51, 37.71, 37.61, 
28.0, 26.44, 26.31, 21.6, 12.0 ppm; HRMS (FAB) m/z:  [M+H]+ calcd. for C28H35NO7 
498.24918; found 498.24837. 
(2R,5S)-5-(1-(tert-Butoxy)-1-oxopropan-2-yl)pyrrolidine-2-carboxylic acid (28). This 
synthesis was adapted from the procedures of Ohta et al.19.   Palladium on carbon (0.4 g, 
8%w/w) was carefully added to a solution of 25 (5 g, 10 mmol) in acetic acid (1 mL) and 
ethanol (40 mL) in a bomb flask. The reaction mixture was pressurized to 50 psi with 
hydrogen gas in a Parr-shaker apparatus and shaken for 16 h.  The reaction mixture was 
then filtered over Celite and concentrated in vacuo.  The as-isolated product is a thick 
foam/oil (near quantitative yield).  TLC (methanol:acetonitrile, 3:7 v/v): Rf = 0.19; 1H-
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NMR (400 MHz; CDCl3): δ  4.05 (t, J = 6.8 Hz, 1H), 3.77-3.59 (m, 1H), 2.85-2.74 (m, 
1H), 2.30-2.21 (m, 2H), 2.12-2.00 (m, 1H), 1.66-1.57 (m, 1H), 1.46 (s, 9H), 1.33 (d, J = 
7.1 Hz, 2H), 1.27 (d, J = 7.3 Hz, 1H) ppm; 13C NMR (101 MHz; CDCl3): δ 173.56, 
173.52, 172.6, 172.0, 82.33, 82.23, 62.3, 61.4, 60.8, 60.4, 42.5, 42.3, 29.2, 29.0, 28.3, 
28.04, 28.01, 27.7, 15.4, 14.4 ppm; HRMS (ESI) m/z:  [M+H]+ calcd. for C12H21NO4  
244.1549; found 244.1551.  1H and 13C NMR matched the data as previously reported in 
the literature19. 
(2R,5S)-5-(1-(tert-Butoxy)-1-oxobutan-2-yl)pyrrolidine-2-carboxylic acid (29).  
Reaction with compound 27 was conducted as described above for 28.  The product is a 
glas (near quantitative yield).  TLC (methanol:acetonitrile, 3:7 v/v): Rf = 0.18; 1H-NMR 
(400 MHz; CDCl3): δ 4.08 (t, J = 6.1 Hz, 1H), 3.82-3.63 (m, 1H), 2.64-2.53 (m, 1H), 
2.31-2.20 (m, 2H), 2.05-2.00 (m, 1H), 1.86-1.69 (m, 2H), 1.69-1.57 (m, 1H), 1.51-1.43 
(m, 9H), 0.97 (t, J = 7.2 Hz, 3H) ppm; 13C NMR (101 MHz; CDCl3): δ 173.50, 173.47, 
172.4, 171.5, 82.7, 82.2, 61.3, 60.76, 60.57, 50.7, 49.4, 29.06, 28.88, 28.3, 28.1, 23.7, 
23.4, 11.61, 11.47 ppm; HRMS (ESI) m/z:  [M+H]+ calcd. for C13H23NO4 258.1705; 
found 258.1699. 1H and 13C NMR matched the data as previously reported in the 
literature19. 
 
The following protections (30-33) result in mixtures of diastereomers/rotamers, so 
NMR analyses were done at 50 °C: 
Methyl (2R,5S)-1-(tert-butyloxycarbonyl)-5-(1-(tert-butoxy)-1-oxopropan-2-
yl)pyrrolidine-2-carboxylate (30).  This synthesis was adapted from the procedures of 
Ohta et al.19. Potassium carbonate (3.49 g, 25 mmol) and sodium hydroxide (0.49 g, 12.5 
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mmol) were added to a solution of 28 (2.05 g, 8.4 mmol) in water (25 mL) at 0 ˚C.  A 
solution of di-tert-butyl dicarbonate (3.67g, 17 mmol) in tetrahydrofuran (33.8 mL) was 
added to the mixture at 0 ˚C over 15 min.  The reaction mixture was stirred for 1 h at 0 ˚C 
and then allowed to warm to room temperature and stirred for 16 h.  The reaction mixture 
was concentrated in vacuo, washed with diethyl ether, and acidified to pH = 2 with 
potassium bisulfate.  The solution was then extracted twice with ethyl acetate and the 
combined organic layers were washed with brine, dried with anhydrous magnesium 
sulfate, and concentrated in vacuo.  The crude residue was dissolved in 
dimethylformamide (84 mL) to which cesium carbonate (3.43 g, 10.5 mmol) was added 
and allowed to stir for 10 min.  Methyl iodide (1.05 mL, 16.9 mmol) was added to the 
reaction mixture dropwise and the solution was stirred for 16 h.  The reaction was 
quenched with saturated ammonium chloride, the phases separated, and the aqueous layer 
was extracted twice with diethyl ether.  The combined organic fractions were dried with 
anhydrous magnesium sulfate and concentrated in vacuo. The crude oil was purified by 
silica gel chromatography using ethyl acetate:hexanes (1:3) to give 30 (2.39 g, 79%) as 
an oil, which became a waxy solid overnight. TLC (ethyl acetate:hexanes, 7:13 v/v): Rf = 
0.77; (major isomer) 1H-NMR (400 MHz; CDCl3): δ 4.20 (dd, J = 19.9, 8.4 Hz, 1H), 
4.03 (app t, J = 8.2 Hz, 1H), 3.65 (s, 3H), 2.39-2.10 (m, 2H), 1.92-1.60 (m, 3H), 1.40 (s, 
9H), 1.36 (s, 9H), 1.16 (d, J = 7.0 Hz, 3H) ppm; (minor isomer) 1H-NMR (400 MHz; 
CDCl3): δ 4.24-4.16 (m, 1H), 4.13-4.08 (m, 1H), 3.65 (s, 3H), 2.39-2.10 (m, 2H), 1.92-
1.60 (m, 3H), 1.40 (s, 9H), 1.36 (s, 9H), 1.03 (d, J = 7.2 Hz, 3H) ppm; (major isomer) 13C 
NMR (101 MHz; CDCl3): δ 173.5, 173.0, 153.6, 79.6, 79.1, 59.3, 59.1, 51.5, 44.7, 27.7, 
27.4, 25.3, 14.7 ppm; (minor isomer) 13C NMR (101 MHz; CDCl3): δ 173.1, 172.8, 
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153.6, 79.4, 79.1, 59.8, 59.3, 51.3, 44.7, 27.7, 27.4, 23.3, 9.5 ppm; HRMS (FAB) 
m/z:  [M+H]+ calcd. for C18H31NO6 358.22296; found 358.22304. 1H and 13C NMR 
matched the data as previously reported in the literature19. 
Methyl (2S,5S)-1-(tert-butyloxycarbonyl)-5-(1-(tert-butoxy)-1-oxobutan-2-
yl)pyrrolidine-2-carboxylate (31).  Reaction with compound 29 was conducted as 
described above.  The crude oil was purified by silica gel chromatography using 20% 
ethyl acetate in hexanes to give 31 (73%) as an oil.  TLC (ethyl acetate:hexanes, 1:4 v/v): 
Rf = 0.52;  (major isomer) 1H-NMR (400 MHz; CDCl3): δ 4.20 (dd, J = 16.3, 7.9 Hz, 
1H), 4.00 (m, 1H), 3.64 (s, 3H), 2.30-2.22 (m, 2H), 1.90-1.52 (m, 5H), 1.41 (s, 9H), 1.36 
(s, 9H), 0.84 (t, J = 7.4 Hz, 3H) ppm; (minor isomer) 1H-NMR (400 MHz; CDCl3): δ 
4.18 (dd, J = 16.1, 7.6 Hz, 1H), 4.00 (m, 1H), 3.64 (s, 3H), 2.15-2.07 (m, 1H), 1.90-1.52 
(m, 6H), 1.40 (s, 9H), 1.36 (s, 9H), 0.83 (t, J = 7.3 Hz, 3H) ppm; (major isomer) 13C 
NMR (101 MHz; CDCl3): δ 173.0, 172.7, 153.5, 79.7, 79.1, 59.3, 59.0, 52.4, 51.4, 28.2, 
27.6, 27.5, 25.4, 22.5, 11.5 ppm; (minor isomer) 13C NMR (101 MHz; CDCl3): δ 172.4, 
172.3, 153.5, 79.4, 59.8, 59.0, 52.4, 51.3, 28.2, 27.6, 27.5, 25.5, 22.5, 12.3 ppm; HRMS 
(FAB) m/z:  [M+H]+ calcd. for C19H33NO6 372.23727; found 372.23770. 
p-Nitrobenzyl (2R,5S)-1-(tert-butyloxycarbonyl)-5-(1-(tert-butoxy)-1-oxopropan-2-
yl)pyrrolidine-2-carboxylate (32).  The Boc protection of 28 was conducted as 
described above for 30.  The residue (0.2 g, 0.58 mmol) was redissolved in 
dimethylformamide (6 mL) and diisopropylethylamine (0.22 ml, 1.3 mmol) followed by 
the addition of p-nitrobenzyl bromide (0.14 g, 0.64 mmol) in dimethylformamide (3 mL).  
Solution was stirred 80 min.  Saturated ammonium chloride was added to the solution 
and was extracted twice with ethyl acetate.  The combined organic layers were washed 
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with brine, dried, and concentrated.  Silica gel chromatography (ethyl acetate/hexanes, 
1:4) was used to purify the oil (0.227 g, 65% over both steps).  TLC (ethyl 
acetate:hexanes, 1:4 v/v): Rf = 0.21; (major isomer) 1H-NMR (400 MHz; CDCl3): δ 8.22 
(d, J = 8.7 Hz, 2H), 7.64 (d, J = 8.7 Hz, 2H), 5.34, 5.23 (ABq, JAB = 14 Hz, 2H), 4.31 (q, 
J = 8.0 Hz, 1H), 4.07-4.02 (m, 1H), 2.39-2.28 (m, 2H), 1.98-1.84 (m, 2H), 1.64 (q, J = 
5.7 Hz, 1H), 1.39 (s, (H), 1.33 (s, 9H), 1.11 (d, J = 7.0 Hz, 3H) ppm; (minor isomer) 1H-
NMR (400 MHz; CDCl3): δ 8.22 (d, J = 8.7 Hz, 2H), 7.64 (d, J = 8.7 Hz, 2H), 5.34, 5.23 
(ABq, JAB = 14 Hz, 2H), 4.31 (q, J = 8.0 Hz, 1H), 4.12 (dt, J = 8.0, 4.2 Hz, 1H), 2.39-
2.28 (m, 1H), 2.21-2.14 (m, 1H), 1.98-1.84 (m, 2H), 1.79-1.73 (m, 1H), 1.39 (s, (H), 1.33 
(s, 9H), 0.99 (d, J = 7.2 Hz, 3H) ppm; (major isomer) 13C NMR (101 MHz; CDCl3): δ 
173.3, 172.1, 153.6, 147.0, 143.4, 128.3, 123.1, 79.5, 79.2, 64.5, 59.4, 59.1, 44.7, 28.8, 
27.6, 27.4, 25.0, 14.7 ppm; (minor isomer) 13C NMR (101 MHz; CDCl3): δ 173.3, 172.7, 
153.6, 147.0, 143.4, 128.3, 123.1, 79.3, 79.2, 64.5, 59.9, 59.4, 44.7, 28.8, 27.6, 27.4, 25.0, 
9.4 ppm; HRMS (FAB) m/z:  [M+H]+ calcd. for C24H34N2O8 479.23934; found 
479.23938. 
p-Nitrobenzyl (2R,5S)-1-(tert-butyloxycarbonyl)-5-(1-(tert-butoxy)-1-oxobutan-2-
yl)pyrrolidine-2-carboxylate (33).  Reaction with 29 was conducted as described above.  
Multiple rounds of silica gel chromatography (ethyl acetate:hexanes, 1:19 to 3:7) were 
used to purify the product as an oil (51%).  TLC (ethyl acetate:hexanes, 1:4 v/v): Rf = 
0.35; (major isomer) 1H-NMR (400 MHz; CDCl3): δ 8.22 (d, J = 8.4 Hz, 2H), 7.63 (d, J 
= 8.5 Hz, 2H), 5.34, 5.22 (ABq, JAB = 13.6 Hz, 2H), 4.34-4.27 (m, 1H), 4.05-3.99 (m, 
1H), 2.25-2.14 (m, 2H), 1.91-1.83 (m, 2H), 1.67-1.60 (m, 2H), 1.57-1.49 (m, 1H), 1.39 
(s, (H), 1.34 (s, 9H), 0.74 (t, J = 8.2 Hz, 3H) ppm; (minor isomer) 1H-NMR (400 MHz; 
196 
CDCl3): δ 8.22 (d, J = 8.4 Hz, 2H), 7.63 (d, J = 8.5 Hz, 2H), 5.28 (s, 2H), 4.34-4.27 (m, 
1H), 4.05-3.99 (m, 1H), 2.35-2.29 (m, 1H), 1.91-1.83 (m, 3H), 1.67-1.60 (m, 2H), 1.57-
1.49 (m, 1H), 1.39 (s, (H), 1.34 (s, 9H), 0.77 (t, J = 8.1 Hz, 3H) ppm; (major isomer) 13C 
NMR (101 MHz; CDCl3): δ 172.6, 172.1, 153.4, 147.1, 143.4, 128.4, 123.2, 79.8, 79.3, 
64.5, 59.5, 59.1, 52.4, 28.3, 27.6, 27.5, 25.5, 22.5, 11.4 ppm; (minor isomer) 13C NMR 
(101 MHz; CDCl3): δ 172.2, 172.1, 153.7, 147.1, 143.4, 128.4, 123.2, 79.4, 79.3, 64.5, 
60.0, 59.1, 52.4, 28.3, 27.6, 27.5, 25.5, 22.5, 12.2 ppm; HRMS (FAB) m/z:  [M+H]+ 
calcd. for C25H36N2O8 493.25499; found 493.25445. 
Methyl (3S,5S,6R)-6-methylcarbapenam-3-carboxylate (34).  This synthesis was 
adapted from the procedures of Ohta et al.19.  2,6-Lutidine (1.44 mL, 12 mmol) and 
trimethylsilyl triflate (1.82 mL, 10 mmol) were added slowly to a solution of 30 (1.2 g, 
3.3 mmol) in dichloromethane (35 mL) at 0 ˚C and the mixture stirred for 2 h.  A solution 
of hydrochloric acid in dioxane (7.65 mL, 4M, 31 mmol) was added at 0 ˚C and stirred 
for 10 min.  The reaction mixture was concentrated in vacuo to yield dark red oil.  The 
crude oil was dissolved in dichloromethane (500 mL) to which diisopropylethylamine 
(2.63 mL, 15 mmol) followed by a solution of N,N'-dicyclohexylcarbodiimide (0.9 g, 4.4 
mmol) in dichloromethane (10 mL) were added at 0 ˚C.  The mixture was allowed to 
slowly warm to ambient temperature while stirring over 23 h.  The reaction mixture was 
concentrated in vacuo and dissolved in dichloromethane and filtered through Celite.  The 
eluate was washed 3 × with a cold solution of acetic acid in water (5%), dried with 
anhydrous sodium sulfate, and concentrated in vacuo.  The crude oil was purified by 
silica gel chromatography using ethyl acetate:hexanes (1:2) to give a clear oil (0.452 g, 
73%).  TLC (ethyl acetate:hexanes, 2:3 v/v): Rf = 0.36.  1,8-Diazabicyclo[5.4.0]undec-7-
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ene (1.13 mL, 7.6 mmol) was added to a solution of the mixture of diastereomers (1.38 g, 
7.5 mmol) in acetonitrile (150 mL) and stirred at 50 ˚C for 5 d.  The reaction mixture was 
concentrated in vacuo to give a brown oil. The crude product was purified from its 
diastereomer by silica gel chromatography using ethyl acetate:hexanes (3:17) to give the 
titled compound (eluted first) as an oil (0.59 g, 43%).  TLC (ethyl acetate:hexanes, 2:3 
v/v): Rf = 0.52; 1H-NMR (300 MHz; CDCl3): δ  4.35 (t, J = 7.3 Hz, 1H), 3.96 (app q, J = 
6.3 Hz, 1H), 3.73 (s, 3H), 3.50 (qd, J = 7.7, 5.5 Hz, 1H), 2.45-2.35 (m, 1H), 2.29-2.17 
(m, 1H), 2.06-1.96 (m, 1H), 1.63 (app. ddt, J = 13.1, 9.0, 7.8 Hz, 1H), 1.13 (d, J = 7.7 Hz, 
3H) ppm; 13C NMR (101 MHz; CDCl3): δ 181.1, 172.0, 58.6, 57.7, 52.5, 45.3, 34.6, 
25.2, 9.3 ppm; HRMS (ESI) m/z:  [M+H]+ calcd. for C9H13NO3 184.0974; found 
184.0966. 1H and 13C NMR matched the data as previously reported in the literature. 
p-Nitrobenzyl (3S,5S,6R)-6-methylcarbapenam-3-carboxylate (35).  The coupling 
reaction was conducted as above using 32, 63% yield overall.  TLC (ethyl 
acetate:hexanes, 2:3 v/v): Rf = 0.31; 1H-NMR (400 MHz; CDCl3): δ  8.23 (d, J = 8.8 Hz, 
2H), 7.52 (d, J = 8.8 Hz, 2H), 5.25 (s, 2H), 4.43 (t, J = 7.3 Hz, 1H), 3.97 (app. dd, J = 
12.9, 6.5 Hz, 1H), 3.52 (qd, J = 7.7, 5.6 Hz, 1H), 2.49-2.41 (m, 1H), 2.29-2.20 (m, 1H), 
2.07-1.99 (m, 1H), 1.71-1.63 (m, 1H), 1.15 (d, J = 7.7 Hz, 3H) ppm; HRMS (FAB) 
m/z:  [M+H]+ calcd. for C15H16N2O5 305.11375; found 305.11333.  The product data 
matched previous characterization40. 
Methyl (3S,5S,6R)-6-ethylcarbapenam-3-carboxylate (36).  The coupling reaction was 
conducted as above using 31, 35% yield overall.  TLC (ethyl acetate:hexanes, 2:3 v/v): Rf 
= 0.61; 1H-NMR (300 MHz; CDCl3): δ  4.34 (t, J = 7.5 Hz, 1H), 3.95 (app dt, J = 7.5, 5.9 
Hz, 1H), 3.73 (s, 3H), 3.33 (ddd, J = 9.6, 7.4, 5.4 Hz, 1H), 2.48-2.37 (m, 1H), 2.29-2.17 
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(m, 1H), 2.09-1.99 (m, 1H), 1.74-1.40 (m, 3H), 0.98 (t, J = 7.4 Hz, 3H) ppm; 13C NMR 
(101 MHz; CDCl3): δ 180.3, 172.1, 58.4, 57.2, 52.52, 52.49, 34.6, 25.3, 18.4, 12.0 ppm; 
HRMS (ESI) m/z:  [M+H]+ calcd. for C10H15NO3 198.1130; found 198.1126. 
p-Nitrobenzyl (3S,5S,6R)-6-ethylcarbapenam-3-carboxylate (37).  The coupling 
reaction was conducted as above using 33, 29% yield overall.  TLC (ethyl 
acetate:hexanes, 2:3 v/v): Rf  = 0.38; 1H-NMR (400 MHz; CDCl3): δ  8.23 (d, J = 8.7 Hz, 
2H), 7.52 (d, J = 8.8 Hz, 2H), 5.25 (s, 2H), 4.41 (t, J = 7.5 Hz, 1H), 3.97-3.92 (m, 1H), 
3.35 (ddd, J = 9.6, 7.4, 5.4 Hz, 1H), 2.52-2.39 (m, 1H), 2.31-2.17 (m, 1H), 2.13-1.99 (m, 
1H), 1.75-1.57 (m, 2H), 1.55-1.42 (m, 1H), 0.99 (t, J = 7.4 Hz, 3H) ppm; HRMS (FAB) 
m/z:  [M+H]+ calcd. for C16H18N2O5 319.12940; found 319.12849.  1H and NMR 
matched the data as previously reported in the literature38. 
Potassium (3S,5S,6R)-6-methylcarbapenam-3-carboxylate (38).  35 (60 mg) was 
dissolved in tetrahydrofuran (4 mL) and potassium phosphate buffer (2 mL, 0.5M, pH 
7.0).  10% palladium on carbon (1:1 w/w with compound S25) was added and placed 
under hydrogen (40 psi) for 1 h with shaking.  The mixture was filtered through Celite 
and washed with water and diethyl ether.  The aqueous solution was washed with diethyl 
ether, filtered (0.2 μm, nylon), and lyophilized.  The resulting powder was desalted by 
passage through HP-20 diaion resin. 1H-NMR (400 MHz; D2O): δ 4.14 (t, J = 7.8 Hz, 
1H), 3.95 (dt, J = 8.1, 5.6 Hz, 1H), 3.50 (qd, J = 7.7, 5.1 Hz, 1H), 2.56-2.48 (m, 1H), 
2.14-2.05 (m, 1H), 2.01-1.94 (m, 1H), 1.67-1.57 (m, 1H), 1.11 (d, J = 7.8 Hz, 3H) ppm; 
HRMS (ESI) m/z:  [M-H]- calcd. for C8H11NO3 168.0661; found 168.0648.  1H NMR 
matched the data as previously reported in the literature38. 
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Potassium (3S,5S,6R)-6-ethylcarbapenam-3-carboxylate (39).  37 was deprotected in a 
similar fashion to the C-6-methyl analog 38). 1H-NMR (400 MHz; D2O): δ 4.12 (t, J = 
7.8 Hz, 1H), 3.96-3.91 (m, 1H), 3.38-3.32 (m, 1H), 2.58-2.50 (m, 1H), 2.11-1.96 (m, 2H), 
1.65-1.47 (m, 3H), 0.93 (t, J = 7.4 Hz, 3H) ppm; 13C NMR (101 MHz; D2O): δ 184.8, 
180.4, 61.6, 57.9, 51.2, 36.1, 25.6, 18.3, 11.6 ppm; HRMS (ESI) m/z:  [M-H]- calcd. for 
C9H13NO3 182.0817; found 182.0804. 
Methyl (5S,6R)-6-methylcarbapenem-3-carboxylate (40).  This synthesis was adapted 
from the procedures of Ohta et al.19.  A solution of lithium hexamethyl-disilazane in 
tetrahydrofuran (3.576 mL, 1M, 3.58 mmol) was added to 34 (301 mg, 1.643 mMol) in 
tetrahydrofuran (16.4 mL) at -78 ˚C and stirred for 5 min.  Phenylselenium bromide (1.16 
g, 4.93 mmol) was added at -78 ˚C and allowed to warm to room temperature over 1h.  
The reaction mixture was diluted with ethyl acetate (20 mL) and washed with water (20 
mL), brine (20 mL), dried with anhydrous sodium sulfate, filtered and concentrated in 
vacuo.  The crude residue was run through a silica plug with 20% ethyl acetate in 
hexanes to remove excess phenyl selenium bromide and then concentrated.  The resulting 
oil (257 mg, 0.760 mmol) was dissolved in dichloromethane (41 mL) to which was then 
added a solution of m-chloroperbenzoic acid (131 mg, 0.760 mmol) in dichloromethane 
(5 mL) at -30˚C.  The reaction was stirred for 15 min at -30 ˚C before it was quenched 
with triethylamine (141 μL, 1.01 mmol) and diluted with dichloromethane (150 mL).  
The reaction mixture was washed twice with saturated ammonium bicarbonate (50 mL), 
brine (50 mL), dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo.  
The crude residue was purified by silica gel chromatography using ethyl acetate:hexanes 
(3:7) to give 40 (52 mg, 17%) as a yellow oil. TLC (ethyl acetate:hexanes, 3:7 v/v): Rf = 
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0.32; 1H-NMR (300 MHz; CDCl3): δ 6.52 (t, J = 2.8 Hz, 1H), 4.37 (ddd, J = 10.0, 8.7, 
6.2 Hz, 1H), 3.83 (s, 3H), 3.74-3.66 (m, 1H), 2.76 (app. qdd, J = 19.4, 9.4, 2.8 Hz, 2H), 
1.27 (d, J = 7.7 Hz, 3H) ppm; 13C NMR (101 MHz; CDCl3): δ 180.8, 161.3, 135.9, 
132.4, 56.1, 52.5, 47.4, 30.65, 9.9 ppm; HRMS (ESI) m/z:  [M+H]+ calcd. for C9H11NO3 
182.0817; found 182.0809.  1H and 13C NMR matched the data as previously reported in 
the literature. 
Methyl (5S,6R)-6-ethylcarbapenem-3-carboxylate (41).  36 was desaturated in a 
similar fashion to the C-6-methyl analog (34) to give 41 (40.8 mg, 9.4%). TLC (ethyl 
acetate:hexanes, 3:7 v/v): Rf = 0.60; 1H-NMR (400 MHz; CDCl3): δ 6.51 (t, J = 2.6 Hz, 
1H), 4.35 (ddd, J = 9.9, 8.9, 6.1 Hz, 1H), 3.82 (s, 3H), 3.53 (dt, J = 9.6, 6.6, 1H), 2.82-
2.68 (m, 2H), 1.89-1.78 (m, 1H), 1.65-1.54 (m, 1H), 1.00 (t, J = 7.4 Hz, 3H) ppm; 13C 
NMR (101 MHz; CDCl3): δ 180.1, 161.3, 135.7, 132.3, 55.7, 54.3, 52.5, 30.9, 18.9, 11.9 
ppm; HRMS (ESI) m/z:  [M+H]+ calcd. for C10H13NO3 196.0974;  found 196.0971. 
Methyl (3R,5S,6R)-6-methyl-2-pantetheinyl-carbapenam-3-carboxylate (42). 
Hydrochloric acid (471 μL, 1M) was added to pantetheine acetonide (157 mg, 0.495 
mmol, as described elsewhere4) in tetrahydrofuran (691 μL) and stirred for 30 min.  
Sodium hydroxide (471 μL, 1M) was then added to neutralize the reaction mixture.  The 
product pantetheine diol was directly added to 40 (64 mg, 0.353 mmol) in acetonitrile 
(960 μL) to which was added triethylamine (25 μL, 0.177 mmol) and stirred for 30 min at 
ambient temperature.  The reaction mixture was diluted with ethyl acetate (15 mL), 
washed with saturated ammonium chloride (4 mL), and brine (10 mL).  The combined 
aqueous layers were extracted with ethyl acetate (15 mL) and the combined organic 
fractions were dried with anhydrous sodium sulfate, filtered, and concentrated in vacuo.  
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The crude oil was purified by silica gel chromatography using ethanol:chloroform (1:9) 
to give 42 (16 mg) as an inseparable mixture of C-2 diastereomers in a ratio of 7:5 
(42a:42b) by 1H-NMR. TLC (ethanol:chloroform, 1:9 v/v): Rf = 0.25; 42a: 1H-NMR 
(400 MHz; MeOD): δ  4.67 (d, J = 7.2 Hz, 1H), 4.2-4.14 (m, 2H), 3.89 (s, 1H), 3.74 (s, 
3H), 3.58-3.53 (m, 3H), 3.50, 3.36 (ABq, JAB = 14.4 Hz, 2H), 2.84-2.65 (m, 4H), 2.43 (t, 
J = 6.5 Hz, 2H), 2.28 (ddd, J = 14.0, 8.2, 3.5 Hz, 1H), 1.97 (ddd, J = 13.8, 10.1, 8.3 Hz, 
1H), 1.15 (d, J = 7.8, 3H), 0.92 (s, 6H) ppm; 42b: 1H-NMR (400 MHz; MeOD): δ 4.17 
(d, J = 6.1 Hz, 1H), 4.2-4.14 (m, 1H) 3.99 (ddd, J = 8.0, 6.5, 5.4 Hz, 1H), 3.85 (s, 1H), 
3.76 (s, 3H), 3.58-3.53 (m, 3H), 3.43, 3.29 (ABq, JAB = 11.2 Hz, 2H), 2.84-2.65 (m, 6H), 
2.43 (t, J = 5.7 Hz, 2H), 1.19 (d, J = 7.7, 3H), 0.92 (s, 6H) ppm; HRMS (ESI) 
m/z:  [M+H]+ calcd. for C20H33N3O7S 460.2117; found 460.2112. 
Methyl (3R,5S,6R)-6-ethyl-2-pantetheinyl-carbapenam-3-carboxylate (43). 
The carbapenem 41 was reacted with pantetheine in a similar fashion to the C-6-methyl 
analogue (carbapenem 40) to give 43(12 mg, 13%) as an inseparable mixture of C-2 
diastereomers in a nearly equal ratio by 1H-NMR.  TLC (ethanol:chloroform, 1:9 v/v): Rf 
= 0.45; 43a: 1H-NMR (400 MHz; MeOD): δ 4.60 (d, J = 7.3 Hz, 1H), 4.15-3.98 (m, 1H), 
3.83-3.78 (m, 1H), 3.81 (s, 1H), 3.71 (s, 3H), 3.48-3.26 (m, 4H),  3.43, 3.29 (ABq, JAB = 
10.8 Hz, 2H), 2.72 (dt, J = 13.0, 6.2, 1H), 2.64 (dt, J = 12.9, 6.5, 1H), 2.36 (t, J = 5.5 Hz, 
2H), 2.31-2.13 (m, 2H), 1.61-1.41 (m, 2H), 0.94 (t, J = 7.8 Hz, 3H), 0.85 (s, 6H) ppm; 
43b: 1H-NMR (400 MHz; MeOD): δ 4.08 (d, J = 6.5 Hz, 1H), 4.15-3.98 (m, 1H), 3.94-
3.86 (m, 1H), 3.82 (s, 1H), 3.67 (s, 3H), 3.49-3.60 (m, 1H), 3.48-3.26 (m, 4H), 3.43, 3.29 
(ABq, JAB = 10.8 Hz, 2H), 3.08-2.79 (m, 2H), 2.55-2.39 (m, 1H), 2.36 (t, J = 5.5 Hz, 2H), 
1.61-1.41 (m, 2H),  0.96 (t, J = 7.5 Hz, 3H), 0.85 (s, 6H) ppm;  43a and 43b: 13C NMR 
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(101 MHz; MeOD): δ 177.0, 175.2, 174.9, 173.1, 172.5, 80.5, 78.3, 71.4, 68.8, 68.4, 
67.3, 67.2, 59.2, 55.4, 55.3, 54.6, 54.5, 54.2, 54.1, 53.4, 53.3, 41.4, 37.5, 37.4, 37.3, 34.1, 
33.1, 22.4, 22.0, 20.7 20.3, 13.3, 13.0 ppm; HRMS (ESI) m/z:  [M+H]+ calcd. for 
C21H35N3O7S 474.2274; found 474.2267. 
Ammonium (3R,5S,6R)-6-methyl-2-pantetheinyl-carbapenam-3-carboxylate (44, 
45).  A solution of lithium hydroxide in water (1M, 20 μL) was added to 42 (8 mg, 
0.0176 mmol) in tetrahydrofuran (500 μL) at 0 ˚C and stirred for 20 min, at which time 
TLC monitoring revealed incomplete reaction.  A second batch of lithium hydroxide 
solution (1M, 20 μL) was then added and after 30 min at 0 ˚C the reaction was quenched 
with K2HPO4 (10 mM, pH = 7.0, 500 μL).  The mixture was concentrated in vacuo to 
remove the organic solvent, and immediately injected onto a preparatory reverse-phase 
HPLC (Phenomonex Luna C18(2) 250 x 21.2 mm 10 micron 100 Å, 10:90 5 mM 
NH4HCO3 in water : acetonitrile, 5 mL/min) for purification.  The C-2/3 “cis” 
diastereomer 45 eluted at 11 min and the C-2/3 “trans” diastereomer 44 eluted at 13 min, 
allowing for enrichment of each diastereomer.  The compounds were collected and 
lyophilized to give carbapenams 44 (1.27 mg, 16%) and 45 (0.63 mg, 8%) as white 
powders. 44: 1H-NMR (400 MHz; D2O): δ 4.06 (d, J = 5.4 Hz, 1H), 4.08-4.04 (m, 1H), 
3.99 (s, 1H), 3.82-3.75 (m, 1H), 3.61 (dd, J = 8.2, 5.3 Hz, 1H), 3.53-3.38 (m, 4H), 3.58, 
3.34 (ABq, JAB = 11.0 Hz, 2H), 2.86 (td, J = 13.3, 6.5 Hz, 1H), 2.78 (td, J = 13.0, 6.3 Hz, 
1H), 2.51 (t, J = 6.3, 2H), 2.45 (dt, J = 13.9, 6.8 Hz, 1H), 1.7 (dt, J = 14.3, 7.2 Hz, 1H), 
1.20 (d, J = 7.9 Hz, 3H), 0.93 (s, 3H), 0.89 (s, 3H) ppm; HRMS (ESI) m/z:  [M+H]+ 
calcd. for C19H31N3O7S 446.1961; found 446.1957; 45: 1H-NMR (400 MHz; D2O): δ 
4.34 (d, J = 7.3 Hz, 1H), 4.10 (dd, J = 13.5, 6.2, 1H), 3.90 (s, 1H), 3.71 (s, 1H), 3.67 (dd, 
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J = 12.3, 6.4 Hz, 1H), 3.56 (dd, J = 11.9, 4.7 Hz, 1H), 3.56-3.34 (m, 3H), 3.48, 3.24 
(ABq, JAB = 11.6 Hz, 2H),  2.41 (t, J = 6.6, 2H), 2.09 (dt, J = 13.5, 6.8 Hz, 1H), 2.00 (dt, 
J = 13.4, 6.7 Hz, 1H), 1.04 (d, J = 7.7 Hz, 3H), 0.83 (s, 3H), 0.80 (s, 3H) ppm; HRMS 
(ESI) m/z:  [M+H]+ calcd. for C19H31N3O7S 446.1961; found 446.1952. 
Sodium (3R,5S,6R)-6-ethyl-2-pantetheinyl-carbapenam-3-carboxylate (46).  An 
analytical amount of the protected methyl ester 43 was dissolved in 1:1 acetonitrile:H2O.  
The solution was adjusted to pH ≥ 10 with NaOH (~1 M) and allowed to react at room 
temperature for 10 min.  The solution was then neutralized to pH = 7 with HCl (~1 M) 
and analyzed by UPLC-MS.  HRMS (ESI) m/z:  [M+H]+ calcd. for C20H33N3O7S 
460.2117; found 460.2112. 
Potassium (2S,3R,5R)-2-(2-acetamidoethylthiol)-carbapenam-3-carboxylate (47) and 
potassium (2R,3R,5R)-2-(2-acetamidoethylthiol)-carbapenam-3-carboxylate (48).  
The title compounds were synthesized using the carbapenem 8 as previously described 
and characterized. The final diastereomers 47 and 48 were purified and separated from 
each other using an Agilent model 1100 HPLC equipped with a multi-wavelength 
ultraviolet–visible detector (210 nm) in conjunction with a reverse-phase Phenomenex 
Luna 10μ C18(2) 100 Å preparatory column (250 x 21.20 mm ID).  The mobile phase 
was 18% methanol and 82% buffer (10 mM potassium phosphate, pH 6.65) at a flow rate 
of 5 ml per min.  Compound 47 eluted at 23 min and compound 48 eluted at 18 min. 
Excess phosphate buffer was removed using Diaion® HP-20 resin.  
Potassium (2S,3R,5R)-2-(4-phosphopantetheinyl)-carbapenam-3-carboxylate (49) 
and potassium (2R,3R,5R)-2-(4-phosphopantetheinyl)-carbapenam-3-carboxylate 
(50). The C-2-phosphopantetheine carbapenams were generated from the C-2-pantetheine 
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analogs 49 and 50 using pantothenate kinase, PanK23, provided by D.H. Long, Townsend 
Lab. Reactions included: ~ 0.40 mg/mL enzyme, 15 mM substrate (~18 mg), 15 mM 
ATP, 20 mM KCl, 10 mM MgCl2, and 50 mM Tris, pH 7.5 and were run for at least 2 
hours at RT. The protein was removed by centrifugal filtration (Amicon, 10 kDa 
MWCO). The titled compounds were purified using the 1100 HPLC as described for 47 
and 48 (detection: 210 nm). The mobile phase was 15% methanol and 85% buffer (10 
mM potassium phosphate, pH 6.65) for 50 and it eluted at approximately 17 min.  The 
mobile phase was 20% methanol and 80% buffer for 49 and it eluted at approximately 17 
min. Excess phosphate buffer was removed using Diaion® HP-20 resin. 
Potassium (2S,3R,5R) 2-(4-phosphopantetheinylthio)-7-oxo-2-
azabicyclo[3.2.0]heptane-3-carboxylate (49). 1H NMR (300 MHz, D2O): δ 4.15 (d, J = 
5.5 Hz, 1H), 4.08 (s, 1H), 3.90-4.0 (m, 1H), 3.69-3.80 (m, 1H), 3.49 (t, J = 6.5 Hz, 2H), 
3.35-3.44 (m, 4H), 3.32 (dd, J = 16.4, 4.9 Hz, 1H), 2.88 (dd, J = 16.3, 2.1 Hz, 1H), 2.70-
2.84 (m, 2H), 2.52-2.64 (m, 1H), 2.49 (t, J = 6.5 Hz, 2H), 1.62-1.74 (m, 1H), 0.96 (s, 
3H), 0.81 (s, 3H) ppm. 31P NMR (121.5 MHz, D2O): δ 2.40 (s); HRMS (ESI) 
m/z:  [M+H]+ calcd. for C18H30N3O10PS 512.1468; found 512.1470. 
Potassium (2R,3R,5R) 2-(4-phosphopantetheinylthio)-7-oxo-2-
azabicyclo[3.2.0]heptane-3-carboxylatemajor (50). 1H NMR (300 MHz, D2O): δ 4.45 
(d, J = 6.8 Hz, 1H), 4.03 (s, 1H), 3.81-3.90 (m, 1H), 3.62-3.70 (m, 1H), 3.42 (t, J = 6.4 
Hz, 2H), 3.28-3.39 (m, 4H), 3.24 (dd, J = 16.4, 4.9 Hz, 1H), 2.74 (dd, J = 16.3, 2.0 Hz), 
2.71 (t, J = 6.8 Hz, 2H), 2.44 (t, J = 6.4 Hz, 2H), 2.20-2.32 (m, 1H), 1.92-2.04 (m, 1H), 
0.94 (s, 3H), 0.76 (s, 3H) ppm. 31P NMR (121.5 MHz, D2O): δ 2.43 (s); HRMS (ESI) 
m/z:  [M+H]+ calcd. for C18H30N3O10PS 512.1468; found 512.1463. 
205 
Potassium (2S,3R,5R)-2-CoA-carbapenam-3-carboxylate (51) and potassium 
(2R,3R,5R)-2-CoA-carbapenam-3-carboxylate (52). A solution of Coenzyme A (49 
mg, 0.064 mmol) and with triethylamine (6.3 μL, 0.045 mmol) in water was added to a 
solution of carbapenem 9 (31 mg, 0.11 mmol) in tetrahydrofuran (0.40 mL). The solution 
was stirred for 75 min. The reaction mixture was then transferred to a pressure tube along 
with a catalytic amound of 10% Pd on carbon, 0.5 mL 0.5 M potassium phosphate (pH 
7), 1 mL water, and 1 mL tetrahydrofuran and shaken on a Parr apparatus for 1 h under 
hydrogen (20 psi). The catalyst was removed by filtration through Celite.  The filtrate 
was washed with diethyl ether (15 mL) and extracted.  The aqueous layer was filtered 
through a 0.2 µm nylon filter and lyophilized. Prior to HPLC injection, the sample was 
dissolved in water and filtered through a centrifugal device (Amicon, 10 kDa MWCO). 
The diastereomers 51 and 52 were separated from each other and purified using an 
Agilent 1100 HPLC (detection: 254 nm). The mobile phase was 13% methanol and 87% 
buffer (10 mM potassium phosphate, pH 6.65) at a flow rate of 5 ml per min.  Compound 
51 eluted at 22 min and compound 52 eluted at 17.5 min. Excess phosphate buffer was 
removed using Diaion® HP-20 resin. 51: 1H-NMR (300 MHz. D2O) δ: 8.51 (s, 1H), 8.24 
(s, 1H), 6.14 (d, J = 6.8 Hz, 1H), 4.52-4.55 (m, 1H), 4.19 (dd, J = 4.5, 3.4 Hz, 2H), 4.10 
(d, J = 5.4 Hz, 1H), 3.95 (s, 1H), 3.90 (dd, J = 4.7. 2.2 Hz, 1H), 3.74 (ddd, J = 18.0, 11.5, 
6.4 Hz, 2H), 3.50 (dd, J = 9.9, 5.0 Hz, 1H), 3.42 (td, J = 6.5, 2.4 Hz, 2H), 3.36-3.40 (m, 
2H), 3.27 (d, J = 5.1 Hz, 1H), 2.84 (dd, J = 16.3, 2.0 Hz, 1H), 2.73 (q, J = 8.0 Hz, 2H), 
2.53 (dt, J = 14.1, 6.6 Hz, 1H), 2.42 (t, J = 6.8 Hz, 2H), 1.62 (dt, J = 14.0, 7.0 Hz, 1H), 
0.82 (s, 3H), 0.69 (s, 3H); HRMS (ESI) m/z:  [M+H]+ calcd. for C28H43N8O19P3S 
921.1656; found 921.1636; 52: 1H-NMR (400 MHz. D2O) δ: 8.51 (s, 1H), 8.25 (s, 1H), 
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6.14 (d, J = 6.8 Hz, 1H), 4.53-4.55 (m, 1H), 4.47 (d, J = 6.7 Hz, 1H), 4.19 (dd, J = 4.6, 
3.4 Hz, 2H), 3.97-4.06 (m, 1H), 3.95 (s, 1H), 3.88 (td, J = 6.5. 3.6 Hz, 1H), 3.73-3.78 (m, 
2H), 3.24-3.49 (m, 6H), 2.75 (dd, J = 16.6, 2.1 Hz, 1H), 2.70 (dd, J = 10.1, 6.8 Hz, 2H), 
2.62-2.65 (m, 1H), 2.42 (t, J = 6.5 Hz, 2H), 2.20-2.29 (m, 2H), 1.95-2.02 (m, 1H), 0.81 
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Inhibitory activity of β-lactam antibiotics against L,D-transpeptidases in 
Mycobacteria and gram negative pathogenic bacteria 
 
Peptidoglycan biosynthesis has been the drug target of choice for the treatment of 
bacterial infections, and inhibition of the enzymes involved has proved to be an excellent 
strategy in the development of some of the most potent antibiotics on the pharmaceutical 
market1.  The final step in peptidoglycan biosynthesis was thought, until recently, to 
primarily be catalyzed by D,D-transpeptidases, commonly referred to as penicillin 
binding proteins (PBPs), catalyze the formation of classical 4→3 linkages between the 
fourth amino acid (D-ala) of one polypeptide stem and the third (often meso-
diaminopimelic acid [mDAP]) of another2.  In 2000, Mainardi and coworkers3 found a 
novel linkage structure that connected the third amino acid of the first chain (mDAP) with 
mDAP thereby generating 3→3 linkages, as shown in Figure 5.1.  In 2005, the same 
group found in Enterococcus faecium that these new cross-links were catalyzed by 
previously unknown enzymes, the L,D-transpeptidases (Ldts), which had no shared 
sequence homology to PBPs4.  Ldts were shortly after found in Mycobacterium 
tuberculosis, as nearly two-thirds of peptidyl linkages are accounted for by 3→3 
linkages5,6. 
Tuberculosis (TB), caused by the infection of Mycobacterium tuberculosis, is 
responsible for more deaths than any other infectious disease worldwide7.  Its widespread 
proliferation, particularly in the third-world, has contributed to the development of drug-
resistant TB, which is now a major problem in treatment of the disease.  New anti-TB 
therapeutics are necessary to mitigate the symptoms and clear the disease in a shorter 
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time frame to alleviate the suffering of patients.  Ldts provide a new target for 
antibacterial activity, and the study of Ldt inhibition may be an approach to solving this 
widespread problem. 
Ldts have been discovered in a myriad of other bacterial pathogens besides M. 
tuberculosis, including Gram-positive and Gram-negative strains in the ESKAPE 
organisms.  The ESKAPE group includes a collection of often drug-resistant bacteria 
responsible for severe nocosomial infections and includes; Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter cloacae.  It is hypothesized that Ldts have evolved as 
possible resistance strategies against conventional transpeptidase inhibitors such as the 
widely prescribed penicillin and cephalosporin antibiotics, which are ineffective against 
these enzymes.  Joint efforts of the Lamichhane lab at JHMI and the Townsend lab at 
JHU have been recently focused on the development of new drugs that are effective 





The work of Gupta et al. showed that the loss of LdtMt2, the major L,D-
transpeptidase in M. tuberculosis, alters cell morphology rendering M. tuberculosis 
avirulent and susceptible to otherwise inactive subclasses of β-lactams6. This evidence 
provided the proof of principle that β-lactams in combination with an inhibitor of LdtMt2 
would be lethal to M. tuberculosis (Figure 5.2, Table 5.1). 
 
Figure 5.2: (a) Scanning electron micrographs of wild-type M. tuberculosis (left panel) 
and a mutant lacking ldtMt2 (right panel). (b) Survival of BALB/c mice infected with 
WT M. tuberculosis (WT), ldtMt2::Tn (MUT) and the complemented strain (COMP). (c) 
Burden of M. tuberculosis infection (CFU) in the lungs of mice infected with either 
WT or MUT after four weeks of daily treatment with amoxicillin (200 mg/kg) and 
clavulanate (50 mg/kg)6. 
 
 In this chapter, experiments for the inhibition of Ldts in Mycobacteria and other 
ESKAPE pathogens are described.  My contribution to these studies was the analysis of 
β-lactam interactions with Ldts using intact protein mass spectrometry for the study of 
covalent inhibition.  Our collaborators in the Lamichhane lab contributed all MIC90 data, 
the crystal structures for inhibitor-bound enzymes, as well as the cloning, expression and 
purification of Ldts for in vitro inhibition assays.  In addition to the work summarized 
here, publications have been accepted and delve into further detail not discussed in this 
chapter, such as kinetics of inhibition through nitrocefin assay, isothermal calorimetry, 
data and methods for crystallization of Ldts, and in vivo mouse studies8–10. 
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MIC90 data against Mycobacteria 
 To test the efficacy of drugs against Ldts in particular, our collaborators in the 
Lamichhane lab, namely Dr. Pankaj Kumar, collected minimum inhibitory concentrations 
(MICs) against M. tuberculosis.   In particular, β-lactams were found to be the most 
successful family of antibiotics against drug-resistant M. tuberculosis as evidenced by 
their MIC90 values.  Their established mode of action against PBPs makes candidates 
from this class of drugs likely to also inhibit Ldts, due to mechanistic similarities D,D- 
and L,D-transpeptidase function.  Containing a catalytic cysteine residue, Ldts are 
susceptible to irreversible electrophilic inhibition by β-lactams whose core heterocycle 
closely mimics the polypeptide residues that the catalytic cysteine typically acylates, as 
shown in Figure 5.3.  As a proposed double-edged sword, β-lactams already are highly 
effective against conventional PBPs, so finding effective β-lactam antibiotics against both 
PBPs and Ldts would be most desirable as inhibition of all transpeptidase activity make a 
much more efficient anti-infective strategy and eliminate one potential resistance 
mechanism. 
 
Figure 5.3: β-lactams mimic the natural substrate of cysteine proteases 
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The Lamichhane lab has collected MICs for 90% growth inhibition (MIC90) for 
all commonly prescribed β-lactams across the penicillins, cephalosporins and 
carbapenems.  While little activity was observed from penicillins and cephalosporins, 
carbapenems were found to be effective.  A heavy focus was placed on carbapenem 
antibiotics inspired by Dr. Clifton Barry and coworkers at the National Institute of 
Allergy and Infectious Diseases (NIAID) who demonstrated that treatment of M. 
tuberculosis in vivo with a regiment of Meropenem and clavulanic acid was successful11.  
Partial results of our collaborators’ whole-cell studies are summarized in Table 5.1, and 
the respective structures of compounds used are shown in Figure 5.4. 
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Figure 5.4.  Representative β-lactams 
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Table 5.1. MIC values of various β-lactams against wild-type M. tuberculosis (H37Rv) 
and LdtMt2 knock-out strain 
Drug H37Rv LdtMt2 knockout Wild-type: LdtMt2 knockout 
Carbenicillin >64 2-4 >16 
Methicillin >64 2-4 >16 
Oxacillin >64 1-2 >32 
Cefdinir 2-4 0.12-0.25 16 
Cefotaxime 2-4 0.12-0.25 16 
Cephalexin 4-8 0.12-0.25 32 
Meropenem 4-8 0.5-1 8 
Doripenem 4-8 0.5-1 8 
Faropenem 0.5-1 0.25-0.50 2 
Tebipenem 1-2 0.25-0.50 4 
 
Acylation of LdtMt2 by β-lactams 
To better understand the varying activities observed against M. tuberculosis, 
acylation of Ldts through an in vitro strategy was carried forward with the incubation of 
purified Ldts from E. coli overexpression against the carbapenems T103-T109.  Initial 
studies from the Lamichhane group using a colorimetric Ninhydrin assay demonstrated 
that the carbapenems were able to inhibit the activity of Ldts12.  To determine if 
inhibition was covalent, samples were prepared for ultraperformance liquid 
chromatography high-resolution mass-spectrometry (UPLC-HRMS), as it is the only 
technique sensitive enough to measure the mass difference between acylation adducts and 




UPLC-HRMS intact protein analysis revealed that carbapenems, including 
clinically used antibiotics such as doripenem are effective at forming covalent adducts 
with most Ldt proteins.  Commonly prescribed imipenem and meropenem, however, did 
not form adducts with most Ldts.  In many cases with carbapenems, the intact protein-
carbapenem adducts were measured to be a lower molecular weight than predicted.  For 
example, an adduct mass of +376 Da was observed for most doripenem-inhibited Ldts 
alongside the predicted adduct of +421 (MW doripenem = 421 Da).  The difference 
between the two adducts is 45 Da, which we correlated to the loss of C2H4O 
(acetaldehyde).  Mechanistically, retroaldol cleavage of the β-hydroxy-thioester is 
possible from the adduct thioester bond, as has been shown in the literature11.  L,D-
transpeptidases have a catalytic cysteine active site residue in comparison to D,D-
transpeptidases, which use serine.  The elimination of acetaldehyde has been observed in 




Scheme 5.1: Mechanism of retroaldol cleavage of acetylaldehyde from carbapenem 
adducts 
 
 In some cases, more complicated fragmentations take place post-inhibition.  For 
example, the only doripenem-LdtMt2 adduct observed affords a mass of 123 Da greater 
than the native protein.  In order to identify the covalently bound fragment, a crystal 
structure of the substrate-enzyme complex was obtained by Dr. Pankaj Kumar in the 
Lamichhane lab9.  Modeling of possible 123 Da candidates for the doripenem fragment 
into the electron density map revealed that only the pyrrolidine ring from the bicyclic 
carbapenem core remains (Figure 5.1).  To support the acylation structure that was 
observed by mass and crystallography, a mechanism was proposed in Scheme 5.2 to 
account for the loss of the C-2 sidechain and necessary saturation of the pyrrolidine ring.  
Bond angles were measured from the electron density modeling, giving confidence to 
assign the stereochemistry and 1,2-double bond as shown. 
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Figure 5.5: Adduct species for Doripenem-LdtMt2 
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Scheme 5.2: Mechanism of pyrrolidine formation after degradation of the Doripenem-
LdtMt2 adduct 
 
 Perhaps the most notable observation of the comprehensive UPLC-HRMS intact 
protein analyses was the efficiency of faropenem in the acylation of Ldts.  A competition 
experiment involving the incubation of equimolar concentrations of faropenem, 
amoxicillin, cephalothin and aztreonam with Ldts was conducted. A similar experiment 
involved faropenem alongside the most potent carbapenems was similarily tested: 
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doripenem, biapenem and tebipenem.  The +86 fragment derived from acylation by 
faropenem was the only major adduct found in all Ldts from both competition 
experiments.  We proposed the mechanism of faropenem adduct degradation in Scheme 
5.3.  Initial fragmentation to cleave the thioether C-1/5 bond is parallel to the reaction of 
clavulanate with β-lactamases14.  The result of this initial step is the formation of an 
aminal at the β-position to the thioester, which is susceptible to retro-aldol cleavage as 
previously described.  The final acylation adduct is a (3R)-β-hydroxybutyroyl thioester, 
which matches the calculated mass increase of C4H6O2 (86 Da). 
 
Figure 5.6: Adduct species for Faropenem with LdtMt1 (a) and LdtMt2 (b)9. 
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Scheme 5.3: Degradation of faropenem following acylation of Ldts. 
 Our collaborators next conducted investigations in vivo.  The Lamichhane lab is 
equipped to perform extensive testing of antibiotics in a murine tuberculosis model, so 
the following experimentation was done by Dr. Amit Kaushik and Dr. Gyanu 
Lamichhane.  Drugs with the best MIC values, doripenem, biapenem, tebipenem and 
faropenem, were injected into separate groups of infected mice twice daily for a course of 
28 days.  The results showed that a dose of 400 mg/kg biapenem was the most effective 
course of treatment.  In combination with rifampin, biapenem was most effective in the 
reduction of M. tuberculosis cell-forming units (CFU) in murine lung tissue even when 
compared to the currently most aggressive regimen of isoniazid / rifampin9. 
 Disappointingly, faropenem did not perform well in vivo when compared to its 
dominant activity in vitro.  A few possibilities may explain failure of the drug in vivo: the 
C-2 sidechain of faropenem is small and lipophilic, potentially advantageous for 
permeating the greasy mycolic acid cell wall, but not polar enough to be as effective in 
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vivo as evidenced by comparison to carbapenems with positively charged C-2 side 
chains, like tebipenem and biapenem.  Additionally, like imipenem, penems have been 
found to be especially susceptible toward degradation by mammalian renal 
dehydropeptidase I (RDH-I) therefore greatly reducing the drug’s half-life in vivo15,16. 
 
The effectiveness of biapenem and tebipenem against LdtMt2 
With the Lamichhane lab’s excellent in vivo results in hand, we further 
investigated the interactions of biapenem and tebipenem with LdtMt2 by ESI Mass 
spectrometry to confirm acylation.  Following a five hour incubation of LdtMt2 with the 
carbapenems at high molar ratios (1:12.5, enzyme:carbapenem) the mass spectra of the 
reacted enzymes were analyzed (Table 5.2; Scheme 5.4).  Tebipenem showed a Δm/z of 
384.5 Da corresponding to the expected mass of an intact tebipenem adduct to LdtMt2 
after accounting for pyrroline tautomerization (Δm/z of 384 Da). A peak corresponding to 
a Δm/z of 339.5 was also observed (Table 5.2; Scheme 5.4). The 339.5 peak corresponds 
to a loss of 45 Da when compared to the intact species, matching the previously 
established loss of the hydroxyethyl group at C-6 and transfer of the proton from His336 
to the adduct (Δm/z of 339.5 Da) as explained mechanistically in Scheme 5.4.  
Surprisingly, when biapenem was incubated with LdtMt2, a Δm/z of 139.5 Da was 
observed as a likely fragmentation product or from further degradation resulting from the 
ESI-TOF sampling conditions (exposure to trifluoroacetic acid, temperature 60 °C, 
ionization energy, etc.). Few biapenem degradation paths can be explained 
mechanistically that correspond to the observed adduct mass; however that this difference 
is unique from all other carbapenem adducts may speak to the ability of the C-2 sidechain 
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to act as a possible leaving group.  The LdtMt2-biapenem crystal structure, like in that of 
doripenem, provides electron density for a much smaller pyrrolidine adduct, confirming 
the hypothesis that the C-2 sidechain is no longer attached.  A mechanism that is 




Mutational analysis of LdtMt2 active site residues 
 To probe the active site of LdtMt2 for mechanistic analysis, intact protein analysis 
was used to study inhibition of LdtMt2 mutants by carbapenems.  The Lamichhane lab 
generated single amino acid mutations for the active site residues as follows: Y318A, 
Y318F, H336A, H336R, H336N, H352A, H352R, H352N, C354A and C354S.  The 
active site residues, Tyr318, His336, His352 and Cys354 are thought, from crystal structure 
data17, to be directly involved in the mechanism of transpeptidase activity.  Cys354 is the 
active site residue for nucleophilic attack of the D-Ala amide bond, which forms 
thioesters with β-lactams.  For the generation of acylation adducts of these mutants, 
tebipenem, biapenem and faropenem were studied.  The cumulative results are shown in 
table 5.3.  Of Tyr318, His336, His352 and Cys354, the only critical residues are the base 
His336 and the nucleophile Cys354 as evidenced by no adduct formation with any β-lactam.  
Interestingly, tebipenem and faropenem were more resilient to mutation of Tyr318 and 
His352 than biapenem, which did not form adduct species with anything other than WT 
enzyme.  Due to biapenem’s particularity, simple mutations of Ldts could arise as a form 
of resistance more easily for biapenem than tebipenem or faropenem.  Unfortunately, 
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H336A and H336R mutants did not form adducts analyzable by UPLC-HRMS, due to 
protein instability. 
Table 5.3: Inhibition of LdMt2 mutants with 
tebipenem, biapenem, and faropenem 
Protein Tebipenem Biapenem Faropenem 
WT +339 +383 +138 +86 
Y318A +339 +383 No adduct +86 
Y318F +339 +383 No adduct +85 
H336A No data No data No data 
H336R No data No data No data 
H336N No adduct No adduct No adduct 
H352A +339 +385 No adduct +86 
H352R No data No data +85 
H352N No data No data +86 
C354A No adduct No adduct No adduct 
C354S No adduct No adduct No adduct 
 
Tebipenem is a potential therapeutic against LdtMav2 in Mycobacterium avium. 
Additional focus was placed on the treatment of problematic pathogens other than 
M. tuberculosis.  One particular focus was on the enzyme LdtMav2, the major L,D-
transpeptidase in Mycobacterium avium. M. avium is a more aggressive mycobacterium 
than M. tuberculosis and is notoriously difficult to treat with antibiotics, partially due to 
an even more efficient β-lactamase than BlaC in M. tuberculosis as well as high 
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resistance to most currently prescribed antibiotics.  A first-world threat, M. avium is an 
increasing problem for patients that are immunocompromised, such as those with 




Scheme 5.4: Proposed mechanism of acylation of LdtMav2 by tebipenem 
 
Dr. Rohini Mattoo obtained MIC90 values (Table 5.4), and M. avium showed 
resistance to most carbapenems in comparison to M. tuberculosis, with the exception of 
tebipenem, which was the only β-lactam with an MIC90 value in the effective therapeutic 




Table 5.4: MIC90 for β-lactams against M. avium 
(μg/mL). (+/- 1 Da) 




Rifampin 4-820 4-8 
Moxifloxacin 0.5-1 0.5-1 
Clarithromycin 2-4 1-2 
β-lactams 
Amoxicillin >64 >64 
Ampicillin >64 >64 
Cephalothin >64 >64 
Cefoxitin >64 >64 
Ertapenem >64 >64 
Meropenem >64 >64 
Imipenem >64 >64 
Doripenem >64 >64 
Biapenem >64 >64 
Tebipenem 2-4 4-8 
Panipenem >64 >64 
Faropenem >64 >64 
 
We studied the nature of the reaction between LdtMav2 and different sub-classes of 
β-lactams through UPLC-HRMS intact protein analysis.  Amoxicillin and ampicillin 
were used as representatives of the penicillin sub-class, cephalothin and cefoxitin as 
representatives of the cephalosporins, and doripenem, biapenem, and tebipenem as 
carbapenems.  Faropenem was the only penem tested.  Dr. Matoo expressed and purified 
LdtMav2 and reacted the protein in vitro with the aforementioned inhibitors.  I performed 
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intact protein analysis of adducts by UPLC-HRMS.  While cephalothin, imipenem, 
doripenem, biapenem, faropenem and tebipenem formed covalent acyl adducts, we were 
unable to detect any reacted masses for amoxicillin, ampicillin, cefoxitin and meropenem 
(Table 5.2). 
Incubation of LdtMav2 with tebipenem (MW=383.5 Da) produced a covalently 
bound acyl adduct of +339 Da (Table 5.2), in agreement with adducts formed with LdMt2 
and other Ldts.  Based on these data, we propose the mechanism for tebipenem adduct 
formation with LdtMav2 in Scheme 5.4. The sulfur atom of the putative catalytic cysteine 
(Cys349) attacks the carbonyl carbon of the β-lactam ring (Figure 5.4). Next, as in 
meropenem and tebipenem reactions with LdtMt29, the hydroxyethyl group at C6 is lost 
resulting in an adduct of +339 Da.  These data support the applicability of tebipenem as a 
potential treatment option against M. avium 
 
Conclusion 
The evidence for Ldt inhibition as a correlation to increased MIC90 is 
substantiated by these extensive crystallographic and mass spectrometric data.  However, 
limitations are met in vivo, as evidenced by testing of our lead carbapenem, biapenem, 
with faropenem in the treatment of a mouse model of tuberculosis infection9.  The data 
summarized in Table 5.3 suggests that faropenem is the most dominant drug in the 
inhibition of Ldts; however, does not perform well in vivo.  We hypothesize that the C-2 
sidechain and resulting RDH-1 susceptibility is the source of inefficacy in vivo.  It is 
theorized that the optimally reactive penem structure against Ldts could be optimized for 
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General methods for mass spectrometry analyses: 
Ldt (2 μM) in 12.5 mM Tris buffer, pH 8 was incubated in the presence or 
absence of 50 μM antibiotic for 5 h at room temperature. Reactions were quenched by the 
addition of trifluoroacetic acid (TFA; final concentration, 0.1%). Samples were filtered 
through a 0.2-μm filter and analyzed by ultraperformance LC/MS at 60 °C. 
Ultraperformance liquid chromatography (LC)-high resolution MS samples were 
analyzed on a Waters Acquity H-Class ultraperformance LC system equipped with a 
multiwavelength ultraviolet-visible diode array detector in conjunction with a Waters 
Acquity BEH-300 ultraperformance LC column packed with a C4 stationary phase (2.1 × 
50 mm; 1.7 μm) in tandem with high resolution MS analysis by a Waters Xevo-G2 
quadrupole-TOF electrospray ionization mass spectrometer.  
The mobile phase was as follows: 0–1 min, isocratic 90% water + 10% ACN + 
0.1% formic acid; 1–7.5 min, gradient to 20% water + 80% ACN + 0.1% formic acid; 
7.5–8.4 min, isocratic 20% water + 80% ACN + 0.1% formic acid; 8.4–8.5 min, gradient 
to 90% water + 10% ACN + 0.1% formic acid; 8.5–10 min, isocratic 90% water + 10% 
ACN + 0.1% formic acid. The flow rate was 0.3 ml min−1. 
Intact protein analysis was performed using the following calculations for MaxEnt1 
deconvolution: Resolution = 10000.0; Lock spray lock mass (Da) = 556.2771; MS mass 
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tolerance = 30 ppm; Time window in UPLC-chromatogram for protein analysis = 5.00-
5.50 min; TIC threshold (Da) = 2000; Deconvolution m/z range (Da) = 800-2000; Protein 
MW range (Da) = [protein mass ] ± 5 kd.  Masses for inhibited proteins were obtained 
and adduct weights were calculated from subtraction of the uninhibited protein mass. 
 
Bacterial strains, growth media and drugs: 
The following bacterial strains were used in this study: M. 
tuberculosis H37Rv, M. abscessus (ATCC 19977), M. avium (strain 104; Clinical 
Microbiology; Johns Hopkins University), A. baumannii (strain 6M-1b; Clinical 
Microbiology, Johns Hopkins University), K. pneumoniae (ATCC 35657), E. 
cloacae (ATCC 13047), P. aeruginosa (PA14), E. faecalis (ATCC 19433) and 
methicillin-sensitive S. aureus (ATCC 29213). M. tuberculosis and M. abscessus were 
grown and assessed as previously described21. Cation-adjusted Mueller–Hinton broth was 
used to grow A. baumannii, K. pneumoniae, E. cloacae, P. aeruginosa, E. faecalis and S. 
aureus at 37 °C according to Clinical and Laboratory Standard Institute guidelines22. 
Rifampin, isoniazid and all β-lactams were obtained from commercial vendors. 
Compounds were 95–99% pure when random samples were analyzed using LC–MS. 
 
Minimum Inhibitory Concentration and Checkerboard Titration Assay (done by 
Rohini Mattoo and Pankaj Kumar): 
Minimum inhibitory concentration (MIC90) of drugs against M. tuberculosis, M. 
abcessus, and M. avium was determined using the standard broth microdilution assay23 
using 96-well plates separately at pH 6.8 (Middlebrook 7H9 broth in the presence of 10% 
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OADC) and pH 7.4 (cation-adjusted Mueller-Hinton broth) in accord with the Clinical 
and Laboratory Standard Institute (CLSI) guidelines22 as described21. MIC90 is expressed 
as a range between two concentrations, where higher concentration represents the lowest 
concentration at which bacterial growth could not be observed following incubation at 37 
°C for seven days. Standard Checkerboard Titration assay24 was used to assess combined 
activity of agents. Briefly, each well containing 105 CFU received two drugs each in two 
fold dilutions below their respective MIC90. The suspensions were incubated at 37 °C and 
growth was evaluated as described above. Fractional Inhibitory Concentration (FIC) of a 
drug was calculated as described24. 
 
Cloning, overexpression, and purification of Ldts (done by Pankaj Kumar and 
Gyanu Lamichhane): L,D- and D,D-transpeptidases were cloned (excluding the N-
terminal transmembrane anchoring domains), expressed and purified to enhance chances 
of obtaining apo and co-crystal structures with drugs. Desired gene fragments were 
cloned into the multiple cloning site in pET28a+ to afford a N-terminal His6-tagged 
protein cleavable by Tobacco Etch Virus (TEV)12. Single amino acid substitutions of 
LdtMt2 (fragment ΔN55) were constructed by site-directed mutagenesis as follows. 
Primers were designed so that mutations resulting in amino acid substitution were placed 
at the center of the oligo9.  For each mutagenesis, two separate PCR reactions, each with 
forward or reverse primer, using New England BioLabs (NEB) high-fidelity buffer was 
used to amplify the pET28a+ vector carrying wild-type sequence for LdtMt2 (fragment 
ΔN55). DNA from the two reactions was combined, denatured at 95 °C, slowly renatured 
to 37 °C and digested with DpnI as described. Escherichia coli DH5α(C2987H, NEB 
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labs) was used for cloning and manipulation of plasmids. E. coli BL21δε3 (C2527H, 
NEB labs) was used to overproduce proteins as described8. 
 
Cloning, overexpression, and purification of LdMav2 (done by Rohini Mattoo): 
Analysis for a potential membrane anchoring domain predicted a high likelihood of 
residues 13-32 as a transmembrane anchor domain25. Therefore, the N-terminal 24 
residues were excluded to avoid the likely transmembrane anchor that could hinder 
solubilization and purification of the protein. Primers 
ATTGCCATATGGTGGGGGCAGTCGCCTGCGGCG and 
CAATACTCGAGTCAGGTGTTGGCGTTGCCCGC and Phusion polymerase (New 
England Biolabs) were used to amplify the region encoding residues 25-403 of LdtMav2. 
The PCR product was cloned into pET28a+TEV to generate an N-terminal H6 tagged 
LdtMav2. This expression plasmid, p1501RM, was sequenced to verify that the cloned 
DNA was identical in sequence to wild-type ldtMav2. E. coli BL21DE3 was used to 
overexpress LdtMav2 following induction with 500 μM IPTG for 22 hrs, 16 °C. Cells were 
harvested by centrifugation at 3,500 x g for 10 mins, 4 °C, lysed by sonication in a buffer 
containing 25 mM Tris-HCl (pH 8), 400 mM NaCl, 1 mM TCEP and protease inhibitor 
cocktail and centrifuged at 29,000 x g for 30 mins. The supernatant was interacted with 
Ni-NTA agarose on a column (BioRad) and washed with three column volumes 331 of 
25 mM Tris-HCl (pH 332 8), 400 mM NaCl, 1 mM TCEP and 10 mM imidazole. Bound 
protein was eluted with 500 mM imidazole in the same lysis buffer and dialyzed at 4 °C 
in freshly prepared TEV protease against buffer containing 25 mM Tris-HCl (pH 8), 150 
mM NaCl, 0.1 mM TCEP, 1 mM PMSF and 10% glycerol to enable cleavage of the N-
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terminal H6 tag. The dialysis buffer was exchanged at least four times at 4 °C to ensure 
complete removal of imidazole. The cleaved protein was separated from TEV protease 
and any uncleaved protein by repeating Ni-NTA chromatography. The purity and 
homogeniety of the tagless LdtMav2 was assesed by 4-15% SDS PAGE. Vivaspin 20 
columns were used to concentrate LdtMav2 to 10-20 mg/mL, flash frozen in liquid nitrogen 
and stored at -80 °C. The oligomeric status and homogeneity of the protein were analyzed 
by size exclusion chromatography using a Superose 12/300 GL column in the presence of 
dialysis buffer containing 25 mM Tris-HCl (pH 8), NaCl 150 mM, TCEP 0.1 mM, 1 mM 
PMSF and 10% glycerol on an AKTA FPLC (GE-Healthcare). 
 
Evaluation of Carbapenems in mice (Done by Amit Kaushik and Gyanu 
Lamichhane): Female BALB/c mice, 4–5 weeks old (Charles River Labs), were used 
according to the protocol approved by the Johns Hopkins University Animal Care & Use 
Committee (MO15M25). An acute model of M. tuberculosis infection in mice to assess 
the activities of faropenem and biapenem was used. Using M. tuberculosis culture at 
exponential phase of growth, a suspension was prepared with an optical density (A600nm) 
of 0.2 and infected mice by aerosolizing 10 ml of this suspension in a Glas-Col chamber. 
This high-dose infection resulted in implantation of 3.7 log10CFU in the lungs of each 
mouse. Treatment was initiated two days after infection, a time when M. 
tuberculosis bacilli are rapidly proliferating. While isoniazid (10 mg/kg) and rifampicin 
(10 mg/kg) were administered by oral gavage once daily (7 d per week), biapenem (200 
mg/kg) and faropenem (200 mg/kg) were administered twice daily by subcutaneous 
injection. Five mice were sacrificed 1 d after infection, lungs homogenized and plated on 
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Middlebrook 7H11 selective medium to determine the actual infection burden. Next, five 
mice were sacrificed on the day of treatment initiation and at three weeks following 
initiation of treatment, the final time point, to determine bacterial burden in the lungs. 
Gross pathology of lungs and mouse body weights were recorded at each time point. 
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Evolution of New Penems against M. tuberculosis and ESKAPE Pathogens 
 
R.B. Woodward hypothesized that the increased β-lactam reactivity of 
cephalosporins combined with the potent inhibitory structure of penicillins could provide 
novel, highly reactive β-lactam antibiotics.  The cephalosporin double bond in 
conjugation with the β-lactam amide was thought to be the source of increased acylation 
reactivity.  Woodward’s antibiotic, the penem, combined the structural features of the 
fused 5-membered ring of penicillin with the internal double bond in cephalosporin1–4.  
His group set out on the synthesis of 6-acylaminopenem-3-carboxylic acids and was 
successful in obtaining and characterizing these new molecules (Figure 6.1).  
Unfortunately, the antibacterial activity of these initial penems was disappointing.  The 
concurrent discovery of carbapenems by Merck Sharp and Dohme, which had excellent 
broad spectrum bactericidal activity, drew pharmaceutical focus away from the 6-
aminopenems.  Researchers Dr. Michael S. Kellogg, Dr. Ernest S. Hamanaka, Dr. Robert 
L. Rosati and others at Pfizer, however, refined Woodward’s penem using the newly 
discovered structural features of carbapenems to enhance potency.  As a result of a 
tremendous effort utilizing the newest chemical methods, the penem group at Pfizer 
developed lead compounds that had potent broad-spectrum antibacterial activity, 
culminating in the advancement of CP-70,429, later named sulopenem, to clinical 
trials5,6.  The project was abandoned at Pfizer at an advanced stage in the mid-1990s, 
possibly the result of lowered fiscal projections as competition by Merck’s blockbuster 
carbapenem antibiotic, imipenem, would limit sales.  Pfizer sold the rights of sulopenem 
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to Iterum Therapeutics, Ltd. in 2015, which plans to initiate phase 3 clinical trials by the 
end of 20177. 
 
Figure 6.1: Evolution of 2-thioalkylpenems 
 
With the passage of 20 years and the appearance of carbapenem-resistant 
organisms, another look at penems is warranted.  Bacterial resistance to common orally-
available drugs, such as penicillin and cephalosporin is increasingly more prevalent, and 
the desirability of both carbapenem availability and the development of new carbapenems 
is at an all-time high.  However, the use of carbapenems requires intravenous 
administration, due to the high susceptibility of the carbapenem core to hydrolysis by 
stomach acid.  Penems are more hydrolytically stable than carbapenems, and drugs such 
as these that would have the bactericidal potency of the carbapenems while retaining the 
possibility of oral administration would be extremely valuable. 
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The success of faropenem against L,D-transpeptidases in vitro8 has led to attempts 
to develop new penems that could be effective therapeutics against tuberculosis and 
members of the ESKAPE pathogens.  We began our push for new compounds by a 
thorough examination of penems in the literature.  The work of Volkmann et al.9 outlined 
the synthesis of sulopenem after early optimization of the C-2 thioether sidechain for 
resistance to the human enzyme renal dehydropeptidase 1 (DHP-1) responsible for 
degradation and removal of penems, like carbapenems, from the blood.  As penems had 
been found by Pfizer to be often rendered ineffective in vivo due to their short half-lives 
in the presence of DHP-1, this structure was a breakthrough10.  In our hands, we noticed a 
similar disadvantage in trials of faropenem as an antibiotic for the treatment of M. 
tuberculosis in a mouse model, and proposed that we could use C-2 sidechains that have 
proven to increase the resistance to degradation by DHP-1 in carbapenems. In the two 
decades since the sulopenem project at Pfizer was scrapped, development of new 
carbapenems have left us with promising structural modification to base the development 
of new penems.  We decided that incorporation of the carbapenem substituent features 
that have been enhanced actively over 40 years of pharmaceutical research could generate 
better penem structures for the treatment of Mycobacterial infection in vivo.   Testing 
penems with different carbapenem C-2 sidechains was our first goal in producing 
compounds for whole-cell M. tuberculosis grown-inhibition assays. 
 
Synthesis of C-2 thioalkylpenems 
 Syntheses of penems had been achieved in the past from either simple starting 
materials or from penicillin11–17; however, we decided to take advantage of a synthesis 
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that incorporated the carbapenem commercial intermediate (3S,4S)-4-acetoxy-3-[(S)-1-
(tert-butyldimethylsilyloxy)ethyl]-azetidin-2-one 1, as a far lower cost of both starting 
material and time was expected with three contiguous stereocenters of the penem 
azetidinone core already in place.  We hoped to develop a late stage intermediate with a 
leaving group at C-2 so that any C-2 thioalkyl nucleophile could be inserted, like Merck 
had developed in the synthesis of imipenem from a 2-oxo-carbapenam18.  From the 
commercially-available azetidinone, the N-acyliminum species was reacted with 
triphenylmethylsulfide, as shown in the early penem literature13,19 to produce the trityl-
protected thioether 2 after recrystallization from methanol in 84% yield.  Alkylation of 
the β-lactam nitrogen with allyl 2-bromoacetate occurred easily after deprotonation with 
potassium hydroxide in the presence of dicyclohexyl-18-c-6 to provide 3 in 90% yield. 
Deprotection of the trityl group occurred readily with silver (I) nitrate, a Lewis acid that 
has a high affinity to sulfur13. The resulting silver thiolate salt 4 was quenched with 
sodium sulfide, extracted into the organic phase with dichloromethane, and the crude 
concentrate was immediately reacted with p-nitrobenzoyl chloride to make the PNB-
thioester 5 in 57% yield over two steps from 3.  The system was now primed for 5-exo-
trig20 cyclization of the α-carbon of the carboxymethyl amide to the thioester carbonyl by 
deprotonation with LiHMDS at -78 °C to provide intermediate 6.  Activation of the 2-
oxopenem 6 by triflic anhydride produced reactive vinyl triflate, which formed the first 2-
thioalkyl penem analogue after reaction with ethanethiol in the presence of an organic 
base18.  Unlike the shelf-stable 2-oxocarbapenem intermediate in the synthesis of 
carbapenems, it was quickly found that the 2-oxopenem 6 was highly unstable and 
purification by chromatography or attempts at crystallization destroyed the compound.  
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The following transformation would only proceed with freshly distilled triflic anhydride 
on the crude 2-oxopenem, and the reaction proceeded in very poor yield (<20%).  This 
unforeseen disaster occurred on precious material at the end of the synthesis, so as much 
product as possible was salvaged through reaction of the entire lot of 6 to ethanethiol 
derivative 7.   It was possible to resue our synthetic strategy, however.  DiNinno and 
coworkers demonstrated that the displacement of thioalkyl sulfoxides was an optimal as a 
strategy for penem derivatization21.  Selective oxidation of the 2-thioethyl chain of 8 was 
possible, albeit in low yield with m-CPBA to produce 9.  Sulfoxide 9 was converted 
reliably to penem allyl esters 10-14 before degradation of the sulfoxide could occur.  
Through these method four initial compounds were made using the sidechains from the 
synthesis of the carbapenems tebipenem, meropenem, and doripenem in addition to the 
ethanethiol derivative.  Deprotection of the allyl ester with palladium followed by 
purification by HPLC provided penems 15, 16, 20, and 21 in milligram quantities. 
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Newly synthesized penems exhibit high potency against M. tuberculosis 
MIC90 values were promising, as both 15 and 16 exhibited growth inhibition in 
the low micromolar range against wild-type Mycobacterium tuberculosis (Table 6.1).  To 
validate our hypothesis that the 2-thioalkyl-penems form covalent adducts with Ldts, 
mass spectrometric analyses of covalent adducts were repeated as described previously 
with Ldts from M. tuberculosis, M. absessus, and ESKAPE pathogens (Table 6.2, Table 
6.3).  In addition, the adducts of 15 and 16 with LdtMt2 were crystallized by our 
collaborators with the Lamichhane Lab, namely Dr. Pankaj Kumar, and their respective 
diffraction data obtained at the Argonne National Laboratory in Illinois (Figure 6.3).  
nitrocefin-competition assay analyses of LdtMt2 in vitro showed greater inhibitory of 15 
and 16 activity in comparison to penicillins, cephalosporins, and carbapenems (Figure 
6.2). 
Table 6.1: Spectrum of activity of the lead penem (15) series: (a) high potency (MIC in 
sub µg/mL range), (b) high potency and selectivity of 16 against Mtb. 
A MIC90 (µg/mL) vs. Mtb H37Rv  B MIC90 (µg/mL) 
15 16-32  Pathogen 16 Meropenem 
16 0.5-1  Mtb H37Rv 0.5 4.0 
17 0.5-1  Rif-resistant Mtb 1 0.5 4.0 
18 2-4  Rif-resistant Mtb 2 0.5 4.0 
19 0.5-1  M. abscessus 1 128 
21 0.5-1  A. baumannii >64 16 
20 8-16  E. faecalis 16 16 
   P. aeruginosa 4 0.25 
   K. pneumoniae 1 0.03 
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Table 6.2: A summary of antimicrobial MIC90 data for penems in the 15 series. M.tb. = 
M. tuberculosis, M.ab. = Mycobacterium abscessus, E.cl. = Enterobacter cloacae, K.pn. 
= Klebsiella pneumoniae, A.ba. = Acinetobacter baumannii, P.ae. = Pesudomonas 
aeruginosa, MRSA = Methicillin Resistant Stapholococcus aureus, MSSA = Methicillin 
Susceptible Stapholococcus aureus. 
Drug Antimicrobial Activities (μg/mL) 
 M. tb M.ab. MRSA MSSA K. pn. E. cl. P. ae. A. ba. 
15 16-32   0.5-1 0.5-1 1-2 16-32   






0.5 4-8 4-8 
17 0.5-1    0.25-0.5 4-8  4-8 
18 2-4    8-16    
19 0.5-1    8-16 4-8  16-32 
21 0.5-1        
20 8-16    2-4 1-2 0.5-1 0.5-1 
 
Table 6.3: Structures of synthetic penem antibiotics 

















































































Although several new and evolved carbapenems have been recently assayed for 
their in vitro potencies against M. tuberculosis and other bacterial pathogens, our most 
successful program for M. tuberculosis has been the penems (15-21) as their potencies for 
this pathogen (Table 6.1, Table 6.2) have been superior to the carbapenems8. The 
carbapenem class exhibits broad-spectrum activity (potent against gram negatives and 
positives) while exhibiting lower potencies for M. tuberculosis than the penems (Table 






Figure 6.2: Nitrocefin hydrolysis by LdtMt2 and BlaC in the presence of various β-
lactams and penems 15 and 16, each at 200 µM. 
 
16 inhibits activity of LdMt2 and β-lactamase BlaC 
In addition to their inability to inhibit L,D-transpeptidases, the (otherwise potent 
broad-spectrum β-lactams) penicillins and cephalosporins lack clinically useful activity 
against M. tuberculosis due to their rapid hydrolysis by a strong β-lactamase, BlaC, of M. 
tuberculosis. Overcoming BlaC is important to any new agent with a β-lactam ring. 
Unlike penicillins and cephalosporins, carbapenems are only slowly hydrolyzed, enabling 
greater potency against M. tuberculosis22. In addition to resistance against BlaC 
hydrolysis, 16 is an effective inhibitor of BlaC activity, as evidenced by slowed 
hydrolysis of nitrocefin in a competition assay (Figure 6.2).  15 and 16 also inhibit LdtMt2 
by covalently forming an acyl adduct (Figure 6.4, Table 6.4). We hypothesize that 16’s 
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more potent activity against BlaC than carbapenems contributes to its potent whole-cell 
activity against M. tuberculosis. 
 
Penems form covalent adducts with LdtMt2 and inhibits activity 
In 2012, the first crystal structure of LdtMt2  was reported23.  Dr. Kumar obtained 
co-crystal structures with the new penems 15 and 16 (Figure 6.3) using established 
methods8. 
 
Figure 6.3: Crystal structures with LdtMt2 incubated with (a) 15, and (b) 16 bound to 
LdtMt2. 
 
Unlike that of carbapenems, the reaction of 16 with Mtb L,D-transpeptidases 
LdtMt2 and LdtMt1, proposed in Figure 6.4, is rapid and yields the inactivated enzymes 
bearing only (3R)-hydroxybutyryl covalently linked to the active site cysteine, Cys354 in 
LdtMt2 (Figure 6.3) (Cys226 in LdtMt1). Nucleophilic attack by this cysteine on the 
reactive β-lactam is proposed to open the 4-membered ring followed by scission of the 
remaining thiazoline ring. Such a cleavage process is known for the analogous masked 
enol opening of clavulanate by seryl β-lactamases24.  The resulting imine/iminium 
A B 
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species, again paralleling clavulanate cleavage, is proposed to hydrate to an aminal, 
whose facile retro-aldol scission affords the observed inactivated enzyme adduct. To 
determine whether carbapenems or our penems were more reactive with LdtMt2 and 
LdtMt1, we incubated these enzymes with equimolar mixtures of doripenem, biapenem, 
tebipenem and 16 and assessed the identities and abundance of acyl-enzyme adducts 
(created when the β-lactam ring reacts with the active site cysteine) using ultra 
performance liquid chromatography-mass spectrometry (UPLC-MS) (Table 6.4). 
Although each carbapenem and 16 produced a unique adduct when reacted individually 
with the L,D-transpeptidases, acylation by 16 was the only adduct (+86 Da) detected in 
the competition assays, indicating that the LdtMt1 and LdtMt2 enzymes preferentially 
bound 16 over the other tested carbapenems, some of which (e.g., doripenem, biapenem 
and tebipenem) exhibit superior potency against Mtb compared to meropenem22. 
 




Table 6.4: UPLC-HRMS Derived Mass 
data for Ldt/Penem adducts.  Relative 
abundance denoted in brackets 
Protein Drug Mass Difference (da) 
LdtMt2 15 +87 
LdtMt2 16 +86 
LdtMab2 15 +86 
LdtMab2 16 +86 
LdtCl 15 +86 +275 
LdtCl 16 +344 +387.5 
LdtKp 15 +86 
LdtKp 16 +342.5 +387.5 
 
Strategies for a gram scale process to 16 
Testing antibiotic efficacy in an in vivo tuberculosis model would require multiple 
grams of 16, our lead compound.  To produce a large amount of material, a different 
synthetic approach was needed due to the unacceptable ring closure and sulfoxidation 
yields outlined above.  Pfizer’s original process to sulopenem was first examined9.   
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Scheme 6.2:  Proposed synthesis of 16 using early incorporation of the tebipenem 
sidechain as the trithiocarbonate 
 
Previously, sulfoxidation of the C-2 thiol 8 followed by conjugate addition / 
elimination proved successful, although it was inefficient as m-CPBA was a poor 
oxidizing agent in terms of regioselectivity.  To avoid unacceptable yields on scale-up, 
the Pfizer synthesis of sulopenem served as a model to add the C-2 side chain as the first 
step, and ultimately yield the product in a much more efficient four steps from commecial 
starting materials.  Generation of the trithiocarbonate 22 proceeded smoothly when using 
freshly generated sodium alkoxide from sodium metal in refluxing alcohol.  The use of 
methanol or ethanol as the solvent in the subsequent reaction with the commercial 4-
acetoxyazetidinone intermediate 1 yielded good conversion to product initially, however, 
upon workup and concentration yields plummeted.  Especially on gram scales, reactions 
in methanol or ethanol caused significant degradation of the desired product.  Elimination 
of the trithiocarbonate 22 by competing addition / elimination from the solvent alcohol 
was favored entropically through the release of carbon disulfide and the thiol sidechain.  
Examination of the work of Volkmann et al.9 gave insight into the degradation, and the 
use of a sterically hindered solvent, such as isopropanol, significantly remedied the 
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problem.  The use of isopropanol resulted in a good yield for reactions of less than 5 g of 
azetidinone 23.  On scale up to 20 g, however, the degradation problem was exacerbated 
as removal of such vast quantities of isopropanol required longer times and higher 
temperatures for vacuum distillation.  The problem was solved when slow precipitation 
of the trithiocarbonate was allowed during low temperature removal of isopropanol 
solvent under high vacuum (<5 Torr).  The addition of hexanes when approximately half 
the isopropanol remained facilitated precipitation, and ultimately led to a yield of 65% for 
23 on a sufficient scale for multigram synthesis of 16. 
 It was expected that the remaining highly precedented chemistry would proceed 
without issue, but another unforeseen roadblock was encountered as initial reaction with 
allyl oxalyl chloride failed.  Despite resounding success across penem literature in the 
reaction of the azetidinone nitrogen with oxalyl chlorides, we found that elimination of 
the trithiocarbonate 22 occurred readily in the presence of organic bases such as 
triethylamine at 0 °C.  Further examination of reaction products found that allyl oxalyl 
chloride had a preference to react with the thiourea group of the trithiocarbonate 
sidechain rather than the azetidinone nitrogen.  We hypothesized that making a formal 
anion at the azetidinone nitrogen at low temperature in the presence of an electrophile 
would make that most acidic position the most nucleophilic, hence changing the 
preference of reaction.  In a dry ice / acetone bath the addition of one equivalent allyl 
oxalyl chloride to 23 was followed by one equivalent LiHMDS in dichloromethane.  
Analysis of the crude reaction mixture by infrared spectroscopy revealed that our 
hypothesis was correct and the proper oxalamide 24 was formed, but only when the 
temperature was allowed to rise to -40 °C (data not shown).  A control reaction was run 
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with diisopropylethylamine instead of LiHMDS and was found to produce the same 
result in higher yield at -40 °C.  Our hypothesis was incorrect, as formal deprotonation of 
the β-lactam was not necessary.  Conversely, reaction preferences were controlled by 
temperature.  On scale up, the reaction proceeded without further issue to provide the 
oxalamide 24 in 81% yield.  To our dismay, these efforts were for naught as all attempts 
at cyclization of the penem with triethylphosphite failed to produce the product penem 
25.  It seemed that the first mechanistic step, addition of the triethylphosphate with the 
oxalamide carbonyl, was successful, however, the cyclization step did not proceed as 
expected.  Degradation and polymerization products prevailed, although difficulty in 
separation of the myriad of product oils couldn’t provide sufficient purity for 
characterization of any major product.  At this point it was decided that the current route 
wouldn’t produce a clear path forward, so attention was focused on other methods. 
Our approach was an inefficient synthesis when compared to the original Pfizer 
route to sulopenem.  Therefore an alternate route to sulopenem was tested as a basis for a 
different strategy.  The new synthesis, published in 2011, focuses on the generation of an 
n-alkyltrithiocarbonate intermediate 28 in effort to favor conditions that avoid 
environmentally unfriendly solvents, achieve a lower cost of purification through 
precipitation and enable crystallization of intermediates resulting in higher yields25.  
Ultimately, improved yield alone made up for the increased number of synthetic steps.  
The keystone reaction that made this process successful was the development of a high-
yielding sulfoxidation reaction of 30 that employs hydrogen peroxide urea complex as the 
oxidant in the presence of an expensive but recoverable solvent, 1,1,1,3,3,3-
hexafluoroisopropanol (HFIP).  The theory behind selective 2-thioalkylsulfoxidation is 
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that the 1-sulfur is protected by fluorine bonds with HFIP.  Modifications to the process 
generated 16 successfully and on scale (Scheme 6.3). 
 
Scheme 6.3: Successful gram scale process to 16 
 
On a scale of 50g (3S,4S)-4-acetoxy-3-[(S)-1-(tert-butyldimethylsilyloxy)ethyl]-
azetidin-2-one 1,  n-propyltrithiocarbonate 26 addition to 1 followed by reaction of 
resulting trithiocarbonate 27 with allyl oxalyl chloride provided the desired oxalamide 28 
in 53% yield.  Attempts at crystallization or chromatographic purification of the free 
amide 27 only gave opportunity for degradation. Immediate formation of the oxalamide 
28 protected the compound from elimination of trithiocarbonate 26 at 0 °C in tert-butyl 
methyl ether (TBME).  The best yield of cyclization was obtained from the slow addition 
of two equivalents triethylphosphite in refluxing alcohol-free chloroform to provide the 
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protected penem 29 as white crystals (isooctane) in 45% yield.  At this point, TBS 
deprotection was favored as it was feared the thiourea functionality of the C-2 sidechain 
would be incompatible with either fluoride or acidic hydrolysis used for TBS protection.  
Another motive was that the high cost of purchased tebipenem side chain could be 
mitigated by adding it as late as possible in the sequence.  Reasonable yields of 73% and 
70% were achieved through TBAF deprotection and hydrogen peroxide / urea 
sulfoxidation to produce 30 and 31 respectively.  32 was produced in 58% yield from 
addition of tebipenem sidechain and subsequent elimination of n-propylsulfoxide from 
crystalline 31 (isooctane).  At this point, the allyl ester of 32 was removed by catalytic 
palladium allyl transfer.  It was found that anhydrous palladium transesterification to 
organic soluble potassium 2-ethylhexanoate in the presence of catalytic 
tetrakis(triphenylphosphane)palladium afforded 16 in 67% yield.  This method was 
preferred to other procedures in the literature, such as those that use palladium acetate 
and sodium benzenesulfinate, due to the fortuitous spontaneous crystallization of our 
desired product from anhydrous tetrahydrofuran.  The crystals obtained from the reaction 
mixture were spectroscopically pure if fresh, dry and anaerobically stored Pd(0)-
tetrakis(PPh3)4 is used, however we were concerned by the presence of trace palladium 
byproducts visible as a deep red / brown color when 16 precipitate was dissolved in 
ddH2O.  Palladium is a hazard for any material to be administered to animals, so our 
concern was justified. 
256 
 
Figure 6.5: Comparison of 16 after (a: UV chromatogram, c: Total Ion 
Chromatogram) and before (b: UV chromatogram, d: Total Ion Chromatogram) organic 
extraction of phosphine-containing contaminants. 
 
 The palladium problem became a focused effort to remove the impurity as 
compound of pharmaceutical quality was needed.  Initially, organic extracts of all 
contaminants were hoped to provide sufficient purification.  UPLC-HRMS analysis 
confirmed that dichloromethane extraction removed the majority of contaminants as 
shown in Figure 6.5 however, injection under the skin of mice resulted in the formation 
of lesions and hair loss after multiple treatments: evidence that contamination still 
remained.  At the suggestion of Dr. James Barrow at the Lieber Instutute for Brain 
Development (LIBD), purification of 16 from palladium impurity was made possible by 
the use of macroporous QuadraPure® thiourea resin that is specifically designed to bind 
palladium and other heavy metals.  An aqueous sample of crude 16 that was incubated 
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with QuadraPure® thiourea resin for 2 h at RT and then purified by reverse-phase HPLC 
was injected under the skin in an acute toxicity study performed by Dr. Amit Kaushik in 
the Lamichhane lab.  After 6 injections over 72 h, no skin irritation was observed. 
 For large scale purification, HPLC was necessary to ensure that no palladium 
contaminants remained.  Through the help of Michael Poslusney in the lab of Dr. James 
Barrow, methodology to purify gram quantities of 16 was developed.  In the presence of 
trifluoroacetic acid, the interaction between the colored palladium impurity and 16 was 
broken, and gradient elution of the colorless, pure compound was possible from C18 
using a 5%-50% gradient of acetonitrile in water with 0.5% TFA. 
 
Synthesis and activity of 5,6-cis-faropenem 
 Through in vitro analysis against LdMt2, we wanted to discern if any value could 
be added from altering the C-6 stereochemistry of penem antibiotics.  The compound 5,6-
cis-faropenem 39 was synthesized using the established methods of Ishiguro and 
coworkers coupled with a key C-5 epimerization developed by the same group using UV 
radiation for epimerization26–28. 
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Scheme 6.4: Synthetic route to 5,6-cis-faropenem 
 
Using D-aspartic acid, the azetidinone 33 was made by the route previously outlined 
in the Chapter 3.  Preparation of the sodium 2-thiocarboxylatetetrahydrofuran nucleophile 
34 was achieved by the addition of sodium sulfide to (R)-2-carboxy-tetrahydrofuranyl 
chloride.  Addition of the thioester 34 to the N-acyliminium species generated from 33 in 
the presence of sodium hydroxide gave the thioester 35 in 38% yield.  Lower than 
expected yield was obtained of 36 in the following reaction when one equivalent of allyl 
oxalyl chloride was added to 35 in the presence of diisopropylethylamine in 
dichloromethane at 0 °C.  Carbene-mediated ring closure of 36 with triethylphosphite in 
refluxing xylenes provided 37 in 59% yield, and subsequent O-TBS deprotection with 
TBAF provided the free alcohol 38 in 94% yield.  At this stage, UV irradiation of a 
solution of 39 in ethyl acetate using a quartz flask provided an equilibrium of 1:2 cis to 
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trans diastereomers which were separable by silica gel chromatography to give epi-
faropenem allyl ester 40 in 22% yield27.  Deprotection of the allyl ester was made 
possible by allyl transfer to 2-ethylhexanoate with tetrakis(triphenylphosphine)palladium 
in THF.  This synthesis provided the desired product 40 in 6 steps from 33, however poor 
yields plagued this route. 
Our coworkers in the Lamichhane lab kindly tested epi-faropenem 40 with LdMt2 in 
vitro using a nitrocefin hydrolysis assay as previously described above and in Chapter 58.  
The also tested 5,6-cis-faropenem against M. tuberculosis for MIC90 data.  No binding to 
LdMt2 was observed and in comparison to faropenem, 5,6-cis-faropenem had poor activity 
(Table 6.4).  None of the 5,6-cis-carbapenems synthesized in Chapter 3 had shown 
significant whole-cell MIC90 activity against M. tuberculosis (Table 6.5).  The lesser 
potency of 5,6-cis-faropenem affirmed our belief that, against Ldts cis-penems are not of 
therapeutic potential. 
Table 6.5: MIC90 data (μg/mL) for carbapenems and 5,6-cis-faropenem submitted for 
ESKAPE and M. tuberculosis testing. M.tb. = M. tuberculosis, E.cl. = Enterobacter 
cloacae, K.pn. = Klebsiella pneumoniae, A.ba. = Acinetobacter baumannii, P.ae. = 
Pesudomonas aeruginosa, MRSA = Methicillin Resistant Stapholococcus aureus, MSSA 
= Methicillin Susceptible Stapholococcus aureus. 



























































































































































































































 Penems, in comparison to carbapenems, were found to be highly potent drugs 
against Ldts and as a result exhibited excellent bactericidal activity against M. 
tuberculosis in particular, as evidenced by MIC90 data (Table 6.1, Table 6.2).  Against 
Mycobacterium abscessus, our lead compound, 16, is the most potent antibiotic tested by 
our collaborators in the Lamichhane group.  The high potency of 16 against M. 
tuberculosis and M. abscessus is attributed to its superior inhibitory activity against both 
Ldts and BlaC shown in colorimetric competition assays (Figure 6.2).  Additional support 
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for covalent Ldt inhibition by 16 comes from intact protein analysis of Ldt-16 adducts 
(Table 6.4).  We have established that therapeutic potential exists for 16, and to confirm 
its legitimacy as a clinical candidate, studies involving its use as a therapeutic in an 
animal model is required.  To accommodate the multigram quantities necessary for such 
experiments, we have modified the Pfizer synthesis of sulopenem for the production of 
16 on scale.  We hope that in vivo, 16 is at least as effective as the carbapenems, and the 
limitations found with faropenem are no longer a concern8.  To prevent low half-lives due 
to potential DHP-1 activity, we plan to co-administer cilastatin to 16 in a control 
experiment.  Additionally, experiments where 16 is administered by gavage, rather than 
subcutaneous injection, would test if these drugs could be orally administered. 
 Penems currently have untapped potential in the market of highly potent late-
stage broad-spectrum antibiotics.  The development of new penems, such as 16, is critical 
for their advantages of oral administration and activity against Ldts in comparison to 
carbapenems.  For optimization, C-6 sidechain modification is not recommended, as the 
activites reported for 5,6-cis-penems and carbapenems are less potent than their 5,6-
trans-counterparts.  Future synthetic work should focus on the selection of the C-2 




Solvents and reagents were purchased from Sigma Aldrich or Fisher Scientific in purity 
of ≥98%.  Silica gel chromatography was performed using 60Å silica gel from Sorbtech.  
Thin layer chromatography (TLC) was performed using 250 μm Analtech GHLF silica 
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plates.  A Bruker Avance (Billerica, MA) 300 or 400 MHz spectrometer was utilized for 
all 1H and 13C NMR spectra, which are reported in parts per million (δ) referenced 
against a TMS standard or residual solvent peak.  The JHU Chemistry Department Mass 
Spectrometry Facility determined exact masses by fast atom bombardment (FAB) or 
electrospray ionization (ESI). 
 
Determination of antimicrobial activity (Work done by Lamichhane Group):  
The standard broth dilution assay that is most widely used to determine Minimum 
Inhibitory Concentration (MIC) of a compound, which is recommended by the Clinical 
and Laboratory Standards Institute, was employed29,30. In this method, an axenic culture 
of a bacterial strain is grown to a defined growth phase in the appropriate culture broth. 
This primary culture is used to prepare a suspension with 106 live bacilli or colony-
forming units per mL.  Simultaneously, in a sterile 96-well plate, 100 µL of culture broth 
and a test compound are added in such a way that consecutive wells (across a row or 
column) contain 2 fold dilutions of the test compound. Next, 100 µL of the bacterial 
suspension is added to each well, the plate is incubated under appropriate conditions and 
growth or lack thereof is assessed at a defined time point. For M. tuberculosis the end 
point reading was taken at 2 weeks. For M. abscessus the end point reading was taken at 
3 days, and for the rest of the pathogens the end point reading was obtained after 
overnight incubation according to the Clinical and Laboratory Standards Institute 
recommendations30.  The lowest concentration at which bacterial growth is inhibited is 
reported as the MIC of the compound (Table 6.3). 
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UPLC-HRMS analysis of L,D-transpeptidase (Ldt)/penem adducts: 
Penems (Table 6.4) were incubated with Ldts (2 µM) at 4 mM concentration in 
400 µL of 25 mM Tris, pH 8, for 5 h at room temperature, quenched with 8 µL of freshly 
prepared 5% TFA and filtered through a 0.2 µm sterile membrane. 3 µL of each sample 
was injected into a Waters Aquity H-Class UPLC system equipped with a multi-
wavelength ultraviolet-visible diode array detector in conjunction with a Waters Aquity 
BEH-300 UPLC column packed with a C4 stationary phase (2.1 x 50 mm, 1.7 μm) in 
tandem with HRMS analysis by a Waters Xevo-G2 Q-ToF ESI mass spectrometer.  
Solvent A = 0.1% formic acid in water, solvent B = 0.1% formic acid in acetonitrile. 
Mobile phase (A:B) = 0-1 min (90:10), 1-7.5 min (20:80), 7.5-8.4 min (20:80), 8.4-8.5 
min (90:10), 8.5-10 min (90:10). Flow rate = 0.3 mL min-1. T = 60 °C. 
 
Penem synthetic methods: 
(3S,4R)-3-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-(tritylsulfanyl)azetidin-2-one 
(2).  The preparation of 2 followed the procedures of Leanza et al.13,19. A suspension of 
sodium hydride in mineral oil (60%, 31.3 mmol, 1.25 g) was added to 
dimethylformamide (16 mL) and the solution was then added to a solution of trityl sulfide 
(8.65 g, 31.3 mmol) in dry dimethylformamide (20 mL).  The resulting mixture was 
stirred for 2 h at 0 °C before it was slowly added to a solution of (3R,4R)-4-acetoxy-3-
[(R)-1-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-one 1 (5 g, 17.4 mmol) in 
dimethylformamide (16 mL) at 0 °C and was stirred for 2 h.  The reaction mixture was 
quenched with saturated ammonium chloride, and the product mixture was extracted with 
diethyl ether and the organic layer was washed with water, brine and dried with 
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anhydrous sodium sulfate, filtered and concentrated in vacuo.  The crude product was 
crystallized from hexanes to provide 2 as yellow needles (7.34 g, 84%). 2: 1H NMR (300 
MHz, CDCl3) δ 7.48 (d, J = 7.2 Hz, 6H), 7.29 (m, 9H), 4.53 (d, J = 2.6 Hz, 1H), 4.34 (s, 
1H), 4.21 (m, J = 3.2 Hz, 1H), 3.10 (t, J = 2.3 Hz, 1H), 1.26 (d, J = 6.2 Hz, 3H), 0.73 (s, 
9H), 0.01 (s, 3H), -0.05 (s, 3H). 1H NMR matched the data reported by Leanza et al.13,19. 
Allyl 2-((3S,4R)-3-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2-oxo-4-trityl-sulfanyl-
azetidin-1-yl)acetate (3).  The preparation of 3 followed the procedures of Leanza et 
al.13,19. Dicyclohexyl-18-crown-6 (543 µL, 1.60 mmol) was added to a solution of 2 (8.1 
g, 16.1 mmol) in benzene (80 mL).  Potassium hydroxide pellets (1.5 g, 26.7 mmol) that 
were crushed in a mortar and pestle were added to the reaction mixture in one portion 
followed by the slow addition of allyl bromoacetate (3.0 mL, 24.0 mmol) in benzene (40 
mL) over 5 min.  The reaction mixture was stirred for 4.5 h, at which time the reaction 
was quenched with saturated ammonium chloride and extracted with ethyl acetate.  The 
combined organic fractions were washed with brine and dried with anhydrous sodium 
sulfate, filtered and concentrated in vacuo.  The crude oil was purified by silica gel 
chromatography (hexanes:ethyl acetate, 9:1) to provide 3 (8.77 g, 90%).  3: 1H NMR 
(400 MHz, CDCl3) δ 7.47 (m, 6H), 7.27 (m, 9H), 5.84 (m, J = 3.6 Hz, 1H), 5.29 (m, 1H), 
5.22 (m, 1H), 4.51 (m, 2H), 4.12 (m, 1H), 3.37 (q, J = 1.8 Hz, 1H), 3.33 (s, 2H), 3.10 
(q, J = 1.6 Hz, 1H), 1.07 (d, J = 6.4 Hz, 3H), 0.77 (s, 9H), -0.01 (s, 3H), -0.05 (s, 3H). 1H 
NMR matched the data reported by Leanza et al.13,19. 
Allyl 2-((2R,3S)-3-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2-(4-nitro-phenoxy-
carbonyl-thio)-4-oxoazetidin-1-yl)acetate (5).  The preparation of 5 followed the 
procedure of Philips and O’Neill18. Pyridine (1.37 mL, 17.02 mmol) followed by a 
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solution of silver nitrate (2.36 g, 13.89 mmol) in methanol (116 mL) was added to a 
solution of 3 (6.28 g, 10.4 mmol) in methanol (68 mL) at 0 °C and was shielded from 
light with aluminum foil and stirred for 30 min.  The reaction mixture was concentrated 
in vacuo and redissolved in dichloromethane and water, and the organic layer was 
washed twice with water, dried with anhydrous sodium sulfate, filtered and concentrated 
in vacuo.  The crude oil was dissolved in tetrahydrofuran (18.8 mL) and was added to a 
solution of N,N-dimethylaminopyridine (1.36 g, 11.17 mmol) and p-
nitrophenylchloroformate (2.25 g, 11.17 mmol) in tetrahydrofuran (218 mL).  A solution 
of diisopropylethylamine (1.95 mL, 11.17 mmol) in tetrahydrofuran (18.8 mL) was added 
to the reaction mixture and was stirred at 0 °C for 30 min during which time a precipitate 
formed.  The reaction mixture was warmed to room temperature and stirred for an 
additional 5 min.  The solution was filtered through Celite and the retentate was washed 
with ethyl acetate.  The combined filtrates were washed with 1N HCl and the organic 
layer was directly concentrated in vacuo.  The resulting black residue is best filtered 
before it is subjected to silica gel chromatography (dichloromethane) to provide 5 as a 
yellow oil (3.27 g, 57%).  5: TLC (dichloromethane) = 0.2. 1H NMR (400 MHz, CDCl3) 
δ 8.26 (d, J = 9.2 Hz, 2H), 7.33 (d, J = 9.2 Hz, 2H), 5.85 (m, 1H), 5.51 (d, J = 2.5 Hz, 
1H), 5.27 (m, 2H), 4.60 (m, 2H), 4.29 (t, J = 5.7 Hz, 1H), 3.31 (q, J = 2.5 Hz, 1H), 3.03 
(s, 1H), 1.27 (d, J = 6.2 Hz, 3H), 0.86 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). 1H NMR 
matched the data reported by Philips and O’Neill18. 
Allyl (5R,6S)-6-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-3-(ethylthio)-7-oxo-4-thia-
1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (7). The preparation of 7 followed the 
procedures of Philips and O’Neill18. A solution of lithium hexamethylsilazane in 
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tetrahydrofuran (1 M, 37.5 mL) was added to a solution of 5 (4.9 g, 9.3 mmol) in 
tetrahydrofuran (336 mL) at -78 °C and was stirred for 30 min at this temperature.  The 
reaction was quenched with acetic acid (1.1 mL, 18.6 mmol) and the mixture allowed to 
warm to room temperature.  The reaction mixture was concentrated in vacuo, redissolved 
in diethyl ether and washed with saturated aqueous sodium bicarbonate, brine, dried over 
anhydrous sodium sulfate, filtered and concentrated in vacuo.  The crude product was run 
through a short plug of silica gel (hexanes:ethyl acetate, 4:1).  The 2-oxopenem 
intermediate was dissolved in dichloromethane (180 mL) and cooled to -78 °C.  
Diisopropylethylamine (6.4 mL, 36.8 mmol) was added followed by freshly distilled 
triflic anhydride (1.63 mL, 9.8 mmol) and the resulting solution was stirred at -78 °C for 
1 h.  Additional diisopropylethylamine (4.85 mL, 28 mmol) and ethanethiol (898 µL, 
14.0 mmol) dissolved in dichloromethane (10 mL) were added to the vinyl triflate in situ 
and the reaction mixture was allowed to warm to room temperature over 2 h.  The 
product was concentrated in vacuo and directly purified by silica gel chromatography 
(hexanes:ethyl acetate, 2:3) to provide an oil that solidified upon standing.  The product 
can be recrystallized from isooctane to provide 7 as white needles (523 mg, 13%).  7: 
TLC (hexanes:ethyl acetate, 1:1) = 0.3. 1H NMR (300 MHz, CDCl3) δ 5.68 (t, J = 1.7 Hz, 
1H), 5.64 (d, J = 1.5 Hz, 1H), 5.38 (m, 1H), 4.86 (m, 1H), 4.65 (m, 1H), 4.25 (m, 1H), 
4.12 (m, 1H), 3.69 (q, J = 2.1 Hz, 1H), 2.98 (m, 3H), 1.66 (m, 2H), 1.12 (d, J= 5.3 Hz, 
3H), 0.92 (s, 9H), 0.08 (s, 6H). 1H NMR matched the data reported by Philips and 
O’Neill18. 
Allyl (5R,6S)-6-((R)-1-hydroxyethyl-3-(ethylthio)-7-oxo-4-thia-1-azabicyclo-[3.2.0]-
hept-2-ene-2-carboxylate (8).  The preparation of 8 followed the procedures of Philips 
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and O’Neill18. A solution of tetra-N-butylammonium fluoride in tetrahydrofuran (1M, 
3.66 mmol, 3.66 mL) was added to a solution of acetic acid (702 µL) and 7 (523 mg, 1.22 
mmol) in tetrahydrofuran (10.5 mL) and was stirred for 2 h. The product mixture was 
partitioned into ethyl acetate (150 mL) and water (310 mL) and the pH was adjusted to 6 
with potassium acetate.  The aqueous layer was separated and washed twice with ethyl 
acetate (50 mL).  The combined organic layers were dried with anhydrous sodium 
sulfate, filtered and concentrated in vacuo.  The crude product was purified by a plug of 
silica gel (methanol:ethyl acetate, 3:17) to provide 8 as a white solid, which can be 
recrystallized from ethyl acetate/isooctane (427 mg, 85%).  8: TLC (methanol:ethyl 
acetate, 3:17) = 0.9. 1H NMR (400 MHz, CDCl3) δ 5.96 (m, 1H), 5.64 (d, J = 1.5 Hz, 
1H), 5.42 (m, 2H), 4.79 (m, 1H), 4.67 (m, 1H), 4.25 (quintet, J = 6.5 Hz, 1H), 3.71 (q, J = 
2.8 Hz, 1H), 2.97 (m, 2H), 1.36 (d, J = 6.3 Hz, 3H), 1.25 (q, J= 4.9 Hz, 3H). 1H NMR 
was in agreement the data reported by Philips and O’Neill18. 
Allyl (5R,6S)-3-(ethylsulfinyl)-6-((R)-1-hydroxyethyl)-7-oxo-4-thia-1-azabicyclo-
[3.2.0]-hept-2-ene-2-carboxylate (9). The preparation of 9 followed the procedures of 
DiNinno et al.21.  A solution of freshly crystallized m-chloroperbenzoic acid (232 mg, 
1.35 mmol) in ethyl acetate (1.5 mL) was added to a solution of 8 (386 mg, 1.22 mmol) 
in dichloromethane (1.2 mL) and ethyl acetate (2.5 mL) and the resulting mixture was 
stirred for 30 min.  The reaction mixture was decanted into a mixture of sodium 
bicarbonate (185 mg, 2.2 mmol) ethyl acetate (2.5 mL) and water (5 mL) and the 
suspension was stirred rapidly for 5 min.  The organic layer was separated, concentrated 
in vacuo and directly purified by silica gel chromatography (hexanes:ethyl acetate, 1:1) to 
provide 9 (127 mg, 31%).  9: TLC (hexanes:ethyl acetate, 1:1) = 0.15. 1H NMR (300 
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MHz, CDCl3) δ 5.91 (m, 1H), 5.72 (d, J = 1.7 Hz, 1H), 5.41 (m, 1H), 5.29 (q, J = 3.9 Hz, 
1H), 4.71 (m, 2H), 4.20 (quintet, J = 6.5 Hz, 1H), 3.91 (m, 1H), 3.10 (m, 2H), 1.43 (t, J = 
2.5 Hz, 3H), 1.34 (d, J = 6.3 Hz, 1H). 1H NMR was in agreement with the data reported 
by DiNinno et al.21. 
Allyl 2-((3R,4S)-3-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-2-oxo-4-(propylthio-
carbonothioyl-thio)azetidin-1-yl)-2-oxoacetate (28).  The preparation of 28 followed 
the procedures of Brenek et al.25. 1-Propanethiol (20.7 mL, 223 mmol) in methyl tert-
butyl ether (100 mL) was slowly added to a suspension of 60% sodium hydride in 
mineral oil (14 g, 350 mmol) in methyl tert-butyl ether (MTBE) (500 mL) and the 
mixture was stirred for 1 h at which time carbon disulfide (20.93 mL, 348 mmol) was 
added and the resulting yellow slurry was stirred for 1 h.  Magnesium sulfate (3 g) was 
added and the slurry was vacuum filtered under nitrogren through Celite to remove 
excess sodium hydride and the filter cake was rinsed with MTBE. (WARNING! The 
Celite filter pad contains trace amounts of MTBE in addition to large quantities of 
residual sodium hydride.  This cake will spontaneously combust and on this scale can 
cause a significant flame.  Great care must be taken to remove as much ether as possible.   
After filtering, keep the solids under nitrogen, suspend the filter cake in dichloromethane, 
cool to 0 °C and quench with isopropanol in the absence of oxygen).  The filtrate 
containing 26 was transferred to a clean flask to which was added (3R,4R)-4-acetoxy-3-
[(R)-1-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-one 1 (50 g, 174 mmol) batchwise 
while stirring the solution rapidly.  After 1 h, the slurry was filtered through a pad of 
silica gel and the solids were washed with methyl tert-butyl ether (200 mL).  The filtrate 
containing 27 was cooled to -10 °C in a salt/ice bath to which was added allyl oxalyl 
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chloride (50 mL, 400 mmol) followed by a solution of triethylamine (56 mL, 400 mmol) 
in methyl tert-butyl ether (100 mL).  The reaction mixture was warmed to room 
temperature and stirred for 1 h before it was quenched with water (100 mL).  The organic 
layer was separated and washed twice with sodium bicarbonate (100 mL), dried with 
anhydrous sodium sulfate, filtered, diluted with heptanes (250 mL) and concentrated in 
vacuo.  Once the majority of solvent was removed, additional heptanes (250 mL) was 
added and concentrated in vacuo to completion to ensure that no methyl tert-butyl ether 
remains.  The crude oil is dissolveed in 400 mL isooctanes and crystallized at 4 °C for 
16-24 h to provide 28 as yellow needles (45.8 g, 53%). 28: TLC (hexanes:ethyl acetate, 
7:3) = 0.4. MP = 65-67 °C.  1H NMR (400MHz ,CDCl3) δ = 6.76 (dd, J = 0.4, 3.5 Hz, 
1H), 5.94 (tdd, J = 6.1, 10.6, 17.0 Hz, 1H), 5.39 (qd, J = 1.4, 17.0 Hz, 1H), 5.31 (qd, J = 
1.0, 10.4 Hz, 1H), 4.78 (qd, J = 1.2, 6.1 Hz, 2H), 4.39 (dq, J = 2.5, 6.3 Hz, 1H), 3.56 (dd, 
J = 2.5, 3.5 Hz, 1H), 3.39 (dt, J = 3.7, 7.2 Hz, 2H), 1.76 (sxt, J = 7.4 Hz, 3H), 1.24 (d, J = 
6.5 Hz, 3H), 1.03 (t, J = 7.4 Hz, 3H), 0.86 (s, 9H), 0.09 (s, 3H), 0.06 (s, 3H). 13C NMR 
(101MHz, CDCl3) δ = 218.3, 163.5, 159.1, 154.4, 130.4, 120.2, 67.4, 66.0, 64.5, 58.9, 
38.9, 26.9, 25.6, 21.9, 21.3, 17.8, 13.4, -4.3, -5.3.   HRMS (FAB), C12H34NO5S3Si 
[M+H+] calculated: 492.1368; found: 492.1370.  1H and 13C NMR is identical to the data 
reported in the literature25. 
Allyl (5S,6R)-6-((R)-1-((tert-butyldimethylsilyl)oxy)ethyl)-7-oxo-3-(propylthio)-4-
thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (29).  The preparation of 29 was 
carried out by modification of the procedure of Brenek et al.25.  A solution of 
triethylphosphite (38.7 mL, 233 mmol) in anhydrous ethanol-free chloroform (450 mL) 
was added over 24 h to a refluxing, stirring solution of 28 (45.8 g, 93 mmol) in 
271 
chloroform (1 L) using a 2L round-bottomed flask fitted with a Claisen adapter, reflux 
condenser and addition funnel.  Once addition was complete, the solution was stirred for 
an additional 24 h, at which time additional triethyl phosphite (15 mL) was added in one 
portion.  The mixture was stirred at reflux for 16 h, cooled to room temperature, and 
washed with aqueous HCl (0.1 N, 250 mL), saturated aqueous sodium bicarbonate (250 
mL) and brine.  The organic fractions were concentrated in vacuo and purified by silica 
gel chromatography (hexanes) to ensure the removal of triethylphosphite.  The product 
oil crystallized from isooctane to produce 29 as white needles (18.57 g, 45%). 29: TLC 
(hexanes:ethyl acetate, 7:3) = 0.5. m.p. = 104-105 °C.  1H NMR (400MHz, CDCl3) δ = 
5.93 (tdd, J = 5.4, 10.7, 17.2 Hz, 1H), 5.59 (d, J = 1.4 Hz, 1H), 5.40 (qd, J = 1.6, 17.2 Hz, 
1H), 5.22 (qd, J = 1.4, 10.4 Hz, 1H), 4.70 (tddd, J = 1.6, 5.5, 13.5, 28.2 Hz, 2H), 4.23 (td, 
J = 6.1, 11.5 Hz, 1H), 3.66 (dd, J = 1.6, 4.9 Hz, 1H), 2.91 (tdd, J = 7.4, 12.5, J3 = 32.3 
Hz, 2H), 1.74 (sxt, J = 7.4 Hz, 2H), 1.25 (d, J = 6.3 Hz, 3H), 1.03 (t, J = 7.3 Hz, 3H), 
0.88 (s, 9H), 0.07 (s, 3H), 0.07 (s, 3H). 13C NMR (101MHz, CDCl3) δ = 172.1, 159.8, 
131.9, 118.1, 117.0, 71.4, 65.3, 63.7, 37.9, 25.7, 23.3, 22.5, 17.9, 13.2, -4.3, -5.1.  HRMS 
(FAB), C20H33NO4S2Si [M+] calculated: 443.1620; found: 443.1624.  1H and 13C NMR is 
identical to the data reported in the literature25. 
Allyl (5S,6R)-6-((R)-1-hydroxyethyl)-7-oxo-3-(propylthio)-4-thia-1-azabicyclo-
[3.2.0]-hept-2-ene-2-carboxylate (30).  A solution of 29 (10.2 g, 22.99 mmol) in 
tetrahydrofuran (64 mL) was added to a mixture of tetra-N-butylammonium fluoride 
(34.5 mmol) and acetic acid (12.5 mL, 218 mmol) in tetrahydrofuran (64 mL).  The 
reaction mixture was stirred for 24 h before it was washed with saturated aqueous sodium 
bicarbonate.  The aqueous layer was back extracted with dichloromethane and the 
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combined organic layers were washed with brine, dried with anhydrous sodium sulfate, 
filtered and concentrated in vacuo.  The crude product was purified by silica gel 
chromatography (hexanes:ethyl acetate, 1:1) and the resulting oil crystallized from ethyl 
acetate/isooctane to provide 30 (5.5 g, 73%). 30: TLC (hexanes:ethyl acetate, 7:3) = 0.2. 
m.p. = 85-86 °C.  1H NMR (400MHz, CDCl3) δ = 5.95 (tdd, J = 5.4, 10.6, 17.2 Hz, 1H), 
5.63 (d, J = 1.6 Hz, 1H), 5.41 (qd, J = 1.5, 17.2 Hz, 1H), 5.23 (qd, J = 1.4, 10.6 Hz, 1H), 
4.78 (tdd, J = 1.5, 5.4, 13.5 Hz, 1H), 4.66 (tdd, J = 1.4, 5.6, J3 = 13.5 Hz, 1H), 4.24 (quin, 
J = 6.5 Hz, 1H), 3.70 (dd, J = 1.4, 6.8 Hz, 1H), 2.98 (td, J = 7.4, 12.7 Hz, 1H), 2.88 (td, J 
= 7.2, 12.5 Hz, 1H), 1.74 (sxt, J = 7.4 Hz, 2H), 1.35 (d, J = 6.3 Hz, 3H), 1.03 (t, J = 7.3 
Hz, 3H). 13C NMR (101MHz, CDCl3) δ = 172.1, 159.8, 156.2, 131.9, 118.2, 116.7, 70.9, 
65.5, 65.5, 64.0, 37.9, 23.3, 21.9, 13.2.  HRMS (FAB), C14H19NO4S2 [M+] calculated: 
329.0756; found: 329.0753. 
Allyl (5S,6R)-6-((R)-1-hydroxyethyl)-7-oxo-3-(propylsulfinyl)-4-thia-1-
azabicyclo[3.2.0]hept-2-ene-2-carboxylate (31).  Urea•hydrogen peroxide (1.62 g, 16.7 
mmol) was dissolved in 1,1,1,3,3,3-hexafluoroisopropanol (16 mL) and added to a 
solution of 29 (5.0 g, 15.2 mmol) 1,1,1,3,3,3-hexafluoroisopropanol (20 mL) in one 
portion and the solution was stirred for 24 h.  Heptanes (50 mL) was added to the product 
mixture and concentrated in vacuo.  The process was repeated as necessary to remove all 
traces of fluorinated solvent prior to purification by silica gel chromatography 
(hexanes:ethyl acetate, 1:1).  The resulting oil recrystallized from ethyl acetate/isooctane 
to provide 31 as a mixture of diasteromeric sulfoxides as yellow needles (4.63 g, 88%).  
31: TLC (hexanes:ethyl acetate, 1:1) = 0.2. m.p. = 90-93 °C.  1H NMR (400MHz, CDCl3) 
δ = 5.98 - 5.87 (m, 1H), 5.86 (d, J = 1.8 Hz, 0.33H), 5.71 (d, J = 1.8 Hz, 0.67H), 5.41 
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(qd, J = 1.6, 17.0 Hz, 0.33H), 5.43 (qd, J = 1.4, 17.2 Hz, 0.66H), 5.29 (qd, J = 1.2, 10.6 
Hz, 1H), 4.77 (qdd, J = 1.6, 5.5, 13.3 Hz, 1H), 4.67 (qdd, J = 1.6, 5.7, 13.3 Hz, 1H), 4.27 
- 4.14 (m, 1H), 3.92 (dd, J = 1.6, 6.8 Hz, 0.66H), 3.88 (dd, J = 2.0, 7.0 Hz, 0.33H), 3.21 - 
3.04 (m, 1H), 2.99 (ddt, J = 7.0, 9.2, 13.3 Hz, 1H), 2.04 - 1.77 (m, 2H), 1.35 (d, J = 6.3 
Hz, 3H), 1.11 (t, J = 7.4 Hz, 3H). 13C NMR (101MHz, CDCl3) δ = 172.7, 171.5, 164.4, 
164.0, 158.2, 158.1, 130.8, 121.6, 121.4, 119.5, 119.5, 73.2, 73.2, 66.7, 66.7, 65.6, 65.4, 
65.4, 63.4, 57.5, 57.0, 21.8, 16.5, 16.1, 13.0.  FAB-MS analysis of sulfoxides 31 did not 
provide parent ions due to susceptibility to degradation. 
 
General procedure for the addition of C-2 thiol side chains to the 2-ethylsulfinyl 
penem: 
Allyl (5S,6R)-3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-hydroxy-
ethyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (32).  A solution of 1-
(4,5-dihydro-2-thiazolyl)-3-azetidinethiol hydrochloride (tebipenem side chain) (3.10 g, 
14.74 mmol) in acetonitrile (50 mL) followed by diisopropylethylamine (3.70 mL, 20.77 
mmol) was added to a stirring solution of 31 (4.63 g, 13.4 mmol) in acetonitrile (100 mL) 
and the mixture was stirred for 2 h at 0 °C.  The solution was diluted with brine and the 
aqueous layer was back extracted three times with ethyl acetate.  The combined organic 
layers were dried with anhydrous sodium sulfate, filtered and concentrated in vacuo.  The 
crude oil was purified by silica gel chromatography (methanol:dichloromethane, 1:40) to 
provide 32 as a yellow oil that became a glass under high vacuum (2.85 g, 50%). 
32: TLC (methanol:dichloromethane, 1:19) = 0.3. 1H NMR (400MHz, CDCl3) δ = 5.94 
(tdd, J = 5.4, 10.7, 17.2 Hz, 1H), 5.69 (d, J = 1.4 Hz, 1H), 5.41 (qd, J = 1.5, 17.1 Hz, 1H), 
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5.24 (qd, J = 1.2, 10.5 Hz, 1H), 4.77 (tdd, J = 1.4, 5.5, 13.4 Hz, 1H), 4.67 (tdd, J = 1.4, 
5.6, 13.4 Hz, 1H), 4.40 (td, J = 8.4, 23.9 Hz, 3H), 4.19 (sxt, J = 6.5 Hz, 1H), 4.25 - 4.10 
(m, 1H), 4.00 (t, J = 7.4 Hz, 2H), 4.06 - 3.90 (m, 2H), 3.72 (dd, J = 1.5, 6.9 Hz, 1H), 3.36 
(t, J = 7.4 Hz, 2H), 1.33 (d, J = 6.5 Hz, 3H).  13C NMR (101MHz, CDCl3) δ = 172.2, 
164.4, 159.5, 152.1, 131.6, 118.5, 117.6, 71.5, 65.8, 65.2, 65.0, 60.4, 59.3, 58.7, 36.2, 
36.1, 21.9.  HRMS (FAB), C17H22N3O4S3 [M+H+] calculated: 428.0773; found: 
428.0765. 
Allyl (5R,6S)-6-((R)-1-hydroxyethyl-3-(ethylthio)-7-oxo-4-thia-1-
azabicyclo[3.2.0]hept-2-ene-2-carboxylate (8): The same procedure was followed as 
used to produce 32.  TLC (methanol:ethyl acetate, 3:17) = 0.9. 1H NMR (400MHz, 
CDCl3) δ = 5.96 (tdd, J = 5.4, 10.7, 17.2 Hz, 1H), 5.64 (d, J = 1.6 Hz, 1H), 5.42 (qd, J = 
1.6, 17.2 Hz, 1H), 5.24 (qd, J = 1.6, 10.4 Hz, 1H), 4.79 (tdd, J = 1.4, 5.4, 13.4 Hz, 1H), 
4.67 (tdd, J = 1.5, 5.5, 13.5 Hz, 1H), 4.25 (quin, J = 6.5 Hz, 1H), 3.71 (dd, J = 1.4, 6.8 
Hz, 1H), 3.01 (qd, J = 7.2, 12.3 Hz, 1H), 2.94 (qd, J = 7.2, 12.5 Hz, 1H), 1.37 (t, J = 7.2 
Hz, 3H), 1.36 (d, J = 6.3 Hz, 3H).  1H NMR is identical to the data reported in the 
literature25. 
Allyl (5R,6S)-6-((R)-1-hydroxyethyl)-3-((2-hydroxyethyl)thio)-7-oxo-4-thia-1-
azabicyclo[3.2.0]hept-2-ene-2-carboxylate (18 allyl ester): The same procedure was 
followed as used to produce 32.   1H NMR (400MHz, CHCl3) δ = 5.95 (ddt, J = 5.4, 10.5, 
17.2, 1H), 5.65 (d, J = 1.4 Hz, 1H), 5.41 (qd, J = 1.5, 17.2 Hz, 1H), 5.24 (qd, J = 1.3, 9.0 
Hz, 1H), 4.78 (tdd, J = 1.4, 5.4, 13.4 Hz, 1H), 4.66 (tdd, J = 1.3, 5.6, 13.4 Hz, 1H), 4.23 
(quin, J = 6.5 Hz, 1H), 3.86 (t, J = 6.2 Hz, 2H), 3.71 (dd, J = 1.5, 6.8 Hz, 1H), 3.14 (tq, J 
= 6.3, 14.0 Hz, 1H), 1.35 (d, J = 6.3 Hz, 3H). 13C NMR (101MHz, CHCl3) δ = 172.2, 
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159.8, 156.3, 131.8, 118.2, 116.7, 70.95, 65.4, 64.0, 37.8, 23.2, 21.7, 13.1. 
Allyl (5R,6S)-6-((R)-1-hydroxyethyl)-3-((3-methoxy-3-oxopropyl)thio)-7-oxo-4-thia-
1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (19 allyl ester): The same procedure was 
followed as used to produce 32.    1H NMR (400MHz, CHCl3) δ = 5.97 (ddt, J = 5.3, 11.7, 
17.2, 1H), 5.66 (d, J = 1.4 Hz, 1H), 5.40 (qd, J = 1.5, 17.2 Hz, 1H), 5.23 (qd, J = 1.3, 
10.5 Hz, 1H), 4.77 (tdd, J = 1.4, 5.4, 13.4 Hz, 1H), 4.65 (tdd, J = 1.4, 5.5, 13.4 Hz, 1H), 
4.23 (quin, J = 6.4 Hz, 1H), 3.72 (m, 1H), 3.71 (s, 3H), 3.21 (tq, J = 4.7, 11.7, 2H), 2.75 
(m, 2H), 1.34 (d, J = 6.4 Hz, 3H). 13C NMR (101MHz, CHCl3) δ = 171.9, 171.2, 159.6, 
154.1, 131.8, 118.3, 117.6, 71.2, 65.6, 64.3, 52.1, 34.6, 30.6, 21.9, 21.1. 
Allyl (5R,6S)-6-((R)-1-hydroxyethyl)-3-(((3R,5R)-1-(((4-nitrobenzyl)oxy)carbonyl)-5-
((sulfamoylamino)methyl)pyrrolidin-3-yl)thio)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-
2-ene-2-carboxylate (10): The same procedure was followed as used to produce 32.    
TLC (hexanes:ethyl acetate, 1:1) = 0.15. 1H NMR (400MHz, MeOD) δ = 8.21 (d, J = 8.6 
Hz, 2H), 7.56 (d, J = 6.1 Hz, 2H), 6.00 - 5.79 (m, 1H), 5.67 (d, J = 2.3 Hz, 1H), 5.37 (qd, 
J = 1.6, 17.0 Hz, 2H), 5.21 (qd, J = 1.0, 7.8 Hz, 1H), 5.27 - 5.15 (m, 2H), 4.28 - 4.15 (m, 
1H), 3.85 - 3.72 (m, 1H), 3.70 (dd, J = 0.8, 7.0 Hz, 1H), 3.48 - 3.32 (m, 2H), 2.69 - 2.54 
(m, 2H), 1.28 (d, J = 6.3 Hz, 3H). 13C NMR (101MHz, 1:1 CHCl3:MeOD) δ = 172.48, 
159.3, 156.6, 146.8, 131.2, 127.6, 127.4, 122.9, 117.0, 115.6, 70.4, 65.0, 64.6, 64.4, 63.8, 
57.2, 37.0, 33.5, 22.6, 20.4, 12.1. 
Allyl (5R,6S)-3-(((3R,5R)-5-(dimethylcarbamoyl)-1-(((4-
nitrobenzyl)oxy)carbonyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-7-oxo-4-thia-
1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (11): TLC (hexanes:ethyl acetate, 1:1) = 
0.15. 1H NMR (400MHz, CDCl3) δ = 8.17 (d, J = 9.6 Hz, 2H), 7.50 (d, J = 8.8 Hz, 2H), 
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5.91 (tdd, J = 5.7, 10.4, 17.0 Hz, 1H), 5.66 (d, J = 1.4 Hz, 1H), 5.46 - 5.32 (m, 1H), 5.31 - 
5.24 (m, 1H), 5.12 - 4.96 (m, 1H), 4.83 - 4.72 (m, 2H), 4.65 (td, J = 13.5, 17.2 Hz, 2H), 
4.36 - 4.22 (m, 1H), 4.22 - 4.13 (m, 1H), 4.13 - 3.98 (m, 1H), 3.69 (dd, J = 1.5, 7.1 Hz, 
1H), 3.60 - 3.31 (m, 3H), 3.08 (s, 3H), 2.96 (s, 3H), 2.83 - 2.68 (m, 1H), 2.64 (d, J = 11.9 
Hz, 1H), 2.05 - 1.79 (m, 2H), 1.31 (d, J = 6.5 Hz, 3H). 13C NMR (101MHz, 1:1 
CHCl3:MeOD) δ = 172.5, 171.4, 171.2, 156.5, 153.4, 152.9, 146.9, 143.4, 131.3, 127.4, 
123.0, 117.2, 65.2, 56.4, 56.2, 55.6, 55.3, 40.2, 39.4, 36.2, 35.3, 34.4, 33.8, 12.3. 
S-((2S,3R)-3-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-4-oxoazetidin-2-yl)-(R)-
tetrahydrofuran-2-carbothioate (35). The preparation of 35 followed the procedure of 
Ishiguro et al.26,28.  Thiocarboxylic acid 34 (2.94 g, 22.3 mmol) was added to a solution 
of 4-acetoxyazetidinone 33 (2 g, 6.96 mmol) in acetone (6 mL) and aqueous NaOH (1N, 
11.97 mL).  The reaction mixture was heated to 55 °C and stirred for 2 h while the pH 
was periodically monitored and maintained at pH = 8 with sodium bicarbonate.  The 
organic layer was separated and the aqueous fraction extracted with ethyl acetate.  The 
combined organic fractions were washed with saturated aqueous sodium bicarbonate and 
dried with brine before concentrated in vacuo.  The crude product was purified by silica 
gel chromatography (hexanes:ethyl acetate, 4:1) to provide 35 as a colorless oil (970 mg, 
39%). 35: TLC (hexanes:ethyl acetate, 2:3) = 0.7. 1H-NMR (300 MHz, CDCl3) 1H NMR 
(300 MHz, CDCl3) δ 6.25 (s, 1H), 5.09 (d, J = 2.4 Hz, 1H), 4.48 (m, J = 2.7 Hz, 1H), 
4.24 (m, J = 4.0 Hz, 1H), 4.04 (t, J = 5.7 Hz, 1H), 3.97 (m, J = 5.4 Hz, 1H), 3.18 (t, J = 
3.2 Hz, 1H), 2.27 (m, J = 6.3 Hz, 1H), 1.95 (q, J = 6.8 Hz, 1H), 1.33 (d, J = 6.4 Hz, 3H), 




tetrahydrofuran-2-carbonyl)thio)azetidin-1-yl)-2-oxoacetate (36).  The preparation of 
36 followed the procedure of Ishiguro et al.26,28.  Allyl oxalyl chloride (798 mg, 5.37 
mmol) was added slowly to a solution of 35 (970 mg, 2.7 mmol) and trimethylamine (1.2 
mL, 8.64 mmol) in dichloromethane (13.5 mL) at 0 °C.  The reaction mixture was 
allowed to warm to room temperature and stirred for 2 h.  The reaction was quenched 
with water and the pH of the aqueous layer was adjested to pH = 7.5 with aqueous 
sodium bicarbonate. The organic layer was separated, washed with water, dried with 
anhydrous sodium sulfate, filtered and concentrated in vacuo.  The crude oil was purified 
by silica gel chromatography (hexanes:ethyl acetate, 7:3) to provide 36 as a colorless oil 
(290 mg, 28%). 36: TLC (hexanes:ethyl acetate, 2:3) = 0.85. 1H NMR (400 MHz, 
CDCl3) δ 5.94 (m, J = 3.9 Hz, 1H), 5.62 (d, J = 3.4 Hz, 1H), 5.40 (d, J = 17.2 Hz, 1H), 
5.32 (d, J = 10.3 Hz, 1H), 4.79 (q, J = 3.3 Hz, 1H), 4.53 (m, J = 3.9 Hz, 1H), 4.35 (m, J = 
3.1 Hz, 1H), 4.07 (q, J = 7.1 Hz, 1H), 3.97 (m, J = 2.5 Hz, 1H), 3.45 (t, J = 3.2 Hz, 1H), 
2.29 (m, J = 4.2 Hz, 1H), 2.20 (m, J = 4.4 Hz, 1H), 1.95 (m, J = 3.6 Hz, 1H), 1.37 (d, J = 
6.4 Hz, 3H), 0.86 (s, J = 2.6 Hz, 9H), 0.16 (s, 3H), 0.05 (s, 3H). 1H NMR matched the 
data reported by Ishiguro et al.26,28. 
Allyl (5S,6R)-6-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-7-oxo-3-((R)-
tetrahydrofuran-2-yl)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (37).  The 
preparation of 37 followed the procedure of Ishiguro et al.26,28.  Triethyl phosphite (630 
µL, 3.65 mmol) was added to a solution of 36 (285 mg, 0.75 mmol) in xylenes (15 mL) 
and the reaction mixture was fitted with a condenser and heated to reflux for 16 h. The 
solution was concentrated and the crude product directly purified by silica gel 
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chromatography (hexanes:ethyl acetate, 5:1) to provide 37 as a crude oil (150  mg, 59%). 
37: TLC (hexanes:ethyl acetate, 1:2) = 0.9. 1H NMR (400 MHz, CDCl3) δ 5.92 (m, 1H), 
5.54 (d, J = 1.6 Hz, 1H), 5.40 (m, 2H), 5.23 (m, 1H), 4.68 (m, 2H), 4.21 (m, J = 4.7 Hz, 
1H), 3.93 (q, J = 7.2 Hz, 1H), 3.82 (t, J = 7.4 Hz, 1H), 3.77 (q, J = 1.8 Hz, 1H), 3.65 
(q, J = 2.3 Hz, 1H), 2.40 (m, J= 3.9 Hz, 1H), 1.95 (m, J = 7.0 Hz, 2H), 1.77 (m, J = 4.4 
Hz, 1H), 1.24 (d, J = 6.2 Hz, 3H), 0.87 (s, 9H), 0.07 (s, 6H). 1H NMR matched the data 
reported by Ishiguro et al. 26,28,31,32. 
Allyl (5S,6R)-6-((S)-1-hydroxyethyl-7-oxo-3-((R)-tetrahydrofuran-2-yl)-4-thia-1-
azabicyclo[3.2.0]hept-2-ene-2-carboxylate (38).  The preparation of 38 followed the 
procedure of Ishiguro et al.26,28.  A solution of tetra-N-butylammonium fluoride in 
tetrahydrofuran (1M, 0.67 mmol, 673 µL) was added to a solution of 37 (150 mg, 0.44 
mmol) and acetic acid (110 mg, 1.94 mmol) in tetrahydrofuran (1.76 mL).  The reaction 
mixture was stirred for 8.5 h at 50 °C.  The reaction solution was poured into water (3.5 
mL) and the mixture was extracted with ethyl acetate (3.5 mL).  The combined organic 
fractions were washed with water, twice with saturated aqueous sodium bicarbonate, and 
brine before the solution was dried with anhydrous sodium sulfate, filtered and 
concentrated in vacuo.  The crude oil was purified by silica gel chromatography 
(hexanes:ethyl acetate, 1:1) to provide the produce as a colorless oil (94.1 mg, 94%). 38: 
TLC (hexanes:ethyl acetate, 1:2) = 0.9. 1H NMR (400 MHz, CDCl3) δ 5.94 (m, 1H), 5.52 
(m, 1H), 5.39 (m, 2H), 5.26 (m, 1H), 4.76 (m, 1H), 4.65 (m, 1H), 4.22 (m , 1H), 3.96 (m, 
1H), 3.83 (m, 1H), 3.71 (m, 1H), 2.43 (m, 1H), 1.96 (m, 2H), 1.80 (m, 2H), 1.40 (d, J = 
6.4 Hz, 3H).  1H NMR matched the data reported by Ishiguro et al.26,28,31,32. 
Allyl (5R,6R)-6-((S)-1-hydroxyethyl-7-oxo-3-((R)-tetrahydrofuran-2-yl)-4-thia-1-
279 
azabicyclo[3.2.0]hept-2-ene-2-carboxylate (39).  The preparation of 39 followed the 
procedure of Tanaka et al.27,31,32.  A solution of 38 (94 mg, 0.289 mmol) in ethyl acetate 
(144 mL) in a quartz flask was stirred at room temperature in the presence of a high-
pressure mercury 450 W Hanovia UV lamp.  The mixture equilibrated to approximately a 
2:1 ratio of 38:39 as observed by TLC after 90 min at which point the mixture was 
concentrated. The diastereomers were separated by silica gel chromatography 
(hexanes:ethyl acetate, 1:1) and crystallized from dichloromethane and hexanes to 
provide 39 as a white solid (30 mg, 32%). 39: TLC (hexanes:ethyl acetate, 1:2) = 0.8. H 
NMR (400 MHz, CDCl3) δ 5.51 (d, J = 4.0 Hz, 1H), 5.35-5.47 (m, 1H), 5.36 (t, J = 7.3 
Hz, 1H), 5.28 (d, J = 11.2 Hz, 1H), 4.78 (dd, J = 5.9, 13.5 Hz, 1H), 4.65 (dd, J = 5.9, 13.5 
Hz, 1H), 4.39-4.51 (m, 2H), 3.78-4.04 (m, 2H), 3.75 (d, J = 4.0 Hz, 1H), 2.35-2.55 (m, 
1H), 1.72-1.87 (m, 4H), 1.23 (d, J = 5.9 Hz, 3H).  1H NMR matched the data reported by 
Ishiguro et al.31,32. 
Potassium (5R,6R)-6-((S)-1-hydroxyethyl-7-oxo-3-((R)-tetrahydrofuran-2-yl)-4-thia-
1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (epi-faropenem, 40).  The preparation of 
39 followed the procedure of Tanaka et al.27,31,32.  A solution of 39 (30 mg, 0.092 mmol) 
in tetrahydrofuran (3 mL) was sparged with nitrogen for 30 min, at which point 
tetrakis(triphenylphosphine)palladium was added (9.2 mg, 0.0079 mmol) in a single 
portion.  A solution of potassium 2-ethylhexanoate (26 mg, 0.119 mmol) in 
tetrahydrofuran (2 mL) was added and the resulting mixture was stirred for 1 h.  The 
solution was diluted with water and extracted with diethyl ether.  The organic layer was 
back extracted twice with water and the combined aqueous fractions were filtered and 
lyophilized.  The crude product was purified by HPLC on a Phenomonex Luna C18(2) 
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stationary phase, 10 x 250 mm (acetonitrile:10 mM NH4HCO3 in water, 10:90; 1 
mL/min; 6.5 min elution). 40: 1H NMR (300 MHz, D2O) δ 8.73 (s, 1H), 5.73 (t, J = 6.8 
Hz, 1H), 4.08 (m, 1H), 3.88 (q, J = 7.4 Hz, 1H), 2.50 (m, 1H), 2.03 (m, 3H), 1.84 (m, 
1H), 1.39 (m, 2H), 1.24 (m, 2H), 0.83 (d, J = 3.1 Hz, 3H). 1H NMR matched the data 
reported by Tanaka et al.27,31,32. 
 
General procedure for allyl deprotection with palladium(II) acetate: 
(5R,6S)-3-(ethylsulfinyl)-6-((R)-1-hydroxyethyl)-7-oxo-4-thia-1-azabicyclo-[3.2.0]-
hept-2-ene-2-carboxylate (15).  Palladium(II) acetate (1 mg, 0.003 mmol) and 
triethylphosphite (3.8 µL, 0.022 mmol) were sequentially added to a mixture of sodium 
bicarbonate (5.9 mg, 0.07 mmol), 5,5-dimethyl-cyclohexane-1,3-dione (5.9 mg, 0.042 
mmol), water (168 µL) and tetrahydrofuran (422 µL) and vigorously stirred for 5 min.  A 
solution of 8 (20 mg, 0.063 mmol) in tetrahydrofuran (85 µL) was added, and the 
reaction mixture was stirred while heating to 35°C for 45 min.  The solution was diluted 
with water (500 µL) and dichloromethane (400 µL), washed three times with 
dichloromethane (5 mL) and the aqueous layer was added directly to a column of Diaion 
polystyrene resin (5 mL) and was eluted with water and the product-containing fractions 
were lyophilized to provide 15 as a white powder.  15: 1H NMR (400MHz, D2O) δ = 5.72 
(d, J = 1.4 Hz, 1H), 4.25 (quin, J = 6.3 Hz, 1H), 3.95 (dd, J = 1.4, 5.9 Hz, 1H), 3.14-2.90 
(m, 2H), 1.34 (t, J = 7.3 Hz, 3H), 1.31 (d, J = 6.5 Hz, 3H).  HRMS (FAB), C10H12NO4S2 
[M-H+] calculated: 274.0208; found: 274.0211; Δ 1.1 ppm.  13C NMR was not obtained as 
the total amount of material was < 1 mg and compounds are not stable enough for 10+ h 
experiments at RT. 
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A general procedure for deallylation with palladium tetrakis: 
Potassium (5S,6R)-3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((R)-1-
hydroxyethyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (16).   
Tetrakis(triphenylphosphine)palladium (43 mg, 0.21 mmol) was added to a solution of 32 
(1.8 g, 4.21 mmol) in freshly distilled tetrahydrofuran (84 mL) at which time the mixture 
became cloudy.  A solution of potassium 2-ethylhexanoate (873 mg, 4.0 mmol) in 
tetrahydrofuran (16.8 mL) was added causing the reaction mixture to initially become 
clear.  After stirring for 30 min, the solution became cloudy with the formation of yellow 
crystalline leaves.  The reaction mixture is cooled to 4 °C and stirred for an additional 2 
h.  The precipitate is filtered and washed with cold tetrahydrofuran to provide 16 as an 
off-white powder (1.2 g, 66%).  The precipitate may be re-dissolved in water and washed 
with dichloromethane to remove trace quantities of 32 and triphenylphosphine; the major 
impurities of the reaction.  No evidence of palladium contamination was found by 
HRMS. 16: 1H NMR (400MHz, D2O) δ = 5.71 (d, J = 1.0 Hz, 1H), 4.50 (td, J = 8.4, 20.9 
Hz, 2H), 4.24 (quin, J = 6.5 Hz, 1H), 4.32 - 4.18 (m, 1H), 4.02 (ddd, J = 4.8, 9.0, 19.1 
Hz, 2H), 3.93 (t, J = 8.0 Hz, 2H), 3.96 - 3.84 (m, 1H), 3.45 (t, J = 7.4 Hz, 2H), 1.30 (d, J 
= 6.5 Hz, 3H).  13C NMR (101MHz, D2O) δ = 175.4, 166.4, 143.6, 124.1, 69.4, 64.7, 
63.8, 59.4, 59.0, 57.7, 51.1, 35.6, 35.1, 20.1.  HRMS (UPLC), C14H18N3O4S3 [M+H+] 





azabicyclo[3.2.0]hept-2-ene-2-carboxylate (17): From 30; 1H NMR (400MHz, D2O) δ 
= 5.66 (d, J = 1.2 Hz, 1H), 4.25 (quin, J = 6.3 Hz, 1H), 3.89 (dd, J = 1.3, 6.0 Hz, 1H), 
3.05 - 2.92 (m, 1H), 2.85 (td, J = 7.4, 13.0 Hz, 1H), 1.71 (dqd, J = 2.6, 7.3, 14.5 Hz, 2H), 
1.31 (d, J = 6.5 Hz, 3H), 0.99 (t, J = 7.4 Hz, 3H).  13C NMR (101MHz, D2O) δ = 175.6, 
166.8, 147.1, 123.3, 69.1, 64.7, 62.9, 37.2, 23.2, 20.1, 12.3.  HRMS (UPLC), 
C11H15NO4S2Na [M+Na+] calculated: 312.0340; found: 312.0341. 
Potassium (5R,6S)-6-((R)-1-hydroxyethyl)-3-((2-hydroxyethyl)thio)-7-oxo-4-thia-1-
azabicyclo[3.2.0]hept-2-ene-2-carboxylate (18): 1H NMR (400MHz, D2O) δ = 5.67 (d, 
J = 1.4 Hz, 1H), 4.25 (quin, J = 6.3 Hz, 1H), 3.91 (dd, J = 1.5, 6.0 Hz, 1H), 3.82 (dt, J = 












= 6.5 Hz, 3H). HRMS (UPLC), C10H14NO5S2 [M+H+] calculated: 292.0308; found: 
292.0297. 13C NMR was not obtained as the total amount of material was < 1 mg and 
compounds are not stable enough for 10+ h experiments at RT. 
 
Potassium (5R,6S)-6-((R)-1-hydroxyethyl)-3-((3-methoxy-3-oxopropyl)thio)-7-oxo-4-
thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (19): 1H NMR (400MHz, D2O) δ = 
5.69 (d, J = 1.8 Hz, 1H), 4.25 (quin, J = 6.3 Hz, 1H), 3.92 (dd, J = 1.5, 6.0 Hz, 1H), 3.72 
(s, 3H), 3.25 (td, J1 = 6.9, J2 = 14.0 Hz, 1H), 3.10 (td, J = 7.1, 14.1 Hz, 1H), 2.83 (dt, J1 = 
1.8, 6.7 Hz, 2H), 1.31 (d, J = 6.5 Hz, 3H).  HRMS (UPLC), C12H16NO6S2 [M+H+] 
calculated: 334.0414; found: 334.0410; Δ 1.2 ppm.  13C NMR was not obtained as the 
total amount of material was < 1 mg and compounds are not stable enough for 10+ h 
experiments at RT. 
Potassium (5R,6S)-6-((R)-1-hydroxyethyl)-7-oxo-3-(((3R,5R)-5-(sulfamoylamino-
methyl)pyrrolidin-3-yl)thio)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (27): 
From 10; 1H NMR (400MHz, D2O) δ = 5.71 (d, J = 1.4 Hz, 1H), 4.25 (quin, J = 6.4 Hz, 
1H), 4.15 - 4.03 (m, 1H), 3.95 (dd, J = 1.5, 6.0 Hz, 1H), 3.81 - 3.70 (m, 2H), 3.64 (dd, J = 
3.7, 11.7 Hz, 1H), 3.70 - 3.60 (m, 1H), 3.51 (dd, J = 7.0, 11.5 Hz, 1H), 3.49 (dd, J1= 5.5, 
7.4 Hz, 1H), 3.38 (dd, J = 8.6, 15.5 Hz, 1H), 2.76 - 2.64 (m, 1H), 1.30 (d, J = 6.5 Hz, 
3H). HRMS (UPLC), C13H21N4O6S3 [M+H+] calculated: 425.0618; found: 425.0617.  13C 
NMR was not obtained as the total amount of material was < 1 mg and compounds are 
not stable enough for 10+ h experiments at RT. 
Potassium (5R,6S)-3-(((3R,5R)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((R)-1-
hydroxyethyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (20): From 
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11; 1H NMR (400MHz, D2O) δ = 5.69 (d, J = 1.4 Hz, 1H), 4.25 (quin, J = 6.3 Hz, 1H), 
4.10 (q, J = 7.0 Hz, 1H), 3.91 (dd, J = 1.4, 6.3 Hz, 1H), 3.74 (dd, J = 3.9, 5.3 Hz, 2H), 
3.64 (dd, J = 4.3, 5.1 Hz, 2H), 3.06 (s, 3H), 2.96 (s, 3H), 1.32 (d, J = 6.8 Hz, 3H).  
HRMS (UPLC), C15H22N3O5S2 [M+H+] calculated: 388.0995; found: 388.0994.  13C 
NMR was not obtained as the total amount of material was < 1 mg and compounds are 
not stable enough for 10+ h experiments at RT. 
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